id	sid	tid	token	lemma	pos
dpc-3703	1	1	dermatology	dermatology	NOUN
dpc-3703	1	2	:	:	PUNCT
dpc-3703	1	3	practical	practical	ADJ
dpc-3703	1	4	and	and	CCONJ
dpc-3703	1	5	conceptual	conceptual	ADJ
dpc-3703	1	6	review	review	NOUN
dpc-3703	1	7	|	|	ADV
dpc-3703	1	8	dermatol	dermatol	ADJ
dpc-3703	1	9	pract	pract	NOUN
dpc-3703	1	10	concept	concept	NOUN
dpc-3703	1	11	.	.	PUNCT
dpc-3703	2	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	2	2	1	1	NUM
dpc-3703	2	3	immunotherapy	immunotherapy	NOUN
dpc-3703	2	4	and	and	CCONJ
dpc-3703	2	5	its	its	PRON
dpc-3703	2	6	timing	timing	NOUN
dpc-3703	2	7	in	in	ADP
dpc-3703	2	8	advanced	advanced	ADJ
dpc-3703	2	9	basal	basal	NOUN
dpc-3703	2	10	cell	cell	NOUN
dpc-3703	2	11	carcinoma	carcinoma	NOUN
dpc-3703	2	12	treatment	treatment	NOUN
dpc-3703	2	13	clio	clio	PROPN
dpc-3703	2	14	dessinioti1	dessinioti1	PROPN
dpc-3703	2	15	,	,	PUNCT
dpc-3703	2	16	alexander	alexander	PROPN
dpc-3703	2	17	j.	j.	PROPN
dpc-3703	2	18	stratigos1	stratigos1	PROPN
dpc-3703	2	19	1	1	NUM
dpc-3703	2	20	skin	skin	NOUN
dpc-3703	2	21	cancer	cancer	NOUN
dpc-3703	2	22	and	and	CCONJ
dpc-3703	2	23	melanoma	melanoma	NOUN
dpc-3703	2	24	unit	unit	NOUN
dpc-3703	2	25	,	,	PUNCT
dpc-3703	2	26	1st	1st	ADJ
dpc-3703	2	27	department	department	NOUN
dpc-3703	2	28	of	of	ADP
dpc-3703	2	29	dermatology	dermatology	NOUN
dpc-3703	2	30	-	-	PUNCT
dpc-3703	2	31	venereology	venereology	NOUN
dpc-3703	2	32	,	,	PUNCT
dpc-3703	2	33	national	national	ADJ
dpc-3703	2	34	and	and	CCONJ
dpc-3703	2	35	kapodistrian	kapodistrian	ADJ
dpc-3703	2	36	university	university	PROPN
dpc-3703	2	37	of	of	ADP
dpc-3703	2	38	athens	athens	PROPN
dpc-3703	2	39	,	,	PUNCT
dpc-3703	2	40	andreas	andreas	PROPN
dpc-3703	2	41	 	 	SPACE
dpc-3703	2	42	sygros	sygros	PROPN
dpc-3703	2	43	hospital	hospital	PROPN
dpc-3703	2	44	,	,	PUNCT
dpc-3703	2	45	athens	athens	PROPN
dpc-3703	2	46	,	,	PUNCT
dpc-3703	2	47	greece	greece	PROPN
dpc-3703	2	48	key	key	ADJ
dpc-3703	2	49	words	word	NOUN
dpc-3703	2	50	:	:	PUNCT
dpc-3703	2	51	basal	basal	ADJ
dpc-3703	2	52	cell	cell	NOUN
dpc-3703	2	53	carcinoma	carcinoma	NOUN
dpc-3703	2	54	,	,	PUNCT
dpc-3703	2	55	advanced	advanced	ADJ
dpc-3703	2	56	,	,	PUNCT
dpc-3703	2	57	anti	anti	ADJ
dpc-3703	2	58	-	-	ADJ
dpc-3703	2	59	pd-1	pd-1	ADJ
dpc-3703	2	60	,	,	PUNCT
dpc-3703	2	61	cemiplimab	cemiplimab	NOUN
dpc-3703	2	62	,	,	PUNCT
dpc-3703	2	63	nivolumab	nivolumab	ADV
dpc-3703	2	64	,	,	PUNCT
dpc-3703	2	65	immunotherapy	immunotherapy	NOUN
dpc-3703	2	66	citation	citation	NOUN
dpc-3703	2	67	:	:	PUNCT
dpc-3703	2	68	dessinioti	dessinioti	PROPN
dpc-3703	2	69	c	c	X
dpc-3703	2	70	,	,	PUNCT
dpc-3703	2	71	stratigos	stratigos	PROPN
dpc-3703	2	72	aj	aj	PROPN
dpc-3703	2	73	.	.	PROPN
dpc-3703	2	74	immunotherapy	immunotherapy	NOUN
dpc-3703	2	75	and	and	CCONJ
dpc-3703	2	76	its	its	PRON
dpc-3703	2	77	timing	timing	NOUN
dpc-3703	2	78	in	in	ADP
dpc-3703	2	79	advanced	advanced	ADJ
dpc-3703	2	80	basal	basal	NOUN
dpc-3703	2	81	cell	cell	NOUN
dpc-3703	2	82	carcinoma	carcinoma	NOUN
dpc-3703	2	83	treatment	treatment	NOUN
dpc-3703	2	84	.	.	PUNCT
dpc-3703	3	1	dermatol	dermatol	NOUN
dpc-3703	3	2	pract	pract	PROPN
dpc-3703	3	3	concept	concept	NOUN
dpc-3703	3	4	.	.	PUNCT
dpc-3703	4	1	2023;13(4):e2023252	2023;13(4):e2023252	X
dpc-3703	4	2	.	.	PUNCT
dpc-3703	4	3	doi	doi	NOUN
dpc-3703	4	4	:	:	PUNCT
dpc-3703	4	5	https://doi.org/10.5826/dpc.1304a252	https://doi.org/10.5826/dpc.1304a252	PROPN
dpc-3703	4	6	accepted	accept	VERB
dpc-3703	4	7	:	:	PUNCT
dpc-3703	4	8	august	august	PROPN
dpc-3703	4	9	9	9	NUM
dpc-3703	4	10	,	,	PUNCT
dpc-3703	4	11	2023	2023	NUM
dpc-3703	4	12	;	;	PUNCT
dpc-3703	4	13	published	publish	VERB
dpc-3703	4	14	:	:	PUNCT
dpc-3703	5	1	october	october	PROPN
dpc-3703	5	2	2023	2023	NUM
dpc-3703	5	3	copyright	copyright	NOUN
dpc-3703	5	4	:	:	PUNCT
dpc-3703	5	5	©	©	PROPN
dpc-3703	5	6	2023	2023	NUM
dpc-3703	5	7	dessinioti	dessinioti	X
dpc-3703	5	8	et	et	PROPN
dpc-3703	5	9	al	al	PROPN
dpc-3703	5	10	.	.	PUNCT
dpc-3703	6	1	this	this	PRON
dpc-3703	6	2	is	be	AUX
dpc-3703	6	3	an	an	DET
dpc-3703	6	4	open	open	ADJ
dpc-3703	6	5	-	-	PUNCT
dpc-3703	6	6	access	access	NOUN
dpc-3703	6	7	article	article	NOUN
dpc-3703	6	8	distributed	distribute	VERB
dpc-3703	6	9	under	under	ADP
dpc-3703	6	10	the	the	DET
dpc-3703	6	11	terms	term	NOUN
dpc-3703	6	12	of	of	ADP
dpc-3703	6	13	the	the	DET
dpc-3703	6	14	creative	creative	ADJ
dpc-3703	6	15	commons	common	NOUN
dpc-3703	6	16	attribution	attribution	NOUN
dpc-3703	6	17	-	-	PUNCT
dpc-3703	6	18	noncommercial	noncommercial	ADJ
dpc-3703	6	19	license	license	NOUN
dpc-3703	6	20	(	(	PUNCT
dpc-3703	6	21	by	by	ADP
dpc-3703	6	22	-	-	PUNCT
dpc-3703	6	23	nc-4.0	nc-4.0	NOUN
dpc-3703	6	24	)	)	PUNCT
dpc-3703	6	25	,	,	PUNCT
dpc-3703	6	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3703	6	27	,	,	PUNCT
dpc-3703	6	28	which	which	PRON
dpc-3703	6	29	permits	permit	VERB
dpc-3703	6	30	unrestricted	unrestricted	ADJ
dpc-3703	6	31	noncommercial	noncommercial	ADJ
dpc-3703	6	32	use	use	NOUN
dpc-3703	6	33	,	,	PUNCT
dpc-3703	6	34	distribution	distribution	NOUN
dpc-3703	6	35	,	,	PUNCT
dpc-3703	6	36	and	and	CCONJ
dpc-3703	6	37	reproduction	reproduction	NOUN
dpc-3703	6	38	in	in	ADP
dpc-3703	6	39	any	any	DET
dpc-3703	6	40	medium	medium	NOUN
dpc-3703	6	41	,	,	PUNCT
dpc-3703	6	42	provided	provide	VERB
dpc-3703	6	43	the	the	DET
dpc-3703	6	44	original	original	ADJ
dpc-3703	6	45	authors	author	NOUN
dpc-3703	6	46	and	and	CCONJ
dpc-3703	6	47	source	source	NOUN
dpc-3703	6	48	are	be	AUX
dpc-3703	6	49	credited	credit	VERB
dpc-3703	6	50	.	.	PUNCT
dpc-3703	7	1	funding	funding	NOUN
dpc-3703	7	2	:	:	PUNCT
dpc-3703	7	3	none	none	NOUN
dpc-3703	7	4	.	.	PUNCT
dpc-3703	8	1	competing	compete	VERB
dpc-3703	8	2	interests	interest	NOUN
dpc-3703	8	3	:	:	PUNCT
dpc-3703	8	4	dr	dr	PROPN
dpc-3703	8	5	dessinioti	dessinioti	PROPN
dpc-3703	8	6	has	have	VERB
dpc-3703	8	7	no	no	DET
dpc-3703	8	8	conflict	conflict	NOUN
dpc-3703	8	9	of	of	ADP
dpc-3703	8	10	interest	interest	NOUN
dpc-3703	8	11	to	to	PART
dpc-3703	8	12	declare	declare	VERB
dpc-3703	8	13	.	.	PUNCT
dpc-3703	9	1	dr	dr	PROPN
dpc-3703	9	2	.	.	PROPN
dpc-3703	9	3	stratigos	stratigos	PROPN
dpc-3703	9	4	reports	report	VERB
dpc-3703	9	5	personal	personal	ADJ
dpc-3703	9	6	fees	fee	NOUN
dpc-3703	9	7	and/or	and/or	CCONJ
dpc-3703	9	8	research	research	NOUN
dpc-3703	9	9	support	support	NOUN
dpc-3703	9	10	from	from	ADP
dpc-3703	9	11	novartis	novartis	PROPN
dpc-3703	9	12	,	,	PUNCT
dpc-3703	9	13	roche	roche	PROPN
dpc-3703	9	14	,	,	PUNCT
dpc-3703	9	15	bms	bms	PROPN
dpc-3703	9	16	,	,	PUNCT
dpc-3703	9	17	abbvie	abbvie	PROPN
dpc-3703	9	18	,	,	PUNCT
dpc-3703	9	19	sanofi	sanofi	PROPN
dpc-3703	9	20	,	,	PUNCT
dpc-3703	9	21	regeneron	regeneron	PROPN
dpc-3703	9	22	,	,	PUNCT
dpc-3703	9	23	genesis	genesis	PROPN
dpc-3703	9	24	pharma	pharma	PROPN
dpc-3703	9	25	,	,	PUNCT
dpc-3703	9	26	outside	outside	ADP
dpc-3703	9	27	the	the	DET
dpc-3703	9	28	submitted	submit	VERB
dpc-3703	9	29	work	work	NOUN
dpc-3703	9	30	.	.	PUNCT
dpc-3703	10	1	authorship	authorship	NOUN
dpc-3703	10	2	:	:	PUNCT
dpc-3703	10	3	all	all	DET
dpc-3703	10	4	authors	author	NOUN
dpc-3703	10	5	have	have	AUX
dpc-3703	10	6	contributed	contribute	VERB
dpc-3703	10	7	significantly	significantly	ADV
dpc-3703	10	8	to	to	ADP
dpc-3703	10	9	this	this	DET
dpc-3703	10	10	publication	publication	NOUN
dpc-3703	10	11	.	.	PUNCT
dpc-3703	11	1	corresponding	correspond	VERB
dpc-3703	11	2	author	author	NOUN
dpc-3703	11	3	:	:	PUNCT
dpc-3703	11	4	alexander	alexander	PROPN
dpc-3703	11	5	j	j	PROPN
dpc-3703	11	6	stratigos	stratigos	PROPN
dpc-3703	11	7	,	,	PUNCT
dpc-3703	11	8	department	department	NOUN
dpc-3703	11	9	of	of	ADP
dpc-3703	11	10	dermato	dermato	PROPN
dpc-3703	11	11	-	-	PUNCT
dpc-3703	11	12	oncology	oncology	NOUN
dpc-3703	11	13	,	,	PUNCT
dpc-3703	11	14	andreas	andreas	PROPN
dpc-3703	11	15	sygros	sygros	PROPN
dpc-3703	11	16	hospital	hospital	PROPN
dpc-3703	11	17	,	,	PUNCT
dpc-3703	11	18	athens	athens	PROPN
dpc-3703	11	19	,	,	PUNCT
dpc-3703	11	20	greece	greece	PROPN
dpc-3703	11	21	.	.	PUNCT
dpc-3703	12	1	e	e	X
dpc-3703	12	2	-	-	NOUN
dpc-3703	12	3	mail	mail	NOUN
dpc-3703	12	4	:	:	PUNCT
dpc-3703	12	5	alstrat2@gmail.com	alstrat2@gmail.com	X
dpc-3703	13	1	for	for	SCONJ
dpc-3703	13	2	patients	patient	NOUN
dpc-3703	13	3	with	with	ADP
dpc-3703	13	4	advanced	advanced	ADJ
dpc-3703	13	5	basal	basal	NOUN
dpc-3703	13	6	cell	cell	NOUN
dpc-3703	13	7	carcinoma	carcinoma	NOUN
dpc-3703	13	8	(	(	PUNCT
dpc-3703	13	9	bcc	bcc	PROPN
dpc-3703	13	10	)	)	PUNCT
dpc-3703	13	11	,	,	PUNCT
dpc-3703	13	12	including	include	VERB
dpc-3703	13	13	locally	locally	ADV
dpc-3703	13	14	advanced	advanced	ADJ
dpc-3703	13	15	or	or	CCONJ
dpc-3703	13	16	metastatic	metastatic	ADJ
dpc-3703	13	17	bcc	bcc	NOUN
dpc-3703	13	18	not	not	PART
dpc-3703	13	19	amenable	amenable	ADJ
dpc-3703	13	20	to	to	PART
dpc-3703	13	21	curative	curative	ADJ
dpc-3703	13	22	surgery	surgery	NOUN
dpc-3703	13	23	or	or	CCONJ
dpc-3703	13	24	radiotherapy	radiotherapy	NOUN
dpc-3703	13	25	,	,	PUNCT
dpc-3703	13	26	hedgehog	hedgehog	ADJ
dpc-3703	13	27	pathway	pathway	NOUN
dpc-3703	13	28	inhibitors	inhibitor	NOUN
dpc-3703	13	29	(	(	PUNCT
dpc-3703	13	30	hhi	hhi	NOUN
dpc-3703	13	31	)	)	PUNCT
dpc-3703	13	32	vismodegib	vismodegib	NOUN
dpc-3703	13	33	and	and	CCONJ
dpc-3703	13	34	sonidegib	sonidegib	NOUN
dpc-3703	13	35	are	be	AUX
dpc-3703	13	36	approved	approve	VERB
dpc-3703	13	37	as	as	ADP
dpc-3703	13	38	first	first	ADJ
dpc-3703	13	39	-	-	PUNCT
dpc-3703	13	40	line	line	NOUN
dpc-3703	13	41	systemic	systemic	ADJ
dpc-3703	13	42	treatment	treatment	NOUN
dpc-3703	13	43	.	.	PUNCT
dpc-3703	14	1	results	result	NOUN
dpc-3703	14	2	from	from	ADP
dpc-3703	14	3	clinical	clinical	ADJ
dpc-3703	14	4	trials	trial	NOUN
dpc-3703	14	5	highlight	highlight	VERB
dpc-3703	14	6	that	that	SCONJ
dpc-3703	14	7	the	the	DET
dpc-3703	14	8	overall	overall	ADJ
dpc-3703	14	9	discontinuation	discontinuation	NOUN
dpc-3703	14	10	rate	rate	NOUN
dpc-3703	14	11	of	of	ADP
dpc-3703	14	12	hhi	hhi	NOUN
dpc-3703	14	13	treatment	treatment	NOUN
dpc-3703	14	14	varies	vary	VERB
dpc-3703	14	15	from	from	ADP
dpc-3703	14	16	88	88	NUM
dpc-3703	14	17	%	%	NOUN
dpc-3703	14	18	to	to	ADP
dpc-3703	14	19	92	92	NUM
dpc-3703	14	20	%	%	NOUN
dpc-3703	14	21	with	with	ADP
dpc-3703	14	22	vismodegib	vismodegib	NOUN
dpc-3703	14	23	and	and	CCONJ
dpc-3703	14	24	is	be	AUX
dpc-3703	14	25	approximately	approximately	ADV
dpc-3703	14	26	92	92	NUM
dpc-3703	14	27	%	%	NOUN
dpc-3703	14	28	with	with	ADP
dpc-3703	14	29	sonidegib	sonidegib	NOUN
dpc-3703	14	30	,	,	PUNCT
dpc-3703	14	31	and	and	CCONJ
dpc-3703	14	32	half	half	NOUN
dpc-3703	14	33	of	of	ADP
dpc-3703	14	34	patients	patient	NOUN
dpc-3703	14	35	will	will	AUX
dpc-3703	14	36	discontinue	discontinue	VERB
dpc-3703	14	37	hhi	hhi	NOUN
dpc-3703	14	38	after	after	ADP
dpc-3703	14	39	approximately	approximately	ADV
dpc-3703	14	40	8	8	NUM
dpc-3703	14	41	to	to	PART
dpc-3703	14	42	12	12	NUM
dpc-3703	14	43	months	month	NOUN
dpc-3703	14	44	.	.	PUNCT
dpc-3703	15	1	the	the	DET
dpc-3703	15	2	main	main	ADJ
dpc-3703	15	3	factors	factor	NOUN
dpc-3703	15	4	weighing	weigh	VERB
dpc-3703	15	5	in	in	ADP
dpc-3703	15	6	on	on	ADP
dpc-3703	15	7	the	the	DET
dpc-3703	15	8	decision	decision	NOUN
dpc-3703	15	9	to	to	PART
dpc-3703	15	10	discontinue	discontinue	VERB
dpc-3703	15	11	hhi	hhi	NOUN
dpc-3703	15	12	include	include	VERB
dpc-3703	15	13	efficacy	efficacy	NOUN
dpc-3703	15	14	(	(	PUNCT
dpc-3703	15	15	tumor	tumor	NOUN
dpc-3703	15	16	response	response	NOUN
dpc-3703	15	17	)	)	PUNCT
dpc-3703	15	18	,	,	PUNCT
dpc-3703	15	19	adverse	adverse	ADJ
dpc-3703	15	20	events	event	NOUN
dpc-3703	15	21	and	and	CCONJ
dpc-3703	15	22	patient	patient	ADJ
dpc-3703	15	23	decision	decision	NOUN
dpc-3703	15	24	.	.	PUNCT
dpc-3703	16	1	in	in	ADP
dpc-3703	16	2	clinical	clinical	ADJ
dpc-3703	16	3	practice	practice	NOUN
dpc-3703	16	4	,	,	PUNCT
dpc-3703	16	5	some	some	PRON
dpc-3703	16	6	of	of	ADP
dpc-3703	16	7	the	the	DET
dpc-3703	16	8	patients	patient	NOUN
dpc-3703	16	9	that	that	PRON
dpc-3703	16	10	stop	stop	VERB
dpc-3703	16	11	hhi	hhi	NOUN
dpc-3703	16	12	may	may	AUX
dpc-3703	16	13	be	be	AUX
dpc-3703	16	14	re	re	VERB
dpc-3703	16	15	-	-	VERB
dpc-3703	16	16	evaluated	evaluate	VERB
dpc-3703	16	17	if	if	SCONJ
dpc-3703	16	18	the	the	DET
dpc-3703	16	19	tumor	tumor	NOUN
dpc-3703	16	20	becomes	become	VERB
dpc-3703	16	21	amenable	amenable	ADJ
dpc-3703	16	22	to	to	ADP
dpc-3703	16	23	surgery	surgery	NOUN
dpc-3703	16	24	,	,	PUNCT
dpc-3703	16	25	or	or	CCONJ
dpc-3703	16	26	restart	restart	NOUN
dpc-3703	16	27	hhi	hhi	NOUN
dpc-3703	16	28	at	at	ADP
dpc-3703	16	29	a	a	DET
dpc-3703	16	30	later	later	ADJ
dpc-3703	16	31	time	time	NOUN
dpc-3703	16	32	,	,	PUNCT
dpc-3703	16	33	while	while	SCONJ
dpc-3703	16	34	others	other	NOUN
dpc-3703	16	35	will	will	AUX
dpc-3703	16	36	need	need	VERB
dpc-3703	16	37	to	to	PART
dpc-3703	16	38	switch	switch	VERB
dpc-3703	16	39	to	to	ADP
dpc-3703	16	40	immunotherapy	immunotherapy	NOUN
dpc-3703	16	41	,	,	PUNCT
dpc-3703	16	42	depending	depend	VERB
dpc-3703	16	43	on	on	ADP
dpc-3703	16	44	the	the	DET
dpc-3703	16	45	reasons	reason	NOUN
dpc-3703	16	46	for	for	ADP
dpc-3703	16	47	hhi	hhi	NOUN
dpc-3703	16	48	discontinuation	discontinuation	NOUN
dpc-3703	16	49	.	.	PUNCT
dpc-3703	17	1	in	in	ADP
dpc-3703	17	2	this	this	DET
dpc-3703	17	3	review	review	NOUN
dpc-3703	17	4	,	,	PUNCT
dpc-3703	17	5	we	we	PRON
dpc-3703	17	6	revisit	revisit	VERB
dpc-3703	17	7	the	the	DET
dpc-3703	17	8	therapeutic	therapeutic	ADJ
dpc-3703	17	9	decisions	decision	NOUN
dpc-3703	17	10	considering	consider	VERB
dpc-3703	17	11	a	a	DET
dpc-3703	17	12	switch	switch	NOUN
dpc-3703	17	13	from	from	ADP
dpc-3703	17	14	hhi	hhi	NOUN
dpc-3703	17	15	to	to	ADP
dpc-3703	17	16	immunotherapy	immunotherapy	NOUN
dpc-3703	17	17	with	with	ADP
dpc-3703	17	18	anti	anti	ADJ
dpc-3703	17	19	-	-	ADJ
dpc-3703	17	20	pd-1	pd-1	ADJ
dpc-3703	17	21	agent	agent	NOUN
dpc-3703	17	22	cemiplimab	cemiplimab	NOUN
dpc-3703	17	23	and	and	CCONJ
dpc-3703	17	24	we	we	PRON
dpc-3703	17	25	highlight	highlight	VERB
dpc-3703	17	26	the	the	DET
dpc-3703	17	27	place	place	NOUN
dpc-3703	17	28	of	of	ADP
dpc-3703	17	29	cemiplimab	cemiplimab	NOUN
dpc-3703	17	30	in	in	ADP
dpc-3703	17	31	the	the	DET
dpc-3703	17	32	therapeutic	therapeutic	ADJ
dpc-3703	17	33	ladder	ladder	NOUN
dpc-3703	17	34	for	for	ADP
dpc-3703	17	35	patients	patient	NOUN
dpc-3703	17	36	with	with	ADP
dpc-3703	17	37	advanced	advanced	ADJ
dpc-3703	17	38	bcc	bcc	PROPN
dpc-3703	17	39	.	.	PUNCT
dpc-3703	18	1	we	we	PRON
dpc-3703	18	2	discuss	discuss	VERB
dpc-3703	18	3	the	the	DET
dpc-3703	18	4	evidence	evidence	NOUN
dpc-3703	18	5	on	on	ADP
dpc-3703	18	6	the	the	DET
dpc-3703	18	7	efficacy	efficacy	NOUN
dpc-3703	18	8	and	and	CCONJ
dpc-3703	18	9	safety	safety	NOUN
dpc-3703	18	10	of	of	ADP
dpc-3703	18	11	anti	anti	ADJ
dpc-3703	18	12	-	-	ADJ
dpc-3703	18	13	pd-1	pd-1	ADJ
dpc-3703	18	14	agents	agent	NOUN
dpc-3703	18	15	as	as	ADP
dpc-3703	18	16	second	second	ADJ
dpc-3703	18	17	-	-	PUNCT
dpc-3703	18	18	line	line	NOUN
dpc-3703	18	19	systemic	systemic	ADJ
dpc-3703	18	20	monotherapy	monotherapy	NOUN
dpc-3703	18	21	,	,	PUNCT
dpc-3703	18	22	or	or	CCONJ
dpc-3703	18	23	in	in	ADP
dpc-3703	18	24	combination	combination	NOUN
dpc-3703	18	25	with	with	ADP
dpc-3703	18	26	other	other	ADJ
dpc-3703	18	27	treatments	treatment	NOUN
dpc-3703	18	28	,	,	PUNCT
dpc-3703	18	29	and	and	CCONJ
dpc-3703	18	30	the	the	DET
dpc-3703	18	31	emergence	emergence	NOUN
dpc-3703	18	32	of	of	ADP
dpc-3703	18	33	checkpoint	checkpoint	NOUN
dpc-3703	18	34	immunotherapy	immunotherapy	NOUN
dpc-3703	18	35	as	as	ADP
dpc-3703	18	36	a	a	DET
dpc-3703	18	37	neoadjuvant	neoadjuvant	ADJ
dpc-3703	18	38	treatment	treatment	NOUN
dpc-3703	18	39	.	.	PUNCT
dpc-3703	19	1	abstract	abstract	ADJ
dpc-3703	19	2	2	2	NUM
dpc-3703	19	3	review	review	NOUN
dpc-3703	19	4	|	|	ADV
dpc-3703	19	5	dermatol	dermatol	ADJ
dpc-3703	19	6	pract	pract	NOUN
dpc-3703	19	7	concept	concept	NOUN
dpc-3703	19	8	.	.	PUNCT
dpc-3703	20	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	20	2	introduction	introduction	NOUN
dpc-3703	20	3	basal	basal	NOUN
dpc-3703	20	4	cell	cell	NOUN
dpc-3703	20	5	carcinoma	carcinoma	NOUN
dpc-3703	20	6	(	(	PUNCT
dpc-3703	20	7	bcc	bcc	PROPN
dpc-3703	20	8	)	)	PUNCT
dpc-3703	20	9	accounts	account	VERB
dpc-3703	20	10	for	for	ADP
dpc-3703	20	11	75	75	NUM
dpc-3703	20	12	%	%	NOUN
dpc-3703	20	13	of	of	ADP
dpc-3703	20	14	all	all	DET
dpc-3703	20	15	skin	skin	NOUN
dpc-3703	20	16	cancers	cancer	NOUN
dpc-3703	20	17	and	and	CCONJ
dpc-3703	20	18	is	be	AUX
dpc-3703	20	19	the	the	DET
dpc-3703	20	20	most	most	ADV
dpc-3703	20	21	common	common	ADJ
dpc-3703	20	22	malignant	malignant	ADJ
dpc-3703	20	23	tumor	tumor	NOUN
dpc-3703	20	24	in	in	ADP
dpc-3703	20	25	white	white	ADJ
dpc-3703	20	26	populations	population	NOUN
dpc-3703	20	27	.	.	PUNCT
dpc-3703	21	1	bcc	bcc	PROPN
dpc-3703	21	2	and	and	CCONJ
dpc-3703	21	3	cutaneous	cutaneous	ADJ
dpc-3703	21	4	squamous	squamous	ADJ
dpc-3703	21	5	cell	cell	NOUN
dpc-3703	21	6	carcinoma	carcinoma	NOUN
dpc-3703	21	7	(	(	PUNCT
dpc-3703	21	8	cscc	cscc	ADJ
dpc-3703	21	9	)	)	PUNCT
dpc-3703	21	10	are	be	AUX
dpc-3703	21	11	referred	refer	VERB
dpc-3703	21	12	to	to	ADP
dpc-3703	21	13	as	as	ADP
dpc-3703	21	14	keratinocyte	keratinocyte	NOUN
dpc-3703	21	15	carcinomas	carcinoma	NOUN
dpc-3703	21	16	(	(	PUNCT
dpc-3703	21	17	formerly	formerly	ADV
dpc-3703	21	18	known	know	VERB
dpc-3703	21	19	as	as	ADP
dpc-3703	21	20	nonmelanoma	nonmelanoma	ADJ
dpc-3703	21	21	skin	skin	NOUN
dpc-3703	21	22	cancers	cancer	NOUN
dpc-3703	21	23	)	)	PUNCT
dpc-3703	22	1	[	[	X
dpc-3703	22	2	1].the	1].the	DET
dpc-3703	22	3	majority	majority	NOUN
dpc-3703	22	4	of	of	ADP
dpc-3703	22	5	bccs	bccs	PROPN
dpc-3703	22	6	is	be	AUX
dpc-3703	22	7	characterized	characterize	VERB
dpc-3703	22	8	by	by	ADP
dpc-3703	22	9	indolent	indolent	ADJ
dpc-3703	22	10	biological	biological	ADJ
dpc-3703	22	11	behavior	behavior	NOUN
dpc-3703	22	12	and	and	CCONJ
dpc-3703	22	13	is	be	AUX
dpc-3703	22	14	cured	cure	VERB
dpc-3703	22	15	with	with	ADP
dpc-3703	22	16	surgical	surgical	ADJ
dpc-3703	22	17	excision	excision	NOUN
dpc-3703	22	18	or	or	CCONJ
dpc-3703	22	19	topical	topical	ADJ
dpc-3703	22	20	treatments	treatment	NOUN
dpc-3703	22	21	.	.	PUNCT
dpc-3703	23	1	however	however	ADV
dpc-3703	23	2	,	,	PUNCT
dpc-3703	23	3	in	in	ADP
dpc-3703	23	4	some	some	DET
dpc-3703	23	5	cases	case	NOUN
dpc-3703	23	6	,	,	PUNCT
dpc-3703	23	7	bcc	bcc	PROPN
dpc-3703	23	8	can	can	AUX
dpc-3703	23	9	infiltrate	infiltrate	VERB
dpc-3703	23	10	locally	locally	ADV
dpc-3703	23	11	into	into	ADP
dpc-3703	23	12	adjacent	adjacent	ADJ
dpc-3703	23	13	and	and	CCONJ
dpc-3703	23	14	deeper	deep	ADJ
dpc-3703	23	15	structures	structure	NOUN
dpc-3703	23	16	and	and	CCONJ
dpc-3703	23	17	cause	cause	VERB
dpc-3703	23	18	extensive	extensive	ADJ
dpc-3703	23	19	tissue	tissue	NOUN
dpc-3703	23	20	destruction	destruction	NOUN
dpc-3703	23	21	.	.	PUNCT
dpc-3703	24	1	metastases	metastasis	NOUN
dpc-3703	24	2	are	be	AUX
dpc-3703	24	3	extremely	extremely	ADV
dpc-3703	24	4	rare	rare	ADJ
dpc-3703	24	5	(	(	PUNCT
dpc-3703	24	6	<	<	NOUN
dpc-3703	24	7	0.1	0.1	NUM
dpc-3703	24	8	%	%	NOUN
dpc-3703	24	9	)	)	PUNCT
dpc-3703	24	10	and	and	CCONJ
dpc-3703	24	11	may	may	AUX
dpc-3703	24	12	affect	affect	VERB
dpc-3703	24	13	the	the	DET
dpc-3703	24	14	regional	regional	ADJ
dpc-3703	24	15	lymph	lymph	NOUN
dpc-3703	24	16	nodes	node	NOUN
dpc-3703	24	17	,	,	PUNCT
dpc-3703	24	18	lung	lung	NOUN
dpc-3703	24	19	,	,	PUNCT
dpc-3703	24	20	spine	spine	NOUN
dpc-3703	24	21	,	,	PUNCT
dpc-3703	24	22	bone	bone	NOUN
dpc-3703	24	23	marrow	marrow	NOUN
dpc-3703	24	24	and	and	CCONJ
dpc-3703	24	25	pelvic	pelvic	ADJ
dpc-3703	24	26	bones	bone	NOUN
dpc-3703	24	27	[	[	X
dpc-3703	24	28	2	2	NUM
dpc-3703	24	29	]	]	PUNCT
dpc-3703	24	30	.	.	PUNCT
dpc-3703	25	1	multiple	multiple	ADJ
dpc-3703	25	2	factors	factor	NOUN
dpc-3703	25	3	are	be	AUX
dpc-3703	25	4	implicated	implicate	VERB
dpc-3703	25	5	in	in	ADP
dpc-3703	25	6	the	the	DET
dpc-3703	25	7	development	development	NOUN
dpc-3703	25	8	of	of	ADP
dpc-3703	25	9	sporadic	sporadic	ADJ
dpc-3703	25	10	bcc	bcc	PROPN
dpc-3703	25	11	including	include	VERB
dpc-3703	25	12	exposure	exposure	NOUN
dpc-3703	25	13	to	to	ADP
dpc-3703	25	14	ultraviolet	ultraviolet	ADJ
dpc-3703	25	15	radiation	radiation	NOUN
dpc-3703	25	16	(	(	PUNCT
dpc-3703	25	17	sun	sun	NOUN
dpc-3703	25	18	or	or	CCONJ
dpc-3703	25	19	indoor	indoor	ADJ
dpc-3703	25	20	tanning	tanning	NOUN
dpc-3703	25	21	beds	bed	NOUN
dpc-3703	25	22	)	)	PUNCT
dpc-3703	25	23	,	,	PUNCT
dpc-3703	25	24	older	old	ADJ
dpc-3703	25	25	age	age	NOUN
dpc-3703	25	26	,	,	PUNCT
dpc-3703	25	27	light	light	ADJ
dpc-3703	25	28	skin	skin	NOUN
dpc-3703	25	29	and	and	CCONJ
dpc-3703	25	30	hair	hair	NOUN
dpc-3703	25	31	tones	tone	NOUN
dpc-3703	25	32	,	,	PUNCT
dpc-3703	25	33	tendency	tendency	NOUN
dpc-3703	25	34	to	to	PART
dpc-3703	25	35	sunburn	sunburn	VERB
dpc-3703	25	36	,	,	PUNCT
dpc-3703	25	37	male	male	ADJ
dpc-3703	25	38	sex	sex	NOUN
dpc-3703	25	39	,	,	PUNCT
dpc-3703	25	40	immunosuppression	immunosuppression	NOUN
dpc-3703	25	41	(	(	PUNCT
dpc-3703	25	42	solid	solid	ADJ
dpc-3703	25	43	organ	organ	NOUN
dpc-3703	25	44	transplantation	transplantation	NOUN
dpc-3703	25	45	)	)	PUNCT
dpc-3703	25	46	and	and	CCONJ
dpc-3703	25	47	genetic	genetic	ADJ
dpc-3703	25	48	factors	factor	NOUN
dpc-3703	25	49	[	[	X
dpc-3703	25	50	3	3	NUM
dpc-3703	25	51	-	-	SYM
dpc-3703	25	52	6	6	NUM
dpc-3703	25	53	]	]	PUNCT
dpc-3703	25	54	.	.	PUNCT
dpc-3703	26	1	gene	gene	NOUN
dpc-3703	26	2	alterations	alteration	NOUN
dpc-3703	26	3	playing	play	VERB
dpc-3703	26	4	some	some	DET
dpc-3703	26	5	role	role	NOUN
dpc-3703	26	6	in	in	ADP
dpc-3703	26	7	bcc	bcc	PROPN
dpc-3703	26	8	pathogenesis	pathogenesis	NOUN
dpc-3703	26	9	include	include	VERB
dpc-3703	26	10	mutations	mutation	NOUN
dpc-3703	26	11	in	in	ADP
dpc-3703	26	12	p53	p53	NOUN
dpc-3703	26	13	(	(	PUNCT
dpc-3703	26	14	17p13	17p13	NUM
dpc-3703	26	15	)	)	PUNCT
dpc-3703	26	16	,	,	PUNCT
dpc-3703	26	17	human	human	ADJ
dpc-3703	26	18	type	type	NOUN
dpc-3703	26	19	ii	ii	PROPN
dpc-3703	26	20	oculo	oculo	ADV
dpc-3703	26	21	-	-	PUNCT
dpc-3703	26	22	cutaneous	cutaneous	ADJ
dpc-3703	26	23	albinism	albinism	NOUN
dpc-3703	26	24	-	-	PUNCT
dpc-3703	26	25	related	relate	VERB
dpc-3703	26	26	gene	gene	NOUN
dpc-3703	26	27	(	(	PUNCT
dpc-3703	26	28	oca2	oca2	PROPN
dpc-3703	26	29	)	)	PUNCT
dpc-3703	26	30	,	,	PUNCT
dpc-3703	26	31	agouti	agouti	NOUN
dpc-3703	26	32	signaling	signal	VERB
dpc-3703	26	33	protein	protein	NOUN
dpc-3703	26	34	(	(	PUNCT
dpc-3703	26	35	asip	asip	NOUN
dpc-3703	26	36	)	)	PUNCT
dpc-3703	26	37	,	,	PUNCT
dpc-3703	26	38	tyrosinase	tyrosinase	NOUN
dpc-3703	26	39	(	(	PUNCT
dpc-3703	26	40	tyr	tyr	PROPN
dpc-3703	26	41	)	)	PUNCT
dpc-3703	26	42	and	and	CCONJ
dpc-3703	26	43	melanocortin	melanocortin	NOUN
dpc-3703	26	44	1	1	NUM
dpc-3703	26	45	receptor	receptor	NOUN
dpc-3703	26	46	gene	gene	NOUN
dpc-3703	26	47	(	(	PUNCT
dpc-3703	26	48	mc1r	mc1r	PROPN
dpc-3703	26	49	,	,	PUNCT
dpc-3703	26	50	16q24.3	16q24.3	NUM
dpc-3703	26	51	)	)	PUNCT
dpc-3703	27	1	[	[	X
dpc-3703	27	2	1,7,8	1,7,8	NUM
dpc-3703	27	3	]	]	PUNCT
dpc-3703	27	4	.	.	PUNCT
dpc-3703	28	1	mutations	mutation	NOUN
dpc-3703	28	2	in	in	ADP
dpc-3703	28	3	the	the	DET
dpc-3703	28	4	hedgehog	hedgehog	PROPN
dpc-3703	28	5	(	(	PUNCT
dpc-3703	28	6	hh	hh	PROPN
dpc-3703	28	7	)	)	PUNCT
dpc-3703	28	8	signaling	signal	VERB
dpc-3703	28	9	pathway	pathway	NOUN
dpc-3703	28	10	have	have	AUX
dpc-3703	28	11	been	be	AUX
dpc-3703	28	12	detected	detect	VERB
dpc-3703	28	13	in	in	ADP
dpc-3703	28	14	practically	practically	ADV
dpc-3703	28	15	all	all	DET
dpc-3703	28	16	bccs	bccs	NOUN
dpc-3703	28	17	.	.	PUNCT
dpc-3703	29	1	the	the	DET
dpc-3703	29	2	hh	hh	PROPN
dpc-3703	29	3	signaling	signal	VERB
dpc-3703	29	4	pathway	pathway	NOUN
dpc-3703	29	5	is	be	AUX
dpc-3703	29	6	normally	normally	ADV
dpc-3703	29	7	required	require	VERB
dpc-3703	29	8	for	for	ADP
dpc-3703	29	9	the	the	DET
dpc-3703	29	10	hair	hair	NOUN
dpc-3703	29	11	follicle	follicle	NOUN
dpc-3703	29	12	morphogenesis	morphogenesis	NOUN
dpc-3703	29	13	during	during	ADP
dpc-3703	29	14	development	development	NOUN
dpc-3703	29	15	and	and	CCONJ
dpc-3703	29	16	regulation	regulation	NOUN
dpc-3703	29	17	of	of	ADP
dpc-3703	29	18	the	the	DET
dpc-3703	29	19	hair	hair	NOUN
dpc-3703	29	20	cycle	cycle	NOUN
dpc-3703	29	21	in	in	ADP
dpc-3703	29	22	adulthood	adulthood	NOUN
dpc-3703	29	23	,	,	PUNCT
dpc-3703	29	24	while	while	SCONJ
dpc-3703	29	25	its	its	PRON
dpc-3703	29	26	aberrant	aberrant	ADJ
dpc-3703	29	27	activation	activation	NOUN
dpc-3703	29	28	,	,	PUNCT
dpc-3703	29	29	due	due	ADP
dpc-3703	29	30	to	to	ADP
dpc-3703	29	31	mutations	mutation	NOUN
dpc-3703	29	32	in	in	ADP
dpc-3703	29	33	the	the	DET
dpc-3703	29	34	ptch1	ptch1	NOUN
dpc-3703	29	35	or	or	CCONJ
dpc-3703	29	36	smo	smo	PROPN
dpc-3703	29	37	genes	gene	NOUN
dpc-3703	29	38	,	,	PUNCT
dpc-3703	29	39	leads	lead	VERB
dpc-3703	29	40	to	to	ADP
dpc-3703	29	41	bcc	bcc	PROPN
dpc-3703	29	42	carcinogenesis	carcinogenesis	NOUN
dpc-3703	30	1	[	[	X
dpc-3703	30	2	9	9	NUM
dpc-3703	30	3	]	]	PUNCT
dpc-3703	30	4	.	.	PUNCT
dpc-3703	31	1	loss	loss	NOUN
dpc-3703	31	2	-	-	PUNCT
dpc-3703	31	3	of	of	ADP
dpc-3703	31	4	-	-	PUNCT
dpc-3703	31	5	function	function	NOUN
dpc-3703	31	6	somatic	somatic	ADJ
dpc-3703	31	7	mutations	mutation	NOUN
dpc-3703	31	8	in	in	ADP
dpc-3703	31	9	ptch1	ptch1	PROPN
dpc-3703	31	10	(	(	PUNCT
dpc-3703	31	11	9q22.3	9q22.3	NUM
dpc-3703	31	12	)	)	PUNCT
dpc-3703	31	13	and	and	CCONJ
dpc-3703	31	14	activating	activate	VERB
dpc-3703	31	15	mutations	mutation	NOUN
dpc-3703	31	16	in	in	ADP
dpc-3703	31	17	the	the	DET
dpc-3703	31	18	g	g	NOUN
dpc-3703	31	19	-	-	PUNCT
dpc-3703	31	20	protein	protein	NOUN
dpc-3703	31	21	coupled	couple	VERB
dpc-3703	31	22	receptor	receptor	NOUN
dpc-3703	31	23	smoothened	smoothen	VERB
dpc-3703	31	24	(	(	PUNCT
dpc-3703	31	25	smo	smo	PROPN
dpc-3703	31	26	)	)	PUNCT
dpc-3703	31	27	have	have	AUX
dpc-3703	31	28	been	be	AUX
dpc-3703	31	29	detected	detect	VERB
dpc-3703	31	30	in	in	ADP
dpc-3703	31	31	up	up	ADP
dpc-3703	31	32	to	to	PART
dpc-3703	31	33	approximately	approximately	ADV
dpc-3703	31	34	90	90	NUM
dpc-3703	31	35	%	%	NOUN
dpc-3703	31	36	and	and	CCONJ
dpc-3703	31	37	10	10	NUM
dpc-3703	31	38	%	%	NOUN
dpc-3703	31	39	of	of	ADP
dpc-3703	31	40	bcc	bcc	PROPN
dpc-3703	31	41	tumors	tumor	NOUN
dpc-3703	31	42	,	,	PUNCT
dpc-3703	31	43	respectively	respectively	ADV
dpc-3703	31	44	[	[	X
dpc-3703	31	45	10	10	NUM
dpc-3703	31	46	]	]	PUNCT
dpc-3703	31	47	.	.	PUNCT
dpc-3703	32	1	in	in	ADP
dpc-3703	32	2	addition	addition	NOUN
dpc-3703	32	3	,	,	PUNCT
dpc-3703	32	4	cancer	cancer	NOUN
dpc-3703	32	5	immunology	immunology	NOUN
dpc-3703	32	6	via	via	ADP
dpc-3703	32	7	the	the	DET
dpc-3703	32	8	innate	innate	ADJ
dpc-3703	32	9	and	and	CCONJ
dpc-3703	32	10	adaptive	adaptive	ADJ
dpc-3703	32	11	immune	immune	ADJ
dpc-3703	32	12	system	system	NOUN
dpc-3703	32	13	plays	play	VERB
dpc-3703	32	14	a	a	DET
dpc-3703	32	15	key	key	ADJ
dpc-3703	32	16	role	role	NOUN
dpc-3703	32	17	in	in	ADP
dpc-3703	32	18	the	the	DET
dpc-3703	32	19	development	development	NOUN
dpc-3703	32	20	of	of	ADP
dpc-3703	32	21	keratinocyte	keratinocyte	NOUN
dpc-3703	32	22	carcinomas	carcinoma	NOUN
dpc-3703	32	23	.	.	PUNCT
dpc-3703	33	1	the	the	DET
dpc-3703	33	2	pd-1	pd-1	ADJ
dpc-3703	33	3	pathway	pathway	NOUN
dpc-3703	33	4	is	be	AUX
dpc-3703	33	5	a	a	DET
dpc-3703	33	6	checkpoint	checkpoint	NOUN
dpc-3703	33	7	that	that	PRON
dpc-3703	33	8	plays	play	VERB
dpc-3703	33	9	a	a	DET
dpc-3703	33	10	central	central	ADJ
dpc-3703	33	11	role	role	NOUN
dpc-3703	33	12	in	in	ADP
dpc-3703	33	13	the	the	DET
dpc-3703	33	14	local	local	ADJ
dpc-3703	33	15	immunosuppression	immunosuppression	NOUN
dpc-3703	33	16	in	in	ADP
dpc-3703	33	17	the	the	DET
dpc-3703	33	18	tumor	tumor	NOUN
dpc-3703	33	19	microenvironment	microenvironment	NOUN
dpc-3703	33	20	[	[	X
dpc-3703	33	21	11,12	11,12	NUM
dpc-3703	33	22	]	]	PUNCT
dpc-3703	33	23	.	.	PUNCT
dpc-3703	34	1	pd	pd	PROPN
dpc-3703	34	2	-	-	PROPN
dpc-3703	34	3	l1	l1	PROPN
dpc-3703	34	4	is	be	AUX
dpc-3703	34	5	expressed	express	VERB
dpc-3703	34	6	on	on	ADP
dpc-3703	34	7	tumor	tumor	NOUN
dpc-3703	34	8	and/or	and/or	CCONJ
dpc-3703	34	9	immune	immune	ADJ
dpc-3703	34	10	cells	cell	NOUN
dpc-3703	34	11	and	and	CCONJ
dpc-3703	34	12	the	the	DET
dpc-3703	34	13	programmed	program	VERB
dpc-3703	34	14	cell	cell	NOUN
dpc-3703	34	15	death	death	NOUN
dpc-3703	34	16	receptor-1	receptor-1	NUM
dpc-3703	34	17	(	(	PUNCT
dpc-3703	34	18	pd-1	pd-1	ADV
dpc-3703	34	19	)	)	PUNCT
dpc-3703	34	20	is	be	AUX
dpc-3703	34	21	expressed	express	VERB
dpc-3703	34	22	on	on	ADP
dpc-3703	34	23	immune	immune	ADJ
dpc-3703	34	24	cells	cell	NOUN
dpc-3703	34	25	,	,	PUNCT
dpc-3703	34	26	including	include	VERB
dpc-3703	34	27	cd8	cd8	PROPN
dpc-3703	34	28	+	+	PROPN
dpc-3703	34	29	and	and	CCONJ
dpc-3703	34	30	cd4	cd4	PROPN
dpc-3703	34	31	+	+	PROPN
dpc-3703	34	32	t	t	PROPN
dpc-3703	34	33	-	-	PUNCT
dpc-3703	34	34	cells	cell	NOUN
dpc-3703	34	35	,	,	PUNCT
dpc-3703	34	36	b	b	X
dpc-3703	34	37	-	-	PUNCT
dpc-3703	34	38	cells	cell	NOUN
dpc-3703	34	39	and	and	CCONJ
dpc-3703	34	40	natural	natural	ADJ
dpc-3703	34	41	killer	killer	NOUN
dpc-3703	34	42	cells	cell	NOUN
dpc-3703	35	1	[	[	X
dpc-3703	35	2	11	11	NUM
dpc-3703	35	3	]	]	PUNCT
dpc-3703	35	4	.	.	PUNCT
dpc-3703	36	1	in	in	ADP
dpc-3703	36	2	response	response	NOUN
dpc-3703	36	3	to	to	ADP
dpc-3703	36	4	endogenous	endogenous	ADJ
dpc-3703	36	5	anti	anti	ADJ
dpc-3703	36	6	-	-	ADJ
dpc-3703	36	7	tumor	tumor	ADJ
dpc-3703	36	8	immunity	immunity	NOUN
dpc-3703	36	9	,	,	PUNCT
dpc-3703	36	10	cancer	cancer	NOUN
dpc-3703	36	11	cells	cell	NOUN
dpc-3703	36	12	express	express	VERB
dpc-3703	36	13	on	on	ADP
dpc-3703	36	14	their	their	PRON
dpc-3703	36	15	surface	surface	NOUN
dpc-3703	36	16	the	the	DET
dpc-3703	36	17	programmed	program	VERB
dpc-3703	36	18	cell	cell	NOUN
dpc-3703	36	19	death	death	NOUN
dpc-3703	36	20	ligand-1	ligand-1	NUM
dpc-3703	36	21	(	(	PUNCT
dpc-3703	36	22	pd	pd	NOUN
dpc-3703	36	23	-	-	PUNCT
dpc-3703	36	24	l1	l1	PROPN
dpc-3703	36	25	)	)	PUNCT
dpc-3703	36	26	,	,	PUNCT
dpc-3703	36	27	in	in	ADP
dpc-3703	36	28	a	a	DET
dpc-3703	36	29	process	process	NOUN
dpc-3703	36	30	termed	term	VERB
dpc-3703	36	31	adaptive	adaptive	ADJ
dpc-3703	36	32	immune	immune	ADJ
dpc-3703	36	33	resistance	resistance	NOUN
dpc-3703	36	34	[	[	X
dpc-3703	36	35	13	13	NUM
dpc-3703	36	36	]	]	PUNCT
dpc-3703	36	37	.	.	PUNCT
dpc-3703	37	1	blocking	block	VERB
dpc-3703	37	2	the	the	DET
dpc-3703	37	3	pd-1	pd-1	ADJ
dpc-3703	37	4	pathway	pathway	NOUN
dpc-3703	37	5	is	be	AUX
dpc-3703	37	6	regarded	regard	VERB
dpc-3703	37	7	as	as	ADP
dpc-3703	37	8	“	"	PUNCT
dpc-3703	37	9	common	common	ADJ
dpc-3703	37	10	denominator	denominator	NOUN
dpc-3703	37	11	”	"	PUNCT
dpc-3703	37	12	for	for	ADP
dpc-3703	37	13	cancer	cancer	NOUN
dpc-3703	37	14	therapy	therapy	NOUN
dpc-3703	37	15	[	[	X
dpc-3703	37	16	14	14	NUM
dpc-3703	37	17	]	]	PUNCT
dpc-3703	37	18	.	.	PUNCT
dpc-3703	38	1	regarding	regard	VERB
dpc-3703	38	2	bcc	bcc	PROPN
dpc-3703	38	3	,	,	PUNCT
dpc-3703	38	4	the	the	DET
dpc-3703	38	5	expression	expression	NOUN
dpc-3703	38	6	of	of	ADP
dpc-3703	38	7	pd	pd	PROPN
dpc-3703	38	8	-	-	PROPN
dpc-3703	38	9	l1	l1	PROPN
dpc-3703	38	10	has	have	AUX
dpc-3703	38	11	been	be	AUX
dpc-3703	38	12	detected	detect	VERB
dpc-3703	38	13	in	in	ADP
dpc-3703	38	14	tumors	tumor	NOUN
dpc-3703	38	15	or	or	CCONJ
dpc-3703	38	16	the	the	DET
dpc-3703	38	17	tumor	tumor	NOUN
dpc-3703	38	18	microenvironment	microenvironment	NOUN
dpc-3703	38	19	[	[	X
dpc-3703	38	20	15,16	15,16	NUM
dpc-3703	38	21	]	]	PUNCT
dpc-3703	38	22	.	.	PUNCT
dpc-3703	39	1	the	the	DET
dpc-3703	39	2	percentage	percentage	NOUN
dpc-3703	39	3	of	of	ADP
dpc-3703	39	4	positive	positive	ADJ
dpc-3703	39	5	pd	pd	ADJ
dpc-3703	39	6	-	-	PUNCT
dpc-3703	39	7	l1	l1	PROPN
dpc-3703	39	8	expression	expression	NOUN
dpc-3703	39	9	(	(	PUNCT
dpc-3703	39	10	defined	define	VERB
dpc-3703	39	11	as	as	ADP
dpc-3703	39	12	greater	great	ADJ
dpc-3703	39	13	than	than	ADP
dpc-3703	39	14	5	5	NUM
dpc-3703	39	15	%	%	NOUN
dpc-3703	39	16	positive	positive	ADJ
dpc-3703	39	17	immuno	immuno	ADJ
dpc-3703	39	18	-	-	ADJ
dpc-3703	39	19	histochemical	histochemical	ADJ
dpc-3703	39	20	staining	staining	NOUN
dpc-3703	39	21	)	)	PUNCT
dpc-3703	39	22	was	be	AUX
dpc-3703	39	23	89.9	89.9	NUM
dpc-3703	39	24	%	%	NOUN
dpc-3703	39	25	in	in	ADP
dpc-3703	39	26	tumor	tumor	NOUN
dpc-3703	39	27	cells	cell	NOUN
dpc-3703	39	28	and	and	CCONJ
dpc-3703	39	29	94.9	94.9	NUM
dpc-3703	39	30	%	%	NOUN
dpc-3703	39	31	in	in	ADP
dpc-3703	39	32	tumor	tumor	NOUN
dpc-3703	39	33	infiltrating	infiltrate	VERB
dpc-3703	39	34	lymphocytes	lymphocyte	NOUN
dpc-3703	39	35	of	of	ADP
dpc-3703	39	36	bccs	bccs	NOUN
dpc-3703	39	37	[	[	X
dpc-3703	39	38	15	15	NUM
dpc-3703	39	39	]	]	PUNCT
dpc-3703	39	40	.	.	PUNCT
dpc-3703	40	1	in	in	ADP
dpc-3703	40	2	another	another	DET
dpc-3703	40	3	study	study	NOUN
dpc-3703	40	4	,	,	PUNCT
dpc-3703	40	5	among	among	ADP
dpc-3703	40	6	40	40	NUM
dpc-3703	40	7	bccs	bccs	NOUN
dpc-3703	40	8	,	,	PUNCT
dpc-3703	40	9	22	22	NUM
dpc-3703	40	10	%	%	NOUN
dpc-3703	40	11	had	have	VERB
dpc-3703	40	12	pd	pd	ADJ
dpc-3703	40	13	-	-	PUNCT
dpc-3703	40	14	l1	l1	PROPN
dpc-3703	40	15	expression	expression	NOUN
dpc-3703	40	16	on	on	ADP
dpc-3703	40	17	tumor	tumor	NOUN
dpc-3703	40	18	cells	cell	NOUN
dpc-3703	40	19	,	,	PUNCT
dpc-3703	40	20	and	and	CCONJ
dpc-3703	40	21	82	82	NUM
dpc-3703	40	22	%	%	NOUN
dpc-3703	40	23	had	have	VERB
dpc-3703	40	24	pd	pd	ADJ
dpc-3703	40	25	-	-	PUNCT
dpc-3703	40	26	l1	l1	PROPN
dpc-3703	40	27	expression	expression	NOUN
dpc-3703	40	28	on	on	ADP
dpc-3703	40	29	tumor	tumor	NOUN
dpc-3703	40	30	-	-	PUNCT
dpc-3703	40	31	infiltrating	infiltrate	VERB
dpc-3703	40	32	lymphocytes	lymphocyte	NOUN
dpc-3703	40	33	and	and	CCONJ
dpc-3703	40	34	macrophages	macrophage	NOUN
dpc-3703	40	35	[	[	X
dpc-3703	40	36	16	16	NUM
dpc-3703	40	37	]	]	PUNCT
dpc-3703	40	38	.	.	PUNCT
dpc-3703	41	1	also	also	ADV
dpc-3703	41	2	,	,	PUNCT
dpc-3703	41	3	bcc	bcc	PROPN
dpc-3703	41	4	is	be	AUX
dpc-3703	41	5	one	one	NUM
dpc-3703	41	6	of	of	ADP
dpc-3703	41	7	the	the	DET
dpc-3703	41	8	malignancies	malignancy	NOUN
dpc-3703	41	9	with	with	ADP
dpc-3703	41	10	the	the	DET
dpc-3703	41	11	highest	high	ADJ
dpc-3703	41	12	tumor	tumor	NOUN
dpc-3703	41	13	mutational	mutational	ADJ
dpc-3703	41	14	burden	burden	NOUN
dpc-3703	41	15	(	(	PUNCT
dpc-3703	41	16	tmb	tmb	NOUN
dpc-3703	41	17	)	)	PUNCT
dpc-3703	41	18	,	,	PUNCT
dpc-3703	41	19	which	which	PRON
dpc-3703	41	20	in	in	ADP
dpc-3703	41	21	turn	turn	NOUN
dpc-3703	41	22	has	have	AUX
dpc-3703	41	23	been	be	AUX
dpc-3703	41	24	associated	associate	VERB
dpc-3703	41	25	with	with	ADP
dpc-3703	41	26	the	the	DET
dpc-3703	41	27	presence	presence	NOUN
dpc-3703	41	28	of	of	ADP
dpc-3703	41	29	tumor	tumor	NOUN
dpc-3703	41	30	neoantigens	neoantigen	NOUN
dpc-3703	41	31	that	that	PRON
dpc-3703	41	32	may	may	AUX
dpc-3703	41	33	be	be	AUX
dpc-3703	41	34	targeted	target	VERB
dpc-3703	41	35	by	by	ADP
dpc-3703	41	36	immune	immune	ADJ
dpc-3703	41	37	cells	cell	NOUN
dpc-3703	41	38	activated	activate	VERB
dpc-3703	41	39	with	with	ADP
dpc-3703	41	40	immunotherapy	immunotherapy	NOUN
dpc-3703	41	41	[	[	X
dpc-3703	41	42	17	17	NUM
dpc-3703	41	43	]	]	PUNCT
dpc-3703	41	44	.	.	PUNCT
dpc-3703	42	1	translational	translational	ADJ
dpc-3703	42	2	research	research	NOUN
dpc-3703	42	3	has	have	AUX
dpc-3703	42	4	linked	link	VERB
dpc-3703	42	5	the	the	DET
dpc-3703	42	6	above	above	ADV
dpc-3703	42	7	mentioned	mention	VERB
dpc-3703	42	8	genetic	genetic	ADJ
dpc-3703	42	9	and	and	CCONJ
dpc-3703	42	10	molecular	molecular	ADJ
dpc-3703	42	11	findings	finding	NOUN
dpc-3703	42	12	in	in	ADP
dpc-3703	42	13	bcc	bcc	PROPN
dpc-3703	42	14	with	with	ADP
dpc-3703	42	15	the	the	DET
dpc-3703	42	16	development	development	NOUN
dpc-3703	42	17	of	of	ADP
dpc-3703	42	18	treatments	treatment	NOUN
dpc-3703	42	19	targeting	target	VERB
dpc-3703	42	20	these	these	DET
dpc-3703	42	21	underlying	underlie	VERB
dpc-3703	42	22	dysregulations	dysregulation	NOUN
dpc-3703	42	23	.	.	PUNCT
dpc-3703	43	1	as	as	ADP
dpc-3703	43	2	a	a	DET
dpc-3703	43	3	result	result	NOUN
dpc-3703	43	4	,	,	PUNCT
dpc-3703	43	5	our	our	PRON
dpc-3703	43	6	therapeutic	therapeutic	ADJ
dpc-3703	43	7	options	option	NOUN
dpc-3703	43	8	have	have	AUX
dpc-3703	43	9	been	be	AUX
dpc-3703	43	10	enriched	enrich	VERB
dpc-3703	43	11	with	with	ADP
dpc-3703	43	12	the	the	DET
dpc-3703	43	13	hedgehog	hedgehog	ADJ
dpc-3703	43	14	pathway	pathway	NOUN
dpc-3703	43	15	inhibitors	inhibitor	NOUN
dpc-3703	43	16	(	(	PUNCT
dpc-3703	43	17	hhi	hhi	NOUN
dpc-3703	43	18	)	)	PUNCT
dpc-3703	43	19	vismodegib	vismodegib	NOUN
dpc-3703	43	20	and	and	CCONJ
dpc-3703	43	21	sonidegib	sonidegib	NOUN
dpc-3703	43	22	,	,	PUNCT
dpc-3703	43	23	and	and	CCONJ
dpc-3703	43	24	the	the	DET
dpc-3703	43	25	anti	anti	ADJ
dpc-3703	43	26	-	-	ADJ
dpc-3703	43	27	pd-1	pd-1	ADJ
dpc-3703	43	28	agent	agent	NOUN
dpc-3703	43	29	cemiplimab	cemiplimab	NOUN
dpc-3703	43	30	,	,	PUNCT
dpc-3703	43	31	that	that	PRON
dpc-3703	43	32	have	have	AUX
dpc-3703	43	33	been	be	AUX
dpc-3703	43	34	regulatory	regulatory	ADJ
dpc-3703	43	35	approved	approve	VERB
dpc-3703	43	36	for	for	ADP
dpc-3703	43	37	advanced	advanced	ADJ
dpc-3703	43	38	bcc	bcc	PROPN
dpc-3703	43	39	by	by	ADP
dpc-3703	43	40	the	the	DET
dpc-3703	43	41	european	european	PROPN
dpc-3703	43	42	medicines	medicines	PROPN
dpc-3703	43	43	agency	agency	NOUN
dpc-3703	43	44	(	(	PUNCT
dpc-3703	43	45	ema	ema	PROPN
dpc-3703	43	46	)	)	PUNCT
dpc-3703	43	47	in	in	ADP
dpc-3703	43	48	europe	europe	PROPN
dpc-3703	43	49	.	.	PUNCT
dpc-3703	44	1	these	these	DET
dpc-3703	44	2	treatments	treatment	NOUN
dpc-3703	44	3	have	have	AUX
dpc-3703	44	4	been	be	AUX
dpc-3703	44	5	a	a	DET
dpc-3703	44	6	breakthrough	breakthrough	NOUN
dpc-3703	44	7	for	for	ADP
dpc-3703	44	8	the	the	DET
dpc-3703	44	9	treatment	treatment	NOUN
dpc-3703	44	10	of	of	ADP
dpc-3703	44	11	patients	patient	NOUN
dpc-3703	44	12	with	with	ADP
dpc-3703	44	13	advanced	advanced	ADJ
dpc-3703	44	14	bcc	bcc	PROPN
dpc-3703	44	15	as	as	SCONJ
dpc-3703	44	16	they	they	PRON
dpc-3703	44	17	have	have	AUX
dpc-3703	44	18	replaced	replace	VERB
dpc-3703	44	19	conventional	conventional	ADJ
dpc-3703	44	20	systemic	systemic	ADJ
dpc-3703	44	21	chemotherapy	chemotherapy	NOUN
dpc-3703	44	22	,	,	PUNCT
dpc-3703	44	23	which	which	PRON
dpc-3703	44	24	was	be	AUX
dpc-3703	44	25	previously	previously	ADV
dpc-3703	44	26	used	use	VERB
dpc-3703	44	27	for	for	ADP
dpc-3703	44	28	advanced	advanced	ADJ
dpc-3703	44	29	bcc	bcc	PROPN
dpc-3703	44	30	.	.	PUNCT
dpc-3703	45	1	platinum	platinum	NOUN
dpc-3703	45	2	-	-	PUNCT
dpc-3703	45	3	based	base	VERB
dpc-3703	45	4	chemotherapy	chemotherapy	NOUN
dpc-3703	45	5	was	be	AUX
dpc-3703	45	6	studied	study	VERB
dpc-3703	45	7	in	in	ADP
dpc-3703	45	8	a	a	DET
dpc-3703	45	9	1978	1978	NUM
dpc-3703	45	10	phase	phase	NOUN
dpc-3703	45	11	i	i	PROPN
dpc-3703	45	12	-	-	PUNCT
dpc-3703	45	13	ii	ii	PROPN
dpc-3703	45	14	clinical	clinical	ADJ
dpc-3703	45	15	trial	trial	NOUN
dpc-3703	45	16	in	in	ADP
dpc-3703	45	17	various	various	ADJ
dpc-3703	45	18	solid	solid	ADJ
dpc-3703	45	19	tumors	tumor	NOUN
dpc-3703	45	20	,	,	PUNCT
dpc-3703	45	21	that	that	PRON
dpc-3703	45	22	reported	report	VERB
dpc-3703	45	23	one	one	NUM
dpc-3703	45	24	complete	complete	ADJ
dpc-3703	45	25	and	and	CCONJ
dpc-3703	45	26	one	one	NUM
dpc-3703	45	27	partial	partial	ADJ
dpc-3703	45	28	response	response	NOUN
dpc-3703	45	29	in	in	ADP
dpc-3703	45	30	two	two	NUM
dpc-3703	45	31	patients	patient	NOUN
dpc-3703	45	32	with	with	ADP
dpc-3703	45	33	disseminated	disseminate	VERB
dpc-3703	45	34	bcc	bcc	PROPN
dpc-3703	45	35	[	[	X
dpc-3703	45	36	18	18	NUM
dpc-3703	45	37	]	]	X
dpc-3703	45	38	,	,	PUNCT
dpc-3703	45	39	however	however	ADV
dpc-3703	45	40	further	further	ADJ
dpc-3703	45	41	reports	report	NOUN
dpc-3703	45	42	of	of	ADP
dpc-3703	45	43	chemotherapy	chemotherapy	NOUN
dpc-3703	45	44	for	for	ADP
dpc-3703	45	45	mbcc	mbcc	NOUN
dpc-3703	45	46	were	be	AUX
dpc-3703	45	47	generally	generally	ADV
dpc-3703	45	48	limited	limit	VERB
dpc-3703	45	49	by	by	ADP
dpc-3703	45	50	poor	poor	ADJ
dpc-3703	45	51	response	response	NOUN
dpc-3703	45	52	,	,	PUNCT
dpc-3703	45	53	or	or	CCONJ
dpc-3703	45	54	short	short	ADJ
dpc-3703	45	55	duration	duration	NOUN
dpc-3703	45	56	of	of	ADP
dpc-3703	45	57	response	response	NOUN
dpc-3703	45	58	,	,	PUNCT
dpc-3703	45	59	short	short	ADJ
dpc-3703	45	60	overall	overall	ADJ
dpc-3703	45	61	survival	survival	NOUN
dpc-3703	45	62	,	,	PUNCT
dpc-3703	45	63	and	and	CCONJ
dpc-3703	45	64	lack	lack	NOUN
dpc-3703	45	65	of	of	ADP
dpc-3703	45	66	serial	serial	ADJ
dpc-3703	45	67	tumor	tumor	NOUN
dpc-3703	45	68	measurements	measurement	NOUN
dpc-3703	45	69	[	[	X
dpc-3703	45	70	19,20	19,20	X
dpc-3703	45	71	]	]	PUNCT
dpc-3703	45	72	.	.	PUNCT
dpc-3703	46	1	in	in	ADP
dpc-3703	46	2	this	this	DET
dpc-3703	46	3	review	review	NOUN
dpc-3703	46	4	,	,	PUNCT
dpc-3703	46	5	we	we	PRON
dpc-3703	46	6	focus	focus	VERB
dpc-3703	46	7	on	on	ADP
dpc-3703	46	8	patients	patient	NOUN
dpc-3703	46	9	with	with	ADP
dpc-3703	46	10	advanced	advanced	ADJ
dpc-3703	46	11	bcc	bcc	PROPN
dpc-3703	46	12	,	,	PUNCT
dpc-3703	46	13	including	include	VERB
dpc-3703	46	14	locally	locally	ADV
dpc-3703	46	15	advanced	advanced	ADJ
dpc-3703	46	16	and	and	CCONJ
dpc-3703	46	17	metastatic	metastatic	ADJ
dpc-3703	46	18	bcc	bcc	PROPN
dpc-3703	46	19	,	,	PUNCT
dpc-3703	46	20	not	not	PART
dpc-3703	46	21	amenable	amenable	ADJ
dpc-3703	46	22	to	to	PART
dpc-3703	46	23	curative	curative	ADJ
dpc-3703	46	24	surgery	surgery	NOUN
dpc-3703	46	25	or	or	CCONJ
dpc-3703	46	26	radiotherapy	radiotherapy	NOUN
dpc-3703	46	27	and	and	CCONJ
dpc-3703	46	28	thus	thus	ADV
dpc-3703	46	29	warranting	warrant	VERB
dpc-3703	46	30	systemic	systemic	ADJ
dpc-3703	46	31	treatment	treatment	NOUN
dpc-3703	46	32	.	.	PUNCT
dpc-3703	47	1	we	we	PRON
dpc-3703	47	2	highlight	highlight	VERB
dpc-3703	47	3	the	the	DET
dpc-3703	47	4	current	current	ADJ
dpc-3703	47	5	recommendations	recommendation	NOUN
dpc-3703	47	6	for	for	ADP
dpc-3703	47	7	the	the	DET
dpc-3703	47	8	use	use	NOUN
dpc-3703	47	9	of	of	ADP
dpc-3703	47	10	oral	oral	ADJ
dpc-3703	47	11	hedgehog	hedgehog	NOUN
dpc-3703	47	12	inhibitors	inhibitor	NOUN
dpc-3703	47	13	and	and	CCONJ
dpc-3703	47	14	intravenous	intravenous	ADJ
dpc-3703	47	15	anti	anti	ADJ
dpc-3703	47	16	-	-	ADJ
dpc-3703	47	17	pd-1	pd-1	ADJ
dpc-3703	47	18	agents	agent	NOUN
dpc-3703	47	19	for	for	ADP
dpc-3703	47	20	the	the	DET
dpc-3703	47	21	treatment	treatment	NOUN
dpc-3703	47	22	of	of	ADP
dpc-3703	47	23	patients	patient	NOUN
dpc-3703	47	24	with	with	ADP
dpc-3703	47	25	advanced	advanced	ADJ
dpc-3703	47	26	bcc	bcc	PROPN
dpc-3703	47	27	.	.	PUNCT
dpc-3703	48	1	we	we	PRON
dpc-3703	48	2	discuss	discuss	VERB
dpc-3703	48	3	the	the	DET
dpc-3703	48	4	evidence	evidence	NOUN
dpc-3703	48	5	on	on	ADP
dpc-3703	48	6	the	the	DET
dpc-3703	48	7	potential	potential	ADJ
dpc-3703	48	8	applicability	applicability	NOUN
dpc-3703	48	9	of	of	ADP
dpc-3703	48	10	anti	anti	ADJ
dpc-3703	48	11	-	-	ADJ
dpc-3703	48	12	pd-1	pd-1	ADJ
dpc-3703	48	13	agents	agent	NOUN
dpc-3703	48	14	as	as	ADP
dpc-3703	48	15	first	first	ADJ
dpc-3703	48	16	-	-	PUNCT
dpc-3703	48	17	line	line	NOUN
dpc-3703	48	18	or	or	CCONJ
dpc-3703	48	19	second	second	ADJ
dpc-3703	48	20	-	-	PUNCT
dpc-3703	48	21	line	line	NOUN
dpc-3703	48	22	systemic	systemic	ADJ
dpc-3703	48	23	monotherapy	monotherapy	NOUN
dpc-3703	48	24	,	,	PUNCT
dpc-3703	48	25	or	or	CCONJ
dpc-3703	48	26	in	in	ADP
dpc-3703	48	27	combination	combination	NOUN
dpc-3703	48	28	with	with	ADP
dpc-3703	48	29	other	other	ADJ
dpc-3703	48	30	treatments	treatment	NOUN
dpc-3703	48	31	and	and	CCONJ
dpc-3703	48	32	the	the	DET
dpc-3703	48	33	emergence	emergence	NOUN
dpc-3703	48	34	of	of	ADP
dpc-3703	48	35	anti	anti	ADJ
dpc-3703	48	36	-	-	ADJ
dpc-3703	48	37	pd-1	pd-1	ADJ
dpc-3703	48	38	agents	agent	NOUN
dpc-3703	48	39	as	as	ADP
dpc-3703	48	40	a	a	DET
dpc-3703	48	41	neoadjuvant	neoadjuvant	ADJ
dpc-3703	48	42	treatment	treatment	NOUN
dpc-3703	48	43	.	.	PUNCT
dpc-3703	49	1	systemic	systemic	ADJ
dpc-3703	49	2	treatments	treatment	NOUN
dpc-3703	49	3	for	for	ADP
dpc-3703	49	4	advanced	advanced	ADJ
dpc-3703	49	5	bcc	bcc	PROPN
dpc-3703	49	6	advanced	advanced	ADJ
dpc-3703	49	7	bcc	bcc	PROPN
dpc-3703	49	8	is	be	AUX
dpc-3703	49	9	classified	classify	VERB
dpc-3703	49	10	as	as	ADP
dpc-3703	49	11	either	either	CCONJ
dpc-3703	49	12	locally	locally	ADV
dpc-3703	49	13	advanced	advanced	ADJ
dpc-3703	49	14	bcc	bcc	NOUN
dpc-3703	49	15	(	(	PUNCT
dpc-3703	49	16	labcc	labcc	PROPN
dpc-3703	49	17	)	)	PUNCT
dpc-3703	49	18	or	or	CCONJ
dpc-3703	49	19	metastatic	metastatic	ADJ
dpc-3703	49	20	bcc	bcc	NOUN
dpc-3703	49	21	(	(	PUNCT
dpc-3703	49	22	mbcc	mbcc	PROPN
dpc-3703	49	23	)	)	PUNCT
dpc-3703	49	24	.	.	PUNCT
dpc-3703	50	1	based	base	VERB
dpc-3703	50	2	on	on	ADP
dpc-3703	50	3	the	the	DET
dpc-3703	50	4	possibility	possibility	NOUN
dpc-3703	50	5	of	of	ADP
dpc-3703	50	6	treatment	treatment	NOUN
dpc-3703	50	7	with	with	ADP
dpc-3703	50	8	surgery	surgery	NOUN
dpc-3703	50	9	and/or	and/or	CCONJ
dpc-3703	50	10	radiotherapy	radiotherapy	NOUN
dpc-3703	50	11	with	with	ADP
dpc-3703	50	12	curative	curative	ADJ
dpc-3703	50	13	definitive	definitive	ADJ
dpc-3703	50	14	intent	intent	NOUN
dpc-3703	50	15	,	,	PUNCT
dpc-3703	50	16	the	the	DET
dpc-3703	50	17	term	term	NOUN
dpc-3703	50	18	locally	locally	ADV
dpc-3703	50	19	advanced	advanced	ADJ
dpc-3703	50	20	bcc	bcc	PROPN
dpc-3703	50	21	has	have	AUX
dpc-3703	50	22	been	be	AUX
dpc-3703	50	23	used	use	VERB
dpc-3703	50	24	to	to	PART
dpc-3703	50	25	describe	describe	VERB
dpc-3703	50	26	difficult	difficult	ADJ
dpc-3703	50	27	-	-	PUNCT
dpc-3703	50	28	to	to	PART
dpc-3703	50	29	-	-	PUNCT
dpc-3703	50	30	treat	treat	VERB
dpc-3703	50	31	or	or	CCONJ
dpc-3703	50	32	high	high	ADJ
dpc-3703	50	33	-	-	PUNCT
dpc-3703	50	34	risk	risk	NOUN
dpc-3703	50	35	bccs	bccs	NOUN
dpc-3703	50	36	in	in	ADP
dpc-3703	50	37	which	which	PRON
dpc-3703	50	38	current	current	ADJ
dpc-3703	50	39	treatment	treatment	NOUN
dpc-3703	50	40	modalities	modality	NOUN
dpc-3703	50	41	are	be	AUX
dpc-3703	50	42	contraindicated	contraindicate	VERB
dpc-3703	50	43	by	by	ADP
dpc-3703	50	44	tumor	tumor	NOUN
dpc-3703	50	45	or	or	CCONJ
dpc-3703	50	46	patient	patient	ADJ
dpc-3703	50	47	factors	factor	NOUN
dpc-3703	50	48	[	[	X
dpc-3703	50	49	21	21	NUM
dpc-3703	50	50	-	-	SYM
dpc-3703	50	51	23	23	NUM
dpc-3703	50	52	]	]	PUNCT
dpc-3703	50	53	.	.	PUNCT
dpc-3703	51	1	such	such	ADJ
dpc-3703	51	2	factors	factor	NOUN
dpc-3703	51	3	may	may	AUX
dpc-3703	51	4	include	include	VERB
dpc-3703	51	5	tumor	tumor	NOUN
dpc-3703	51	6	size	size	NOUN
dpc-3703	51	7	and	and	CCONJ
dpc-3703	51	8	location	location	NOUN
dpc-3703	51	9	that	that	PRON
dpc-3703	51	10	may	may	AUX
dpc-3703	51	11	pose	pose	VERB
dpc-3703	51	12	technical	technical	ADJ
dpc-3703	51	13	difficulties	difficulty	NOUN
dpc-3703	51	14	of	of	ADP
dpc-3703	51	15	maintaining	maintain	VERB
dpc-3703	51	16	function	function	NOUN
dpc-3703	51	17	and	and	CCONJ
dpc-3703	51	18	aesthetics	aesthetic	NOUN
dpc-3703	51	19	,	,	PUNCT
dpc-3703	51	20	large	large	ADJ
dpc-3703	51	21	numbers	number	NOUN
dpc-3703	51	22	of	of	ADP
dpc-3703	51	23	bccs	bccs	NOUN
dpc-3703	51	24	,	,	PUNCT
dpc-3703	51	25	tumor	tumor	NOUN
dpc-3703	51	26	subtype	subtype	NOUN
dpc-3703	51	27	,	,	PUNCT
dpc-3703	51	28	multiple	multiple	ADJ
dpc-3703	51	29	recurrences	recurrence	NOUN
dpc-3703	51	30	,	,	PUNCT
dpc-3703	51	31	and	and	CCONJ
dpc-3703	51	32	patient	patient	ADJ
dpc-3703	51	33	comorbidities	comorbiditie	NOUN
dpc-3703	51	34	and	and	CCONJ
dpc-3703	51	35	frailty	frailty	NOUN
dpc-3703	51	36	[	[	PUNCT
dpc-3703	51	37	21	21	NUM
dpc-3703	51	38	-	-	SYM
dpc-3703	51	39	23	23	NUM
dpc-3703	51	40	]	]	PUNCT
dpc-3703	51	41	.	.	PUNCT
dpc-3703	52	1	systemic	systemic	ADJ
dpc-3703	52	2	treatments	treatment	NOUN
dpc-3703	52	3	for	for	ADP
dpc-3703	52	4	advanced	advanced	ADJ
dpc-3703	52	5	bcc	bcc	PROPN
dpc-3703	52	6	include	include	VERB
dpc-3703	52	7	hhi	hhi	NOUN
dpc-3703	52	8	and	and	CCONJ
dpc-3703	52	9	immunotherapy	immunotherapy	NOUN
dpc-3703	52	10	.	.	PUNCT
dpc-3703	53	1	systemic	systemic	ADJ
dpc-3703	53	2	therapy	therapy	NOUN
dpc-3703	53	3	is	be	AUX
dpc-3703	53	4	considered	consider	VERB
dpc-3703	53	5	for	for	ADP
dpc-3703	53	6	labcc	labcc	NOUN
dpc-3703	53	7	and	and	CCONJ
dpc-3703	53	8	mbcc	mbcc	PROPN
dpc-3703	53	9	,	,	PUNCT
dpc-3703	53	10	when	when	SCONJ
dpc-3703	53	11	curative	curative	ADJ
dpc-3703	53	12	surgery	surgery	NOUN
dpc-3703	53	13	and	and	CCONJ
dpc-3703	53	14	rt	rt	PROPN
dpc-3703	53	15	are	be	AUX
dpc-3703	53	16	not	not	PART
dpc-3703	53	17	feasible	feasible	ADJ
dpc-3703	53	18	review	review	NOUN
dpc-3703	53	19	|	|	ADV
dpc-3703	53	20	dermatol	dermatol	ADJ
dpc-3703	53	21	pract	pract	NOUN
dpc-3703	53	22	concept	concept	NOUN
dpc-3703	53	23	.	.	PUNCT
dpc-3703	54	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	54	2	3	3	NUM
dpc-3703	55	1	[	[	X
dpc-3703	55	2	22,23	22,23	NOUN
dpc-3703	55	3	]	]	X
dpc-3703	55	4	.	.	PUNCT
dpc-3703	56	1	a	a	DET
dpc-3703	56	2	multidisciplinary	multidisciplinary	ADJ
dpc-3703	56	3	board	board	NOUN
dpc-3703	56	4	discussion	discussion	NOUN
dpc-3703	56	5	is	be	AUX
dpc-3703	56	6	required	require	VERB
dpc-3703	56	7	to	to	PART
dpc-3703	56	8	determine	determine	VERB
dpc-3703	56	9	if	if	SCONJ
dpc-3703	56	10	bcc	bcc	PROPN
dpc-3703	56	11	is	be	AUX
dpc-3703	56	12	not	not	PART
dpc-3703	56	13	amenable	amenable	ADJ
dpc-3703	56	14	to	to	PART
dpc-3703	56	15	curative	curative	ADJ
dpc-3703	56	16	surgery	surgery	NOUN
dpc-3703	56	17	and/	and/	NOUN
dpc-3703	56	18	or	or	CCONJ
dpc-3703	56	19	rt	rt	PROPN
dpc-3703	56	20	and	and	CCONJ
dpc-3703	56	21	further	far	ADV
dpc-3703	56	22	decide	decide	VERB
dpc-3703	56	23	on	on	ADP
dpc-3703	56	24	the	the	DET
dpc-3703	56	25	type	type	NOUN
dpc-3703	56	26	of	of	ADP
dpc-3703	56	27	systemic	systemic	ADJ
dpc-3703	56	28	therapy	therapy	NOUN
dpc-3703	57	1	[	[	X
dpc-3703	57	2	22,23	22,23	NOUN
dpc-3703	57	3	]	]	PUNCT
dpc-3703	57	4	.	.	PUNCT
dpc-3703	58	1	hhi	hhi	NOUN
dpc-3703	58	2	for	for	ADP
dpc-3703	58	3	advanced	advanced	ADJ
dpc-3703	58	4	bcc	bcc	PROPN
dpc-3703	58	5	include	include	VERB
dpc-3703	58	6	vismodegib	vismodegib	NOUN
dpc-3703	58	7	and	and	CCONJ
dpc-3703	58	8	sonidegib	sonidegib	NOUN
dpc-3703	58	9	,	,	PUNCT
dpc-3703	58	10	which	which	PRON
dpc-3703	58	11	are	be	AUX
dpc-3703	58	12	taken	take	VERB
dpc-3703	58	13	orally	orally	ADV
dpc-3703	58	14	.	.	PUNCT
dpc-3703	59	1	vismodegib	vismodegib	NOUN
dpc-3703	59	2	was	be	AUX
dpc-3703	59	3	approved	approve	VERB
dpc-3703	59	4	in	in	ADP
dpc-3703	59	5	2012	2012	NUM
dpc-3703	59	6	by	by	ADP
dpc-3703	59	7	the	the	DET
dpc-3703	59	8	us	us	PROPN
dpc-3703	59	9	fda	fda	PROPN
dpc-3703	59	10	and	and	CCONJ
dpc-3703	59	11	in	in	ADP
dpc-3703	59	12	2013	2013	NUM
dpc-3703	59	13	by	by	ADP
dpc-3703	59	14	ema	ema	PROPN
dpc-3703	59	15	for	for	ADP
dpc-3703	59	16	the	the	DET
dpc-3703	59	17	treatment	treatment	NOUN
dpc-3703	59	18	of	of	ADP
dpc-3703	59	19	adults	adult	NOUN
dpc-3703	59	20	with	with	ADP
dpc-3703	59	21	symptomatic	symptomatic	ADJ
dpc-3703	59	22	metastatic	metastatic	ADJ
dpc-3703	59	23	bcc	bcc	NOUN
dpc-3703	59	24	or	or	CCONJ
dpc-3703	59	25	with	with	ADP
dpc-3703	59	26	locally	locally	ADV
dpc-3703	59	27	advanced	advanced	ADJ
dpc-3703	59	28	bcc	bcc	PROPN
dpc-3703	59	29	inappropriate	inappropriate	ADJ
dpc-3703	59	30	for	for	ADP
dpc-3703	59	31	surgery	surgery	NOUN
dpc-3703	59	32	or	or	CCONJ
dpc-3703	59	33	radiotherapy	radiotherapy	NOUN
dpc-3703	59	34	[	[	X
dpc-3703	59	35	24	24	NUM
dpc-3703	59	36	]	]	PUNCT
dpc-3703	59	37	.	.	PUNCT
dpc-3703	60	1	sonidegib	sonidegib	NOUN
dpc-3703	60	2	was	be	AUX
dpc-3703	60	3	approved	approve	VERB
dpc-3703	60	4	in	in	ADP
dpc-3703	60	5	2015	2015	NUM
dpc-3703	60	6	by	by	ADP
dpc-3703	60	7	the	the	DET
dpc-3703	60	8	us	us	PROPN
dpc-3703	60	9	fda	fda	PROPN
dpc-3703	60	10	and	and	CCONJ
dpc-3703	60	11	ema	ema	PROPN
dpc-3703	60	12	for	for	ADP
dpc-3703	60	13	the	the	DET
dpc-3703	60	14	treatment	treatment	NOUN
dpc-3703	60	15	of	of	ADP
dpc-3703	60	16	adults	adult	NOUN
dpc-3703	60	17	with	with	ADP
dpc-3703	60	18	locally	locally	ADV
dpc-3703	60	19	advanced	advanced	ADJ
dpc-3703	60	20	bcc	bcc	PROPN
dpc-3703	60	21	who	who	PRON
dpc-3703	60	22	are	be	AUX
dpc-3703	60	23	not	not	PART
dpc-3703	60	24	amenable	amenable	ADJ
dpc-3703	60	25	to	to	PART
dpc-3703	60	26	curative	curative	ADJ
dpc-3703	60	27	surgery	surgery	NOUN
dpc-3703	60	28	or	or	CCONJ
dpc-3703	60	29	radiotherapy	radiotherapy	NOUN
dpc-3703	61	1	[	[	X
dpc-3703	61	2	25	25	NUM
dpc-3703	61	3	]	]	PUNCT
dpc-3703	61	4	.	.	PUNCT
dpc-3703	62	1	cemiplimab	cemiplimab	NOUN
dpc-3703	62	2	is	be	AUX
dpc-3703	62	3	a	a	DET
dpc-3703	62	4	human	human	ADJ
dpc-3703	62	5	programmed	program	VERB
dpc-3703	62	6	death	death	NOUN
dpc-3703	62	7	receptor	receptor	NOUN
dpc-3703	62	8	(	(	PUNCT
dpc-3703	62	9	pd)-1	pd)-1	NOUN
dpc-3703	62	10	monoclonal	monoclonal	NOUN
dpc-3703	62	11	antibody	antibody	NOUN
dpc-3703	62	12	that	that	PRON
dpc-3703	62	13	belongs	belong	VERB
dpc-3703	62	14	to	to	ADP
dpc-3703	62	15	the	the	DET
dpc-3703	62	16	family	family	NOUN
dpc-3703	62	17	of	of	ADP
dpc-3703	62	18	immune	immune	ADJ
dpc-3703	62	19	checkpoint	checkpoint	NOUN
dpc-3703	62	20	inhibitors	inhibitor	NOUN
dpc-3703	62	21	(	(	PUNCT
dpc-3703	62	22	icis	icis	NOUN
dpc-3703	62	23	)	)	PUNCT
dpc-3703	63	1	[	[	X
dpc-3703	63	2	26	26	NUM
dpc-3703	63	3	]	]	PUNCT
dpc-3703	63	4	.	.	PUNCT
dpc-3703	64	1	cemiplimab	cemiplimab	NOUN
dpc-3703	64	2	was	be	AUX
dpc-3703	64	3	approved	approve	VERB
dpc-3703	64	4	in	in	ADP
dpc-3703	64	5	2021	2021	NUM
dpc-3703	64	6	by	by	ADP
dpc-3703	64	7	the	the	DET
dpc-3703	64	8	us	us	PROPN
dpc-3703	64	9	fda	fda	PROPN
dpc-3703	64	10	and	and	CCONJ
dpc-3703	64	11	in	in	ADP
dpc-3703	64	12	2019	2019	NUM
dpc-3703	64	13	by	by	ADP
dpc-3703	64	14	ema	ema	PROPN
dpc-3703	64	15	as	as	ADP
dpc-3703	64	16	monotherapy	monotherapy	NOUN
dpc-3703	64	17	for	for	ADP
dpc-3703	64	18	the	the	DET
dpc-3703	64	19	treatment	treatment	NOUN
dpc-3703	64	20	of	of	ADP
dpc-3703	64	21	adult	adult	NOUN
dpc-3703	64	22	patients	patient	NOUN
dpc-3703	64	23	with	with	ADP
dpc-3703	64	24	metastatic	metastatic	ADJ
dpc-3703	64	25	or	or	CCONJ
dpc-3703	64	26	locally	locally	ADV
dpc-3703	64	27	advanced	advanced	ADJ
dpc-3703	64	28	bcc	bcc	PROPN
dpc-3703	64	29	who	who	PRON
dpc-3703	64	30	have	have	AUX
dpc-3703	64	31	progressed	progress	VERB
dpc-3703	64	32	on	on	ADP
dpc-3703	64	33	or	or	CCONJ
dpc-3703	64	34	are	be	AUX
dpc-3703	64	35	intolerant	intolerant	ADJ
dpc-3703	64	36	to	to	ADP
dpc-3703	64	37	a	a	DET
dpc-3703	64	38	hedgehog	hedgehog	NOUN
dpc-3703	64	39	pathway	pathway	NOUN
dpc-3703	64	40	inhibitor	inhibitor	NOUN
dpc-3703	65	1	[	[	X
dpc-3703	65	2	27	27	NUM
dpc-3703	65	3	]	]	PUNCT
dpc-3703	65	4	.	.	PUNCT
dpc-3703	66	1	it	it	PRON
dpc-3703	66	2	is	be	AUX
dpc-3703	66	3	administered	administer	VERB
dpc-3703	66	4	by	by	ADP
dpc-3703	66	5	intravenous	intravenous	ADJ
dpc-3703	66	6	infusion	infusion	NOUN
dpc-3703	66	7	over	over	ADP
dpc-3703	66	8	30	30	NUM
dpc-3703	66	9	minutes	minute	NOUN
dpc-3703	66	10	and	and	CCONJ
dpc-3703	66	11	the	the	DET
dpc-3703	66	12	recommended	recommend	VERB
dpc-3703	66	13	dosage	dosage	NOUN
dpc-3703	66	14	is	be	AUX
dpc-3703	66	15	350	350	NUM
dpc-3703	66	16	mg	mg	NOUN
dpc-3703	66	17	every	every	DET
dpc-3703	66	18	3	3	NUM
dpc-3703	66	19	weeks	week	NOUN
dpc-3703	66	20	until	until	ADP
dpc-3703	66	21	disease	disease	NOUN
dpc-3703	66	22	progression	progression	NOUN
dpc-3703	66	23	or	or	CCONJ
dpc-3703	66	24	unacceptable	unacceptable	ADJ
dpc-3703	66	25	toxicity	toxicity	NOUN
dpc-3703	66	26	[	[	X
dpc-3703	66	27	27].in	27].in	NUM
dpc-3703	66	28	the	the	DET
dpc-3703	66	29	following	follow	VERB
dpc-3703	66	30	sections	section	NOUN
dpc-3703	66	31	,	,	PUNCT
dpc-3703	66	32	we	we	PRON
dpc-3703	66	33	will	will	AUX
dpc-3703	66	34	discuss	discuss	VERB
dpc-3703	66	35	the	the	DET
dpc-3703	66	36	evidence	evidence	NOUN
dpc-3703	66	37	on	on	ADP
dpc-3703	66	38	the	the	DET
dpc-3703	66	39	place	place	NOUN
dpc-3703	66	40	of	of	ADP
dpc-3703	66	41	cemiplimab	cemiplimab	NOUN
dpc-3703	66	42	immunotherapy	immunotherapy	NOUN
dpc-3703	66	43	in	in	ADP
dpc-3703	66	44	the	the	DET
dpc-3703	66	45	therapeutic	therapeutic	ADJ
dpc-3703	66	46	ladder	ladder	NOUN
dpc-3703	66	47	for	for	ADP
dpc-3703	66	48	patients	patient	NOUN
dpc-3703	66	49	with	with	ADP
dpc-3703	66	50	advanced	advanced	ADJ
dpc-3703	66	51	bcc	bcc	PROPN
dpc-3703	66	52	.	.	PUNCT
dpc-3703	67	1	switching	switch	VERB
dpc-3703	67	2	from	from	ADP
dpc-3703	67	3	hedgehog	hedgehog	ADJ
dpc-3703	67	4	pathway	pathway	NOUN
dpc-3703	67	5	inhibitors	inhibitor	NOUN
dpc-3703	67	6	to	to	ADP
dpc-3703	67	7	anti	anti	ADJ
dpc-3703	67	8	-	-	ADJ
dpc-3703	67	9	pd-1	pd-1	ADJ
dpc-3703	67	10	immunotherapy	immunotherapy	NOUN
dpc-3703	67	11	for	for	ADP
dpc-3703	67	12	advanced	advanced	ADJ
dpc-3703	67	13	bcc	bcc	PROPN
dpc-3703	67	14	hedgehog	hedgehog	NOUN
dpc-3703	67	15	pathway	pathway	NOUN
dpc-3703	67	16	inhibitors	inhibitor	NOUN
dpc-3703	67	17	(	(	PUNCT
dpc-3703	67	18	hhi	hhi	NOUN
dpc-3703	67	19	)	)	PUNCT
dpc-3703	67	20	vismodegib	vismodegib	NOUN
dpc-3703	67	21	(	(	PUNCT
dpc-3703	67	22	150	150	NUM
dpc-3703	67	23	mg	mg	NUM
dpc-3703	67	24	/	/	SYM
dpc-3703	67	25	day	day	NOUN
dpc-3703	67	26	)	)	PUNCT
dpc-3703	67	27	and	and	CCONJ
dpc-3703	67	28	sonidegib	sonidegib	NOUN
dpc-3703	67	29	(	(	PUNCT
dpc-3703	67	30	200	200	NUM
dpc-3703	67	31	mg	mg	NUM
dpc-3703	67	32	/	/	SYM
dpc-3703	67	33	day	day	NOUN
dpc-3703	67	34	)	)	PUNCT
dpc-3703	67	35	are	be	AUX
dpc-3703	67	36	approved	approve	VERB
dpc-3703	67	37	as	as	ADP
dpc-3703	67	38	first	first	ADJ
dpc-3703	67	39	-	-	PUNCT
dpc-3703	67	40	line	line	NOUN
dpc-3703	67	41	systemic	systemic	ADJ
dpc-3703	67	42	treatment	treatment	NOUN
dpc-3703	67	43	for	for	ADP
dpc-3703	67	44	patients	patient	NOUN
dpc-3703	67	45	with	with	ADP
dpc-3703	67	46	advanced	advanced	ADJ
dpc-3703	67	47	bcc	bcc	PROPN
dpc-3703	67	48	.	.	PUNCT
dpc-3703	68	1	the	the	DET
dpc-3703	68	2	reported	report	VERB
dpc-3703	68	3	overall	overall	ADJ
dpc-3703	68	4	discontinuation	discontinuation	NOUN
dpc-3703	68	5	rate	rate	NOUN
dpc-3703	68	6	of	of	ADP
dpc-3703	68	7	hhi	hhi	NOUN
dpc-3703	68	8	treatment	treatment	NOUN
dpc-3703	68	9	is	be	AUX
dpc-3703	68	10	88	88	NUM
dpc-3703	68	11	%	%	NOUN
dpc-3703	68	12	to	to	ADP
dpc-3703	68	13	92	92	NUM
dpc-3703	68	14	%	%	NOUN
dpc-3703	68	15	with	with	ADP
dpc-3703	68	16	vismodegib	vismodegib	NOUN
dpc-3703	68	17	and	and	CCONJ
dpc-3703	68	18	92	92	NUM
dpc-3703	68	19	%	%	NOUN
dpc-3703	68	20	with	with	ADP
dpc-3703	68	21	sonidegib	sonidegib	NOUN
dpc-3703	68	22	[	[	X
dpc-3703	68	23	2830	2830	NUM
dpc-3703	68	24	]	]	PUNCT
dpc-3703	68	25	.	.	PUNCT
dpc-3703	69	1	median	median	PROPN
dpc-3703	69	2	vismodegib	vismodegib	PROPN
dpc-3703	69	3	treatment	treatment	NOUN
dpc-3703	69	4	duration	duration	NOUN
dpc-3703	69	5	was	be	AUX
dpc-3703	69	6	8.6	8.6	NUM
dpc-3703	69	7	(	(	PUNCT
dpc-3703	69	8	range	range	NOUN
dpc-3703	69	9	:	:	PUNCT
dpc-3703	69	10	0	0	NUM
dpc-3703	69	11	-	-	SYM
dpc-3703	69	12	44	44	NUM
dpc-3703	69	13	)	)	PUNCT
dpc-3703	69	14	months	month	NOUN
dpc-3703	69	15	in	in	ADP
dpc-3703	69	16	the	the	DET
dpc-3703	69	17	stevie	stevie	NOUN
dpc-3703	69	18	study	study	NOUN
dpc-3703	69	19	and	and	CCONJ
dpc-3703	69	20	12.7	12.7	NUM
dpc-3703	69	21	(	(	PUNCT
dpc-3703	69	22	range	range	NOUN
dpc-3703	69	23	:	:	PUNCT
dpc-3703	69	24	1.1	1.1	NUM
dpc-3703	69	25	-	-	SYM
dpc-3703	69	26	47.8	47.8	NUM
dpc-3703	69	27	)	)	PUNCT
dpc-3703	69	28	months	month	NOUN
dpc-3703	69	29	in	in	ADP
dpc-3703	69	30	the	the	DET
dpc-3703	69	31	erivance	erivance	NOUN
dpc-3703	69	32	bcc	bcc	PROPN
dpc-3703	69	33	study	study	NOUN
dpc-3703	69	34	[	[	X
dpc-3703	69	35	28,29	28,29	NUM
dpc-3703	69	36	]	]	PUNCT
dpc-3703	69	37	.	.	PUNCT
dpc-3703	70	1	median	median	PROPN
dpc-3703	70	2	sonidegib	sonidegib	PROPN
dpc-3703	70	3	treatment	treatment	NOUN
dpc-3703	70	4	duration	duration	NOUN
dpc-3703	70	5	was	be	AUX
dpc-3703	70	6	11	11	NUM
dpc-3703	70	7	months	month	NOUN
dpc-3703	70	8	[	[	X
dpc-3703	70	9	30	30	NUM
dpc-3703	70	10	]	]	PUNCT
dpc-3703	70	11	.	.	PUNCT
dpc-3703	71	1	these	these	DET
dpc-3703	71	2	results	result	NOUN
dpc-3703	71	3	from	from	ADP
dpc-3703	71	4	clinical	clinical	ADJ
dpc-3703	71	5	trials	trial	NOUN
dpc-3703	71	6	highlight	highlight	VERB
dpc-3703	71	7	that	that	SCONJ
dpc-3703	71	8	half	half	NOUN
dpc-3703	71	9	of	of	ADP
dpc-3703	71	10	patients	patient	NOUN
dpc-3703	71	11	with	with	ADP
dpc-3703	71	12	advanced	advanced	ADJ
dpc-3703	71	13	bcc	bcc	PROPN
dpc-3703	71	14	will	will	AUX
dpc-3703	71	15	discontinue	discontinue	VERB
dpc-3703	71	16	hhi	hhi	NOUN
dpc-3703	71	17	after	after	ADP
dpc-3703	71	18	approximately	approximately	ADV
dpc-3703	71	19	8	8	NUM
dpc-3703	71	20	to	to	PART
dpc-3703	71	21	12	12	NUM
dpc-3703	71	22	months	month	NOUN
dpc-3703	71	23	.	.	PUNCT
dpc-3703	72	1	the	the	DET
dpc-3703	72	2	main	main	ADJ
dpc-3703	72	3	factors	factor	NOUN
dpc-3703	72	4	weighing	weigh	VERB
dpc-3703	72	5	in	in	ADP
dpc-3703	72	6	on	on	ADP
dpc-3703	72	7	the	the	DET
dpc-3703	72	8	decision	decision	NOUN
dpc-3703	72	9	to	to	PART
dpc-3703	72	10	discontinue	discontinue	VERB
dpc-3703	72	11	hhi	hhi	PROPN
dpc-3703	72	12	,	,	PUNCT
dpc-3703	72	13	include	include	VERB
dpc-3703	72	14	efficacy	efficacy	NOUN
dpc-3703	72	15	(	(	PUNCT
dpc-3703	72	16	tumor	tumor	NOUN
dpc-3703	72	17	response	response	NOUN
dpc-3703	72	18	)	)	PUNCT
dpc-3703	72	19	,	,	PUNCT
dpc-3703	72	20	adverse	adverse	ADJ
dpc-3703	72	21	events	event	NOUN
dpc-3703	72	22	and	and	CCONJ
dpc-3703	72	23	patient	patient	ADJ
dpc-3703	72	24	decision	decision	NOUN
dpc-3703	72	25	.	.	PUNCT
dpc-3703	73	1	in	in	ADP
dpc-3703	73	2	clinical	clinical	ADJ
dpc-3703	73	3	practice	practice	NOUN
dpc-3703	73	4	,	,	PUNCT
dpc-3703	73	5	some	some	PRON
dpc-3703	73	6	of	of	ADP
dpc-3703	73	7	the	the	DET
dpc-3703	73	8	patients	patient	NOUN
dpc-3703	73	9	that	that	PRON
dpc-3703	73	10	discontinue	discontinue	VERB
dpc-3703	73	11	hhi	hhi	NOUN
dpc-3703	73	12	may	may	AUX
dpc-3703	73	13	be	be	AUX
dpc-3703	73	14	re	re	VERB
dpc-3703	73	15	-	-	VERB
dpc-3703	73	16	evaluated	evaluate	VERB
dpc-3703	73	17	for	for	ADP
dpc-3703	73	18	surgical	surgical	ADJ
dpc-3703	73	19	excision	excision	NOUN
dpc-3703	73	20	if	if	SCONJ
dpc-3703	73	21	the	the	DET
dpc-3703	73	22	tumor	tumor	NOUN
dpc-3703	73	23	becomes	become	VERB
dpc-3703	73	24	amenable	amenable	ADJ
dpc-3703	73	25	to	to	ADP
dpc-3703	73	26	surgery	surgery	NOUN
dpc-3703	73	27	,	,	PUNCT
dpc-3703	73	28	or	or	CCONJ
dpc-3703	73	29	restart	restart	NOUN
dpc-3703	73	30	hhi	hhi	NOUN
dpc-3703	73	31	at	at	ADP
dpc-3703	73	32	a	a	DET
dpc-3703	73	33	later	later	ADJ
dpc-3703	73	34	time	time	NOUN
dpc-3703	73	35	,	,	PUNCT
dpc-3703	73	36	while	while	SCONJ
dpc-3703	73	37	others	other	NOUN
dpc-3703	73	38	will	will	AUX
dpc-3703	73	39	need	need	VERB
dpc-3703	73	40	to	to	PART
dpc-3703	73	41	switch	switch	VERB
dpc-3703	73	42	to	to	ADP
dpc-3703	73	43	immunotherapy	immunotherapy	NOUN
dpc-3703	73	44	,	,	PUNCT
dpc-3703	73	45	depending	depend	VERB
dpc-3703	73	46	on	on	ADP
dpc-3703	73	47	the	the	DET
dpc-3703	73	48	reasons	reason	NOUN
dpc-3703	73	49	for	for	ADP
dpc-3703	73	50	hhi	hhi	NOUN
dpc-3703	73	51	discontinuation	discontinuation	NOUN
dpc-3703	73	52	.	.	PUNCT
dpc-3703	74	1	the	the	DET
dpc-3703	74	2	results	result	NOUN
dpc-3703	74	3	of	of	ADP
dpc-3703	74	4	clinical	clinical	ADJ
dpc-3703	74	5	trials	trial	NOUN
dpc-3703	74	6	of	of	ADP
dpc-3703	74	7	hhi	hhi	NOUN
dpc-3703	74	8	treatment	treatment	NOUN
dpc-3703	74	9	in	in	ADP
dpc-3703	74	10	patients	patient	NOUN
dpc-3703	74	11	with	with	ADP
dpc-3703	74	12	labcc	labcc	NOUN
dpc-3703	74	13	,	,	PUNCT
dpc-3703	74	14	that	that	PRON
dpc-3703	74	15	may	may	AUX
dpc-3703	74	16	affect	affect	VERB
dpc-3703	74	17	decision	decision	NOUN
dpc-3703	74	18	to	to	PART
dpc-3703	74	19	switch	switch	VERB
dpc-3703	74	20	treatment	treatment	NOUN
dpc-3703	74	21	are	be	AUX
dpc-3703	74	22	presented	present	VERB
dpc-3703	74	23	in	in	ADP
dpc-3703	74	24	table	table	NOUN
dpc-3703	74	25	1	1	NUM
dpc-3703	74	26	.	.	PUNCT
dpc-3703	75	1	the	the	DET
dpc-3703	75	2	therapeutic	therapeutic	ADJ
dpc-3703	75	3	decisions	decision	NOUN
dpc-3703	75	4	considering	consider	VERB
dpc-3703	75	5	a	a	DET
dpc-3703	75	6	switch	switch	NOUN
dpc-3703	75	7	from	from	ADP
dpc-3703	75	8	hhi	hhi	NOUN
dpc-3703	75	9	to	to	ADP
dpc-3703	75	10	cemiplimab	cemiplimab	NOUN
dpc-3703	75	11	are	be	AUX
dpc-3703	75	12	shown	show	VERB
dpc-3703	75	13	in	in	ADP
dpc-3703	75	14	figure	figure	NOUN
dpc-3703	75	15	1	1	NUM
dpc-3703	75	16	.	.	PUNCT
dpc-3703	76	1	first	first	ADV
dpc-3703	76	2	,	,	PUNCT
dpc-3703	76	3	regarding	regard	VERB
dpc-3703	76	4	efficacy	efficacy	NOUN
dpc-3703	76	5	,	,	PUNCT
dpc-3703	76	6	the	the	DET
dpc-3703	76	7	overall	overall	ADJ
dpc-3703	76	8	response	response	NOUN
dpc-3703	76	9	rate	rate	NOUN
dpc-3703	76	10	(	(	PUNCT
dpc-3703	76	11	orr	orr	PROPN
dpc-3703	76	12	:	:	PUNCT
dpc-3703	76	13	complete	complete	ADJ
dpc-3703	76	14	response	response	NOUN
dpc-3703	76	15	or	or	CCONJ
dpc-3703	76	16	partial	partial	ADJ
dpc-3703	76	17	response	response	NOUN
dpc-3703	76	18	)	)	PUNCT
dpc-3703	76	19	with	with	ADP
dpc-3703	76	20	vismodegib	vismodegib	NOUN
dpc-3703	76	21	in	in	ADP
dpc-3703	76	22	the	the	DET
dpc-3703	76	23	primary	primary	ADJ
dpc-3703	76	24	analysis	analysis	NOUN
dpc-3703	76	25	of	of	ADP
dpc-3703	76	26	the	the	DET
dpc-3703	76	27	pivotal	pivotal	ADJ
dpc-3703	76	28	erivance	erivance	NOUN
dpc-3703	76	29	bcc	bcc	PROPN
dpc-3703	76	30	trial	trial	NOUN
dpc-3703	76	31	was	be	AUX
dpc-3703	76	32	45	45	NUM
dpc-3703	76	33	%	%	NOUN
dpc-3703	76	34	for	for	ADP
dpc-3703	76	35	mbcc	mbcc	NOUN
dpc-3703	76	36	and	and	CCONJ
dpc-3703	76	37	60	60	NUM
dpc-3703	76	38	%	%	NOUN
dpc-3703	76	39	for	for	ADP
dpc-3703	76	40	labcc	labcc	NOUN
dpc-3703	76	41	[	[	X
dpc-3703	76	42	31	31	NUM
dpc-3703	76	43	]	]	PUNCT
dpc-3703	76	44	.	.	PUNCT
dpc-3703	77	1	the	the	DET
dpc-3703	77	2	final	final	ADJ
dpc-3703	77	3	39	39	NUM
dpc-3703	77	4	-	-	PUNCT
dpc-3703	77	5	month	month	NOUN
dpc-3703	77	6	update	update	NOUN
dpc-3703	77	7	of	of	ADP
dpc-3703	77	8	this	this	DET
dpc-3703	77	9	trial	trial	NOUN
dpc-3703	77	10	reported	report	VERB
dpc-3703	77	11	that	that	SCONJ
dpc-3703	77	12	investigator	investigator	NOUN
dpc-3703	77	13	assessed	assess	VERB
dpc-3703	77	14	orr	orr	PROPN
dpc-3703	77	15	was	be	AUX
dpc-3703	77	16	48.5	48.5	NUM
dpc-3703	77	17	%	%	NOUN
dpc-3703	77	18	for	for	ADP
dpc-3703	77	19	mbcc	mbcc	NOUN
dpc-3703	77	20	(	(	PUNCT
dpc-3703	77	21	all	all	DET
dpc-3703	77	22	partial	partial	ADJ
dpc-3703	77	23	responses	response	NOUN
dpc-3703	77	24	)	)	PUNCT
dpc-3703	77	25	and	and	CCONJ
dpc-3703	77	26	60.3	60.3	NUM
dpc-3703	77	27	%	%	NOUN
dpc-3703	77	28	for	for	ADP
dpc-3703	77	29	labcc	labcc	NOUN
dpc-3703	77	30	.	.	PUNCT
dpc-3703	78	1	also	also	ADV
dpc-3703	78	2	,	,	PUNCT
dpc-3703	78	3	there	there	PRON
dpc-3703	78	4	was	be	VERB
dpc-3703	78	5	stable	stable	ADJ
dpc-3703	78	6	disease	disease	NOUN
dpc-3703	78	7	in	in	ADP
dpc-3703	78	8	42.4	42.4	NUM
dpc-3703	78	9	%	%	NOUN
dpc-3703	78	10	of	of	ADP
dpc-3703	78	11	mbcc	mbcc	NOUN
dpc-3703	78	12	[	[	X
dpc-3703	78	13	29	29	NUM
dpc-3703	78	14	]	]	PUNCT
dpc-3703	78	15	.	.	PUNCT
dpc-3703	79	1	at	at	ADP
dpc-3703	79	2	the	the	DET
dpc-3703	79	3	39	39	NUM
dpc-3703	79	4	-	-	PUNCT
dpc-3703	79	5	month	month	NOUN
dpc-3703	79	6	study	study	NOUN
dpc-3703	79	7	,	,	PUNCT
dpc-3703	79	8	disease	disease	NOUN
dpc-3703	79	9	progression	progression	NOUN
dpc-3703	79	10	was	be	AUX
dpc-3703	79	11	the	the	DET
dpc-3703	79	12	reason	reason	NOUN
dpc-3703	79	13	to	to	PART
dpc-3703	79	14	discontinue	discontinue	VERB
dpc-3703	79	15	vismodegib	vismodegib	NOUN
dpc-3703	79	16	in	in	ADP
dpc-3703	79	17	51.5	51.5	NUM
dpc-3703	79	18	%	%	NOUN
dpc-3703	79	19	of	of	ADP
dpc-3703	79	20	patients	patient	NOUN
dpc-3703	79	21	with	with	ADP
dpc-3703	79	22	mbcc	mbcc	NOUN
dpc-3703	79	23	and	and	CCONJ
dpc-3703	79	24	in	in	ADP
dpc-3703	79	25	16.9	16.9	NUM
dpc-3703	79	26	%	%	NOUN
dpc-3703	79	27	of	of	ADP
dpc-3703	79	28	patients	patient	NOUN
dpc-3703	79	29	with	with	ADP
dpc-3703	79	30	labcc	labcc	PROPN
dpc-3703	79	31	[	[	X
dpc-3703	79	32	29	29	NUM
dpc-3703	79	33	]	]	PUNCT
dpc-3703	79	34	.	.	PUNCT
dpc-3703	80	1	similar	similar	ADJ
dpc-3703	80	2	results	result	NOUN
dpc-3703	80	3	have	have	AUX
dpc-3703	80	4	been	be	AUX
dpc-3703	80	5	shown	show	VERB
dpc-3703	80	6	with	with	ADP
dpc-3703	80	7	sonidegib	sonidegib	NOUN
dpc-3703	80	8	[	[	X
dpc-3703	80	9	30,32	30,32	NUM
dpc-3703	80	10	-	-	SYM
dpc-3703	80	11	35	35	NUM
dpc-3703	80	12	]	]	PUNCT
dpc-3703	80	13	.	.	PUNCT
dpc-3703	81	1	secondary	secondary	ADJ
dpc-3703	81	2	acquired	acquire	VERB
dpc-3703	81	3	resistance	resistance	NOUN
dpc-3703	81	4	of	of	ADP
dpc-3703	81	5	bcc	bcc	PROPN
dpc-3703	81	6	with	with	ADP
dpc-3703	81	7	a	a	DET
dpc-3703	81	8	secondary	secondary	ADJ
dpc-3703	81	9	loss	loss	NOUN
dpc-3703	81	10	of	of	ADP
dpc-3703	81	11	response	response	NOUN
dpc-3703	81	12	may	may	AUX
dpc-3703	81	13	occur	occur	VERB
dpc-3703	81	14	during	during	ADP
dpc-3703	81	15	hhi	hhi	NOUN
dpc-3703	81	16	treatment	treatment	NOUN
dpc-3703	81	17	and	and	CCONJ
dpc-3703	81	18	is	be	AUX
dpc-3703	81	19	frequently	frequently	ADV
dpc-3703	81	20	due	due	ADJ
dpc-3703	81	21	to	to	ADP
dpc-3703	81	22	mutation	mutation	NOUN
dpc-3703	81	23	of	of	ADP
dpc-3703	81	24	smo	smo	PROPN
dpc-3703	82	1	[	[	X
dpc-3703	82	2	36,37	36,37	X
dpc-3703	82	3	]	]	X
dpc-3703	82	4	.	.	PUNCT
dpc-3703	83	1	a	a	DET
dpc-3703	83	2	study	study	NOUN
dpc-3703	83	3	of	of	ADP
dpc-3703	83	4	9	9	NUM
dpc-3703	83	5	patients	patient	NOUN
dpc-3703	83	6	with	with	ADP
dpc-3703	83	7	primary	primary	ADJ
dpc-3703	83	8	or	or	CCONJ
dpc-3703	83	9	secondary	secondary	ADJ
dpc-3703	83	10	resistance	resistance	NOUN
dpc-3703	83	11	to	to	ADP
dpc-3703	83	12	vismodegib	vismodegib	NOUN
dpc-3703	83	13	reported	report	VERB
dpc-3703	83	14	absence	absence	NOUN
dpc-3703	83	15	of	of	ADP
dpc-3703	83	16	response	response	NOUN
dpc-3703	83	17	after	after	ADP
dpc-3703	83	18	switch	switch	NOUN
dpc-3703	83	19	to	to	ADP
dpc-3703	83	20	sonidegib	sonidegib	NOUN
dpc-3703	83	21	,	,	PUNCT
dpc-3703	83	22	suggesting	suggest	VERB
dpc-3703	83	23	a	a	DET
dpc-3703	83	24	class	class	NOUN
dpc-3703	83	25	-	-	PUNCT
dpc-3703	83	26	relating	relate	VERB
dpc-3703	83	27	effect	effect	NOUN
dpc-3703	83	28	[	[	X
dpc-3703	83	29	38	38	NUM
dpc-3703	83	30	]	]	PUNCT
dpc-3703	83	31	.	.	PUNCT
dpc-3703	84	1	however	however	ADV
dpc-3703	84	2	,	,	PUNCT
dpc-3703	84	3	the	the	DET
dpc-3703	84	4	early	early	ADJ
dpc-3703	84	5	discontinuation	discontinuation	NOUN
dpc-3703	84	6	of	of	ADP
dpc-3703	84	7	sonidegib	sonidegib	NOUN
dpc-3703	84	8	in	in	ADP
dpc-3703	84	9	4	4	NUM
dpc-3703	84	10	patients	patient	NOUN
dpc-3703	84	11	,	,	PUNCT
dpc-3703	84	12	due	due	ADP
dpc-3703	84	13	to	to	ADP
dpc-3703	84	14	adverse	adverse	ADJ
dpc-3703	84	15	events	event	NOUN
dpc-3703	84	16	or	or	CCONJ
dpc-3703	84	17	patient	patient	ADJ
dpc-3703	84	18	decision	decision	NOUN
dpc-3703	84	19	,	,	PUNCT
dpc-3703	84	20	may	may	AUX
dpc-3703	84	21	have	have	AUX
dpc-3703	84	22	contributed	contribute	VERB
dpc-3703	84	23	for	for	ADP
dpc-3703	84	24	not	not	PART
dpc-3703	84	25	observing	observe	VERB
dpc-3703	84	26	a	a	DET
dpc-3703	84	27	response	response	NOUN
dpc-3703	84	28	[	[	X
dpc-3703	84	29	38,39	38,39	NOUN
dpc-3703	84	30	]	]	X
dpc-3703	84	31	.	.	PUNCT
dpc-3703	85	1	regarding	regard	VERB
dpc-3703	85	2	those	those	DET
dpc-3703	85	3	patients	patient	NOUN
dpc-3703	85	4	that	that	PRON
dpc-3703	85	5	achieve	achieve	VERB
dpc-3703	85	6	a	a	DET
dpc-3703	85	7	complete	complete	ADJ
dpc-3703	85	8	response	response	NOUN
dpc-3703	85	9	with	with	ADP
dpc-3703	85	10	vismodegib	vismodegib	NOUN
dpc-3703	85	11	and	and	CCONJ
dpc-3703	85	12	stop	stop	VERB
dpc-3703	85	13	treatment	treatment	NOUN
dpc-3703	85	14	,	,	PUNCT
dpc-3703	85	15	the	the	DET
dpc-3703	85	16	median	median	ADJ
dpc-3703	85	17	relapse	relapse	NOUN
dpc-3703	85	18	-	-	PUNCT
dpc-3703	85	19	free	free	ADJ
dpc-3703	85	20	survival	survival	NOUN
dpc-3703	85	21	was	be	AUX
dpc-3703	85	22	18.4	18.4	NUM
dpc-3703	85	23	months	month	NOUN
dpc-3703	85	24	or	or	CCONJ
dpc-3703	85	25	24	24	NUM
dpc-3703	85	26	months	month	NOUN
dpc-3703	86	1	[	[	X
dpc-3703	86	2	40,41	40,41	NOUN
dpc-3703	86	3	]	]	PUNCT
dpc-3703	86	4	.	.	PUNCT
dpc-3703	87	1	relapse	relapse	NOUN
dpc-3703	87	2	in	in	ADP
dpc-3703	87	3	complete	complete	ADJ
dpc-3703	87	4	responders	responder	NOUN
dpc-3703	87	5	is	be	AUX
dpc-3703	87	6	attributed	attribute	VERB
dpc-3703	87	7	to	to	ADP
dpc-3703	87	8	a	a	DET
dpc-3703	87	9	persisting	persist	VERB
dpc-3703	87	10	,	,	PUNCT
dpc-3703	87	11	slow	slow	ADV
dpc-3703	87	12	-	-	PUNCT
dpc-3703	87	13	cycling	cycling	NOUN
dpc-3703	87	14	tumor	tumor	NOUN
dpc-3703	87	15	cell	cell	NOUN
dpc-3703	87	16	population	population	NOUN
dpc-3703	87	17	,	,	PUNCT
dpc-3703	87	18	induced	induce	VERB
dpc-3703	87	19	by	by	ADP
dpc-3703	87	20	vismodegib	vismodegib	NOUN
dpc-3703	87	21	via	via	ADP
dpc-3703	87	22	a	a	DET
dpc-3703	87	23	shift	shift	NOUN
dpc-3703	87	24	in	in	ADP
dpc-3703	87	25	tumor	tumor	NOUN
dpc-3703	87	26	cell	cell	NOUN
dpc-3703	87	27	identity	identity	NOUN
dpc-3703	87	28	and	and	CCONJ
dpc-3703	87	29	activation	activation	NOUN
dpc-3703	87	30	of	of	ADP
dpc-3703	87	31	the	the	DET
dpc-3703	87	32	wnt	wnt	PROPN
dpc-3703	87	33	pathway	pathway	NOUN
dpc-3703	88	1	[	[	X
dpc-3703	88	2	42,43	42,43	X
dpc-3703	88	3	]	]	X
dpc-3703	88	4	.	.	PUNCT
dpc-3703	89	1	when	when	SCONJ
dpc-3703	89	2	bcc	bcc	PROPN
dpc-3703	89	3	relapses	relapse	VERB
dpc-3703	89	4	in	in	ADP
dpc-3703	89	5	complete	complete	ADJ
dpc-3703	89	6	responders	responder	NOUN
dpc-3703	89	7	,	,	PUNCT
dpc-3703	89	8	re	re	NOUN
dpc-3703	89	9	-	-	NOUN
dpc-3703	89	10	treatment	treatment	NOUN
dpc-3703	89	11	with	with	ADP
dpc-3703	89	12	vismodegib	vismodegib	NOUN
dpc-3703	89	13	can	can	AUX
dpc-3703	89	14	be	be	AUX
dpc-3703	89	15	successful	successful	ADJ
dpc-3703	89	16	(	(	PUNCT
dpc-3703	89	17	response	response	NOUN
dpc-3703	89	18	in	in	ADP
dpc-3703	89	19	65.7	65.7	NUM
dpc-3703	89	20	%	%	NOUN
dpc-3703	89	21	or	or	CCONJ
dpc-3703	89	22	85	85	NUM
dpc-3703	89	23	%	%	NOUN
dpc-3703	89	24	)	)	PUNCT
dpc-3703	89	25	but	but	CCONJ
dpc-3703	89	26	some	some	DET
dpc-3703	89	27	patients	patient	NOUN
dpc-3703	89	28	will	will	AUX
dpc-3703	89	29	not	not	PART
dpc-3703	89	30	respond	respond	VERB
dpc-3703	89	31	again	again	ADV
dpc-3703	90	1	[	[	X
dpc-3703	90	2	40,41,44	40,41,44	X
dpc-3703	90	3	]	]	X
dpc-3703	90	4	.	.	PUNCT
dpc-3703	91	1	these	these	DET
dpc-3703	91	2	results	result	NOUN
dpc-3703	91	3	highlight	highlight	VERB
dpc-3703	91	4	that	that	SCONJ
dpc-3703	91	5	non	non	ADJ
dpc-3703	91	6	-	-	ADJ
dpc-3703	91	7	responding	respond	VERB
dpc-3703	91	8	patients	patient	NOUN
dpc-3703	91	9	could	could	AUX
dpc-3703	91	10	be	be	AUX
dpc-3703	91	11	considered	consider	VERB
dpc-3703	91	12	for	for	ADP
dpc-3703	91	13	switching	switch	VERB
dpc-3703	91	14	from	from	ADP
dpc-3703	91	15	hhi	hhi	NOUN
dpc-3703	91	16	to	to	ADP
dpc-3703	91	17	second	second	ADJ
dpc-3703	91	18	-	-	PUNCT
dpc-3703	91	19	line	line	NOUN
dpc-3703	91	20	anti	anti	ADJ
dpc-3703	91	21	-	-	ADJ
dpc-3703	91	22	pd-1	pd-1	ADJ
dpc-3703	91	23	immunotherapy	immunotherapy	NOUN
dpc-3703	91	24	(	(	PUNCT
dpc-3703	91	25	figure	figure	NOUN
dpc-3703	91	26	1	1	NUM
dpc-3703	91	27	)	)	PUNCT
dpc-3703	91	28	.	.	PUNCT
dpc-3703	92	1	second	second	ADJ
dpc-3703	92	2	,	,	PUNCT
dpc-3703	92	3	although	although	SCONJ
dpc-3703	92	4	adverse	adverse	ADJ
dpc-3703	92	5	events	event	NOUN
dpc-3703	92	6	are	be	AUX
dpc-3703	92	7	mostly	mostly	ADV
dpc-3703	92	8	reversible	reversible	ADJ
dpc-3703	92	9	after	after	ADP
dpc-3703	92	10	hhi	hhi	NOUN
dpc-3703	92	11	withdrawal	withdrawal	NOUN
dpc-3703	92	12	and	and	CCONJ
dpc-3703	92	13	are	be	AUX
dpc-3703	92	14	usually	usually	ADV
dpc-3703	92	15	of	of	ADP
dpc-3703	92	16	mild	mild	ADJ
dpc-3703	92	17	or	or	CCONJ
dpc-3703	92	18	moderate	moderate	ADJ
dpc-3703	92	19	severity	severity	NOUN
dpc-3703	92	20	,	,	PUNCT
dpc-3703	92	21	they	they	PRON
dpc-3703	92	22	can	can	AUX
dpc-3703	92	23	be	be	AUX
dpc-3703	92	24	considerably	considerably	ADV
dpc-3703	92	25	distressing	distressing	ADJ
dpc-3703	92	26	to	to	ADP
dpc-3703	92	27	patients	patient	NOUN
dpc-3703	92	28	and	and	CCONJ
dpc-3703	92	29	are	be	AUX
dpc-3703	92	30	a	a	DET
dpc-3703	92	31	frequent	frequent	ADJ
dpc-3703	92	32	cause	cause	NOUN
dpc-3703	92	33	of	of	ADP
dpc-3703	92	34	drug	drug	NOUN
dpc-3703	92	35	discontinuation	discontinuation	NOUN
dpc-3703	92	36	[	[	X
dpc-3703	92	37	45	45	NUM
dpc-3703	92	38	-	-	SYM
dpc-3703	92	39	47	47	NUM
dpc-3703	92	40	]	]	PUNCT
dpc-3703	92	41	.	.	PUNCT
dpc-3703	93	1	adverse	adverse	ADJ
dpc-3703	93	2	events	event	NOUN
dpc-3703	93	3	occur	occur	VERB
dpc-3703	93	4	in	in	ADP
dpc-3703	93	5	all	all	PRON
dpc-3703	93	6	(	(	PUNCT
dpc-3703	93	7	100	100	NUM
dpc-3703	93	8	%	%	NOUN
dpc-3703	93	9	)	)	PUNCT
dpc-3703	94	1	patients	patient	NOUN
dpc-3703	94	2	treated	treat	VERB
dpc-3703	94	3	with	with	ADP
dpc-3703	94	4	hhi	hhi	NOUN
dpc-3703	94	5	and	and	CCONJ
dpc-3703	94	6	are	be	AUX
dpc-3703	94	7	class	class	NOUN
dpc-3703	94	8	-	-	PUNCT
dpc-3703	94	9	related	relate	VERB
dpc-3703	94	10	,	,	PUNCT
dpc-3703	94	11	e.g.	e.g.	ADV
dpc-3703	94	12	they	they	PRON
dpc-3703	94	13	are	be	AUX
dpc-3703	94	14	similar	similar	ADJ
dpc-3703	94	15	for	for	ADP
dpc-3703	94	16	vismodegib	vismodegib	NOUN
dpc-3703	94	17	and	and	CCONJ
dpc-3703	94	18	sonidegib	sonidegib	NOUN
dpc-3703	95	1	[	[	X
dpc-3703	95	2	29,31,46,48	29,31,46,48	NUM
dpc-3703	95	3	]	]	PUNCT
dpc-3703	95	4	.	.	PUNCT
dpc-3703	96	1	adverse	adverse	ADJ
dpc-3703	96	2	events	event	NOUN
dpc-3703	96	3	more	more	ADV
dpc-3703	96	4	frequently	frequently	ADV
dpc-3703	96	5	observed	observe	VERB
dpc-3703	96	6	in	in	ADP
dpc-3703	96	7	clinical	clinical	ADJ
dpc-3703	96	8	trials	trial	NOUN
dpc-3703	96	9	with	with	ADP
dpc-3703	96	10	hhi	hhi	NOUN
dpc-3703	96	11	include	include	VERB
dpc-3703	96	12	muscle	muscle	NOUN
dpc-3703	96	13	cramps	cramp	NOUN
dpc-3703	96	14	in	in	ADP
dpc-3703	96	15	49%-71	49%-71	NUM
dpc-3703	96	16	%	%	NOUN
dpc-3703	96	17	,	,	PUNCT
dpc-3703	96	18	alopecia	alopecia	NOUN
dpc-3703	96	19	in	in	ADP
dpc-3703	96	20	55%-66	55%-66	NUM
dpc-3703	96	21	%	%	NOUN
dpc-3703	96	22	,	,	PUNCT
dpc-3703	96	23	dysgeusia	dysgeusia	NOUN
dpc-3703	96	24	in	in	ADP
dpc-3703	96	25	38	38	NUM
dpc-3703	96	26	%	%	NOUN
dpc-3703	96	27	to	to	ADP
dpc-3703	96	28	71	71	NUM
dpc-3703	96	29	%	%	NOUN
dpc-3703	96	30	,	,	PUNCT
dpc-3703	96	31	weight	weight	NOUN
dpc-3703	96	32	loss	loss	NOUN
dpc-3703	96	33	in	in	ADP
dpc-3703	96	34	16	16	NUM
dpc-3703	96	35	%	%	NOUN
dpc-3703	96	36	to	to	ADP
dpc-3703	96	37	52	52	NUM
dpc-3703	96	38	%	%	NOUN
dpc-3703	96	39	,	,	PUNCT
dpc-3703	96	40	fatigue	fatigue	NOUN
dpc-3703	96	41	in	in	ADP
dpc-3703	96	42	16	16	NUM
dpc-3703	96	43	%	%	NOUN
dpc-3703	96	44	to	to	PART
dpc-3703	96	45	43	43	NUM
dpc-3703	96	46	%	%	NOUN
dpc-3703	96	47	,	,	PUNCT
dpc-3703	96	48	loss	loss	NOUN
dpc-3703	96	49	of	of	ADP
dpc-3703	96	50	appetite	appetite	NOUN
dpc-3703	96	51	in	in	ADP
dpc-3703	96	52	11	11	NUM
dpc-3703	96	53	%	%	NOUN
dpc-3703	96	54	to	to	PART
dpc-3703	96	55	31	31	NUM
dpc-3703	96	56	%	%	NOUN
dpc-3703	96	57	and	and	CCONJ
dpc-3703	96	58	diarrhea	diarrhea	NOUN
dpc-3703	96	59	in	in	ADP
dpc-3703	96	60	8	8	NUM
dpc-3703	96	61	%	%	NOUN
dpc-3703	96	62	to	to	PART
dpc-3703	96	63	27	27	NUM
dpc-3703	96	64	%	%	NOUN
dpc-3703	96	65	[	[	X
dpc-3703	96	66	46	46	NUM
dpc-3703	96	67	]	]	PUNCT
dpc-3703	96	68	.	.	PUNCT
dpc-3703	97	1	during	during	ADP
dpc-3703	97	2	hhi	hhi	PROPN
dpc-3703	97	3	treatment	treatment	NOUN
dpc-3703	97	4	,	,	PUNCT
dpc-3703	97	5	the	the	DET
dpc-3703	97	6	procedures	procedure	NOUN
dpc-3703	97	7	to	to	PART
dpc-3703	97	8	assess	assess	VERB
dpc-3703	97	9	bcc	bcc	PROPN
dpc-3703	97	10	response	response	NOUN
dpc-3703	97	11	and	and	CCONJ
dpc-3703	97	12	monitor	monitor	VERB
dpc-3703	97	13	for	for	ADP
dpc-3703	97	14	adverse	adverse	ADJ
dpc-3703	97	15	events	event	NOUN
dpc-3703	97	16	,	,	PUNCT
dpc-3703	97	17	and	and	CCONJ
dpc-3703	97	18	the	the	DET
dpc-3703	97	19	management	management	NOUN
dpc-3703	97	20	of	of	ADP
dpc-3703	97	21	adverse	adverse	ADJ
dpc-3703	97	22	events	event	NOUN
dpc-3703	97	23	,	,	PUNCT
dpc-3703	97	24	have	have	AUX
dpc-3703	97	25	been	be	AUX
dpc-3703	97	26	reviewed	review	VERB
dpc-3703	97	27	previously	previously	ADV
dpc-3703	97	28	and	and	CCONJ
dpc-3703	97	29	are	be	AUX
dpc-3703	97	30	outside	outside	ADP
dpc-3703	97	31	the	the	DET
dpc-3703	97	32	scope	scope	NOUN
dpc-3703	97	33	of	of	ADP
dpc-3703	97	34	this	this	DET
dpc-3703	97	35	article	article	NOUN
dpc-3703	97	36	[	[	X
dpc-3703	97	37	46,47,49	46,47,49	NUM
dpc-3703	97	38	]	]	X
dpc-3703	97	39	.	.	PUNCT
dpc-3703	98	1	the	the	DET
dpc-3703	98	2	stevie	stevie	PROPN
dpc-3703	98	3	study	study	PROPN
dpc-3703	98	4	reported	report	VERB
dpc-3703	98	5	long	long	ADJ
dpc-3703	98	6	-	-	PUNCT
dpc-3703	98	7	term	term	NOUN
dpc-3703	98	8	safety	safety	NOUN
dpc-3703	98	9	results	result	NOUN
dpc-3703	98	10	among	among	ADP
dpc-3703	98	11	patients	patient	NOUN
dpc-3703	98	12	with	with	ADP
dpc-3703	98	13	mbcc	mbcc	NOUN
dpc-3703	98	14	or	or	CCONJ
dpc-3703	98	15	labcc	labcc	PROPN
dpc-3703	98	16	treated	treat	VERB
dpc-3703	98	17	with	with	ADP
dpc-3703	98	18	vismodegib	vismodegib	NOUN
dpc-3703	98	19	for	for	ADP
dpc-3703	98	20	at	at	ADV
dpc-3703	98	21	least	least	ADV
dpc-3703	98	22	12	12	NUM
dpc-3703	98	23	months	month	NOUN
dpc-3703	99	1	[	[	X
dpc-3703	99	2	50	50	NUM
dpc-3703	99	3	]	]	PUNCT
dpc-3703	99	4	.	.	PUNCT
dpc-3703	100	1	among	among	ADP
dpc-3703	100	2	499	499	NUM
dpc-3703	100	3	patients	patient	NOUN
dpc-3703	100	4	,	,	PUNCT
dpc-3703	100	5	400	400	NUM
dpc-3703	100	6	(	(	PUNCT
dpc-3703	100	7	80	80	NUM
dpc-3703	100	8	%	%	NOUN
dpc-3703	100	9	)	)	PUNCT
dpc-3703	100	10	discontinued	discontinue	VERB
dpc-3703	100	11	treatment	treatment	NOUN
dpc-3703	100	12	,	,	PUNCT
dpc-3703	100	13	including	include	VERB
dpc-3703	100	14	180/499	180/499	PROPN
dpc-3703	100	15	(	(	PUNCT
dpc-3703	100	16	36	36	NUM
dpc-3703	100	17	%	%	NOUN
dpc-3703	100	18	)	)	PUNCT
dpc-3703	100	19	due	due	ADP
dpc-3703	100	20	to	to	ADP
dpc-3703	100	21	adverse	adverse	ADJ
dpc-3703	100	22	events	event	NOUN
dpc-3703	100	23	,	,	PUNCT
dpc-3703	100	24	14	14	NUM
dpc-3703	100	25	%	%	NOUN
dpc-3703	100	26	due	due	ADP
dpc-3703	100	27	to	to	ADP
dpc-3703	100	28	disease	disease	NOUN
dpc-3703	100	29	progression	progression	NOUN
dpc-3703	100	30	,	,	PUNCT
dpc-3703	100	31	and	and	CCONJ
dpc-3703	100	32	10	10	NUM
dpc-3703	100	33	%	%	NOUN
dpc-3703	100	34	due	due	ADP
dpc-3703	100	35	to	to	ADP
dpc-3703	100	36	patient	patient	ADJ
dpc-3703	100	37	request	request	NOUN
dpc-3703	100	38	[	[	X
dpc-3703	100	39	50	50	NUM
dpc-3703	100	40	]	]	PUNCT
dpc-3703	100	41	.	.	PUNCT
dpc-3703	101	1	among	among	ADP
dpc-3703	101	2	the	the	DET
dpc-3703	101	3	180	180	NUM
dpc-3703	101	4	patients	patient	NOUN
dpc-3703	101	5	who	who	PRON
dpc-3703	101	6	discontinued	discontinue	VERB
dpc-3703	101	7	vismodegib	vismodegib	NOUN
dpc-3703	101	8	due	due	ADP
dpc-3703	101	9	to	to	ADP
dpc-3703	101	10	adverse	adverse	ADJ
dpc-3703	101	11	events	event	NOUN
dpc-3703	101	12	,	,	PUNCT
dpc-3703	101	13	those	those	PRON
dpc-3703	101	14	were	be	AUX
dpc-3703	101	15	of	of	ADP
dpc-3703	101	16	mild	mild	ADJ
dpc-3703	101	17	severity	severity	NOUN
dpc-3703	101	18	(	(	PUNCT
dpc-3703	101	19	grade	grade	NOUN
dpc-3703	101	20	1	1	NUM
dpc-3703	101	21	or	or	CCONJ
dpc-3703	101	22	2	2	NUM
dpc-3703	101	23	)	)	PUNCT
dpc-3703	101	24	in	in	ADP
dpc-3703	101	25	106	106	NUM
dpc-3703	101	26	patients	patient	NOUN
dpc-3703	101	27	(	(	PUNCT
dpc-3703	101	28	59	59	NUM
dpc-3703	101	29	%	%	NOUN
dpc-3703	101	30	)	)	PUNCT
dpc-3703	101	31	,	,	PUNCT
dpc-3703	101	32	and	and	CCONJ
dpc-3703	101	33	most	most	ADJ
dpc-3703	101	34	4	4	NUM
dpc-3703	101	35	review	review	NOUN
dpc-3703	101	36	|	|	ADV
dpc-3703	101	37	dermatol	dermatol	ADJ
dpc-3703	101	38	pract	pract	NOUN
dpc-3703	101	39	concept	concept	NOUN
dpc-3703	101	40	.	.	PUNCT
dpc-3703	102	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	102	2	figure	figure	NOUN
dpc-3703	102	3	1	1	NUM
dpc-3703	102	4	.	.	PUNCT
dpc-3703	103	1	a	a	DET
dpc-3703	103	2	schematic	schematic	ADJ
dpc-3703	103	3	of	of	ADP
dpc-3703	103	4	therapeutic	therapeutic	ADJ
dpc-3703	103	5	decisions	decision	NOUN
dpc-3703	103	6	on	on	ADP
dpc-3703	103	7	switching	switch	VERB
dpc-3703	103	8	from	from	ADP
dpc-3703	103	9	hedgehog	hedgehog	ADJ
dpc-3703	103	10	pathway	pathway	NOUN
dpc-3703	103	11	inhibitors	inhibitor	NOUN
dpc-3703	103	12	to	to	ADP
dpc-3703	103	13	anti	anti	ADJ
dpc-3703	103	14	-	-	ADJ
dpc-3703	103	15	pd-1	pd-1	ADJ
dpc-3703	103	16	immunotherapy	immunotherapy	NOUN
dpc-3703	103	17	with	with	ADP
dpc-3703	103	18	cemiplimab	cemiplimab	NOUN
dpc-3703	103	19	.	.	PUNCT
dpc-3703	104	1	hhi	hhi	NOUN
dpc-3703	104	2	=	=	PUNCT
dpc-3703	104	3	hedgehog	hedgehog	NOUN
dpc-3703	104	4	pathway	pathway	NOUN
dpc-3703	104	5	inhibitors	inhibitor	NOUN
dpc-3703	104	6	;	;	PUNCT
dpc-3703	104	7	labcc	labcc	NOUN
dpc-3703	104	8	=	=	SYM
dpc-3703	104	9	locally	locally	ADV
dpc-3703	104	10	advanced	advance	VERB
dpc-3703	104	11	basal	basal	NOUN
dpc-3703	104	12	cell	cell	NOUN
dpc-3703	104	13	carcinoma	carcinoma	NOUN
dpc-3703	104	14	;	;	PUNCT
dpc-3703	104	15	mbcc	mbcc	NOUN
dpc-3703	104	16	=	=	PUNCT
dpc-3703	104	17	metastatic	metastatic	ADJ
dpc-3703	104	18	basal	basal	NOUN
dpc-3703	104	19	cell	cell	NOUN
dpc-3703	104	20	carcinoma	carcinoma	NOUN
dpc-3703	104	21	;	;	PUNCT
dpc-3703	104	22	pd	pd	X
dpc-3703	104	23	=	=	PROPN
dpc-3703	104	24	progressive	progressive	ADJ
dpc-3703	104	25	disease	disease	NOUN
dpc-3703	104	26	;	;	PUNCT
dpc-3703	104	27	rfs	rfs	PROPN
dpc-3703	104	28	=	=	SYM
dpc-3703	104	29	relapse	relapse	NOUN
dpc-3703	104	30	-	-	PUNCT
dpc-3703	104	31	free	free	ADJ
dpc-3703	104	32	survival	survival	NOUN
dpc-3703	104	33	.	.	PUNCT
dpc-3703	105	1	a	a	DET
dpc-3703	105	2	results	result	NOUN
dpc-3703	105	3	from	from	ADP
dpc-3703	105	4	the	the	DET
dpc-3703	105	5	final	final	ADJ
dpc-3703	105	6	update	update	NOUN
dpc-3703	105	7	of	of	ADP
dpc-3703	105	8	the	the	DET
dpc-3703	105	9	erivance	erivance	NOUN
dpc-3703	105	10	bcc	bcc	PROPN
dpc-3703	105	11	study	study	NOUN
dpc-3703	105	12	[	[	X
dpc-3703	105	13	29	29	NUM
dpc-3703	105	14	]	]	SYM
dpc-3703	105	15	b	b	NOUN
dpc-3703	105	16	results	result	NOUN
dpc-3703	105	17	from	from	ADP
dpc-3703	105	18	stevie	stevie	PROPN
dpc-3703	105	19	study	study	PROPN
dpc-3703	105	20	[	[	X
dpc-3703	105	21	50	50	NUM
dpc-3703	105	22	]	]	PUNCT
dpc-3703	105	23	:	:	PUNCT
dpc-3703	105	24	results	result	NOUN
dpc-3703	105	25	from	from	ADP
dpc-3703	105	26	herms	herm	NOUN
dpc-3703	105	27	[	[	X
dpc-3703	105	28	40	40	NUM
dpc-3703	105	29	]	]	X
dpc-3703	105	30	d	d	NOUN
dpc-3703	105	31	results	result	VERB
dpc-3703	105	32	from	from	ADP
dpc-3703	105	33	bassompierre	bassompierre	NOUN
dpc-3703	105	34	[	[	X
dpc-3703	105	35	41	41	NUM
dpc-3703	105	36	]	]	SYM
dpc-3703	105	37	table	table	NOUN
dpc-3703	105	38	1	1	NUM
dpc-3703	105	39	.	.	PUNCT
dpc-3703	106	1	summary	summary	NOUN
dpc-3703	106	2	of	of	ADP
dpc-3703	106	3	results	result	NOUN
dpc-3703	106	4	of	of	ADP
dpc-3703	106	5	clinical	clinical	ADJ
dpc-3703	106	6	trials	trial	NOUN
dpc-3703	106	7	of	of	ADP
dpc-3703	106	8	hhi	hhi	NOUN
dpc-3703	106	9	treatments	treatment	NOUN
dpc-3703	106	10	in	in	ADP
dpc-3703	106	11	patients	patient	NOUN
dpc-3703	106	12	with	with	ADP
dpc-3703	106	13	advanced	advanced	ADJ
dpc-3703	106	14	bcc	bcc	PROPN
dpc-3703	106	15	,	,	PUNCT
dpc-3703	106	16	that	that	PRON
dpc-3703	106	17	may	may	AUX
dpc-3703	106	18	affect	affect	VERB
dpc-3703	106	19	decision	decision	NOUN
dpc-3703	106	20	to	to	PART
dpc-3703	106	21	switch	switch	VERB
dpc-3703	106	22	to	to	ADP
dpc-3703	106	23	anti	anti	ADJ
dpc-3703	106	24	-	-	ADJ
dpc-3703	106	25	pd-1	pd-1	ADJ
dpc-3703	106	26	immunotherapy	immunotherapy	NOUN
dpc-3703	106	27	:	:	PUNCT
dpc-3703	106	28	response	response	NOUN
dpc-3703	106	29	,	,	PUNCT
dpc-3703	106	30	rates	rate	NOUN
dpc-3703	106	31	and	and	CCONJ
dpc-3703	106	32	reasons	reason	NOUN
dpc-3703	106	33	of	of	ADP
dpc-3703	106	34	 	 	SPACE
dpc-3703	106	35	discontinuation	discontinuation	NOUN
dpc-3703	106	36	.	.	PUNCT
dpc-3703	107	1	outcome	outcome	NOUN
dpc-3703	107	2	vismodegib	vismodegib	NOUN
dpc-3703	107	3	(	(	PUNCT
dpc-3703	107	4	150	150	NUM
dpc-3703	107	5	mg	mg	NUM
dpc-3703	107	6	/	/	SYM
dpc-3703	107	7	day	day	NOUN
dpc-3703	107	8	)	)	PUNCT
dpc-3703	107	9	sonidegib	sonidegib	NOUN
dpc-3703	107	10	(	(	PUNCT
dpc-3703	107	11	200	200	NUM
dpc-3703	107	12	mg	mg	NUM
dpc-3703	107	13	/	/	SYM
dpc-3703	107	14	day	day	NOUN
dpc-3703	107	15	)	)	PUNCT
dpc-3703	107	16	erivance	erivance	NOUN
dpc-3703	107	17	study	study	NOUN
dpc-3703	107	18	(	(	PUNCT
dpc-3703	107	19	39	39	NUM
dpc-3703	107	20	-	-	PUNCT
dpc-3703	107	21	month	month	NOUN
dpc-3703	107	22	update	update	NOUN
dpc-3703	107	23	)	)	PUNCT
dpc-3703	108	1	[	[	X
dpc-3703	108	2	29	29	NUM
dpc-3703	108	3	]	]	X
dpc-3703	108	4	stevie	stevie	PROPN
dpc-3703	108	5	study	study	PROPN
dpc-3703	108	6	(	(	PUNCT
dpc-3703	108	7	median	median	ADJ
dpc-3703	108	8	follow	follow	NOUN
dpc-3703	108	9	-	-	PUNCT
dpc-3703	108	10	up	up	NOUN
dpc-3703	108	11	:	:	PUNCT
dpc-3703	108	12	17.9	17.9	NUM
dpc-3703	108	13	m	m	NOUN
dpc-3703	108	14	)	)	PUNCT
dpc-3703	109	1	[	[	X
dpc-3703	109	2	28	28	NUM
dpc-3703	109	3	]	]	PUNCT
dpc-3703	109	4	bolt	bolt	NOUN
dpc-3703	109	5	study	study	NOUN
dpc-3703	109	6	(	(	PUNCT
dpc-3703	109	7	30month	30month	NUM
dpc-3703	109	8	and	and	CCONJ
dpc-3703	109	9	42	42	NUM
dpc-3703	109	10	-	-	PUNCT
dpc-3703	109	11	month	month	NOUN
dpc-3703	109	12	update	update	NOUN
dpc-3703	109	13	)	)	PUNCT
dpc-3703	110	1	[	[	X
dpc-3703	110	2	30,34	30,34	NOUN
dpc-3703	110	3	]	]	X
dpc-3703	110	4	n	n	PROPN
dpc-3703	110	5	=	=	SYM
dpc-3703	110	6	63	63	NUM
dpc-3703	110	7	labcc	labcc	NOUN
dpc-3703	110	8	n	n	PRON
dpc-3703	110	9	=	=	NOUN
dpc-3703	110	10	1119	1119	NUM
dpc-3703	110	11	labcc	labcc	NOUN
dpc-3703	110	12	n	n	PROPN
dpc-3703	110	13	=	=	NOUN
dpc-3703	110	14	1215	1215	NUM
dpc-3703	110	15	total	total	NOUN
dpc-3703	110	16	n	n	PRON
dpc-3703	110	17	=	=	SYM
dpc-3703	110	18	66	66	NUM
dpc-3703	110	19	labcc	labcc	NOUN
dpc-3703	110	20	n	n	PROPN
dpc-3703	110	21	=	=	SYM
dpc-3703	110	22	79	79	NUM
dpc-3703	110	23	total	total	NOUN
dpc-3703	110	24	investigator	investigator	NOUN
dpc-3703	110	25	-	-	PUNCT
dpc-3703	110	26	assessed	assess	VERB
dpc-3703	110	27	orr	orr	PROPN
dpc-3703	110	28	,	,	PUNCT
dpc-3703	110	29	n	n	PROPN
dpc-3703	110	30	(	(	PUNCT
dpc-3703	110	31	%	%	INTJ
dpc-3703	110	32	)	)	PUNCT
dpc-3703	110	33	cr	cr	NOUN
dpc-3703	110	34	pr	pr	PROPN
dpc-3703	110	35	sd	sd	ADP
dpc-3703	110	36	pd	pd	PROPN
dpc-3703	110	37	38	38	NUM
dpc-3703	110	38	(	(	PUNCT
dpc-3703	110	39	60.3	60.3	NUM
dpc-3703	110	40	)	)	PUNCT
dpc-3703	110	41	20	20	NUM
dpc-3703	110	42	18	18	NUM
dpc-3703	110	43	15	15	NUM
dpc-3703	110	44	6	6	NUM
dpc-3703	110	45	738	738	NUM
dpc-3703	110	46	(	(	PUNCT
dpc-3703	110	47	68.5	68.5	NUM
dpc-3703	110	48	)	)	PUNCT
dpc-3703	110	49	360	360	NUM
dpc-3703	110	50	(	(	PUNCT
dpc-3703	110	51	33.4	33.4	NUM
dpc-3703	110	52	)	)	PUNCT
dpc-3703	110	53	378	378	NUM
dpc-3703	110	54	(	(	PUNCT
dpc-3703	110	55	35.1	35.1	NUM
dpc-3703	110	56	)	)	PUNCT
dpc-3703	110	57	270	270	NUM
dpc-3703	110	58	(	(	PUNCT
dpc-3703	110	59	25.1	25.1	NUM
dpc-3703	110	60	)	)	SYM
dpc-3703	110	61	21	21	NUM
dpc-3703	110	62	(	(	PUNCT
dpc-3703	110	63	1.9	1.9	NUM
dpc-3703	110	64	)	)	PUNCT
dpc-3703	110	65	769	769	NUM
dpc-3703	110	66	(	(	PUNCT
dpc-3703	110	67	66.2	66.2	NUM
dpc-3703	110	68	)	)	SYM
dpc-3703	110	69	364	364	NUM
dpc-3703	110	70	(	(	PUNCT
dpc-3703	110	71	31.4	31.4	NUM
dpc-3703	110	72	)	)	PUNCT
dpc-3703	110	73	405	405	NUM
dpc-3703	110	74	(	(	PUNCT
dpc-3703	110	75	34.9	34.9	NUM
dpc-3703	110	76	)	)	PUNCT
dpc-3703	110	77	309	309	NUM
dpc-3703	110	78	(	(	PUNCT
dpc-3703	110	79	26.6	26.6	NUM
dpc-3703	110	80	)	)	PUNCT
dpc-3703	110	81	30	30	NUM
dpc-3703	110	82	(	(	PUNCT
dpc-3703	110	83	2.6	2.6	NUM
dpc-3703	110	84	)	)	PUNCT
dpc-3703	110	85	47	47	NUM
dpc-3703	110	86	(	(	PUNCT
dpc-3703	110	87	71.2	71.2	NUM
dpc-3703	110	88	%	%	NOUN
dpc-3703	110	89	)	)	PUNCT
dpc-3703	111	1	[	[	X
dpc-3703	111	2	34	34	NUM
dpc-3703	111	3	]	]	SYM
dpc-3703	111	4	6	6	NUM
dpc-3703	111	5	(	(	PUNCT
dpc-3703	111	6	9.1	9.1	NUM
dpc-3703	111	7	)	)	PUNCT
dpc-3703	111	8	41	41	NUM
dpc-3703	111	9	(	(	PUNCT
dpc-3703	111	10	62.1	62.1	NUM
dpc-3703	111	11	)	)	PUNCT
dpc-3703	111	12	13	13	NUM
dpc-3703	111	13	(	(	PUNCT
dpc-3703	111	14	19.7	19.7	NUM
dpc-3703	111	15	)	)	SYM
dpc-3703	111	16	1	1	NUM
dpc-3703	111	17	(	(	PUNCT
dpc-3703	111	18	1.5	1.5	NUM
dpc-3703	111	19	)	)	PUNCT
dpc-3703	111	20	nr	nr	NOUN
dpc-3703	111	21	median	median	ADJ
dpc-3703	111	22	duration	duration	NOUN
dpc-3703	111	23	of	of	ADP
dpc-3703	111	24	response	response	NOUN
dpc-3703	111	25	in	in	ADP
dpc-3703	111	26	responders	responder	NOUN
dpc-3703	111	27	,	,	PUNCT
dpc-3703	111	28	m	m	PROPN
dpc-3703	111	29	(	(	PUNCT
dpc-3703	111	30	95	95	NUM
dpc-3703	111	31	%	%	NOUN
dpc-3703	111	32	ci	ci	NOUN
dpc-3703	111	33	)	)	PUNCT
dpc-3703	111	34	26.2	26.2	NUM
dpc-3703	111	35	(	(	PUNCT
dpc-3703	111	36	9.0	9.0	NUM
dpc-3703	111	37	-	-	SYM
dpc-3703	111	38	37.6	37.6	NUM
dpc-3703	111	39	)	)	PUNCT
dpc-3703	111	40	23	23	NUM
dpc-3703	111	41	(	(	PUNCT
dpc-3703	111	42	20.4	20.4	NUM
dpc-3703	111	43	-	-	SYM
dpc-3703	111	44	26.7	26.7	NUM
dpc-3703	111	45	)	)	PUNCT
dpc-3703	111	46	22.7	22.7	NUM
dpc-3703	111	47	(	(	PUNCT
dpc-3703	111	48	20.3	20.3	NUM
dpc-3703	111	49	-	-	SYM
dpc-3703	111	50	24.8	24.8	NUM
dpc-3703	111	51	)	)	PUNCT
dpc-3703	111	52	26.1	26.1	NUM
dpc-3703	111	53	(	(	PUNCT
dpc-3703	111	54	central	central	ADJ
dpc-3703	111	55	review	review	NOUN
dpc-3703	111	56	)	)	PUNCT
dpc-3703	111	57	30,34	30,34	NUM
dpc-3703	111	58	nr	nr	PROPN
dpc-3703	111	59	median	median	ADJ
dpc-3703	111	60	treatment	treatment	NOUN
dpc-3703	111	61	duration	duration	NOUN
dpc-3703	111	62	,	,	PUNCT
dpc-3703	111	63	m	m	PROPN
dpc-3703	111	64	(	(	PUNCT
dpc-3703	111	65	range	range	NOUN
dpc-3703	111	66	)	)	PUNCT
dpc-3703	111	67	12.7	12.7	NUM
dpc-3703	111	68	(	(	PUNCT
dpc-3703	111	69	1.1	1.1	NUM
dpc-3703	111	70	-	-	SYM
dpc-3703	111	71	47.8	47.8	NUM
dpc-3703	111	72	)	)	PUNCT
dpc-3703	111	73	nr	nr	NOUN
dpc-3703	111	74	8.6	8.6	NUM
dpc-3703	111	75	(	(	PUNCT
dpc-3703	111	76	0	0	NUM
dpc-3703	111	77	-	-	SYM
dpc-3703	111	78	44	44	NUM
dpc-3703	111	79	)	)	PUNCT
dpc-3703	111	80	nr	nr	NOUN
dpc-3703	111	81	11.0	11.0	NUM
dpc-3703	111	82	[	[	NOUN
dpc-3703	111	83	30	30	NUM
dpc-3703	111	84	]	]	PUNCT
dpc-3703	111	85	discontinuation	discontinuation	NOUN
dpc-3703	111	86	,	,	PUNCT
dpc-3703	111	87	n	n	CCONJ
dpc-3703	111	88	(	(	PUNCT
dpc-3703	111	89	%	%	INTJ
dpc-3703	111	90	)	)	PUNCT
dpc-3703	111	91	main	main	ADJ
dpc-3703	111	92	reason	reason	NOUN
dpc-3703	111	93	for	for	ADP
dpc-3703	111	94	discontinuation	discontinuation	NOUN
dpc-3703	111	95	patient	patient	NOUN
dpc-3703	111	96	decision	decision	NOUN
dpc-3703	111	97	adverse	adverse	ADJ
dpc-3703	111	98	event	event	NOUN
dpc-3703	111	99	progressive	progressive	ADJ
dpc-3703	111	100	disease	disease	NOUN
dpc-3703	111	101	physician	physician	NOUN
dpc-3703	111	102	decision	decision	NOUN
dpc-3703	111	103	death	death	NOUN
dpc-3703	111	104	lost	lose	VERB
dpc-3703	111	105	to	to	PART
dpc-3703	111	106	follow	follow	VERB
dpc-3703	111	107	-	-	PUNCT
dpc-3703	111	108	up	up	ADP
dpc-3703	111	109	other	other	ADJ
dpc-3703	111	110	64/71	64/71	NUM
dpc-3703	111	111	(	(	PUNCT
dpc-3703	111	112	90.1	90.1	NUM
dpc-3703	111	113	)	)	PUNCT
dpc-3703	111	114	23	23	NUM
dpc-3703	111	115	(	(	PUNCT
dpc-3703	111	116	32.4	32.4	NUM
dpc-3703	111	117	)	)	PUNCT
dpc-3703	111	118	17	17	NUM
dpc-3703	111	119	(	(	PUNCT
dpc-3703	111	120	23.9	23.9	NUM
dpc-3703	111	121	)	)	PUNCT
dpc-3703	111	122	12	12	NUM
dpc-3703	111	123	(	(	PUNCT
dpc-3703	111	124	16.9	16.9	NUM
dpc-3703	111	125	)	)	PUNCT
dpc-3703	111	126	7	7	NUM
dpc-3703	111	127	(	(	PUNCT
dpc-3703	111	128	9.9	9.9	NUM
dpc-3703	111	129	)	)	PUNCT
dpc-3703	111	130	2	2	NUM
dpc-3703	111	131	(	(	PUNCT
dpc-3703	111	132	2.8	2.8	NUM
dpc-3703	111	133	)	)	PUNCT
dpc-3703	111	134	2	2	NUM
dpc-3703	111	135	(	(	PUNCT
dpc-3703	111	136	2.8	2.8	NUM
dpc-3703	111	137	)	)	PUNCT
dpc-3703	111	138	1	1	NUM
dpc-3703	111	139	(	(	PUNCT
dpc-3703	111	140	1.4	1.4	NUM
dpc-3703	111	141	)	)	PUNCT
dpc-3703	111	142	nr	nr	PROPN
dpc-3703	111	143	1068	1068	NUM
dpc-3703	111	144	(	(	PUNCT
dpc-3703	111	145	88	88	NUM
dpc-3703	111	146	)	)	SYM
dpc-3703	111	147	113	113	NUM
dpc-3703	111	148	(	(	PUNCT
dpc-3703	111	149	9.3	9.3	NUM
dpc-3703	111	150	)	)	PUNCT
dpc-3703	111	151	349	349	NUM
dpc-3703	111	152	(	(	PUNCT
dpc-3703	111	153	28.7	28.7	NUM
dpc-3703	111	154	)	)	PUNCT
dpc-3703	111	155	189	189	NUM
dpc-3703	111	156	(	(	PUNCT
dpc-3703	111	157	15.5	15.5	NUM
dpc-3703	111	158	%	%	NOUN
dpc-3703	111	159	)	)	PUNCT
dpc-3703	111	160	76	76	NUM
dpc-3703	111	161	(	(	PUNCT
dpc-3703	111	162	6.3	6.3	NUM
dpc-3703	111	163	)	)	PUNCT
dpc-3703	111	164	37	37	NUM
dpc-3703	111	165	(	(	PUNCT
dpc-3703	111	166	3	3	NUM
dpc-3703	111	167	)	)	PUNCT
dpc-3703	111	168	21	21	NUM
dpc-3703	111	169	(	(	PUNCT
dpc-3703	111	170	1.7	1.7	NUM
dpc-3703	111	171	)	)	PUNCT
dpc-3703	111	172	283	283	NUM
dpc-3703	111	173	(	(	PUNCT
dpc-3703	111	174	23.3	23.3	NUM
dpc-3703	111	175	)	)	PUNCT
dpc-3703	111	176	nr	nr	PROPN
dpc-3703	111	177	73	73	NUM
dpc-3703	111	178	(	(	PUNCT
dpc-3703	111	179	92.4	92.4	NUM
dpc-3703	111	180	%	%	NOUN
dpc-3703	111	181	)	)	PUNCT
dpc-3703	112	1	[	[	X
dpc-3703	112	2	30	30	NUM
dpc-3703	112	3	]	]	SYM
dpc-3703	112	4	8	8	NUM
dpc-3703	112	5	(	(	PUNCT
dpc-3703	112	6	10.1	10.1	NUM
dpc-3703	112	7	)	)	PUNCT
dpc-3703	112	8	23	23	NUM
dpc-3703	112	9	(	(	PUNCT
dpc-3703	112	10	29.1	29.1	NUM
dpc-3703	112	11	)	)	PUNCT
dpc-3703	112	12	29	29	NUM
dpc-3703	112	13	(	(	PUNCT
dpc-3703	112	14	36.7	36.7	NUM
dpc-3703	112	15	)	)	PUNCT
dpc-3703	112	16	10	10	NUM
dpc-3703	112	17	(	(	PUNCT
dpc-3703	112	18	12.6	12.6	NUM
dpc-3703	112	19	)	)	PUNCT
dpc-3703	112	20	1	1	NUM
dpc-3703	112	21	(	(	PUNCT
dpc-3703	112	22	1.3	1.3	NUM
dpc-3703	112	23	)	)	SYM
dpc-3703	112	24	2	2	NUM
dpc-3703	112	25	(	(	PUNCT
dpc-3703	112	26	2.5	2.5	NUM
dpc-3703	113	1	)	)	PUNCT
dpc-3703	113	2	ci	ci	NOUN
dpc-3703	113	3	=	=	NOUN
dpc-3703	113	4	confidence	confidence	NOUN
dpc-3703	113	5	interval	interval	NOUN
dpc-3703	113	6	;	;	PUNCT
dpc-3703	113	7	cr	cr	NOUN
dpc-3703	113	8	=	=	PUNCT
dpc-3703	113	9	complete	complete	ADJ
dpc-3703	113	10	response	response	NOUN
dpc-3703	113	11	;	;	PUNCT
dpc-3703	113	12	labcc	labcc	NOUN
dpc-3703	113	13	=	=	SYM
dpc-3703	113	14	locally	locally	ADV
dpc-3703	113	15	advanced	advance	VERB
dpc-3703	113	16	bcc	bcc	PROPN
dpc-3703	113	17	;	;	PUNCT
dpc-3703	113	18	m	m	NOUN
dpc-3703	113	19	=	=	NOUN
dpc-3703	113	20	months	month	NOUN
dpc-3703	113	21	;	;	PUNCT
dpc-3703	113	22	n	n	NOUN
dpc-3703	113	23	=	=	SYM
dpc-3703	113	24	number	number	NOUN
dpc-3703	113	25	;	;	PUNCT
dpc-3703	113	26	nr	nr	NOUN
dpc-3703	113	27	=	=	PUNCT
dpc-3703	113	28	not	not	PART
dpc-3703	113	29	reported	report	VERB
dpc-3703	113	30	;	;	PUNCT
dpc-3703	113	31	orr	orr	PROPN
dpc-3703	113	32	=	=	PUNCT
dpc-3703	113	33	objective	objective	ADJ
dpc-3703	113	34	response	response	NOUN
dpc-3703	113	35	rate	rate	NOUN
dpc-3703	113	36	;	;	PUNCT
dpc-3703	113	37	pd	pd	X
dpc-3703	113	38	=	=	PROPN
dpc-3703	113	39	progressive	progressive	ADJ
dpc-3703	113	40	disease	disease	NOUN
dpc-3703	113	41	;	;	PUNCT
dpc-3703	113	42	pr	pr	NOUN
dpc-3703	113	43	=	=	PUNCT
dpc-3703	113	44	partial	partial	ADJ
dpc-3703	113	45	response	response	NOUN
dpc-3703	113	46	;	;	PUNCT
dpc-3703	113	47	sd	sd	NOUN
dpc-3703	113	48	=	=	SYM
dpc-3703	113	49	stable	stable	ADJ
dpc-3703	113	50	disease	disease	NOUN
dpc-3703	113	51	.	.	PUNCT
dpc-3703	114	1	review	review	VERB
dpc-3703	114	2	|	|	ADV
dpc-3703	114	3	dermatol	dermatol	ADJ
dpc-3703	114	4	pract	pract	NOUN
dpc-3703	114	5	concept	concept	NOUN
dpc-3703	114	6	.	.	PUNCT
dpc-3703	115	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	115	2	5	5	NUM
dpc-3703	115	3	had	have	VERB
dpc-3703	115	4	complete	complete	ADJ
dpc-3703	115	5	or	or	CCONJ
dpc-3703	115	6	partial	partial	ADJ
dpc-3703	115	7	response	response	NOUN
dpc-3703	115	8	[	[	X
dpc-3703	115	9	50	50	NUM
dpc-3703	115	10	]	]	PUNCT
dpc-3703	115	11	.	.	PUNCT
dpc-3703	116	1	the	the	DET
dpc-3703	116	2	primary	primary	ADJ
dpc-3703	116	3	analysis	analysis	NOUN
dpc-3703	116	4	of	of	ADP
dpc-3703	116	5	stevie	stevie	NOUN
dpc-3703	116	6	study	study	NOUN
dpc-3703	116	7	in	in	ADP
dpc-3703	116	8	1215	1215	NUM
dpc-3703	116	9	patients	patient	NOUN
dpc-3703	116	10	with	with	ADP
dpc-3703	116	11	advanced	advanced	ADJ
dpc-3703	116	12	bcc	bcc	PROPN
dpc-3703	116	13	showed	show	VERB
dpc-3703	116	14	similar	similar	ADJ
dpc-3703	116	15	results	result	NOUN
dpc-3703	116	16	,	,	PUNCT
dpc-3703	116	17	and	and	CCONJ
dpc-3703	116	18	the	the	DET
dpc-3703	116	19	leading	lead	VERB
dpc-3703	116	20	cause	cause	NOUN
dpc-3703	116	21	of	of	ADP
dpc-3703	116	22	vismodegib	vismodegib	NOUN
dpc-3703	116	23	discontinuation	discontinuation	NOUN
dpc-3703	116	24	were	be	AUX
dpc-3703	116	25	adverse	adverse	ADJ
dpc-3703	116	26	events	event	NOUN
dpc-3703	116	27	(	(	PUNCT
dpc-3703	116	28	28.7	28.7	NUM
dpc-3703	116	29	%	%	NOUN
dpc-3703	116	30	)	)	PUNCT
dpc-3703	117	1	[	[	X
dpc-3703	117	2	28	28	NUM
dpc-3703	117	3	]	]	X
dpc-3703	117	4	(	(	PUNCT
dpc-3703	117	5	table	table	NOUN
dpc-3703	117	6	1	1	NUM
dpc-3703	117	7	)	)	PUNCT
dpc-3703	117	8	.	.	PUNCT
dpc-3703	118	1	in	in	ADP
dpc-3703	118	2	the	the	DET
dpc-3703	118	3	final	final	ADJ
dpc-3703	118	4	update	update	NOUN
dpc-3703	118	5	of	of	ADP
dpc-3703	118	6	the	the	DET
dpc-3703	118	7	erivance	erivance	NOUN
dpc-3703	118	8	bcc	bcc	PROPN
dpc-3703	118	9	study	study	NOUN
dpc-3703	118	10	,	,	PUNCT
dpc-3703	118	11	overall	overall	ADJ
dpc-3703	118	12	92.3	92.3	NUM
dpc-3703	118	13	%	%	NOUN
dpc-3703	118	14	patients	patient	NOUN
dpc-3703	118	15	discontinued	discontinue	VERB
dpc-3703	118	16	vismodegib	vismodegib	NOUN
dpc-3703	118	17	,	,	PUNCT
dpc-3703	118	18	mainly	mainly	ADV
dpc-3703	118	19	because	because	SCONJ
dpc-3703	118	20	of	of	ADP
dpc-3703	118	21	disease	disease	NOUN
dpc-3703	118	22	progression	progression	NOUN
dpc-3703	118	23	(	(	PUNCT
dpc-3703	118	24	27.9	27.9	NUM
dpc-3703	118	25	%	%	NOUN
dpc-3703	118	26	)	)	PUNCT
dpc-3703	118	27	,	,	PUNCT
dpc-3703	118	28	patient	patient	ADJ
dpc-3703	118	29	decision	decision	NOUN
dpc-3703	118	30	(	(	PUNCT
dpc-3703	118	31	26	26	NUM
dpc-3703	118	32	%	%	NOUN
dpc-3703	118	33	)	)	PUNCT
dpc-3703	118	34	and	and	CCONJ
dpc-3703	118	35	adverse	adverse	ADJ
dpc-3703	118	36	events	event	NOUN
dpc-3703	118	37	(	(	PUNCT
dpc-3703	118	38	21.2	21.2	NUM
dpc-3703	118	39	%	%	NOUN
dpc-3703	118	40	)	)	PUNCT
dpc-3703	119	1	[	[	X
dpc-3703	119	2	29	29	NUM
dpc-3703	119	3	]	]	PUNCT
dpc-3703	119	4	.	.	PUNCT
dpc-3703	120	1	in	in	ADP
dpc-3703	120	2	the	the	DET
dpc-3703	120	3	group	group	NOUN
dpc-3703	120	4	of	of	ADP
dpc-3703	120	5	labcc	labcc	PROPN
dpc-3703	120	6	,	,	PUNCT
dpc-3703	120	7	90.1	90.1	NUM
dpc-3703	120	8	%	%	NOUN
dpc-3703	120	9	discontinued	discontinue	VERB
dpc-3703	120	10	vismodegib	vismodegib	NOUN
dpc-3703	120	11	,	,	PUNCT
dpc-3703	120	12	but	but	CCONJ
dpc-3703	120	13	the	the	DET
dpc-3703	120	14	leading	lead	VERB
dpc-3703	120	15	cause	cause	NOUN
dpc-3703	120	16	of	of	ADP
dpc-3703	120	17	discontinuation	discontinuation	NOUN
dpc-3703	120	18	was	be	AUX
dpc-3703	120	19	patient	patient	ADJ
dpc-3703	120	20	decision	decision	NOUN
dpc-3703	120	21	(	(	PUNCT
dpc-3703	120	22	32.4	32.4	NUM
dpc-3703	120	23	%	%	NOUN
dpc-3703	120	24	)	)	PUNCT
dpc-3703	120	25	,	,	PUNCT
dpc-3703	120	26	followed	follow	VERB
dpc-3703	120	27	by	by	ADP
dpc-3703	120	28	adverse	adverse	ADJ
dpc-3703	120	29	events	event	NOUN
dpc-3703	120	30	(	(	PUNCT
dpc-3703	120	31	23.9	23.9	NUM
dpc-3703	120	32	%	%	NOUN
dpc-3703	120	33	)	)	PUNCT
dpc-3703	120	34	and	and	CCONJ
dpc-3703	120	35	disease	disease	NOUN
dpc-3703	120	36	progression	progression	NOUN
dpc-3703	120	37	(	(	PUNCT
dpc-3703	120	38	16.9	16.9	NUM
dpc-3703	120	39	%	%	NOUN
dpc-3703	120	40	)	)	PUNCT
dpc-3703	121	1	[	[	X
dpc-3703	121	2	29	29	NUM
dpc-3703	121	3	]	]	PUNCT
dpc-3703	121	4	.	.	PUNCT
dpc-3703	122	1	in	in	ADP
dpc-3703	122	2	the	the	DET
dpc-3703	122	3	42	42	NUM
dpc-3703	122	4	-	-	PUNCT
dpc-3703	122	5	month	month	NOUN
dpc-3703	122	6	update	update	NOUN
dpc-3703	122	7	of	of	ADP
dpc-3703	122	8	the	the	DET
dpc-3703	122	9	bolt	bolt	NOUN
dpc-3703	122	10	study	study	NOUN
dpc-3703	122	11	,	,	PUNCT
dpc-3703	122	12	of	of	ADP
dpc-3703	122	13	those	those	PRON
dpc-3703	122	14	who	who	PRON
dpc-3703	122	15	discontinued	discontinue	VERB
dpc-3703	122	16	sonidegib	sonidegib	NOUN
dpc-3703	122	17	,	,	PUNCT
dpc-3703	122	18	29.1	29.1	NUM
dpc-3703	122	19	%	%	NOUN
dpc-3703	122	20	discontinued	discontinue	VERB
dpc-3703	122	21	due	due	ADJ
dpc-3703	122	22	to	to	ADP
dpc-3703	122	23	adverse	adverse	ADJ
dpc-3703	122	24	events	event	NOUN
dpc-3703	122	25	,	,	PUNCT
dpc-3703	122	26	despite	despite	SCONJ
dpc-3703	122	27	the	the	DET
dpc-3703	122	28	fact	fact	NOUN
dpc-3703	122	29	that	that	SCONJ
dpc-3703	122	30	most	most	ADJ
dpc-3703	122	31	had	have	AUX
dpc-3703	122	32	only	only	ADV
dpc-3703	122	33	mild	mild	ADJ
dpc-3703	122	34	(	(	PUNCT
dpc-3703	122	35	grade	grade	NOUN
dpc-3703	122	36	1	1	NUM
dpc-3703	122	37	or	or	CCONJ
dpc-3703	122	38	2	2	NUM
dpc-3703	122	39	)	)	PUNCT
dpc-3703	122	40	adverse	adverse	ADJ
dpc-3703	122	41	events	event	NOUN
dpc-3703	122	42	[	[	X
dpc-3703	122	43	30,33	30,33	NUM
dpc-3703	122	44	]	]	PUNCT
dpc-3703	122	45	(	(	PUNCT
dpc-3703	122	46	table	table	NOUN
dpc-3703	122	47	1	1	NUM
dpc-3703	122	48	)	)	PUNCT
dpc-3703	122	49	.	.	PUNCT
dpc-3703	123	1	using	use	VERB
dpc-3703	123	2	hhi	hhi	NOUN
dpc-3703	123	3	as	as	ADP
dpc-3703	123	4	first	first	ADJ
dpc-3703	123	5	-	-	PUNCT
dpc-3703	123	6	line	line	NOUN
dpc-3703	123	7	treatment	treatment	NOUN
dpc-3703	123	8	followed	follow	VERB
dpc-3703	123	9	by	by	ADP
dpc-3703	123	10	anti	anti	ADJ
dpc-3703	123	11	-	-	ADJ
dpc-3703	123	12	pd-1	pd-1	ADJ
dpc-3703	123	13	therapy	therapy	NOUN
dpc-3703	123	14	as	as	SCONJ
dpc-3703	123	15	second	second	ADJ
dpc-3703	123	16	-	-	PUNCT
dpc-3703	123	17	line	line	NOUN
dpc-3703	123	18	treatment	treatment	NOUN
dpc-3703	123	19	may	may	AUX
dpc-3703	123	20	increase	increase	VERB
dpc-3703	123	21	the	the	DET
dpc-3703	123	22	tumor	tumor	NOUN
dpc-3703	123	23	likelihood	likelihood	NOUN
dpc-3703	123	24	to	to	PART
dpc-3703	123	25	respond	respond	VERB
dpc-3703	123	26	to	to	ADP
dpc-3703	123	27	anti	anti	ADJ
dpc-3703	123	28	-	-	ADJ
dpc-3703	123	29	pd-1	pd-1	ADJ
dpc-3703	123	30	therapy	therapy	NOUN
dpc-3703	123	31	.	.	PUNCT
dpc-3703	124	1	the	the	DET
dpc-3703	124	2	treatment	treatment	NOUN
dpc-3703	124	3	with	with	ADP
dpc-3703	124	4	hhi	hhi	NOUN
dpc-3703	124	5	promotes	promote	VERB
dpc-3703	124	6	adaptive	adaptive	ADJ
dpc-3703	124	7	immune	immune	ADJ
dpc-3703	124	8	responses	response	NOUN
dpc-3703	124	9	,	,	PUNCT
dpc-3703	124	10	upregulates	upregulate	VERB
dpc-3703	124	11	mhc	mhc	PROPN
dpc-3703	124	12	-	-	PUNCT
dpc-3703	124	13	i	i	PROPN
dpc-3703	124	14	expression	expression	NOUN
dpc-3703	124	15	and	and	CCONJ
dpc-3703	124	16	increases	increase	VERB
dpc-3703	124	17	the	the	DET
dpc-3703	124	18	intra	intra	ADJ
dpc-3703	124	19	-	-	ADJ
dpc-3703	124	20	tumor	tumor	ADJ
dpc-3703	124	21	infiltration	infiltration	NOUN
dpc-3703	124	22	with	with	ADP
dpc-3703	124	23	cd4	cd4	PROPN
dpc-3703	124	24	+	+	PROPN
dpc-3703	124	25	and	and	CCONJ
dpc-3703	124	26	cytotoxic	cytotoxic	ADJ
dpc-3703	124	27	cd8	cd8	PROPN
dpc-3703	124	28	+	+	PROPN
dpc-3703	124	29	t	t	PROPN
dpc-3703	124	30	cells	cell	NOUN
dpc-3703	124	31	[	[	X
dpc-3703	124	32	51	51	NUM
dpc-3703	124	33	]	]	PUNCT
dpc-3703	124	34	.	.	PUNCT
dpc-3703	125	1	another	another	DET
dpc-3703	125	2	study	study	NOUN
dpc-3703	125	3	showed	show	VERB
dpc-3703	125	4	significantly	significantly	ADV
dpc-3703	125	5	higher	high	ADJ
dpc-3703	125	6	pd	pd	PROPN
dpc-3703	125	7	-	-	PROPN
dpc-3703	125	8	l1	l1	PROPN
dpc-3703	125	9	immunohistochemical	immunohistochemical	ADJ
dpc-3703	125	10	staining	staining	ADJ
dpc-3703	125	11	intensity	intensity	NOUN
dpc-3703	125	12	in	in	ADP
dpc-3703	125	13	tumor	tumor	NOUN
dpc-3703	125	14	cells	cell	NOUN
dpc-3703	125	15	of	of	ADP
dpc-3703	125	16	previous	previous	ADJ
dpc-3703	125	17	treated	treat	VERB
dpc-3703	125	18	bcc	bcc	PROPN
dpc-3703	125	19	versus	versus	ADP
dpc-3703	125	20	naïve	naïve	ADJ
dpc-3703	125	21	bcc	bcc	PROPN
dpc-3703	125	22	(	(	PUNCT
dpc-3703	125	23	32	32	NUM
dpc-3703	125	24	%	%	NOUN
dpc-3703	125	25	versus	versus	ADP
dpc-3703	125	26	7	7	NUM
dpc-3703	125	27	%	%	NOUN
dpc-3703	125	28	,	,	PUNCT
dpc-3703	125	29	respectively	respectively	ADV
dpc-3703	125	30	)	)	PUNCT
dpc-3703	125	31	.	.	PUNCT
dpc-3703	126	1	previous	previous	ADJ
dpc-3703	126	2	treatments	treatment	NOUN
dpc-3703	126	3	included	include	VERB
dpc-3703	126	4	hhi	hhi	NOUN
dpc-3703	126	5	,	,	PUNCT
dpc-3703	126	6	platinum	platinum	NOUN
dpc-3703	126	7	chemotherapy	chemotherapy	NOUN
dpc-3703	126	8	,	,	PUNCT
dpc-3703	126	9	gefitinib	gefitinib	NOUN
dpc-3703	126	10	,	,	PUNCT
dpc-3703	126	11	topical	topical	ADJ
dpc-3703	126	12	chemotherapy	chemotherapy	NOUN
dpc-3703	126	13	,	,	PUNCT
dpc-3703	126	14	surgery	surgery	NOUN
dpc-3703	126	15	,	,	PUNCT
dpc-3703	126	16	and	and	CCONJ
dpc-3703	126	17	radiotherapy	radiotherapy	NOUN
dpc-3703	126	18	[	[	X
dpc-3703	126	19	15	15	NUM
dpc-3703	126	20	]	]	PUNCT
dpc-3703	126	21	.	.	PUNCT
dpc-3703	127	1	the	the	DET
dpc-3703	127	2	evidence	evidence	NOUN
dpc-3703	127	3	on	on	ADP
dpc-3703	127	4	the	the	DET
dpc-3703	127	5	efficacy	efficacy	NOUN
dpc-3703	127	6	and	and	CCONJ
dpc-3703	127	7	safety	safety	NOUN
dpc-3703	127	8	of	of	ADP
dpc-3703	127	9	anti	anti	ADJ
dpc-3703	127	10	-	-	ADJ
dpc-3703	127	11	pd-1	pd-1	ADJ
dpc-3703	127	12	immunotherapy	immunotherapy	NOUN
dpc-3703	127	13	for	for	ADP
dpc-3703	127	14	advanced	advanced	ADJ
dpc-3703	127	15	bcc	bcc	PROPN
dpc-3703	127	16	is	be	AUX
dpc-3703	127	17	presented	present	VERB
dpc-3703	127	18	in	in	ADP
dpc-3703	127	19	the	the	DET
dpc-3703	127	20	following	follow	VERB
dpc-3703	127	21	sections	section	NOUN
dpc-3703	127	22	.	.	PUNCT
dpc-3703	128	1	efficacy	efficacy	NOUN
dpc-3703	128	2	and	and	CCONJ
dpc-3703	128	3	safety	safety	NOUN
dpc-3703	128	4	of	of	ADP
dpc-3703	128	5	anti	anti	ADJ
dpc-3703	128	6	-	-	ADJ
dpc-3703	128	7	pd-1	pd-1	ADJ
dpc-3703	128	8	immunotherapy	immunotherapy	NOUN
dpc-3703	128	9	as	as	ADP
dpc-3703	128	10	second	second	ADJ
dpc-3703	128	11	-	-	PUNCT
dpc-3703	128	12	line	line	NOUN
dpc-3703	128	13	systemic	systemic	ADJ
dpc-3703	128	14	therapy	therapy	NOUN
dpc-3703	128	15	for	for	ADP
dpc-3703	128	16	advanced	advanced	ADJ
dpc-3703	128	17	bcc	bcc	PROPN
dpc-3703	128	18	the	the	DET
dpc-3703	128	19	investigation	investigation	NOUN
dpc-3703	128	20	of	of	ADP
dpc-3703	128	21	antipd-1	antipd-1	NUM
dpc-3703	128	22	agents	agent	NOUN
dpc-3703	128	23	for	for	ADP
dpc-3703	128	24	advanced	advanced	ADJ
dpc-3703	128	25	bcc	bcc	PROPN
dpc-3703	128	26	followed	follow	VERB
dpc-3703	128	27	the	the	DET
dpc-3703	128	28	clinical	clinical	ADJ
dpc-3703	128	29	trials	trial	NOUN
dpc-3703	128	30	and	and	CCONJ
dpc-3703	128	31	regulatory	regulatory	ADJ
dpc-3703	128	32	approval	approval	NOUN
dpc-3703	128	33	of	of	ADP
dpc-3703	128	34	anti	anti	X
dpc-3703	128	35	pd-1	pd-1	ADP
dpc-3703	128	36	immunotherapy	immunotherapy	NOUN
dpc-3703	128	37	for	for	ADP
dpc-3703	128	38	the	the	DET
dpc-3703	128	39	treatment	treatment	NOUN
dpc-3703	128	40	of	of	ADP
dpc-3703	128	41	other	other	ADJ
dpc-3703	128	42	advanced	advanced	ADJ
dpc-3703	128	43	skin	skin	NOUN
dpc-3703	128	44	cancers	cancer	NOUN
dpc-3703	128	45	,	,	PUNCT
dpc-3703	128	46	including	include	VERB
dpc-3703	128	47	cutaneous	cutaneous	ADJ
dpc-3703	128	48	melanoma	melanoma	NOUN
dpc-3703	128	49	and	and	CCONJ
dpc-3703	128	50	squamous	squamous	ADJ
dpc-3703	128	51	cell	cell	NOUN
dpc-3703	128	52	carcinoma	carcinoma	NOUN
dpc-3703	128	53	.	.	PUNCT
dpc-3703	129	1	anti	anti	ADJ
dpc-3703	129	2	-	-	ADJ
dpc-3703	129	3	pd-1	pd-1	ADJ
dpc-3703	129	4	immunotherapy	immunotherapy	NOUN
dpc-3703	129	5	for	for	ADP
dpc-3703	129	6	advanced	advanced	ADJ
dpc-3703	129	7	bcc	bcc	PROPN
dpc-3703	129	8	was	be	AUX
dpc-3703	129	9	first	first	ADV
dpc-3703	129	10	reported	report	VERB
dpc-3703	129	11	in	in	ADP
dpc-3703	129	12	various	various	ADJ
dpc-3703	129	13	case	case	NOUN
dpc-3703	129	14	reports	report	NOUN
dpc-3703	129	15	treated	treat	VERB
dpc-3703	129	16	with	with	ADP
dpc-3703	129	17	cemiplimab	cemiplimab	NOUN
dpc-3703	129	18	,	,	PUNCT
dpc-3703	129	19	nivolumab	nivolumab	NOUN
dpc-3703	129	20	,	,	PUNCT
dpc-3703	129	21	or	or	CCONJ
dpc-3703	129	22	pembrolizumab	pembrolizumab	NOUN
dpc-3703	129	23	,	,	PUNCT
dpc-3703	129	24	mostly	mostly	ADV
dpc-3703	129	25	with	with	ADP
dpc-3703	129	26	benefit	benefit	NOUN
dpc-3703	129	27	[	[	X
dpc-3703	129	28	52	52	NUM
dpc-3703	129	29	-	-	SYM
dpc-3703	129	30	64	64	NUM
dpc-3703	129	31	]	]	PUNCT
dpc-3703	129	32	.	.	PUNCT
dpc-3703	130	1	regulatory	regulatory	ADJ
dpc-3703	130	2	approvals	approval	NOUN
dpc-3703	130	3	for	for	ADP
dpc-3703	130	4	bcc	bcc	PROPN
dpc-3703	130	5	indications	indication	NOUN
dpc-3703	130	6	were	be	AUX
dpc-3703	130	7	based	base	VERB
dpc-3703	130	8	on	on	ADP
dpc-3703	130	9	a	a	DET
dpc-3703	130	10	pivotal	pivotal	ADJ
dpc-3703	130	11	phase	phase	NOUN
dpc-3703	130	12	2	2	NUM
dpc-3703	130	13	open	open	ADJ
dpc-3703	130	14	-	-	PUNCT
dpc-3703	130	15	label	label	NOUN
dpc-3703	130	16	,	,	PUNCT
dpc-3703	130	17	multicenter	multicenter	NOUN
dpc-3703	130	18	,	,	PUNCT
dpc-3703	130	19	single	single	ADJ
dpc-3703	130	20	-	-	PUNCT
dpc-3703	130	21	arm	arm	NOUN
dpc-3703	130	22	trial	trial	NOUN
dpc-3703	130	23	that	that	PRON
dpc-3703	130	24	assessed	assess	VERB
dpc-3703	130	25	cemiplimab	cemiplimab	NOUN
dpc-3703	130	26	monotherapy	monotherapy	NOUN
dpc-3703	130	27	in	in	ADP
dpc-3703	130	28	patients	patient	NOUN
dpc-3703	130	29	with	with	ADP
dpc-3703	130	30	advanced	advanced	ADJ
dpc-3703	130	31	bcc	bcc	NOUN
dpc-3703	130	32	(	(	PUNCT
dpc-3703	130	33	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	130	34	identifier	identifier	NOUN
dpc-3703	130	35	nct03132636	nct03132636	NOUN
dpc-3703	130	36	)	)	PUNCT
dpc-3703	131	1	[	[	X
dpc-3703	131	2	65,66	65,66	NOUN
dpc-3703	131	3	]	]	X
dpc-3703	131	4	.	.	PUNCT
dpc-3703	132	1	this	this	DET
dpc-3703	132	2	pivotal	pivotal	ADJ
dpc-3703	132	3	trial	trial	NOUN
dpc-3703	132	4	included	include	VERB
dpc-3703	132	5	84	84	NUM
dpc-3703	132	6	patients	patient	NOUN
dpc-3703	132	7	with	with	ADP
dpc-3703	132	8	labcc	labcc	PROPN
dpc-3703	132	9	(	(	PUNCT
dpc-3703	132	10	group	group	NOUN
dpc-3703	132	11	2	2	NUM
dpc-3703	132	12	)	)	PUNCT
dpc-3703	132	13	previously	previously	ADV
dpc-3703	132	14	treated	treat	VERB
dpc-3703	132	15	with	with	ADP
dpc-3703	132	16	hhi	hhi	NOUN
dpc-3703	132	17	,	,	PUNCT
dpc-3703	132	18	who	who	PRON
dpc-3703	132	19	were	be	AUX
dpc-3703	132	20	not	not	PART
dpc-3703	132	21	candidates	candidate	NOUN
dpc-3703	132	22	for	for	ADP
dpc-3703	132	23	further	further	ADJ
dpc-3703	132	24	hhi	hhi	NOUN
dpc-3703	132	25	therapy	therapy	NOUN
dpc-3703	132	26	due	due	ADP
dpc-3703	132	27	to	to	ADP
dpc-3703	132	28	progression	progression	NOUN
dpc-3703	132	29	of	of	ADP
dpc-3703	132	30	disease	disease	NOUN
dpc-3703	132	31	(	(	PUNCT
dpc-3703	132	32	71	71	NUM
dpc-3703	132	33	%	%	NOUN
dpc-3703	132	34	)	)	PUNCT
dpc-3703	132	35	,	,	PUNCT
dpc-3703	132	36	or	or	CCONJ
dpc-3703	132	37	no	no	ADV
dpc-3703	132	38	better	well	ADJ
dpc-3703	132	39	than	than	ADP
dpc-3703	132	40	stable	stable	ADJ
dpc-3703	132	41	disease	disease	NOUN
dpc-3703	132	42	after	after	ADP
dpc-3703	132	43	9	9	NUM
dpc-3703	132	44	months	month	NOUN
dpc-3703	132	45	of	of	ADP
dpc-3703	132	46	hhi	hhi	NOUN
dpc-3703	132	47	therapy	therapy	NOUN
dpc-3703	132	48	(	(	PUNCT
dpc-3703	132	49	8	8	NUM
dpc-3703	132	50	%	%	NOUN
dpc-3703	132	51	)	)	PUNCT
dpc-3703	132	52	,	,	PUNCT
dpc-3703	132	53	or	or	CCONJ
dpc-3703	132	54	intolerance	intolerance	NOUN
dpc-3703	132	55	(	(	PUNCT
dpc-3703	132	56	38	38	NUM
dpc-3703	132	57	%	%	NOUN
dpc-3703	132	58	)	)	PUNCT
dpc-3703	133	1	[	[	X
dpc-3703	133	2	65	65	NUM
dpc-3703	133	3	]	]	PUNCT
dpc-3703	133	4	.	.	PUNCT
dpc-3703	134	1	patients	patient	NOUN
dpc-3703	134	2	received	receive	VERB
dpc-3703	134	3	cemiplimab	cemiplimab	NOUN
dpc-3703	134	4	350	350	NUM
dpc-3703	134	5	mg	mg	NOUN
dpc-3703	134	6	by	by	ADP
dpc-3703	134	7	iv	iv	NUM
dpc-3703	134	8	infusion	infusion	NOUN
dpc-3703	134	9	every	every	DET
dpc-3703	134	10	3	3	NUM
dpc-3703	134	11	weeks	week	NOUN
dpc-3703	134	12	for	for	ADP
dpc-3703	134	13	up	up	ADP
dpc-3703	134	14	to	to	PART
dpc-3703	134	15	93	93	NUM
dpc-3703	134	16	weeks	week	NOUN
dpc-3703	134	17	.	.	PUNCT
dpc-3703	135	1	at	at	ADP
dpc-3703	135	2	a	a	DET
dpc-3703	135	3	median	median	ADJ
dpc-3703	135	4	follow	follow	NOUN
dpc-3703	135	5	-	-	PUNCT
dpc-3703	135	6	up	up	NOUN
dpc-3703	135	7	of	of	ADP
dpc-3703	135	8	15	15	NUM
dpc-3703	135	9	months	month	NOUN
dpc-3703	135	10	(	(	PUNCT
dpc-3703	135	11	iqr	iqr	NOUN
dpc-3703	135	12	8	8	NUM
dpc-3703	135	13	-	-	SYM
dpc-3703	135	14	18	18	NUM
dpc-3703	135	15	)	)	PUNCT
dpc-3703	135	16	,	,	PUNCT
dpc-3703	135	17	an	an	DET
dpc-3703	135	18	objective	objective	ADJ
dpc-3703	135	19	response	response	NOUN
dpc-3703	135	20	(	(	PUNCT
dpc-3703	135	21	by	by	ADP
dpc-3703	135	22	independent	independent	ADJ
dpc-3703	135	23	central	central	ADJ
dpc-3703	135	24	review	review	NOUN
dpc-3703	135	25	)	)	PUNCT
dpc-3703	135	26	was	be	AUX
dpc-3703	135	27	observed	observe	VERB
dpc-3703	135	28	in	in	ADP
dpc-3703	135	29	31	31	NUM
dpc-3703	135	30	%	%	NOUN
dpc-3703	135	31	,	,	PUNCT
dpc-3703	135	32	including	include	VERB
dpc-3703	135	33	6	6	NUM
dpc-3703	135	34	%	%	NOUN
dpc-3703	135	35	with	with	ADP
dpc-3703	135	36	complete	complete	ADJ
dpc-3703	135	37	response	response	NOUN
dpc-3703	135	38	and	and	CCONJ
dpc-3703	135	39	25	25	NUM
dpc-3703	135	40	%	%	NOUN
dpc-3703	135	41	with	with	ADP
dpc-3703	135	42	partial	partial	ADJ
dpc-3703	135	43	response	response	NOUN
dpc-3703	135	44	.	.	PUNCT
dpc-3703	136	1	the	the	DET
dpc-3703	136	2	response	response	NOUN
dpc-3703	136	3	rate	rate	NOUN
dpc-3703	136	4	was	be	AUX
dpc-3703	136	5	similar	similar	ADJ
dpc-3703	136	6	across	across	ADP
dpc-3703	136	7	subgroups	subgroup	NOUN
dpc-3703	136	8	regarding	regard	VERB
dpc-3703	136	9	age	age	NOUN
dpc-3703	136	10	,	,	PUNCT
dpc-3703	136	11	sex	sex	NOUN
dpc-3703	136	12	,	,	PUNCT
dpc-3703	136	13	and	and	CCONJ
dpc-3703	136	14	intolerance	intolerance	NOUN
dpc-3703	136	15	or	or	CCONJ
dpc-3703	136	16	progression	progression	NOUN
dpc-3703	136	17	/	/	SYM
dpc-3703	136	18	lack	lack	NOUN
dpc-3703	136	19	of	of	ADP
dpc-3703	136	20	response	response	NOUN
dpc-3703	136	21	to	to	ADP
dpc-3703	136	22	previous	previous	ADJ
dpc-3703	136	23	hhi	hhi	NOUN
dpc-3703	136	24	.	.	PUNCT
dpc-3703	137	1	cemiplimab	cemiplimab	NOUN
dpc-3703	137	2	was	be	AUX
dpc-3703	137	3	discontinued	discontinue	VERB
dpc-3703	137	4	in	in	ADP
dpc-3703	137	5	62	62	NUM
dpc-3703	137	6	%	%	NOUN
dpc-3703	137	7	of	of	ADP
dpc-3703	137	8	patients	patient	NOUN
dpc-3703	137	9	,	,	PUNCT
dpc-3703	137	10	due	due	ADP
dpc-3703	137	11	to	to	ADP
dpc-3703	137	12	disease	disease	NOUN
dpc-3703	137	13	progression	progression	NOUN
dpc-3703	137	14	(	(	PUNCT
dpc-3703	137	15	35	35	NUM
dpc-3703	137	16	%	%	NOUN
dpc-3703	137	17	)	)	PUNCT
dpc-3703	137	18	,	,	PUNCT
dpc-3703	137	19	adverse	adverse	ADJ
dpc-3703	137	20	event	event	NOUN
dpc-3703	137	21	(	(	PUNCT
dpc-3703	137	22	16	16	NUM
dpc-3703	137	23	%	%	NOUN
dpc-3703	137	24	)	)	PUNCT
dpc-3703	137	25	,	,	PUNCT
dpc-3703	137	26	or	or	CCONJ
dpc-3703	137	27	patient	patient	ADJ
dpc-3703	137	28	decision	decision	NOUN
dpc-3703	137	29	(	(	PUNCT
dpc-3703	137	30	6	6	NUM
dpc-3703	137	31	%	%	NOUN
dpc-3703	137	32	)	)	PUNCT
dpc-3703	138	1	[	[	X
dpc-3703	138	2	65	65	NUM
dpc-3703	138	3	]	]	X
dpc-3703	138	4	(	(	PUNCT
dpc-3703	138	5	table	table	NOUN
dpc-3703	138	6	2	2	NUM
dpc-3703	138	7	)	)	PUNCT
dpc-3703	138	8	.	.	PUNCT
dpc-3703	139	1	in	in	ADP
dpc-3703	139	2	this	this	DET
dpc-3703	139	3	pivotal	pivotal	ADJ
dpc-3703	139	4	study	study	NOUN
dpc-3703	139	5	,	,	PUNCT
dpc-3703	139	6	the	the	DET
dpc-3703	139	7	safety	safety	NOUN
dpc-3703	139	8	profile	profile	NOUN
dpc-3703	139	9	of	of	ADP
dpc-3703	139	10	cemiplimab	cemiplimab	NOUN
dpc-3703	139	11	for	for	ADP
dpc-3703	139	12	bcc	bcc	PROPN
dpc-3703	139	13	was	be	AUX
dpc-3703	139	14	consistent	consistent	ADJ
dpc-3703	139	15	with	with	ADP
dpc-3703	139	16	that	that	PRON
dpc-3703	139	17	of	of	ADP
dpc-3703	139	18	other	other	ADJ
dpc-3703	139	19	anti	anti	ADJ
dpc-3703	139	20	-	-	ADJ
dpc-3703	139	21	pd-1	pd-1	ADJ
dpc-3703	139	22	agents	agent	NOUN
dpc-3703	139	23	for	for	ADP
dpc-3703	139	24	cutaneous	cutaneous	ADJ
dpc-3703	139	25	melanoma	melanoma	NOUN
dpc-3703	139	26	and	and	CCONJ
dpc-3703	139	27	cscc	cscc	ADJ
dpc-3703	139	28	.	.	PUNCT
dpc-3703	140	1	treatment	treatment	NOUN
dpc-3703	140	2	-	-	PUNCT
dpc-3703	140	3	emergent	emergent	ADJ
dpc-3703	140	4	adverse	adverse	ADJ
dpc-3703	140	5	events	event	NOUN
dpc-3703	140	6	grade	grade	NOUN
dpc-3703	140	7	3	3	NUM
dpc-3703	140	8	or	or	CCONJ
dpc-3703	140	9	4	4	NUM
dpc-3703	140	10	occurred	occur	VERB
dpc-3703	140	11	in	in	ADP
dpc-3703	140	12	48	48	NUM
dpc-3703	140	13	%	%	NOUN
dpc-3703	140	14	of	of	ADP
dpc-3703	140	15	patients	patient	NOUN
dpc-3703	140	16	,	,	PUNCT
dpc-3703	140	17	including	include	VERB
dpc-3703	140	18	hypertension	hypertension	NOUN
dpc-3703	140	19	,	,	PUNCT
dpc-3703	140	20	colitis	colitis	NOUN
dpc-3703	140	21	,	,	PUNCT
dpc-3703	140	22	and	and	CCONJ
dpc-3703	140	23	fatigue	fatigue	NOUN
dpc-3703	140	24	.	.	PUNCT
dpc-3703	141	1	immune	immune	NOUN
dpc-3703	141	2	-	-	PUNCT
dpc-3703	141	3	related	relate	VERB
dpc-3703	141	4	adverse	adverse	ADJ
dpc-3703	141	5	events	event	NOUN
dpc-3703	141	6	(	(	PUNCT
dpc-3703	141	7	none	none	NOUN
dpc-3703	141	8	of	of	ADP
dpc-3703	141	9	grade	grade	NOUN
dpc-3703	141	10	4	4	NUM
dpc-3703	141	11	or	or	CCONJ
dpc-3703	141	12	5	5	NUM
dpc-3703	141	13	)	)	PUNCT
dpc-3703	141	14	occurred	occur	VERB
dpc-3703	141	15	in	in	ADP
dpc-3703	141	16	25	25	NUM
dpc-3703	141	17	%	%	NOUN
dpc-3703	141	18	of	of	ADP
dpc-3703	141	19	patients	patient	NOUN
dpc-3703	141	20	and	and	CCONJ
dpc-3703	141	21	included	include	VERB
dpc-3703	141	22	hypothyroidism	hypothyroidism	NOUN
dpc-3703	141	23	(	(	PUNCT
dpc-3703	141	24	10	10	NUM
dpc-3703	141	25	%	%	NOUN
dpc-3703	141	26	)	)	PUNCT
dpc-3703	141	27	,	,	PUNCT
dpc-3703	141	28	hyperthyroidism	hyperthyroidism	NOUN
dpc-3703	141	29	(	(	PUNCT
dpc-3703	141	30	2	2	NUM
dpc-3703	141	31	%	%	NOUN
dpc-3703	141	32	)	)	PUNCT
dpc-3703	141	33	,	,	PUNCT
dpc-3703	141	34	thyroiditis	thyroiditis	NOUN
dpc-3703	141	35	(	(	PUNCT
dpc-3703	141	36	2	2	NUM
dpc-3703	141	37	%	%	NOUN
dpc-3703	141	38	)	)	PUNCT
dpc-3703	141	39	,	,	PUNCT
dpc-3703	141	40	adrenal	adrenal	ADJ
dpc-3703	141	41	insufficiency	insufficiency	NOUN
dpc-3703	141	42	(	(	PUNCT
dpc-3703	141	43	2	2	NUM
dpc-3703	141	44	%	%	NOUN
dpc-3703	141	45	)	)	PUNCT
dpc-3703	141	46	,	,	PUNCT
dpc-3703	141	47	immune	immune	NOUN
dpc-3703	141	48	-	-	PUNCT
dpc-3703	141	49	related	relate	VERB
dpc-3703	141	50	colitis	colitis	NOUN
dpc-3703	141	51	(	(	PUNCT
dpc-3703	141	52	4	4	NUM
dpc-3703	141	53	%	%	NOUN
dpc-3703	141	54	)	)	PUNCT
dpc-3703	141	55	,	,	PUNCT
dpc-3703	141	56	and	and	CCONJ
dpc-3703	141	57	hypophysitis	hypophysitis	NOUN
dpc-3703	141	58	,	,	PUNCT
dpc-3703	141	59	immune	immune	NOUN
dpc-3703	141	60	-	-	PUNCT
dpc-3703	141	61	mediated	mediate	VERB
dpc-3703	141	62	hepatitis	hepatitis	NOUN
dpc-3703	141	63	and	and	CCONJ
dpc-3703	141	64	maculopapular	maculopapular	ADJ
dpc-3703	141	65	rash	rash	NOUN
dpc-3703	141	66	(	(	PUNCT
dpc-3703	141	67	each	each	PRON
dpc-3703	141	68	in	in	ADP
dpc-3703	141	69	one	one	NUM
dpc-3703	141	70	patient	patient	NOUN
dpc-3703	141	71	)	)	PUNCT
dpc-3703	141	72	(	(	PUNCT
dpc-3703	141	73	table	table	NOUN
dpc-3703	141	74	2	2	NUM
dpc-3703	141	75	)	)	PUNCT
dpc-3703	142	1	[	[	X
dpc-3703	142	2	65	65	NUM
dpc-3703	142	3	]	]	PUNCT
dpc-3703	142	4	.	.	PUNCT
dpc-3703	143	1	the	the	DET
dpc-3703	143	2	unicancer	unicancer	ADJ
dpc-3703	143	3	acse	acse	NOUN
dpc-3703	143	4	nivolumab	nivolumab	ADP
dpc-3703	143	5	phase	phase	NOUN
dpc-3703	143	6	2	2	NUM
dpc-3703	143	7	basket	basket	NOUN
dpc-3703	143	8	trial	trial	NOUN
dpc-3703	143	9	(	(	PUNCT
dpc-3703	143	10	nct03012581	nct03012581	NOUN
dpc-3703	143	11	)	)	PUNCT
dpc-3703	143	12	evaluated	evaluate	VERB
dpc-3703	143	13	nivolumab	nivolumab	ADV
dpc-3703	143	14	in	in	ADP
dpc-3703	143	15	a	a	DET
dpc-3703	143	16	relatively	relatively	ADV
dpc-3703	143	17	small	small	ADJ
dpc-3703	143	18	number	number	NOUN
dpc-3703	143	19	of	of	ADP
dpc-3703	143	20	32	32	NUM
dpc-3703	143	21	patients	patient	NOUN
dpc-3703	143	22	with	with	ADP
dpc-3703	143	23	advanced	advanced	ADJ
dpc-3703	143	24	bcc	bcc	PROPN
dpc-3703	143	25	,	,	PUNCT
dpc-3703	143	26	including	include	VERB
dpc-3703	143	27	29	29	NUM
dpc-3703	143	28	labcc	labcc	NOUN
dpc-3703	143	29	and	and	CCONJ
dpc-3703	143	30	3	3	NUM
dpc-3703	143	31	mbcc	mbcc	NOUN
dpc-3703	143	32	.	.	PUNCT
dpc-3703	144	1	patients	patient	NOUN
dpc-3703	144	2	received	receive	VERB
dpc-3703	144	3	nivolumab	nivolumab	NOUN
dpc-3703	144	4	240	240	NUM
dpc-3703	144	5	mg	mg	NOUN
dpc-3703	144	6	by	by	ADP
dpc-3703	144	7	iv	iv	NUM
dpc-3703	144	8	infusion	infusion	NOUN
dpc-3703	144	9	every	every	DET
dpc-3703	144	10	2	2	NUM
dpc-3703	144	11	weeks	week	NOUN
dpc-3703	144	12	for	for	ADP
dpc-3703	144	13	up	up	ADP
dpc-3703	144	14	to	to	PART
dpc-3703	144	15	24	24	NUM
dpc-3703	144	16	months	month	NOUN
dpc-3703	144	17	[	[	X
dpc-3703	144	18	67	67	NUM
dpc-3703	144	19	]	]	PUNCT
dpc-3703	144	20	.	.	PUNCT
dpc-3703	145	1	the	the	DET
dpc-3703	145	2	median	median	ADJ
dpc-3703	145	3	follow	follow	NOUN
dpc-3703	145	4	-	-	PUNCT
dpc-3703	145	5	up	up	NOUN
dpc-3703	145	6	was	be	AUX
dpc-3703	145	7	17	17	NUM
dpc-3703	145	8	months	month	NOUN
dpc-3703	145	9	(	(	PUNCT
dpc-3703	145	10	iqr	iqr	NOUN
dpc-3703	145	11	12	12	NUM
dpc-3703	145	12	-	-	SYM
dpc-3703	145	13	23	23	NUM
dpc-3703	145	14	)	)	PUNCT
dpc-3703	145	15	.	.	PUNCT
dpc-3703	146	1	in	in	ADP
dpc-3703	146	2	this	this	DET
dpc-3703	146	3	study	study	NOUN
dpc-3703	146	4	,	,	PUNCT
dpc-3703	146	5	the	the	DET
dpc-3703	146	6	objective	objective	ADJ
dpc-3703	146	7	response	response	NOUN
dpc-3703	146	8	(	(	PUNCT
dpc-3703	146	9	radiologically	radiologically	ADV
dpc-3703	146	10	)	)	PUNCT
dpc-3703	146	11	was	be	AUX
dpc-3703	146	12	assessed	assess	VERB
dpc-3703	146	13	early	early	ADV
dpc-3703	146	14	at	at	ADP
dpc-3703	146	15	12	12	NUM
dpc-3703	146	16	weeks	week	NOUN
dpc-3703	146	17	,	,	PUNCT
dpc-3703	146	18	and	and	CCONJ
dpc-3703	146	19	was	be	AUX
dpc-3703	146	20	observed	observe	VERB
dpc-3703	146	21	in	in	ADP
dpc-3703	146	22	22	22	NUM
dpc-3703	146	23	%	%	NOUN
dpc-3703	146	24	,	,	PUNCT
dpc-3703	146	25	including	include	VERB
dpc-3703	146	26	3.1	3.1	NUM
dpc-3703	146	27	%	%	NOUN
dpc-3703	146	28	with	with	ADP
dpc-3703	146	29	complete	complete	ADJ
dpc-3703	146	30	response	response	NOUN
dpc-3703	146	31	and	and	CCONJ
dpc-3703	146	32	18.8	18.8	NUM
dpc-3703	146	33	%	%	NOUN
dpc-3703	146	34	with	with	ADP
dpc-3703	146	35	partial	partial	ADJ
dpc-3703	146	36	response	response	NOUN
dpc-3703	146	37	(	(	PUNCT
dpc-3703	146	38	table	table	NOUN
dpc-3703	146	39	 	 	SPACE
dpc-3703	146	40	2	2	NUM
dpc-3703	146	41	)	)	PUNCT
dpc-3703	146	42	.	.	PUNCT
dpc-3703	147	1	adverse	adverse	ADJ
dpc-3703	147	2	events	event	NOUN
dpc-3703	147	3	occurred	occur	VERB
dpc-3703	147	4	in	in	ADP
dpc-3703	147	5	28	28	NUM
dpc-3703	147	6	%	%	NOUN
dpc-3703	147	7	of	of	ADP
dpc-3703	147	8	patients	patient	NOUN
dpc-3703	147	9	and	and	CCONJ
dpc-3703	147	10	almost	almost	ADV
dpc-3703	147	11	half	half	NOUN
dpc-3703	147	12	were	be	AUX
dpc-3703	147	13	considered	consider	VERB
dpc-3703	147	14	treatment	treatment	NOUN
dpc-3703	147	15	related	relate	VERB
dpc-3703	147	16	.	.	PUNCT
dpc-3703	148	1	only	only	ADV
dpc-3703	148	2	one	one	NUM
dpc-3703	148	3	related	relate	VERB
dpc-3703	148	4	adverse	adverse	ADJ
dpc-3703	148	5	event	event	NOUN
dpc-3703	148	6	led	lead	VERB
dpc-3703	148	7	to	to	ADP
dpc-3703	148	8	treatment	treatment	NOUN
dpc-3703	148	9	discontinuation	discontinuation	NOUN
dpc-3703	148	10	.	.	PUNCT
dpc-3703	149	1	more	more	ADV
dpc-3703	149	2	frequent	frequent	ADJ
dpc-3703	149	3	adverse	adverse	ADJ
dpc-3703	149	4	events	event	NOUN
dpc-3703	149	5	were	be	AUX
dpc-3703	149	6	diabetes	diabetes	NOUN
dpc-3703	149	7	mellitus	mellitus	NOUN
dpc-3703	149	8	,	,	PUNCT
dpc-3703	149	9	colitis	colitis	NOUN
dpc-3703	149	10	,	,	PUNCT
dpc-3703	149	11	pneumonitis	pneumonitis	NOUN
dpc-3703	149	12	,	,	PUNCT
dpc-3703	149	13	myocardial	myocardial	ADJ
dpc-3703	149	14	infarction	infarction	NOUN
dpc-3703	149	15	,	,	PUNCT
dpc-3703	149	16	lymphopenia	lymphopenia	NOUN
dpc-3703	149	17	and	and	CCONJ
dpc-3703	149	18	bullous	bullous	ADJ
dpc-3703	149	19	pemphigoid	pemphigoid	NOUN
dpc-3703	149	20	[	[	X
dpc-3703	149	21	67	67	NUM
dpc-3703	149	22	]	]	PUNCT
dpc-3703	149	23	.	.	PUNCT
dpc-3703	150	1	the	the	DET
dpc-3703	150	2	above	above	ADV
dpc-3703	150	3	mentioned	mention	VERB
dpc-3703	150	4	findings	finding	NOUN
dpc-3703	150	5	of	of	ADP
dpc-3703	150	6	clinical	clinical	ADJ
dpc-3703	150	7	trials	trial	NOUN
dpc-3703	150	8	show	show	VERB
dpc-3703	150	9	the	the	DET
dpc-3703	150	10	efficacy	efficacy	NOUN
dpc-3703	150	11	of	of	ADP
dpc-3703	150	12	second	second	ADJ
dpc-3703	150	13	-	-	PUNCT
dpc-3703	150	14	line	line	NOUN
dpc-3703	150	15	anti	anti	ADJ
dpc-3703	150	16	-	-	ADJ
dpc-3703	150	17	pd-1	pd-1	ADJ
dpc-3703	150	18	ici	ici	NOUN
dpc-3703	150	19	in	in	ADP
dpc-3703	150	20	some	some	DET
dpc-3703	150	21	patients	patient	NOUN
dpc-3703	150	22	while	while	SCONJ
dpc-3703	150	23	others	other	NOUN
dpc-3703	150	24	will	will	AUX
dpc-3703	150	25	not	not	PART
dpc-3703	150	26	respond	respond	VERB
dpc-3703	150	27	,	,	PUNCT
dpc-3703	150	28	indicating	indicate	VERB
dpc-3703	150	29	a	a	DET
dpc-3703	150	30	considerable	considerable	ADJ
dpc-3703	150	31	group	group	NOUN
dpc-3703	150	32	of	of	ADP
dpc-3703	150	33	patients	patient	NOUN
dpc-3703	150	34	with	with	ADP
dpc-3703	150	35	primary	primary	ADJ
dpc-3703	150	36	or	or	CCONJ
dpc-3703	150	37	secondary	secondary	ADJ
dpc-3703	150	38	resistance	resistance	NOUN
dpc-3703	150	39	to	to	ADP
dpc-3703	150	40	anti	anti	ADJ
dpc-3703	150	41	-	-	ADJ
dpc-3703	150	42	pd-1	pd-1	ADJ
dpc-3703	150	43	therapy	therapy	NOUN
dpc-3703	150	44	.	.	PUNCT
dpc-3703	151	1	to	to	PART
dpc-3703	151	2	overcome	overcome	VERB
dpc-3703	151	3	these	these	DET
dpc-3703	151	4	limitations	limitation	NOUN
dpc-3703	151	5	,	,	PUNCT
dpc-3703	151	6	the	the	DET
dpc-3703	151	7	use	use	NOUN
dpc-3703	151	8	of	of	ADP
dpc-3703	151	9	anti	anti	ADJ
dpc-3703	151	10	-	-	ADJ
dpc-3703	151	11	pd	pd	ADJ
dpc-3703	151	12	therapies	therapy	NOUN
dpc-3703	151	13	against	against	ADP
dpc-3703	151	14	earlier	early	ADJ
dpc-3703	151	15	stages	stage	NOUN
dpc-3703	151	16	of	of	ADP
dpc-3703	151	17	cancer	cancer	NOUN
dpc-3703	151	18	as	as	SCONJ
dpc-3703	151	19	neo	neo	NOUN
dpc-3703	151	20	-	-	PUNCT
dpc-3703	151	21	adjuvant	adjuvant	ADJ
dpc-3703	151	22	treatment	treatment	NOUN
dpc-3703	151	23	has	have	AUX
dpc-3703	151	24	been	be	AUX
dpc-3703	151	25	considered	consider	VERB
dpc-3703	151	26	[	[	PUNCT
dpc-3703	151	27	11	11	NUM
dpc-3703	151	28	]	]	PUNCT
dpc-3703	151	29	.	.	PUNCT
dpc-3703	152	1	is	be	AUX
dpc-3703	152	2	there	there	PRON
dpc-3703	152	3	a	a	DET
dpc-3703	152	4	place	place	NOUN
dpc-3703	152	5	for	for	ADP
dpc-3703	152	6	anti	anti	ADJ
dpc-3703	152	7	-	-	ADJ
dpc-3703	152	8	pd-1	pd-1	ADJ
dpc-3703	152	9	agents	agent	NOUN
dpc-3703	152	10	as	as	ADP
dpc-3703	152	11	neoadjuvant	neoadjuvant	ADJ
dpc-3703	152	12	or	or	CCONJ
dpc-3703	152	13	adjuvant	adjuvant	ADJ
dpc-3703	152	14	treatment	treatment	NOUN
dpc-3703	152	15	for	for	ADP
dpc-3703	152	16	advanced	advanced	ADJ
dpc-3703	152	17	bcc	bcc	PROPN
dpc-3703	152	18	?	?	PUNCT
dpc-3703	153	1	the	the	DET
dpc-3703	153	2	aim	aim	NOUN
dpc-3703	153	3	of	of	ADP
dpc-3703	153	4	neoadjuvant	neoadjuvant	ADJ
dpc-3703	153	5	(	(	PUNCT
dpc-3703	153	6	presurgical	presurgical	ADJ
dpc-3703	153	7	)	)	PUNCT
dpc-3703	153	8	treatment	treatment	NOUN
dpc-3703	153	9	for	for	ADP
dpc-3703	153	10	advanced	advanced	ADJ
dpc-3703	153	11	skin	skin	NOUN
dpc-3703	153	12	cancer	cancer	NOUN
dpc-3703	153	13	has	have	AUX
dpc-3703	153	14	traditionally	traditionally	ADV
dpc-3703	153	15	been	be	AUX
dpc-3703	153	16	to	to	PART
dpc-3703	153	17	improve	improve	VERB
dpc-3703	153	18	the	the	DET
dpc-3703	153	19	operability	operability	NOUN
dpc-3703	153	20	of	of	ADP
dpc-3703	153	21	tumors	tumor	NOUN
dpc-3703	153	22	.	.	PUNCT
dpc-3703	154	1	currently	currently	ADV
dpc-3703	154	2	there	there	PRON
dpc-3703	154	3	is	be	VERB
dpc-3703	154	4	no	no	DET
dpc-3703	154	5	treatment	treatment	NOUN
dpc-3703	154	6	approved	approve	VERB
dpc-3703	154	7	for	for	ADP
dpc-3703	154	8	advanced	advanced	ADJ
dpc-3703	154	9	bcc	bcc	PROPN
dpc-3703	154	10	in	in	ADP
dpc-3703	154	11	the	the	DET
dpc-3703	154	12	neoadjuvant	neoadjuvant	ADJ
dpc-3703	154	13	setting	setting	NOUN
dpc-3703	154	14	.	.	PUNCT
dpc-3703	155	1	neoadjuvant	neoadjuvant	ADJ
dpc-3703	155	2	vismodegib	vismodegib	NOUN
dpc-3703	155	3	was	be	AUX
dpc-3703	155	4	used	use	VERB
dpc-3703	155	5	in	in	ADP
dpc-3703	155	6	the	the	DET
dpc-3703	155	7	vismoneo	vismoneo	NOUN
dpc-3703	155	8	phase	phase	NOUN
dpc-3703	155	9	2	2	NUM
dpc-3703	155	10	trial	trial	NOUN
dpc-3703	155	11	in	in	ADP
dpc-3703	155	12	55	55	NUM
dpc-3703	155	13	patients	patient	NOUN
dpc-3703	155	14	with	with	ADP
dpc-3703	155	15	locally	locally	ADV
dpc-3703	155	16	advanced	advanced	ADJ
dpc-3703	155	17	bcc	bcc	NOUN
dpc-3703	155	18	of	of	ADP
dpc-3703	155	19	the	the	DET
dpc-3703	155	20	face	face	NOUN
dpc-3703	155	21	,	,	PUNCT
dpc-3703	155	22	and	and	CCONJ
dpc-3703	155	23	resulted	result	VERB
dpc-3703	155	24	in	in	ADP
dpc-3703	155	25	downstaging	downstage	VERB
dpc-3703	155	26	in	in	ADP
dpc-3703	155	27	surgical	surgical	ADJ
dpc-3703	155	28	resection	resection	NOUN
dpc-3703	155	29	complexity	complexity	NOUN
dpc-3703	155	30	in	in	ADP
dpc-3703	155	31	44	44	NUM
dpc-3703	155	32	(	(	PUNCT
dpc-3703	155	33	80	80	NUM
dpc-3703	155	34	%	%	NOUN
dpc-3703	155	35	)	)	PUNCT
dpc-3703	155	36	,	,	PUNCT
dpc-3703	155	37	of	of	ADP
dpc-3703	155	38	whom	whom	PRON
dpc-3703	155	39	27	27	NUM
dpc-3703	155	40	had	have	VERB
dpc-3703	155	41	complete	complete	ADJ
dpc-3703	155	42	response	response	NOUN
dpc-3703	155	43	.	.	PUNCT
dpc-3703	156	1	a	a	DET
dpc-3703	156	2	recurrence	recurrence	NOUN
dpc-3703	156	3	6	6	NUM
dpc-3703	156	4	review	review	NOUN
dpc-3703	156	5	|	|	ADV
dpc-3703	156	6	dermatol	dermatol	ADJ
dpc-3703	156	7	pract	pract	NOUN
dpc-3703	156	8	concept	concept	NOUN
dpc-3703	156	9	.	.	PUNCT
dpc-3703	157	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	157	2	table	table	NOUN
dpc-3703	157	3	2	2	NUM
dpc-3703	157	4	.	.	PUNCT
dpc-3703	157	5	results	result	NOUN
dpc-3703	157	6	from	from	ADP
dpc-3703	157	7	clinical	clinical	ADJ
dpc-3703	157	8	trials	trial	NOUN
dpc-3703	157	9	with	with	ADP
dpc-3703	157	10	anti	anti	ADJ
dpc-3703	157	11	-	-	ADJ
dpc-3703	157	12	pd-1	pd-1	ADJ
dpc-3703	157	13	immunotherapy	immunotherapy	NOUN
dpc-3703	157	14	for	for	ADP
dpc-3703	157	15	advanced	advanced	ADJ
dpc-3703	157	16	bcc	bcc	PROPN
dpc-3703	157	17	.	.	PUNCT
dpc-3703	158	1	stratigos	stratigos	PROPN
dpc-3703	158	2	,	,	PUNCT
dpc-3703	158	3	2021	2021	NUM
dpc-3703	159	1	[	[	X
dpc-3703	159	2	65	65	NUM
dpc-3703	159	3	]	]	X
dpc-3703	159	4	veron	veron	PROPN
dpc-3703	159	5	,	,	PUNCT
dpc-3703	159	6	2022	2022	NUM
dpc-3703	159	7	[	[	X
dpc-3703	159	8	67	67	NUM
dpc-3703	159	9	]	]	X
dpc-3703	159	10	anti	anti	ADJ
dpc-3703	159	11	-	-	ADJ
dpc-3703	159	12	pd-1	pd-1	ADJ
dpc-3703	159	13	agent	agent	NOUN
dpc-3703	159	14	cemiplimab	cemiplimab	NOUN
dpc-3703	159	15	nivolumab	nivolumab	ADV
dpc-3703	159	16	n	n	PRON
dpc-3703	159	17	84	84	NUM
dpc-3703	159	18	labcc	labcc	ADV
dpc-3703	159	19	29	29	NUM
dpc-3703	159	20	labcc	labcc	NOUN
dpc-3703	159	21	and	and	CCONJ
dpc-3703	159	22	3	3	NUM
dpc-3703	159	23	mbcc	mbcc	NOUN
dpc-3703	159	24	prior	prior	ADV
dpc-3703	159	25	systemic	systemic	ADJ
dpc-3703	159	26	treatment	treatment	NOUN
dpc-3703	159	27	hhi	hhi	NOUN
dpc-3703	159	28	(	(	PUNCT
dpc-3703	159	29	vismodegib	vismodegib	NOUN
dpc-3703	159	30	or	or	CCONJ
dpc-3703	159	31	sonidegib	sonidegib	NOUN
dpc-3703	159	32	)	)	PUNCT
dpc-3703	159	33	chemotherapy	chemotherapy	NOUN
dpc-3703	159	34	all	all	PRON
dpc-3703	159	35	nr	nr	PRON
dpc-3703	159	36	all	all	PRON
dpc-3703	159	37	17	17	NUM
dpc-3703	159	38	(	(	PUNCT
dpc-3703	159	39	53	53	NUM
dpc-3703	159	40	%	%	NOUN
dpc-3703	159	41	)	)	PUNCT
dpc-3703	159	42	median	median	PROPN
dpc-3703	159	43	fu	fu	PROPN
dpc-3703	159	44	,	,	PUNCT
dpc-3703	159	45	m	m	VERB
dpc-3703	159	46	15	15	NUM
dpc-3703	159	47	17	17	NUM
dpc-3703	159	48	orr	orr	PROPN
dpc-3703	159	49	(	(	PUNCT
dpc-3703	159	50	icr	icr	PROPN
dpc-3703	159	51	)	)	PUNCT
dpc-3703	159	52	,	,	PUNCT
dpc-3703	159	53	n	n	PROPN
dpc-3703	159	54	(	(	PUNCT
dpc-3703	159	55	%	%	INTJ
dpc-3703	159	56	)	)	PUNCT
dpc-3703	159	57	complete	complete	ADJ
dpc-3703	159	58	response	response	NOUN
dpc-3703	159	59	partial	partial	ADJ
dpc-3703	159	60	response	response	NOUN
dpc-3703	159	61	stable	stable	ADJ
dpc-3703	159	62	disease	disease	NOUN
dpc-3703	159	63	progressive	progressive	ADJ
dpc-3703	159	64	disease	disease	NOUN
dpc-3703	159	65	not	not	PART
dpc-3703	159	66	evaluable	evaluable	ADJ
dpc-3703	159	67	26	26	NUM
dpc-3703	159	68	(	(	PUNCT
dpc-3703	159	69	31	31	NUM
dpc-3703	159	70	%	%	NOUN
dpc-3703	159	71	)	)	PUNCT
dpc-3703	159	72	5	5	NUM
dpc-3703	159	73	(	(	PUNCT
dpc-3703	159	74	6	6	NUM
dpc-3703	159	75	%	%	NOUN
dpc-3703	159	76	)	)	PUNCT
dpc-3703	159	77	21	21	NUM
dpc-3703	159	78	(	(	PUNCT
dpc-3703	159	79	25	25	NUM
dpc-3703	159	80	%	%	NOUN
dpc-3703	159	81	)	)	PUNCT
dpc-3703	159	82	41	41	NUM
dpc-3703	159	83	(	(	PUNCT
dpc-3703	159	84	49	49	NUM
dpc-3703	159	85	%	%	NOUN
dpc-3703	159	86	)	)	PUNCT
dpc-3703	159	87	9	9	NUM
dpc-3703	159	88	(	(	PUNCT
dpc-3703	159	89	11	11	NUM
dpc-3703	159	90	%	%	NOUN
dpc-3703	159	91	)	)	PUNCT
dpc-3703	159	92	8	8	NUM
dpc-3703	159	93	(	(	PUNCT
dpc-3703	159	94	10	10	NUM
dpc-3703	159	95	%	%	NOUN
dpc-3703	159	96	)	)	PUNCT
dpc-3703	159	97	at	at	ADP
dpc-3703	159	98	12	12	NUM
dpc-3703	159	99	weeks	week	NOUN
dpc-3703	159	100	21.9	21.9	NUM
dpc-3703	159	101	%	%	NOUN
dpc-3703	159	102	1	1	NUM
dpc-3703	159	103	(	(	PUNCT
dpc-3703	159	104	3.1	3.1	NUM
dpc-3703	159	105	%	%	NOUN
dpc-3703	159	106	)	)	PUNCT
dpc-3703	159	107	6	6	NUM
dpc-3703	159	108	(	(	PUNCT
dpc-3703	159	109	18.8	18.8	NUM
dpc-3703	159	110	%	%	NOUN
dpc-3703	159	111	)	)	PUNCT
dpc-3703	159	112	14	14	NUM
dpc-3703	159	113	(	(	PUNCT
dpc-3703	159	114	43.8	43.8	NUM
dpc-3703	159	115	%	%	NOUN
dpc-3703	159	116	)	)	PUNCT
dpc-3703	159	117	11	11	NUM
dpc-3703	159	118	(	(	PUNCT
dpc-3703	159	119	34.3	34.3	NUM
dpc-3703	159	120	%	%	NOUN
dpc-3703	159	121	)	)	PUNCT
dpc-3703	159	122	median	median	ADJ
dpc-3703	159	123	time	time	NOUN
dpc-3703	159	124	to	to	PART
dpc-3703	159	125	response	response	NOUN
dpc-3703	159	126	(	(	PUNCT
dpc-3703	159	127	iqr	iqr	NOUN
dpc-3703	159	128	)	)	PUNCT
dpc-3703	159	129	,	,	PUNCT
dpc-3703	159	130	m	m	VERB
dpc-3703	159	131	4.3	4.3	NUM
dpc-3703	159	132	(	(	PUNCT
dpc-3703	159	133	4.2	4.2	NUM
dpc-3703	159	134	,	,	PUNCT
dpc-3703	159	135	7.2	7.2	NUM
dpc-3703	159	136	)	)	PUNCT
dpc-3703	159	137	5.3	5.3	NUM
dpc-3703	159	138	disease	disease	NOUN
dpc-3703	159	139	control	control	NOUN
dpc-3703	159	140	rate	rate	NOUN
dpc-3703	159	141	,	,	PUNCT
dpc-3703	159	142	n	n	CCONJ
dpc-3703	159	143	(	(	PUNCT
dpc-3703	159	144	%	%	INTJ
dpc-3703	159	145	)	)	PUNCT
dpc-3703	159	146	67	67	NUM
dpc-3703	159	147	(	(	PUNCT
dpc-3703	159	148	80	80	NUM
dpc-3703	159	149	%	%	NOUN
dpc-3703	159	150	)	)	PUNCT
dpc-3703	159	151	21	21	NUM
dpc-3703	159	152	(	(	PUNCT
dpc-3703	159	153	65.7	65.7	NUM
dpc-3703	159	154	%	%	NOUN
dpc-3703	159	155	)	)	PUNCT
dpc-3703	159	156	duration	duration	NOUN
dpc-3703	159	157	of	of	ADP
dpc-3703	159	158	response	response	NOUN
dpc-3703	159	159	in	in	ADP
dpc-3703	159	160	responders	responder	NOUN
dpc-3703	159	161	median	median	PROPN
dpc-3703	159	162	≥	≥	NUM
dpc-3703	159	163	12	12	NUM
dpc-3703	159	164	months	month	NOUN
dpc-3703	159	165	not	not	PART
dpc-3703	159	166	reached	reach	VERB
dpc-3703	159	167	11	11	NUM
dpc-3703	159	168	(	(	PUNCT
dpc-3703	159	169	46	46	NUM
dpc-3703	159	170	%	%	NOUN
dpc-3703	159	171	)	)	PUNCT
dpc-3703	159	172	13.8	13.8	NUM
dpc-3703	159	173	m	m	VERB
dpc-3703	159	174	estimated	estimate	VERB
dpc-3703	159	175	duration	duration	NOUN
dpc-3703	159	176	of	of	ADP
dpc-3703	159	177	response	response	NOUN
dpc-3703	159	178	at	at	ADP
dpc-3703	159	179	12	12	NUM
dpc-3703	159	180	months	month	NOUN
dpc-3703	159	181	(	(	PUNCT
dpc-3703	159	182	95	95	NUM
dpc-3703	159	183	%	%	NOUN
dpc-3703	159	184	ci	ci	NOUN
dpc-3703	159	185	)	)	PUNCT
dpc-3703	159	186	85	85	NUM
dpc-3703	159	187	%	%	NOUN
dpc-3703	159	188	(	(	PUNCT
dpc-3703	159	189	61	61	NUM
dpc-3703	159	190	-	-	SYM
dpc-3703	159	191	95	95	NUM
dpc-3703	159	192	)	)	PUNCT
dpc-3703	159	193	estimated	estimate	VERB
dpc-3703	159	194	1	1	NUM
dpc-3703	159	195	-	-	PUNCT
dpc-3703	159	196	year	year	NOUN
dpc-3703	159	197	pfs	pfs	PROPN
dpc-3703	159	198	(	(	PUNCT
dpc-3703	159	199	95%c	95%c	NUM
dpc-3703	159	200	ci	ci	NOUN
dpc-3703	159	201	)	)	PUNCT
dpc-3703	159	202	57	57	NUM
dpc-3703	159	203	%	%	NOUN
dpc-3703	159	204	(	(	PUNCT
dpc-3703	159	205	44	44	NUM
dpc-3703	159	206	-	-	SYM
dpc-3703	159	207	67	67	NUM
dpc-3703	159	208	)	)	PUNCT
dpc-3703	159	209	estimated	estimate	VERB
dpc-3703	159	210	2	2	NUM
dpc-3703	159	211	-	-	PUNCT
dpc-3703	159	212	year	year	NOUN
dpc-3703	159	213	os	os	NOUN
dpc-3703	159	214	(	(	PUNCT
dpc-3703	159	215	95%c	95%c	NUM
dpc-3703	159	216	ci	ci	NOUN
dpc-3703	159	217	)	)	PUNCT
dpc-3703	159	218	80	80	NUM
dpc-3703	159	219	%	%	NOUN
dpc-3703	159	220	(	(	PUNCT
dpc-3703	159	221	63	63	NUM
dpc-3703	159	222	-	-	SYM
dpc-3703	159	223	90	90	NUM
dpc-3703	159	224	)	)	PUNCT
dpc-3703	159	225	os	os	NOUN
dpc-3703	159	226	,	,	PUNCT
dpc-3703	159	227	median	median	NOUN
dpc-3703	159	228	not	not	PART
dpc-3703	159	229	reached	reach	VERB
dpc-3703	159	230	discontinued	discontinue	VERB
dpc-3703	159	231	52	52	NUM
dpc-3703	159	232	(	(	PUNCT
dpc-3703	159	233	62	62	NUM
dpc-3703	159	234	%	%	NOUN
dpc-3703	159	235	)	)	PUNCT
dpc-3703	159	236	median	median	ADJ
dpc-3703	159	237	treatment	treatment	NOUN
dpc-3703	159	238	duration	duration	NOUN
dpc-3703	159	239	,	,	PUNCT
dpc-3703	159	240	w	w	PROPN
dpc-3703	159	241	(	(	PUNCT
dpc-3703	159	242	iqr	iqr	PROPN
dpc-3703	159	243	)	)	PUNCT
dpc-3703	159	244	47	47	NUM
dpc-3703	159	245	(	(	PUNCT
dpc-3703	159	246	27	27	NUM
dpc-3703	159	247	-	-	SYM
dpc-3703	159	248	80	80	NUM
dpc-3703	159	249	)	)	PUNCT
dpc-3703	159	250	32	32	NUM
dpc-3703	159	251	ddc	ddc	NOUN
dpc-3703	159	252	=	=	SYM
dpc-3703	159	253	durable	durable	ADJ
dpc-3703	159	254	disease	disease	NOUN
dpc-3703	159	255	control	control	NOUN
dpc-3703	159	256	;	;	PUNCT
dpc-3703	160	1	hhi	hhi	NOUN
dpc-3703	160	2	=	=	SYM
dpc-3703	160	3	hedgehog	hedgehog	VERB
dpc-3703	160	4	inhibitors	inhibitor	NOUN
dpc-3703	160	5	vismodegib	vismodegib	NOUN
dpc-3703	160	6	or	or	CCONJ
dpc-3703	160	7	sonidegib	sonidegib	NOUN
dpc-3703	160	8	;	;	PUNCT
dpc-3703	160	9	icr	icr	PROPN
dpc-3703	160	10	=	=	PROPN
dpc-3703	160	11	independent	independent	ADJ
dpc-3703	160	12	central	central	ADJ
dpc-3703	160	13	review	review	NOUN
dpc-3703	160	14	;	;	PUNCT
dpc-3703	160	15	iqr	iqr	PROPN
dpc-3703	160	16	=	=	NOUN
dpc-3703	160	17	interquartile	interquartile	NOUN
dpc-3703	160	18	range	range	NOUN
dpc-3703	160	19	;	;	PUNCT
dpc-3703	160	20	labcc	labcc	NOUN
dpc-3703	160	21	=	=	SYM
dpc-3703	160	22	locally	locally	ADV
dpc-3703	160	23	advanced	advance	VERB
dpc-3703	160	24	basal	basal	NOUN
dpc-3703	160	25	cell	cell	NOUN
dpc-3703	160	26	carcinoma	carcinoma	NOUN
dpc-3703	160	27	;	;	PUNCT
dpc-3703	161	1	mbcc	mbcc	NOUN
dpc-3703	161	2	=	=	PUNCT
dpc-3703	161	3	metastatic	metastatic	ADJ
dpc-3703	161	4	basal	basal	NOUN
dpc-3703	161	5	cell	cell	NOUN
dpc-3703	161	6	carcinoma	carcinoma	NOUN
dpc-3703	161	7	;	;	PUNCT
dpc-3703	161	8	m	m	NOUN
dpc-3703	161	9	=	=	NOUN
dpc-3703	161	10	months	month	NOUN
dpc-3703	161	11	;	;	PUNCT
dpc-3703	161	12	n	n	NOUN
dpc-3703	161	13	=	=	NOUN
dpc-3703	161	14	number	number	NOUN
dpc-3703	161	15	of	of	ADP
dpc-3703	161	16	patients	patient	NOUN
dpc-3703	161	17	;	;	PUNCT
dpc-3703	161	18	nr	nr	PRON
dpc-3703	161	19	=	=	PUNCT
dpc-3703	161	20	not	not	PART
dpc-3703	161	21	reported	report	VERB
dpc-3703	161	22	;	;	PUNCT
dpc-3703	161	23	os	os	NOUN
dpc-3703	161	24	=	=	VERB
dpc-3703	161	25	overall	overall	ADJ
dpc-3703	161	26	survival	survival	NOUN
dpc-3703	161	27	;	;	PUNCT
dpc-3703	161	28	pfs	pfs	PROPN
dpc-3703	161	29	=	=	SYM
dpc-3703	161	30	progression	progression	NOUN
dpc-3703	161	31	-	-	PUNCT
dpc-3703	161	32	free	free	ADJ
dpc-3703	161	33	survival	survival	NOUN
dpc-3703	161	34	;	;	PUNCT
dpc-3703	161	35	w	w	NOUN
dpc-3703	161	36	=	=	PUNCT
dpc-3703	161	37	weeks	week	NOUN
dpc-3703	161	38	.	.	PUNCT
dpc-3703	162	1	was	be	AUX
dpc-3703	162	2	noted	note	VERB
dpc-3703	162	3	in	in	ADP
dpc-3703	162	4	36	36	NUM
dpc-3703	162	5	%	%	NOUN
dpc-3703	162	6	at	at	ADP
dpc-3703	162	7	3	3	NUM
dpc-3703	162	8	-	-	PUNCT
dpc-3703	162	9	year	year	NOUN
dpc-3703	162	10	follow	follow	NOUN
dpc-3703	162	11	-	-	PUNCT
dpc-3703	162	12	up	up	NOUN
dpc-3703	162	13	[	[	X
dpc-3703	162	14	68	68	NUM
dpc-3703	162	15	]	]	PUNCT
dpc-3703	162	16	.	.	PUNCT
dpc-3703	163	1	also	also	ADV
dpc-3703	163	2	,	,	PUNCT
dpc-3703	163	3	the	the	DET
dpc-3703	163	4	nccn	nccn	ADJ
dpc-3703	163	5	guidelines	guideline	NOUN
dpc-3703	163	6	recommend	recommend	VERB
dpc-3703	163	7	that	that	SCONJ
dpc-3703	163	8	for	for	ADP
dpc-3703	163	9	patients	patient	NOUN
dpc-3703	163	10	with	with	ADP
dpc-3703	163	11	high	high	ADJ
dpc-3703	163	12	-	-	PUNCT
dpc-3703	163	13	risk	risk	NOUN
dpc-3703	163	14	bcc	bcc	NOUN
dpc-3703	163	15	in	in	ADP
dpc-3703	163	16	whom	whom	PRON
dpc-3703	163	17	surgery	surgery	NOUN
dpc-3703	163	18	may	may	AUX
dpc-3703	163	19	cause	cause	VERB
dpc-3703	163	20	significant	significant	ADJ
dpc-3703	163	21	functional	functional	ADJ
dpc-3703	163	22	damage	damage	NOUN
dpc-3703	163	23	,	,	PUNCT
dpc-3703	163	24	neoadjuvant	neoadjuvant	ADJ
dpc-3703	163	25	vismodegib	vismodegib	NOUN
dpc-3703	163	26	followed	follow	VERB
dpc-3703	163	27	by	by	ADP
dpc-3703	163	28	pdema	pdema	NOUN
dpc-3703	163	29	may	may	AUX
dpc-3703	163	30	be	be	AUX
dpc-3703	163	31	considered	consider	VERB
dpc-3703	163	32	[	[	PUNCT
dpc-3703	163	33	22	22	NUM
dpc-3703	163	34	]	]	PUNCT
dpc-3703	163	35	.	.	PUNCT
dpc-3703	164	1	regarding	regard	VERB
dpc-3703	164	2	neoadjuvant	neoadjuvant	ADJ
dpc-3703	164	3	immunotherapy	immunotherapy	NOUN
dpc-3703	164	4	,	,	PUNCT
dpc-3703	164	5	most	most	ADJ
dpc-3703	164	6	evidence	evidence	NOUN
dpc-3703	164	7	comes	come	VERB
dpc-3703	164	8	from	from	ADP
dpc-3703	164	9	studies	study	NOUN
dpc-3703	164	10	in	in	ADP
dpc-3703	164	11	cutaneous	cutaneous	ADJ
dpc-3703	164	12	melanoma	melanoma	NOUN
dpc-3703	164	13	,	,	PUNCT
dpc-3703	164	14	and	and	CCONJ
dpc-3703	164	15	there	there	PRON
dpc-3703	164	16	are	be	VERB
dpc-3703	164	17	limited	limited	ADJ
dpc-3703	164	18	studies	study	NOUN
dpc-3703	164	19	in	in	ADP
dpc-3703	164	20	keratinocyte	keratinocyte	NOUN
dpc-3703	164	21	cancers	cancer	NOUN
dpc-3703	164	22	,	,	PUNCT
dpc-3703	164	23	eg	eg	NOUN
dpc-3703	164	24	cscc	cscc	PROPN
dpc-3703	164	25	and	and	CCONJ
dpc-3703	164	26	bcc	bcc	PROPN
dpc-3703	164	27	.	.	PUNCT
dpc-3703	165	1	the	the	DET
dpc-3703	165	2	effects	effect	NOUN
dpc-3703	165	3	of	of	ADP
dpc-3703	165	4	systemic	systemic	ADJ
dpc-3703	165	5	checkpoint	checkpoint	NOUN
dpc-3703	165	6	inhibitors	inhibitor	NOUN
dpc-3703	165	7	in	in	ADP
dpc-3703	165	8	the	the	DET
dpc-3703	165	9	neoadjuvant	neoadjuvant	ADJ
dpc-3703	165	10	setting	setting	NOUN
dpc-3703	165	11	for	for	ADP
dpc-3703	165	12	melanoma	melanoma	NOUN
dpc-3703	165	13	surpass	surpass	ADJ
dpc-3703	165	14	improved	improved	ADJ
dpc-3703	165	15	operability	operability	NOUN
dpc-3703	165	16	as	as	ADP
dpc-3703	165	17	,	,	PUNCT
dpc-3703	165	18	even	even	ADV
dpc-3703	165	19	more	more	ADV
dpc-3703	165	20	importantly	importantly	ADV
dpc-3703	165	21	,	,	PUNCT
dpc-3703	165	22	impact	impact	VERB
dpc-3703	165	23	the	the	DET
dpc-3703	165	24	long	long	ADJ
dpc-3703	165	25	-	-	PUNCT
dpc-3703	165	26	term	term	NOUN
dpc-3703	165	27	tumor	tumor	NOUN
dpc-3703	165	28	control	control	NOUN
dpc-3703	165	29	and	and	CCONJ
dpc-3703	165	30	possibly	possibly	ADV
dpc-3703	165	31	survival	survival	VERB
dpc-3703	165	32	through	through	ADP
dpc-3703	165	33	the	the	DET
dpc-3703	165	34	induction	induction	NOUN
dpc-3703	165	35	of	of	ADP
dpc-3703	165	36	a	a	DET
dpc-3703	165	37	systemic	systemic	ADJ
dpc-3703	165	38	immune	immune	ADJ
dpc-3703	165	39	response	response	NOUN
dpc-3703	165	40	to	to	ADP
dpc-3703	165	41	cancer	cancer	NOUN
dpc-3703	165	42	cells	cell	NOUN
dpc-3703	165	43	[	[	X
dpc-3703	165	44	11,69	11,69	NUM
dpc-3703	165	45	]	]	PUNCT
dpc-3703	165	46	.	.	PUNCT
dpc-3703	166	1	in	in	ADP
dpc-3703	166	2	resectable	resectable	ADJ
dpc-3703	166	3	advanced	advanced	ADJ
dpc-3703	166	4	(	(	PUNCT
dpc-3703	166	5	stage	stage	NOUN
dpc-3703	166	6	iiib	iiib	NOUN
dpc-3703	166	7	-	-	PUNCT
dpc-3703	166	8	iv	iv	NOUN
dpc-3703	166	9	)	)	PUNCT
dpc-3703	166	10	cutaneous	cutaneous	ADJ
dpc-3703	166	11	melanoma	melanoma	NOUN
dpc-3703	166	12	,	,	PUNCT
dpc-3703	166	13	the	the	DET
dpc-3703	166	14	combined	combined	ADJ
dpc-3703	166	15	neoadjuvant	neoadjuvant	ADJ
dpc-3703	166	16	plus	plus	CCONJ
dpc-3703	166	17	adjuvant	adjuvant	ADJ
dpc-3703	166	18	pembrolizumab	pembrolizumab	NOUN
dpc-3703	166	19	regimen	regiman	NOUN
dpc-3703	166	20	(	(	PUNCT
dpc-3703	166	21	200	200	NUM
dpc-3703	166	22	 	 	SPACE
dpc-3703	166	23	mg	mg	PROPN
dpc-3703	166	24	iv	iv	NUM
dpc-3703	166	25	every	every	DET
dpc-3703	166	26	3	3	NUM
dpc-3703	166	27	weeks	week	NOUN
dpc-3703	166	28	,	,	PUNCT
dpc-3703	166	29	in	in	ADP
dpc-3703	166	30	3	3	NUM
dpc-3703	166	31	doses	dose	NOUN
dpc-3703	166	32	before	before	ADP
dpc-3703	166	33	surgery	surgery	NOUN
dpc-3703	166	34	and	and	CCONJ
dpc-3703	166	35	the	the	DET
dpc-3703	166	36	remaining	remain	VERB
dpc-3703	166	37	15	15	NUM
dpc-3703	166	38	doses	dose	NOUN
dpc-3703	166	39	after	after	ADP
dpc-3703	166	40	surgery	surgery	NOUN
dpc-3703	166	41	)	)	PUNCT
dpc-3703	166	42	was	be	AUX
dpc-3703	166	43	studied	study	VERB
dpc-3703	166	44	in	in	ADP
dpc-3703	166	45	the	the	DET
dpc-3703	166	46	randomized	randomize	VERB
dpc-3703	166	47	swogs1801	swogs1801	NOUN
dpc-3703	166	48	trial	trial	NOUN
dpc-3703	166	49	compared	compare	VERB
dpc-3703	166	50	to	to	ADP
dpc-3703	166	51	standard	standard	ADJ
dpc-3703	166	52	-	-	PUNCT
dpc-3703	166	53	care	care	NOUN
dpc-3703	166	54	adjuvant	adjuvant	ADJ
dpc-3703	166	55	pembrolizumab	pembrolizumab	NOUN
dpc-3703	166	56	(	(	PUNCT
dpc-3703	166	57	18	18	NUM
dpc-3703	166	58	doses	dose	NOUN
dpc-3703	166	59	after	after	ADP
dpc-3703	166	60	lymph	lymph	NOUN
dpc-3703	166	61	-	-	PUNCT
dpc-3703	166	62	node	node	NOUN
dpc-3703	166	63	dissection	dissection	NOUN
dpc-3703	166	64	)	)	PUNCT
dpc-3703	166	65	.	.	PUNCT
dpc-3703	167	1	the	the	DET
dpc-3703	167	2	estimated	estimate	VERB
dpc-3703	167	3	event	event	NOUN
dpc-3703	167	4	-	-	PUNCT
dpc-3703	167	5	free	free	ADJ
dpc-3703	167	6	survival	survival	NOUN
dpc-3703	167	7	was	be	AUX
dpc-3703	167	8	72	72	NUM
dpc-3703	167	9	%	%	NOUN
dpc-3703	167	10	in	in	ADP
dpc-3703	167	11	the	the	DET
dpc-3703	167	12	neoadjuvant	neoadjuvant	ADJ
dpc-3703	167	13	plus	plus	CCONJ
dpc-3703	167	14	adjuvant	adjuvant	ADJ
dpc-3703	167	15	group	group	NOUN
dpc-3703	167	16	versus	versus	ADP
dpc-3703	167	17	49	49	NUM
dpc-3703	167	18	%	%	NOUN
dpc-3703	167	19	in	in	ADP
dpc-3703	167	20	the	the	DET
dpc-3703	167	21	adjuvant	adjuvant	ADJ
dpc-3703	167	22	group	group	NOUN
dpc-3703	167	23	(	(	PUNCT
dpc-3703	167	24	hr	hr	NOUN
dpc-3703	167	25	:	:	PUNCT
dpc-3703	167	26	0.58	0.58	NUM
dpc-3703	167	27	,	,	PUNCT
dpc-3703	167	28	p	p	X
dpc-3703	167	29	=	=	NOUN
dpc-3703	167	30	0.004	0.004	NUM
dpc-3703	167	31	)	)	PUNCT
dpc-3703	167	32	.	.	PUNCT
dpc-3703	168	1	there	there	PRON
dpc-3703	168	2	was	be	VERB
dpc-3703	168	3	a	a	DET
dpc-3703	168	4	similar	similar	ADJ
dpc-3703	168	5	frequency	frequency	NOUN
dpc-3703	168	6	of	of	ADP
dpc-3703	168	7	grade	grade	NOUN
dpc-3703	168	8	3	3	NUM
dpc-3703	168	9	or	or	CCONJ
dpc-3703	168	10	higher	high	ADJ
dpc-3703	168	11	adverse	adverse	ADJ
dpc-3703	168	12	events	event	NOUN
dpc-3703	168	13	of	of	ADP
dpc-3703	168	14	12	12	NUM
dpc-3703	168	15	%	%	NOUN
dpc-3703	168	16	in	in	ADP
dpc-3703	168	17	the	the	DET
dpc-3703	168	18	neoadjuvant	neoadjuvant	ADJ
dpc-3703	168	19	-	-	PUNCT
dpc-3703	168	20	adjuvant	adjuvant	ADJ
dpc-3703	168	21	group	group	NOUN
dpc-3703	168	22	and	and	CCONJ
dpc-3703	168	23	14	14	NUM
dpc-3703	168	24	%	%	NOUN
dpc-3703	168	25	in	in	ADP
dpc-3703	168	26	the	the	DET
dpc-3703	168	27	adjuvant	adjuvant	NOUN
dpc-3703	168	28	-	-	PUNCT
dpc-3703	168	29	only	only	ADV
dpc-3703	168	30	group	group	NOUN
dpc-3703	168	31	[	[	X
dpc-3703	168	32	70	70	NUM
dpc-3703	168	33	]	]	PUNCT
dpc-3703	168	34	.	.	PUNCT
dpc-3703	169	1	the	the	DET
dpc-3703	169	2	prado	prado	PROPN
dpc-3703	169	3	melanoma	melanoma	PROPN
dpc-3703	169	4	trial	trial	NOUN
dpc-3703	169	5	investigated	investigate	VERB
dpc-3703	169	6	whether	whether	SCONJ
dpc-3703	169	7	surgery	surgery	NOUN
dpc-3703	169	8	and/or	and/or	CCONJ
dpc-3703	169	9	subsequent	subsequent	ADJ
dpc-3703	169	10	adjuvant	adjuvant	NOUN
dpc-3703	169	11	therapy	therapy	NOUN
dpc-3703	169	12	could	could	AUX
dpc-3703	169	13	be	be	AUX
dpc-3703	169	14	omitted	omit	VERB
dpc-3703	169	15	in	in	ADP
dpc-3703	169	16	the	the	DET
dpc-3703	169	17	case	case	NOUN
dpc-3703	169	18	of	of	ADP
dpc-3703	169	19	a	a	DET
dpc-3703	169	20	major	major	ADJ
dpc-3703	169	21	(	(	PUNCT
dpc-3703	169	22	complete	complete	ADJ
dpc-3703	169	23	or	or	CCONJ
dpc-3703	169	24	near	near	ADP
dpc-3703	169	25	complete	complete	ADJ
dpc-3703	169	26	)	)	PUNCT
dpc-3703	169	27	pathological	pathological	ADJ
dpc-3703	169	28	response	response	NOUN
dpc-3703	169	29	(	(	PUNCT
dpc-3703	169	30	0	0	NUM
dpc-3703	169	31	%	%	NOUN
dpc-3703	169	32	or	or	CCONJ
dpc-3703	169	33	0	0	NUM
dpc-3703	169	34	%	%	NOUN
dpc-3703	169	35	to	to	ADP
dpc-3703	169	36	≤10	≤10	NOUN
dpc-3703	169	37	%	%	NOUN
dpc-3703	169	38	viable	viable	ADJ
dpc-3703	169	39	tumor	tumor	NOUN
dpc-3703	169	40	cells	cell	NOUN
dpc-3703	169	41	in	in	ADP
dpc-3703	169	42	surgical	surgical	ADJ
dpc-3703	169	43	specimen	speciman	NOUN
dpc-3703	169	44	,	,	PUNCT
dpc-3703	169	45	respectively	respectively	ADV
dpc-3703	169	46	)	)	PUNCT
dpc-3703	169	47	.	.	PUNCT
dpc-3703	170	1	in	in	ADP
dpc-3703	170	2	these	these	DET
dpc-3703	170	3	cases	case	NOUN
dpc-3703	170	4	,	,	PUNCT
dpc-3703	170	5	the	the	DET
dpc-3703	170	6	landmark	landmark	NOUN
dpc-3703	170	7	two	two	NUM
dpc-3703	170	8	-	-	PUNCT
dpc-3703	170	9	year	year	NOUN
dpc-3703	170	10	recurrence	recurrence	NOUN
dpc-3703	170	11	-	-	PUNCT
dpc-3703	170	12	free	free	ADJ
dpc-3703	170	13	survival	survival	NOUN
dpc-3703	170	14	and	and	CCONJ
dpc-3703	170	15	distant	distant	ADJ
dpc-3703	170	16	-	-	PUNCT
dpc-3703	170	17	metastasis	metastasis	NOUN
dpc-3703	170	18	-	-	PUNCT
dpc-3703	170	19	free	free	ADJ
dpc-3703	170	20	survival	survival	NOUN
dpc-3703	170	21	were	be	AUX
dpc-3703	170	22	93	93	NUM
dpc-3703	170	23	%	%	NOUN
dpc-3703	170	24	and	and	CCONJ
dpc-3703	170	25	98	98	NUM
dpc-3703	170	26	%	%	NOUN
dpc-3703	170	27	respectively	respectively	ADV
dpc-3703	170	28	[	[	X
dpc-3703	170	29	71	71	NUM
dpc-3703	170	30	]	]	PUNCT
dpc-3703	170	31	.	.	PUNCT
dpc-3703	171	1	in	in	ADP
dpc-3703	171	2	resectable	resectable	VERB
dpc-3703	171	3	cscc	cscc	ADJ
dpc-3703	171	4	with	with	ADP
dpc-3703	171	5	primary	primary	ADJ
dpc-3703	171	6	tumors	tumor	NOUN
dpc-3703	171	7	with	with	ADP
dpc-3703	171	8	diameter	diameter	NOUN
dpc-3703	171	9	of	of	ADP
dpc-3703	171	10	at	at	ADV
dpc-3703	171	11	least	least	ADV
dpc-3703	171	12	3	3	NUM
dpc-3703	171	13	 	 	SPACE
dpc-3703	171	14	cm	cm	NOUN
dpc-3703	171	15	or	or	CCONJ
dpc-3703	171	16	with	with	ADP
dpc-3703	171	17	nodal	nodal	ADJ
dpc-3703	171	18	metastasis	metastasis	NOUN
dpc-3703	171	19	(	(	PUNCT
dpc-3703	171	20	stage	stage	NOUN
dpc-3703	171	21	ii	ii	PROPN
dpc-3703	171	22	,	,	PUNCT
dpc-3703	171	23	iii	iii	PROPN
dpc-3703	171	24	or	or	CCONJ
dpc-3703	171	25	iv	iv	NUM
dpc-3703	171	26	m0	m0	NOUN
dpc-3703	171	27	)	)	PUNCT
dpc-3703	171	28	,	,	PUNCT
dpc-3703	171	29	a	a	DET
dpc-3703	171	30	phase	phase	NOUN
dpc-3703	171	31	2	2	NUM
dpc-3703	171	32	study	study	NOUN
dpc-3703	171	33	evaluated	evaluate	VERB
dpc-3703	171	34	neoadjuvant	neoadjuvant	ADJ
dpc-3703	171	35	cemiplimab	cemiplimab	NOUN
dpc-3703	171	36	(	(	PUNCT
dpc-3703	171	37	350	350	NUM
dpc-3703	171	38	mg	mg	NOUN
dpc-3703	171	39	every	every	DET
dpc-3703	171	40	3	3	NUM
dpc-3703	171	41	weeks	week	NOUN
dpc-3703	171	42	for	for	ADP
dpc-3703	171	43	up	up	ADP
dpc-3703	171	44	to	to	PART
dpc-3703	171	45	4	4	NUM
dpc-3703	171	46	doses	dose	NOUN
dpc-3703	171	47	)	)	PUNCT
dpc-3703	171	48	followed	follow	VERB
dpc-3703	171	49	by	by	ADP
dpc-3703	171	50	surgery	surgery	NOUN
dpc-3703	171	51	in	in	ADP
dpc-3703	171	52	79	79	NUM
dpc-3703	171	53	patients	patient	NOUN
dpc-3703	171	54	.	.	PUNCT
dpc-3703	172	1	a	a	DET
dpc-3703	172	2	pathological	pathological	ADJ
dpc-3703	172	3	complete	complete	ADJ
dpc-3703	172	4	response	response	NOUN
dpc-3703	172	5	was	be	AUX
dpc-3703	172	6	observed	observe	VERB
dpc-3703	172	7	in	in	ADP
dpc-3703	172	8	40	40	NUM
dpc-3703	172	9	patients	patient	NOUN
dpc-3703	172	10	(	(	PUNCT
dpc-3703	172	11	51	51	NUM
dpc-3703	172	12	%	%	NOUN
dpc-3703	172	13	)	)	PUNCT
dpc-3703	172	14	,	,	PUNCT
dpc-3703	172	15	and	and	CCONJ
dpc-3703	172	16	a	a	DET
dpc-3703	172	17	pathological	pathological	ADJ
dpc-3703	172	18	near	near	ADJ
dpc-3703	172	19	-	-	PUNCT
dpc-3703	172	20	complete	complete	ADJ
dpc-3703	172	21	response	response	NOUN
dpc-3703	172	22	in	in	ADP
dpc-3703	172	23	10	10	NUM
dpc-3703	172	24	patients	patient	NOUN
dpc-3703	172	25	(	(	PUNCT
dpc-3703	172	26	13	13	NUM
dpc-3703	172	27	%	%	NOUN
dpc-3703	172	28	)	)	PUNCT
dpc-3703	172	29	.	.	PUNCT
dpc-3703	173	1	the	the	DET
dpc-3703	173	2	results	result	NOUN
dpc-3703	173	3	on	on	ADP
dpc-3703	173	4	relapse	relapse	NOUN
dpc-3703	173	5	-	-	PUNCT
dpc-3703	173	6	free	free	ADJ
dpc-3703	173	7	survival	survival	NOUN
dpc-3703	173	8	have	have	AUX
dpc-3703	173	9	not	not	PART
dpc-3703	173	10	been	be	AUX
dpc-3703	173	11	reported	report	VERB
dpc-3703	173	12	yet	yet	ADV
dpc-3703	173	13	[	[	X
dpc-3703	173	14	72	72	NUM
dpc-3703	173	15	]	]	PUNCT
dpc-3703	173	16	.	.	PUNCT
dpc-3703	174	1	the	the	DET
dpc-3703	174	2	nccn	nccn	PROPN
dpc-3703	174	3	version	version	NOUN
dpc-3703	174	4	1.2023	1.2023	NUM
dpc-3703	174	5	guidelines	guideline	NOUN
dpc-3703	174	6	recommend	recommend	VERB
dpc-3703	174	7	that	that	SCONJ
dpc-3703	174	8	neoadjuvant	neoadjuvant	ADJ
dpc-3703	174	9	cemiplimab	cemiplimab	NOUN
dpc-3703	174	10	may	may	AUX
dpc-3703	174	11	be	be	AUX
dpc-3703	174	12	considered	consider	VERB
dpc-3703	174	13	in	in	ADP
dpc-3703	174	14	patients	patient	NOUN
dpc-3703	174	15	with	with	ADP
dpc-3703	174	16	cscc	cscc	ADJ
dpc-3703	174	17	with	with	ADP
dpc-3703	174	18	nodal	nodal	NOUN
dpc-3703	174	19	metastasis	metastasis	NOUN
dpc-3703	174	20	who	who	PRON
dpc-3703	174	21	are	be	AUX
dpc-3703	174	22	considered	consider	VERB
dpc-3703	174	23	borderline	borderline	NOUN
dpc-3703	174	24	resectable	resectable	NOUN
dpc-3703	174	25	,	,	PUNCT
dpc-3703	174	26	unresectable	unresectable	ADJ
dpc-3703	174	27	,	,	PUNCT
dpc-3703	174	28	or	or	CCONJ
dpc-3703	174	29	for	for	ADP
dpc-3703	174	30	whom	whom	PRON
dpc-3703	174	31	surgery	surgery	NOUN
dpc-3703	174	32	may	may	AUX
dpc-3703	174	33	carry	carry	VERB
dpc-3703	174	34	a	a	DET
dpc-3703	174	35	high	high	ADJ
dpc-3703	174	36	morbidity	morbidity	NOUN
dpc-3703	175	1	[	[	X
dpc-3703	175	2	73	73	NUM
dpc-3703	175	3	]	]	PUNCT
dpc-3703	175	4	.	.	PUNCT
dpc-3703	176	1	review	review	VERB
dpc-3703	176	2	|	|	ADV
dpc-3703	176	3	dermatol	dermatol	ADJ
dpc-3703	176	4	pract	pract	NOUN
dpc-3703	176	5	concept	concept	NOUN
dpc-3703	176	6	.	.	PUNCT
dpc-3703	177	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	177	2	7	7	NUM
dpc-3703	177	3	responses	response	NOUN
dpc-3703	177	4	compared	compare	VERB
dpc-3703	177	5	to	to	ADP
dpc-3703	177	6	pembrolizumab	pembrolizumab	NOUN
dpc-3703	177	7	alone	alone	ADV
dpc-3703	177	8	(	(	PUNCT
dpc-3703	177	9	in	in	ADP
dpc-3703	177	10	9	9	NUM
dpc-3703	177	11	patients	patient	NOUN
dpc-3703	177	12	)	)	PUNCT
dpc-3703	177	13	in	in	ADP
dpc-3703	177	14	the	the	DET
dpc-3703	177	15	proof	proof	NOUN
dpc-3703	177	16	-	-	PUNCT
dpc-3703	177	17	of	of	ADP
dpc-3703	177	18	-	-	PUNCT
dpc-3703	177	19	concept	concept	NOUN
dpc-3703	177	20	study	study	NOUN
dpc-3703	177	21	by	by	ADP
dpc-3703	177	22	chang	chang	PROPN
dpc-3703	177	23	et	et	PROPN
dpc-3703	177	24	al	al	PROPN
dpc-3703	177	25	,	,	PUNCT
dpc-3703	177	26	for	for	ADP
dpc-3703	177	27	advanced	advanced	ADJ
dpc-3703	177	28	bcc	bcc	PROPN
dpc-3703	177	29	.	.	PUNCT
dpc-3703	178	1	the	the	DET
dpc-3703	178	2	orr	orr	PROPN
dpc-3703	178	3	at	at	ADP
dpc-3703	178	4	18	18	NUM
dpc-3703	178	5	weeks	week	NOUN
dpc-3703	178	6	was	be	AUX
dpc-3703	178	7	and	and	CCONJ
dpc-3703	178	8	29	29	NUM
dpc-3703	178	9	%	%	NOUN
dpc-3703	178	10	for	for	ADP
dpc-3703	178	11	the	the	DET
dpc-3703	178	12	combination	combination	NOUN
dpc-3703	178	13	regimen	regiman	NOUN
dpc-3703	178	14	and	and	CCONJ
dpc-3703	178	15	44	44	NUM
dpc-3703	178	16	%	%	NOUN
dpc-3703	178	17	for	for	ADP
dpc-3703	178	18	the	the	DET
dpc-3703	178	19	pembrolizumab	pembrolizumab	NOUN
dpc-3703	178	20	monotherapy	monotherapy	NOUN
dpc-3703	178	21	[	[	X
dpc-3703	178	22	82	82	NUM
dpc-3703	178	23	]	]	PUNCT
dpc-3703	178	24	.	.	PUNCT
dpc-3703	179	1	a	a	DET
dpc-3703	179	2	case	case	NOUN
dpc-3703	179	3	of	of	ADP
dpc-3703	179	4	labcc	labcc	PRON
dpc-3703	179	5	which	which	PRON
dpc-3703	179	6	developed	develop	VERB
dpc-3703	179	7	during	during	ADP
dpc-3703	179	8	cemiplimab	cemiplimab	NOUN
dpc-3703	179	9	therapy	therapy	NOUN
dpc-3703	179	10	for	for	ADP
dpc-3703	179	11	lacscc	lacscc	NOUN
dpc-3703	179	12	,	,	PUNCT
dpc-3703	179	13	was	be	AUX
dpc-3703	179	14	treated	treat	VERB
dpc-3703	179	15	with	with	ADP
dpc-3703	179	16	concomitant	concomitant	ADJ
dpc-3703	179	17	sonidegib	sonidegib	NOUN
dpc-3703	179	18	with	with	ADP
dpc-3703	179	19	a	a	DET
dpc-3703	179	20	clinical	clinical	ADJ
dpc-3703	179	21	response	response	NOUN
dpc-3703	179	22	.	.	PUNCT
dpc-3703	180	1	the	the	DET
dpc-3703	180	2	combination	combination	NOUN
dpc-3703	180	3	treatment	treatment	NOUN
dpc-3703	180	4	was	be	AUX
dpc-3703	180	5	well	well	ADV
dpc-3703	180	6	tolerated	tolerate	VERB
dpc-3703	180	7	and	and	CCONJ
dpc-3703	180	8	the	the	DET
dpc-3703	180	9	patient	patient	NOUN
dpc-3703	180	10	received	receive	VERB
dpc-3703	180	11	31	31	NUM
dpc-3703	180	12	cycles	cycle	NOUN
dpc-3703	180	13	of	of	ADP
dpc-3703	180	14	cemiplimab	cemiplimab	NOUN
dpc-3703	180	15	and	and	CCONJ
dpc-3703	180	16	10	10	NUM
dpc-3703	180	17	cycles	cycle	NOUN
dpc-3703	180	18	of	of	ADP
dpc-3703	180	19	sonidegib	sonidegib	NOUN
dpc-3703	180	20	.	.	PUNCT
dpc-3703	181	1	the	the	DET
dpc-3703	181	2	patient	patient	NOUN
dpc-3703	181	3	died	die	VERB
dpc-3703	181	4	due	due	ADJ
dpc-3703	181	5	to	to	ADP
dpc-3703	181	6	sepsis	sepsis	NOUN
dpc-3703	181	7	that	that	PRON
dpc-3703	181	8	was	be	AUX
dpc-3703	181	9	considered	consider	VERB
dpc-3703	181	10	unrelated	unrelated	ADJ
dpc-3703	181	11	to	to	ADP
dpc-3703	181	12	treatment	treatment	NOUN
dpc-3703	181	13	[	[	X
dpc-3703	181	14	80	80	NUM
dpc-3703	181	15	]	]	PUNCT
dpc-3703	181	16	.	.	PUNCT
dpc-3703	182	1	ongoing	ongoing	ADJ
dpc-3703	182	2	clinical	clinical	ADJ
dpc-3703	182	3	trials	trial	NOUN
dpc-3703	182	4	aim	aim	VERB
dpc-3703	182	5	to	to	PART
dpc-3703	182	6	investigate	investigate	VERB
dpc-3703	182	7	the	the	DET
dpc-3703	182	8	combination	combination	NOUN
dpc-3703	182	9	of	of	ADP
dpc-3703	182	10	cemiplimab	cemiplimab	NOUN
dpc-3703	182	11	with	with	ADP
dpc-3703	182	12	pulsed	pulsed	ADJ
dpc-3703	182	13	sonidegib	sonidegib	NOUN
dpc-3703	182	14	therapy	therapy	NOUN
dpc-3703	182	15	,	,	PUNCT
dpc-3703	182	16	and	and	CCONJ
dpc-3703	182	17	the	the	DET
dpc-3703	182	18	combination	combination	NOUN
dpc-3703	182	19	of	of	ADP
dpc-3703	182	20	nivolumab	nivolumab	NOUN
dpc-3703	182	21	plus	plus	CCONJ
dpc-3703	182	22	relatlimab	relatlimab	NOUN
dpc-3703	182	23	or	or	CCONJ
dpc-3703	182	24	ipilimumab	ipilimumab	VERB
dpc-3703	182	25	for	for	ADP
dpc-3703	182	26	patients	patient	NOUN
dpc-3703	182	27	with	with	ADP
dpc-3703	182	28	labcc	labcc	NOUN
dpc-3703	182	29	or	or	CCONJ
dpc-3703	182	30	mbcc	mbcc	NOUN
dpc-3703	183	1	[	[	X
dpc-3703	183	2	83,84	83,84	X
dpc-3703	183	3	]	]	X
dpc-3703	183	4	.	.	PUNCT
dpc-3703	184	1	the	the	DET
dpc-3703	184	2	combination	combination	NOUN
dpc-3703	184	3	of	of	ADP
dpc-3703	184	4	immunotherapeutic	immunotherapeutic	ADJ
dpc-3703	184	5	agents	agent	NOUN
dpc-3703	184	6	,	,	PUNCT
dpc-3703	184	7	such	such	ADJ
dpc-3703	184	8	as	as	ADP
dpc-3703	184	9	immune	immune	ADJ
dpc-3703	184	10	checkpoint	checkpoint	NOUN
dpc-3703	184	11	inhibitors	inhibitor	NOUN
dpc-3703	184	12	and	and	CCONJ
dpc-3703	184	13	intralesional	intralesional	ADJ
dpc-3703	184	14	oncolytic	oncolytic	ADJ
dpc-3703	184	15	viruses	virus	NOUN
dpc-3703	184	16	,	,	PUNCT
dpc-3703	184	17	is	be	AUX
dpc-3703	184	18	studied	study	VERB
dpc-3703	184	19	with	with	ADP
dpc-3703	184	20	the	the	DET
dpc-3703	184	21	aim	aim	NOUN
dpc-3703	184	22	to	to	PART
dpc-3703	184	23	improve	improve	VERB
dpc-3703	184	24	the	the	DET
dpc-3703	184	25	t	t	NOUN
dpc-3703	184	26	-	-	PUNCT
dpc-3703	184	27	cell	cell	NOUN
dpc-3703	184	28	exhaustion	exhaustion	NOUN
dpc-3703	184	29	,	,	PUNCT
dpc-3703	184	30	prolong	prolong	VERB
dpc-3703	184	31	the	the	DET
dpc-3703	184	32	duration	duration	NOUN
dpc-3703	184	33	of	of	ADP
dpc-3703	184	34	response	response	NOUN
dpc-3703	184	35	and	and	CCONJ
dpc-3703	184	36	delay	delay	NOUN
dpc-3703	184	37	resistance	resistance	NOUN
dpc-3703	184	38	,	,	PUNCT
dpc-3703	184	39	associated	associate	VERB
dpc-3703	184	40	with	with	ADP
dpc-3703	184	41	immune	immune	ADJ
dpc-3703	184	42	checkpoint	checkpoint	NOUN
dpc-3703	184	43	inhibitor	inhibitor	NOUN
dpc-3703	184	44	therapy	therapy	NOUN
dpc-3703	184	45	[	[	X
dpc-3703	184	46	85,86	85,86	NUM
dpc-3703	184	47	]	]	PUNCT
dpc-3703	184	48	.	.	PUNCT
dpc-3703	185	1	talimogene	talimogene	PROPN
dpc-3703	185	2	laherparepvec	laherparepvec	PROPN
dpc-3703	185	3	was	be	AUX
dpc-3703	185	4	approved	approve	VERB
dpc-3703	185	5	in	in	ADP
dpc-3703	185	6	2015	2015	NUM
dpc-3703	185	7	as	as	ADP
dpc-3703	185	8	the	the	DET
dpc-3703	185	9	first	first	ADJ
dpc-3703	185	10	engineered	engineer	VERB
dpc-3703	185	11	oncolytic	oncolytic	ADJ
dpc-3703	185	12	herpes	herpe	NOUN
dpc-3703	185	13	simplex	simplex	NOUN
dpc-3703	185	14	virus	virus	NOUN
dpc-3703	185	15	type	type	NOUN
dpc-3703	185	16	1	1	NUM
dpc-3703	185	17	(	(	PUNCT
dpc-3703	185	18	hsv-1	hsv-1	X
dpc-3703	185	19	)	)	PUNCT
dpc-3703	185	20	for	for	ADP
dpc-3703	185	21	the	the	DET
dpc-3703	185	22	treatment	treatment	NOUN
dpc-3703	185	23	of	of	ADP
dpc-3703	185	24	advanced	advanced	ADJ
dpc-3703	185	25	melanoma	melanoma	NOUN
dpc-3703	186	1	[	[	X
dpc-3703	186	2	85,87	85,87	NUM
dpc-3703	186	3	]	]	PUNCT
dpc-3703	186	4	.	.	PUNCT
dpc-3703	187	1	oncolytic	oncolytic	ADJ
dpc-3703	187	2	viruses	virus	NOUN
dpc-3703	187	3	selectively	selectively	ADV
dpc-3703	187	4	infect	infect	VERB
dpc-3703	187	5	and	and	CCONJ
dpc-3703	187	6	induce	induce	VERB
dpc-3703	187	7	the	the	DET
dpc-3703	187	8	lysis	lysis	NOUN
dpc-3703	187	9	of	of	ADP
dpc-3703	187	10	cancer	cancer	NOUN
dpc-3703	187	11	cells	cell	NOUN
dpc-3703	187	12	with	with	ADP
dpc-3703	187	13	subsequent	subsequent	ADJ
dpc-3703	187	14	release	release	NOUN
dpc-3703	187	15	of	of	ADP
dpc-3703	187	16	tumor	tumor	NOUN
dpc-3703	187	17	-	-	PUNCT
dpc-3703	187	18	derived	derive	VERB
dpc-3703	187	19	antigens	antigen	NOUN
dpc-3703	187	20	,	,	PUNCT
dpc-3703	187	21	express	express	VERB
dpc-3703	187	22	immunostimulatory	immunostimulatory	ADJ
dpc-3703	187	23	cytokines	cytokine	NOUN
dpc-3703	187	24	and	and	CCONJ
dpc-3703	187	25	chemokines	chemokine	NOUN
dpc-3703	187	26	,	,	PUNCT
dpc-3703	187	27	such	such	ADJ
dpc-3703	187	28	as	as	ADP
dpc-3703	187	29	granulocyte	granulocyte	ADJ
dpc-3703	187	30	-	-	PUNCT
dpc-3703	187	31	macrophage	macrophage	ADJ
dpc-3703	187	32	colony	colony	NOUN
dpc-3703	187	33	-	-	PUNCT
dpc-3703	187	34	stimulating	stimulate	VERB
dpc-3703	187	35	factor	factor	NOUN
dpc-3703	187	36	(	(	PUNCT
dpc-3703	187	37	gm	gm	PROPN
dpc-3703	187	38	-	-	PUNCT
dpc-3703	187	39	csf	csf	NOUN
dpc-3703	187	40	)	)	PUNCT
dpc-3703	187	41	expressed	express	VERB
dpc-3703	187	42	by	by	ADP
dpc-3703	187	43	t	t	PROPN
dpc-3703	187	44	-	-	PUNCT
dpc-3703	187	45	vec	vec	PROPN
dpc-3703	187	46	,	,	PUNCT
dpc-3703	187	47	and	and	CCONJ
dpc-3703	187	48	may	may	AUX
dpc-3703	187	49	trigger	trigger	VERB
dpc-3703	187	50	a	a	DET
dpc-3703	187	51	systemic	systemic	ADJ
dpc-3703	187	52	anti	anti	ADJ
dpc-3703	187	53	-	-	ADJ
dpc-3703	187	54	tumor	tumor	ADJ
dpc-3703	187	55	response	response	NOUN
dpc-3703	188	1	[	[	X
dpc-3703	188	2	85,87	85,87	X
dpc-3703	188	3	]	]	PUNCT
dpc-3703	188	4	.	.	PUNCT
dpc-3703	189	1	intra	intra	ADJ
dpc-3703	189	2	-	-	ADJ
dpc-3703	189	3	tumoural	tumoural	ADJ
dpc-3703	189	4	immunotherapy	immunotherapy	NOUN
dpc-3703	189	5	with	with	ADP
dpc-3703	189	6	t	t	PROPN
dpc-3703	189	7	-	-	PUNCT
dpc-3703	189	8	vec	vec	PROPN
dpc-3703	189	9	is	be	AUX
dpc-3703	189	10	being	be	AUX
dpc-3703	189	11	studied	study	VERB
dpc-3703	189	12	in	in	ADP
dpc-3703	189	13	clinical	clinical	ADJ
dpc-3703	189	14	trials	trial	NOUN
dpc-3703	189	15	,	,	PUNCT
dpc-3703	189	16	in	in	ADP
dpc-3703	189	17	combination	combination	NOUN
dpc-3703	189	18	with	with	ADP
dpc-3703	189	19	panitumumab	panitumumab	NOUN
dpc-3703	189	20	for	for	ADP
dpc-3703	189	21	for	for	ADP
dpc-3703	189	22	advanced	advanced	ADJ
dpc-3703	189	23	bcc	bcc	PROPN
dpc-3703	189	24	,	,	PUNCT
dpc-3703	189	25	neoadjuvant	neoadjuvant	ADJ
dpc-3703	189	26	anti	anti	ADJ
dpc-3703	189	27	-	-	ADJ
dpc-3703	189	28	pd-1	pd-1	ADJ
dpc-3703	189	29	immunotherapy	immunotherapy	NOUN
dpc-3703	189	30	is	be	AUX
dpc-3703	189	31	currently	currently	ADV
dpc-3703	189	32	investigated	investigate	VERB
dpc-3703	189	33	in	in	ADP
dpc-3703	189	34	clinical	clinical	ADJ
dpc-3703	189	35	trials	trial	NOUN
dpc-3703	189	36	which	which	PRON
dpc-3703	189	37	are	be	AUX
dpc-3703	189	38	summarized	summarize	VERB
dpc-3703	189	39	in	in	ADP
dpc-3703	189	40	table	table	NOUN
dpc-3703	189	41	3	3	NUM
dpc-3703	190	1	[	[	X
dpc-3703	190	2	74,75	74,75	NOUN
dpc-3703	190	3	]	]	PUNCT
dpc-3703	190	4	.	.	PUNCT
dpc-3703	191	1	for	for	ADP
dpc-3703	191	2	labcc	labcc	PROPN
dpc-3703	191	3	,	,	PUNCT
dpc-3703	191	4	neoadjuvant	neoadjuvant	ADJ
dpc-3703	191	5	nivolumab	nivolumab	NOUN
dpc-3703	191	6	was	be	AUX
dpc-3703	191	7	used	use	VERB
dpc-3703	191	8	in	in	ADP
dpc-3703	191	9	2	2	NUM
dpc-3703	191	10	patients	patient	NOUN
dpc-3703	191	11	with	with	ADP
dpc-3703	191	12	labcc	labcc	NOUN
dpc-3703	191	13	as	as	ADP
dpc-3703	191	14	first	first	ADJ
dpc-3703	191	15	-	-	PUNCT
dpc-3703	191	16	line	line	NOUN
dpc-3703	191	17	treatment	treatment	NOUN
dpc-3703	191	18	[	[	X
dpc-3703	191	19	76	76	NUM
dpc-3703	191	20	]	]	PUNCT
dpc-3703	191	21	.	.	PUNCT
dpc-3703	192	1	neoadjuvant	neoadjuvant	ADJ
dpc-3703	192	2	cemiplimab	cemiplimab	NOUN
dpc-3703	192	3	is	be	AUX
dpc-3703	192	4	investigated	investigate	VERB
dpc-3703	192	5	in	in	ADP
dpc-3703	192	6	patients	patient	NOUN
dpc-3703	192	7	with	with	ADP
dpc-3703	192	8	advanced	advanced	ADJ
dpc-3703	192	9	bcc	bcc	PROPN
dpc-3703	192	10	requiring	require	VERB
dpc-3703	192	11	greater	great	ADJ
dpc-3703	192	12	than	than	ADP
dpc-3703	192	13	30	30	NUM
dpc-3703	192	14	%	%	NOUN
dpc-3703	192	15	auriculectomy	auriculectomy	NOUN
dpc-3703	192	16	,	,	PUNCT
dpc-3703	192	17	rhinectomy	rhinectomy	ADJ
dpc-3703	192	18	,	,	PUNCT
dpc-3703	192	19	upper	upper	ADJ
dpc-3703	192	20	or	or	CCONJ
dpc-3703	192	21	lower	low	ADJ
dpc-3703	192	22	lip	lip	NOUN
dpc-3703	192	23	resection	resection	NOUN
dpc-3703	192	24	,	,	PUNCT
dpc-3703	192	25	orbital	orbital	ADJ
dpc-3703	192	26	exenteration	exenteration	NOUN
dpc-3703	192	27	(	(	PUNCT
dpc-3703	192	28	due	due	ADP
dpc-3703	192	29	to	to	ADP
dpc-3703	192	30	lid	lid	NOUN
dpc-3703	192	31	or	or	CCONJ
dpc-3703	192	32	orbital	orbital	ADJ
dpc-3703	192	33	involvement	involvement	NOUN
dpc-3703	192	34	)	)	PUNCT
dpc-3703	192	35	,	,	PUNCT
dpc-3703	192	36	facial	facial	ADJ
dpc-3703	192	37	nerve	nerve	NOUN
dpc-3703	192	38	sacrifice	sacrifice	NOUN
dpc-3703	192	39	or	or	CCONJ
dpc-3703	192	40	brigham	brigham	PROPN
dpc-3703	192	41	and	and	CCONJ
dpc-3703	192	42	women	woman	NOUN
dpc-3703	192	43	's	's	PART
dpc-3703	192	44	stage	stage	NOUN
dpc-3703	192	45	2b	2b	NOUN
dpc-3703	192	46	or	or	CCONJ
dpc-3703	192	47	3	3	NUM
dpc-3703	192	48	disease	disease	NOUN
dpc-3703	192	49	of	of	ADP
dpc-3703	192	50	head	head	NOUN
dpc-3703	192	51	and	and	CCONJ
dpc-3703	192	52	neck	neck	NOUN
dpc-3703	193	1	[	[	X
dpc-3703	193	2	74].neoadjuvant	74].neoadjuvant	ADJ
dpc-3703	193	3	pembrolizumab	pembrolizumab	NOUN
dpc-3703	193	4	is	be	AUX
dpc-3703	193	5	investigated	investigate	VERB
dpc-3703	193	6	in	in	ADP
dpc-3703	193	7	patients	patient	NOUN
dpc-3703	193	8	with	with	ADP
dpc-3703	193	9	resectable	resectable	ADJ
dpc-3703	193	10	high	high	ADJ
dpc-3703	193	11	-	-	PUNCT
dpc-3703	193	12	risk	risk	NOUN
dpc-3703	193	13	bcc	bcc	NOUN
dpc-3703	194	1	[	[	X
dpc-3703	194	2	75	75	NUM
dpc-3703	194	3	]	]	PUNCT
dpc-3703	194	4	.	.	PUNCT
dpc-3703	195	1	there	there	PRON
dpc-3703	195	2	is	be	VERB
dpc-3703	195	3	no	no	DET
dpc-3703	195	4	recommendation	recommendation	NOUN
dpc-3703	195	5	on	on	ADP
dpc-3703	195	6	adjuvant	adjuvant	ADJ
dpc-3703	195	7	anti	anti	ADJ
dpc-3703	195	8	-	-	ADJ
dpc-3703	195	9	pd-1	pd-1	ADJ
dpc-3703	195	10	treatment	treatment	NOUN
dpc-3703	195	11	for	for	ADP
dpc-3703	195	12	resected	resect	VERB
dpc-3703	195	13	advanced	advanced	ADJ
dpc-3703	195	14	bcc	bcc	PROPN
dpc-3703	195	15	outside	outside	ADP
dpc-3703	195	16	the	the	DET
dpc-3703	195	17	context	context	NOUN
dpc-3703	195	18	of	of	ADP
dpc-3703	195	19	clinical	clinical	ADJ
dpc-3703	195	20	trials	trial	NOUN
dpc-3703	195	21	in	in	ADP
dpc-3703	195	22	current	current	ADJ
dpc-3703	195	23	guidelines	guideline	NOUN
dpc-3703	195	24	[	[	X
dpc-3703	195	25	21,23	21,23	NOUN
dpc-3703	195	26	]	]	PUNCT
dpc-3703	195	27	.	.	PUNCT
dpc-3703	196	1	have	have	AUX
dpc-3703	196	2	anti	anti	ADJ
dpc-3703	196	3	-	-	ADJ
dpc-3703	196	4	pd-1	pd-1	ADJ
dpc-3703	196	5	agents	agent	NOUN
dpc-3703	196	6	been	be	AUX
dpc-3703	196	7	combined	combine	VERB
dpc-3703	196	8	with	with	ADP
dpc-3703	196	9	other	other	ADJ
dpc-3703	196	10	treatments	treatment	NOUN
dpc-3703	196	11	for	for	ADP
dpc-3703	196	12	advanced	advanced	ADJ
dpc-3703	196	13	bcc	bcc	PROPN
dpc-3703	196	14	?	?	PUNCT
dpc-3703	197	1	current	current	ADJ
dpc-3703	197	2	guidelines	guideline	NOUN
dpc-3703	197	3	recommend	recommend	VERB
dpc-3703	197	4	cemiplimab	cemiplimab	NOUN
dpc-3703	197	5	as	as	ADP
dpc-3703	197	6	monotherapy	monotherapy	NOUN
dpc-3703	197	7	for	for	ADP
dpc-3703	197	8	advanced	advanced	ADJ
dpc-3703	197	9	cscc	cscc	ADJ
dpc-3703	197	10	and	and	CCONJ
dpc-3703	197	11	for	for	ADP
dpc-3703	197	12	advanced	advanced	ADJ
dpc-3703	197	13	bcc	bcc	PROPN
dpc-3703	197	14	[	[	X
dpc-3703	197	15	22,73,77,78	22,73,77,78	NUM
dpc-3703	197	16	]	]	PUNCT
dpc-3703	197	17	.	.	PUNCT
dpc-3703	198	1	the	the	DET
dpc-3703	198	2	need	need	NOUN
dpc-3703	198	3	to	to	PART
dpc-3703	198	4	combine	combine	VERB
dpc-3703	198	5	anti	anti	ADJ
dpc-3703	198	6	-	-	NOUN
dpc-3703	198	7	pd-1	pd-1	ADJ
dpc-3703	198	8	with	with	ADP
dpc-3703	198	9	another	another	DET
dpc-3703	198	10	treatment	treatment	NOUN
dpc-3703	198	11	may	may	AUX
dpc-3703	198	12	arise	arise	VERB
dpc-3703	198	13	in	in	ADP
dpc-3703	198	14	the	the	DET
dpc-3703	198	15	case	case	NOUN
dpc-3703	198	16	of	of	ADP
dpc-3703	198	17	failure	failure	NOUN
dpc-3703	198	18	of	of	ADP
dpc-3703	198	19	bcc	bcc	PROPN
dpc-3703	198	20	to	to	PART
dpc-3703	198	21	respond	respond	VERB
dpc-3703	198	22	to	to	ADP
dpc-3703	198	23	anti	anti	NOUN
dpc-3703	198	24	-	-	NOUN
dpc-3703	198	25	pd-1	pd-1	NOUN
dpc-3703	198	26	in	in	ADP
dpc-3703	198	27	some	some	DET
dpc-3703	198	28	patients	patient	NOUN
dpc-3703	198	29	,	,	PUNCT
dpc-3703	198	30	as	as	SCONJ
dpc-3703	198	31	described	describe	VERB
dpc-3703	198	32	in	in	ADP
dpc-3703	198	33	the	the	DET
dpc-3703	198	34	studies	study	NOUN
dpc-3703	198	35	above	above	ADV
dpc-3703	198	36	and	and	CCONJ
dpc-3703	198	37	in	in	ADP
dpc-3703	198	38	case	case	NOUN
dpc-3703	198	39	reports	report	VERB
dpc-3703	198	40	,	,	PUNCT
dpc-3703	198	41	if	if	SCONJ
dpc-3703	198	42	new	new	ADJ
dpc-3703	198	43	bccs	bccs	NOUN
dpc-3703	198	44	develop	develop	VERB
dpc-3703	198	45	during	during	ADP
dpc-3703	198	46	anti	anti	ADJ
dpc-3703	198	47	-	-	ADJ
dpc-3703	198	48	pd-1	pd-1	ADJ
dpc-3703	198	49	immunotherapy	immunotherapy	NOUN
dpc-3703	198	50	for	for	ADP
dpc-3703	198	51	other	other	ADJ
dpc-3703	198	52	indications	indication	NOUN
dpc-3703	198	53	or	or	CCONJ
dpc-3703	198	54	despite	despite	SCONJ
dpc-3703	198	55	response	response	NOUN
dpc-3703	198	56	of	of	ADP
dpc-3703	198	57	the	the	DET
dpc-3703	198	58	index	index	NOUN
dpc-3703	198	59	advanced	advance	VERB
dpc-3703	198	60	bcc	bcc	PROPN
dpc-3703	199	1	[	[	X
dpc-3703	199	2	53,79	53,79	NUM
dpc-3703	199	3	-	-	SYM
dpc-3703	199	4	81	81	NUM
dpc-3703	199	5	]	]	PUNCT
dpc-3703	199	6	.	.	PUNCT
dpc-3703	200	1	in	in	ADP
dpc-3703	200	2	these	these	DET
dpc-3703	200	3	lines	line	NOUN
dpc-3703	200	4	,	,	PUNCT
dpc-3703	200	5	the	the	DET
dpc-3703	200	6	combination	combination	NOUN
dpc-3703	200	7	of	of	ADP
dpc-3703	200	8	anti	anti	ADJ
dpc-3703	200	9	-	-	ADJ
dpc-3703	200	10	pd-1	pd-1	ADJ
dpc-3703	200	11	therapy	therapy	NOUN
dpc-3703	200	12	with	with	ADP
dpc-3703	200	13	hhi	hhi	NOUN
dpc-3703	200	14	,	,	PUNCT
dpc-3703	200	15	or	or	CCONJ
dpc-3703	200	16	talimogene	talimogene	VERB
dpc-3703	200	17	laherparepvec	laherparepvec	ADJ
dpc-3703	200	18	for	for	ADP
dpc-3703	200	19	advanced	advanced	ADJ
dpc-3703	200	20	bcc	bcc	PROPN
dpc-3703	200	21	is	be	AUX
dpc-3703	200	22	currently	currently	ADV
dpc-3703	200	23	evaluated	evaluate	VERB
dpc-3703	200	24	in	in	ADP
dpc-3703	200	25	clinical	clinical	ADJ
dpc-3703	200	26	trials	trial	NOUN
dpc-3703	200	27	.	.	PUNCT
dpc-3703	201	1	the	the	DET
dpc-3703	201	2	combination	combination	NOUN
dpc-3703	201	3	of	of	ADP
dpc-3703	201	4	pembrolizumab	pembrolizumab	NOUN
dpc-3703	201	5	200	200	NUM
dpc-3703	201	6	mg	mg	NUM
dpc-3703	201	7	iv	iv	NUM
dpc-3703	201	8	every	every	DET
dpc-3703	201	9	3	3	NUM
dpc-3703	201	10	weeks	week	NOUN
dpc-3703	201	11	with	with	ADP
dpc-3703	201	12	vismodegib	vismodegib	NOUN
dpc-3703	201	13	(	(	PUNCT
dpc-3703	201	14	in	in	ADP
dpc-3703	201	15	7	7	NUM
dpc-3703	201	16	patients	patient	NOUN
dpc-3703	201	17	)	)	PUNCT
dpc-3703	201	18	showed	show	VERB
dpc-3703	201	19	lower	low	ADJ
dpc-3703	201	20	table	table	NOUN
dpc-3703	201	21	3	3	NUM
dpc-3703	201	22	.	.	PUNCT
dpc-3703	202	1	clinical	clinical	ADJ
dpc-3703	202	2	trials	trial	NOUN
dpc-3703	202	3	on	on	ADP
dpc-3703	202	4	neoadjuvant	neoadjuvant	ADJ
dpc-3703	202	5	immunotherapy	immunotherapy	NOUN
dpc-3703	202	6	in	in	ADP
dpc-3703	202	7	patients	patient	NOUN
dpc-3703	202	8	with	with	ADP
dpc-3703	202	9	advanced	advanced	ADJ
dpc-3703	202	10	basal	basal	NOUN
dpc-3703	202	11	cell	cell	NOUN
dpc-3703	202	12	 	 	SPACE
dpc-3703	202	13	carcinoma	carcinoma	NOUN
dpc-3703	202	14	.	.	PUNCT
dpc-3703	203	1	study	study	NOUN
dpc-3703	203	2	i	i	PROPN
dpc-3703	203	3	d	d	PROPN
dpc-3703	203	4	phase	phase	NOUN
dpc-3703	203	5	(	(	PUNCT
dpc-3703	203	6	status	status	NOUN
dpc-3703	203	7	)	)	PUNCT
dpc-3703	203	8	therapy	therapy	NOUN
dpc-3703	203	9	enrollment	enrollment	NOUN
dpc-3703	203	10	,	,	PUNCT
dpc-3703	203	11	n	n	CCONJ
dpc-3703	203	12	bcc	bcc	PROPN
dpc-3703	203	13	classification	classification	VERB
dpc-3703	203	14	main	main	ADJ
dpc-3703	203	15	outcomes	outcome	NOUN
dpc-3703	203	16	nct05929664	nct05929664	NOUN
dpc-3703	203	17	[	[	X
dpc-3703	203	18	74	74	NUM
dpc-3703	203	19	]	]	SYM
dpc-3703	203	20	ii	ii	NOUN
dpc-3703	203	21	(	(	PUNCT
dpc-3703	203	22	active	active	ADJ
dpc-3703	203	23	,	,	PUNCT
dpc-3703	203	24	not	not	PART
dpc-3703	203	25	yet	yet	ADV
dpc-3703	203	26	recruiting	recruit	VERB
dpc-3703	203	27	)	)	PUNCT
dpc-3703	203	28	cemiplimab	cemiplimab	NOUN
dpc-3703	203	29	35	35	NUM
dpc-3703	203	30	labcc	labcc	NOUN
dpc-3703	203	31	of	of	ADP
dpc-3703	203	32	the	the	DET
dpc-3703	203	33	head	head	NOUN
dpc-3703	203	34	and	and	CCONJ
dpc-3703	203	35	neck	neck	NOUN
dpc-3703	203	36	requiring	require	VERB
dpc-3703	203	37	greater	great	ADJ
dpc-3703	203	38	than	than	ADP
dpc-3703	203	39	30	30	NUM
dpc-3703	203	40	%	%	NOUN
dpc-3703	203	41	auriculectomy	auriculectomy	NOUN
dpc-3703	203	42	,	,	PUNCT
dpc-3703	203	43	rhinectomy	rhinectomy	ADJ
dpc-3703	203	44	,	,	PUNCT
dpc-3703	203	45	upper	upper	ADJ
dpc-3703	203	46	or	or	CCONJ
dpc-3703	203	47	lower	low	ADJ
dpc-3703	203	48	lip	lip	NOUN
dpc-3703	203	49	resection	resection	NOUN
dpc-3703	203	50	,	,	PUNCT
dpc-3703	203	51	orbital	orbital	ADJ
dpc-3703	203	52	exenteration	exenteration	NOUN
dpc-3703	203	53	(	(	PUNCT
dpc-3703	203	54	due	due	ADP
dpc-3703	203	55	to	to	ADP
dpc-3703	203	56	lid	lid	NOUN
dpc-3703	203	57	or	or	CCONJ
dpc-3703	203	58	orbital	orbital	ADJ
dpc-3703	203	59	involvement	involvement	NOUN
dpc-3703	203	60	)	)	PUNCT
dpc-3703	203	61	,	,	PUNCT
dpc-3703	203	62	facial	facial	ADJ
dpc-3703	203	63	nerve	nerve	NOUN
dpc-3703	203	64	sacrifice	sacrifice	NOUN
dpc-3703	203	65	or	or	CCONJ
dpc-3703	203	66	brigham	brigham	PROPN
dpc-3703	203	67	and	and	CCONJ
dpc-3703	203	68	women	woman	NOUN
dpc-3703	203	69	's	's	PART
dpc-3703	203	70	stage	stage	NOUN
dpc-3703	203	71	2b	2b	NOUN
dpc-3703	203	72	or	or	CCONJ
dpc-3703	203	73	3	3	NUM
dpc-3703	203	74	disease	disease	NOUN
dpc-3703	203	75	of	of	ADP
dpc-3703	203	76	head	head	NOUN
dpc-3703	203	77	and	and	CCONJ
dpc-3703	203	78	neck	neck	NOUN
dpc-3703	203	79	primary	primary	NOUN
dpc-3703	203	80	:	:	PUNCT
dpc-3703	203	81	orr	orr	PROPN
dpc-3703	203	82	,	,	PUNCT
dpc-3703	203	83	dcr	dcr	PROPN
dpc-3703	203	84	secondary	secondary	ADJ
dpc-3703	203	85	:	:	PUNCT
dpc-3703	203	86	sbr	sbr	NOUN
dpc-3703	203	87	,	,	PUNCT
dpc-3703	203	88	pcr	pcr	PROPN
dpc-3703	203	89	,	,	PUNCT
dpc-3703	203	90	mpr	mpr	NOUN
dpc-3703	203	91	,	,	PUNCT
dpc-3703	203	92	adverse	adverse	ADJ
dpc-3703	203	93	events	event	NOUN
dpc-3703	203	94	,	,	PUNCT
dpc-3703	203	95	quality	quality	NOUN
dpc-3703	203	96	of	of	ADP
dpc-3703	203	97	life	life	NOUN
dpc-3703	203	98	nct04323202	nct04323202	NOUN
dpc-3703	204	1	[	[	X
dpc-3703	204	2	75	75	NUM
dpc-3703	204	3	]	]	X
dpc-3703	204	4	i	i	PRON
dpc-3703	204	5	(	(	PUNCT
dpc-3703	204	6	active	active	ADJ
dpc-3703	204	7	,	,	PUNCT
dpc-3703	204	8	not	not	PART
dpc-3703	204	9	recruiting	recruit	VERB
dpc-3703	204	10	)	)	PUNCT
dpc-3703	204	11	pembrolizumab	pembrolizumab	NOUN
dpc-3703	204	12	13	13	NUM
dpc-3703	204	13	locoregionally	locoregionally	ADV
dpc-3703	204	14	advanced	advanced	ADJ
dpc-3703	204	15	,	,	PUNCT
dpc-3703	204	16	resectable	resectable	VERB
dpc-3703	204	17	bcc	bcc	PROPN
dpc-3703	204	18	of	of	ADP
dpc-3703	204	19	the	the	DET
dpc-3703	204	20	head	head	NOUN
dpc-3703	204	21	and	and	CCONJ
dpc-3703	204	22	 	 	SPACE
dpc-3703	204	23	neck	neck	NOUN
dpc-3703	204	24	primary	primary	NOUN
dpc-3703	204	25	:	:	PUNCT
dpc-3703	204	26	pathologic	pathologic	ADJ
dpc-3703	204	27	response	response	NOUN
dpc-3703	204	28	assessed	assess	VERB
dpc-3703	204	29	by	by	ADP
dpc-3703	204	30	tumor	tumor	NOUN
dpc-3703	204	31	volume	volume	NOUN
dpc-3703	204	32	.	.	PUNCT
dpc-3703	205	1	secondary	secondary	ADJ
dpc-3703	205	2	:	:	PUNCT
dpc-3703	205	3	adverse	adverse	ADJ
dpc-3703	205	4	events	event	NOUN
dpc-3703	205	5	,	,	PUNCT
dpc-3703	205	6	one	one	NUM
dpc-3703	205	7	-	-	PUNCT
dpc-3703	205	8	year	year	NOUN
dpc-3703	205	9	recurrence	recurrence	NOUN
dpc-3703	205	10	rates	rate	NOUN
dpc-3703	205	11	bcc	bcc	PROPN
dpc-3703	205	12	=	=	SYM
dpc-3703	205	13	basal	basal	PROPN
dpc-3703	205	14	cell	cell	NOUN
dpc-3703	205	15	carcinoma	carcinoma	NOUN
dpc-3703	205	16	;	;	PUNCT
dpc-3703	205	17	dcr	dcr	PROPN
dpc-3703	205	18	=	=	PUNCT
dpc-3703	205	19	disease	disease	NOUN
dpc-3703	205	20	control	control	NOUN
dpc-3703	205	21	rate	rate	NOUN
dpc-3703	205	22	;	;	PUNCT
dpc-3703	205	23	labcc	labcc	NOUN
dpc-3703	205	24	=	=	SYM
dpc-3703	205	25	locally	locally	ADV
dpc-3703	205	26	advanced	advance	VERB
dpc-3703	205	27	basal	basal	NOUN
dpc-3703	205	28	cell	cell	NOUN
dpc-3703	205	29	carcinoma	carcinoma	NOUN
dpc-3703	205	30	;	;	PUNCT
dpc-3703	205	31	mpr	mpr	NOUN
dpc-3703	205	32	=	=	NOUN
dpc-3703	205	33	major	major	ADJ
dpc-3703	205	34	pathologic	pathologic	ADJ
dpc-3703	205	35	response	response	NOUN
dpc-3703	205	36	;	;	PUNCT
dpc-3703	205	37	orr=	orr=	VERB
dpc-3703	205	38	objective	objective	ADJ
dpc-3703	205	39	response	response	NOUN
dpc-3703	205	40	rate	rate	NOUN
dpc-3703	205	41	;	;	PUNCT
dpc-3703	205	42	pcr	pcr	ADJ
dpc-3703	205	43	=	=	SYM
dpc-3703	205	44	pathologic	pathologic	ADJ
dpc-3703	205	45	complete	complete	ADJ
dpc-3703	205	46	response	response	NOUN
dpc-3703	205	47	;	;	PUNCT
dpc-3703	205	48	sbr	sbr	NOUN
dpc-3703	205	49	=	=	PUNCT
dpc-3703	205	50	surgical	surgical	ADJ
dpc-3703	205	51	/	/	SYM
dpc-3703	205	52	clinical	clinical	ADJ
dpc-3703	205	53	benefit	benefit	NOUN
dpc-3703	205	54	rate	rate	NOUN
dpc-3703	205	55	.	.	PUNCT
dpc-3703	206	1	8	8	NUM
dpc-3703	206	2	review	review	NOUN
dpc-3703	206	3	|	|	ADV
dpc-3703	206	4	dermatol	dermatol	ADJ
dpc-3703	206	5	pract	pract	NOUN
dpc-3703	206	6	concept	concept	NOUN
dpc-3703	206	7	.	.	PUNCT
dpc-3703	207	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	208	1	albeit	albeit	SCONJ
dpc-3703	208	2	high	high	ADJ
dpc-3703	208	3	,	,	PUNCT
dpc-3703	208	4	median	median	NOUN
dpc-3703	208	5	tmb	tmb	PROPN
dpc-3703	208	6	(	(	PUNCT
dpc-3703	208	7	58	58	NUM
dpc-3703	208	8	versus	versus	ADP
dpc-3703	208	9	23	23	NUM
dpc-3703	208	10	mut	mut	NOUN
dpc-3703	208	11	/	/	SYM
dpc-3703	208	12	mb	mb	NOUN
dpc-3703	208	13	)	)	PUNCT
dpc-3703	208	14	and	and	CCONJ
dpc-3703	208	15	similar	similar	ADJ
dpc-3703	208	16	median	median	ADJ
dpc-3703	208	17	mhc	mhc	PROPN
dpc-3703	208	18	-	-	PUNCT
dpc-3703	208	19	i	i	PROPN
dpc-3703	208	20	expression	expression	NOUN
dpc-3703	208	21	level	level	NOUN
dpc-3703	208	22	on	on	ADP
dpc-3703	208	23	tumor	tumor	NOUN
dpc-3703	208	24	cells	cell	NOUN
dpc-3703	208	25	(	(	PUNCT
dpc-3703	208	26	37	37	NUM
dpc-3703	208	27	,	,	PUNCT
dpc-3703	208	28	iqr	iqr	X
dpc-3703	208	29	21	21	NUM
dpc-3703	208	30	-	-	SYM
dpc-3703	208	31	72	72	NUM
dpc-3703	208	32	versus	versus	ADP
dpc-3703	208	33	21	21	NUM
dpc-3703	208	34	,	,	PUNCT
dpc-3703	208	35	iqr	iqr	X
dpc-3703	208	36	5	5	NUM
dpc-3703	208	37	-	-	SYM
dpc-3703	208	38	62	62	NUM
dpc-3703	208	39	)	)	PUNCT
dpc-3703	208	40	,	,	PUNCT
dpc-3703	208	41	in	in	ADP
dpc-3703	208	42	responders	responder	NOUN
dpc-3703	208	43	versus	versus	ADP
dpc-3703	208	44	non	non	NOUN
dpc-3703	208	45	-	-	NOUN
dpc-3703	208	46	responders	responder	NOUN
dpc-3703	208	47	,	,	PUNCT
dpc-3703	208	48	respectively	respectively	ADV
dpc-3703	208	49	.	.	PUNCT
dpc-3703	209	1	notably	notably	ADV
dpc-3703	209	2	,	,	PUNCT
dpc-3703	209	3	among	among	ADP
dpc-3703	209	4	some	some	DET
dpc-3703	209	5	patients	patient	NOUN
dpc-3703	209	6	with	with	ADP
dpc-3703	209	7	high	high	ADJ
dpc-3703	209	8	tmb	tmb	NOUN
dpc-3703	209	9	levels	level	NOUN
dpc-3703	209	10	who	who	PRON
dpc-3703	209	11	did	do	AUX
dpc-3703	209	12	not	not	PART
dpc-3703	209	13	have	have	VERB
dpc-3703	209	14	objective	objective	ADJ
dpc-3703	209	15	response	response	NOUN
dpc-3703	209	16	,	,	PUNCT
dpc-3703	209	17	major	major	ADJ
dpc-3703	209	18	histocompatibility	histocompatibility	NOUN
dpc-3703	209	19	complex	complex	NOUN
dpc-3703	209	20	i	i	PRON
dpc-3703	209	21	(	(	PUNCT
dpc-3703	209	22	mhc	mhc	PROPN
dpc-3703	209	23	-	-	PUNCT
dpc-3703	209	24	i	i	PROPN
dpc-3703	209	25	)	)	PUNCT
dpc-3703	209	26	expression	expression	NOUN
dpc-3703	209	27	was	be	AUX
dpc-3703	209	28	low	low	ADJ
dpc-3703	209	29	or	or	CCONJ
dpc-3703	209	30	absent	absent	ADJ
dpc-3703	209	31	[	[	X
dpc-3703	209	32	65	65	NUM
dpc-3703	209	33	]	]	PUNCT
dpc-3703	209	34	.	.	PUNCT
dpc-3703	210	1	the	the	DET
dpc-3703	210	2	downregulation	downregulation	NOUN
dpc-3703	210	3	of	of	ADP
dpc-3703	210	4	mhc	mhc	PROPN
dpc-3703	210	5	-	-	PROPN
dpc-3703	210	6	i	i	PRON
dpc-3703	210	7	has	have	AUX
dpc-3703	210	8	been	be	AUX
dpc-3703	210	9	implicated	implicate	VERB
dpc-3703	210	10	in	in	ADP
dpc-3703	210	11	lower	low	ADJ
dpc-3703	210	12	antigen	antigen	ADJ
dpc-3703	210	13	modification	modification	NOUN
dpc-3703	210	14	and	and	CCONJ
dpc-3703	210	15	presentation	presentation	NOUN
dpc-3703	210	16	,	,	PUNCT
dpc-3703	210	17	contributing	contribute	VERB
dpc-3703	210	18	to	to	ADP
dpc-3703	210	19	a	a	DET
dpc-3703	210	20	possible	possible	ADJ
dpc-3703	210	21	lower	low	ADJ
dpc-3703	210	22	immunogenicity	immunogenicity	NOUN
dpc-3703	210	23	of	of	ADP
dpc-3703	210	24	bcc	bcc	PROPN
dpc-3703	210	25	compared	compare	VERB
dpc-3703	210	26	to	to	ADP
dpc-3703	210	27	cscc	cscc	PROPN
dpc-3703	210	28	[	[	X
dpc-3703	210	29	93	93	NUM
dpc-3703	210	30	]	]	PUNCT
dpc-3703	210	31	.	.	PUNCT
dpc-3703	211	1	recently	recently	ADV
dpc-3703	211	2	,	,	PUNCT
dpc-3703	211	3	the	the	DET
dpc-3703	211	4	dysregulation	dysregulation	NOUN
dpc-3703	211	5	of	of	ADP
dpc-3703	211	6	regulatory	regulatory	ADJ
dpc-3703	211	7	non	non	ADJ
dpc-3703	211	8	-	-	ADJ
dpc-3703	211	9	coding	coding	ADJ
dpc-3703	211	10	rnas	rna	NOUN
dpc-3703	211	11	,	,	PUNCT
dpc-3703	211	12	including	include	VERB
dpc-3703	211	13	microrna	microrna	PROPN
dpc-3703	211	14	(	(	PUNCT
dpc-3703	211	15	mirna	mirna	PROPN
dpc-3703	211	16	)	)	PUNCT
dpc-3703	211	17	,	,	PUNCT
dpc-3703	211	18	has	have	AUX
dpc-3703	211	19	been	be	AUX
dpc-3703	211	20	identified	identify	VERB
dpc-3703	211	21	in	in	ADP
dpc-3703	211	22	bcc	bcc	PROPN
dpc-3703	211	23	.	.	PUNCT
dpc-3703	212	1	some	some	DET
dpc-3703	212	2	mirnas	mirna	NOUN
dpc-3703	212	3	may	may	AUX
dpc-3703	212	4	act	act	VERB
dpc-3703	212	5	as	as	ADP
dpc-3703	212	6	tumor	tumor	NOUN
dpc-3703	212	7	suppressors	suppressor	NOUN
dpc-3703	212	8	while	while	SCONJ
dpc-3703	212	9	others	other	NOUN
dpc-3703	212	10	act	act	VERB
dpc-3703	212	11	as	as	ADP
dpc-3703	212	12	oncogenes	oncogene	NOUN
dpc-3703	212	13	(	(	PUNCT
dpc-3703	212	14	oncomir	oncomir	PROPN
dpc-3703	212	15	)	)	PUNCT
dpc-3703	212	16	,	,	PUNCT
dpc-3703	212	17	and	and	CCONJ
dpc-3703	212	18	mirnas	mirna	NOUN
dpc-3703	212	19	have	have	AUX
dpc-3703	212	20	been	be	AUX
dpc-3703	212	21	associated	associate	VERB
dpc-3703	212	22	with	with	ADP
dpc-3703	212	23	specific	specific	ADJ
dpc-3703	212	24	high	high	ADJ
dpc-3703	212	25	-	-	PUNCT
dpc-3703	212	26	risk	risk	NOUN
dpc-3703	212	27	bcc	bcc	PROPN
dpc-3703	212	28	subtypes	subtype	NOUN
dpc-3703	212	29	,	,	PUNCT
dpc-3703	212	30	suggesting	suggest	VERB
dpc-3703	212	31	a	a	DET
dpc-3703	212	32	potential	potential	ADJ
dpc-3703	212	33	prognostic	prognostic	ADJ
dpc-3703	212	34	role	role	NOUN
dpc-3703	212	35	.	.	PUNCT
dpc-3703	213	1	in	in	ADP
dpc-3703	213	2	addition	addition	NOUN
dpc-3703	213	3	,	,	PUNCT
dpc-3703	213	4	several	several	ADJ
dpc-3703	213	5	mirnas	mirna	NOUN
dpc-3703	213	6	have	have	AUX
dpc-3703	213	7	been	be	AUX
dpc-3703	213	8	shown	show	VERB
dpc-3703	213	9	to	to	PART
dpc-3703	213	10	affect	affect	VERB
dpc-3703	213	11	drug	drug	NOUN
dpc-3703	213	12	resistance	resistance	NOUN
dpc-3703	213	13	to	to	ADP
dpc-3703	213	14	braf	braf	NOUN
dpc-3703	213	15	inhibition	inhibition	NOUN
dpc-3703	213	16	in	in	ADP
dpc-3703	213	17	melanoma	melanoma	NOUN
dpc-3703	213	18	,	,	PUNCT
dpc-3703	213	19	underscoring	underscore	VERB
dpc-3703	213	20	the	the	DET
dpc-3703	213	21	possibility	possibility	NOUN
dpc-3703	213	22	to	to	PART
dpc-3703	213	23	add	add	VERB
dpc-3703	213	24	predictive	predictive	ADJ
dpc-3703	213	25	information	information	NOUN
dpc-3703	213	26	for	for	ADP
dpc-3703	213	27	response	response	NOUN
dpc-3703	213	28	to	to	ADP
dpc-3703	213	29	therapy	therapy	NOUN
dpc-3703	213	30	[	[	X
dpc-3703	213	31	94	94	NUM
dpc-3703	213	32	]	]	PUNCT
dpc-3703	213	33	.	.	PUNCT
dpc-3703	214	1	conclusions	conclusion	NOUN
dpc-3703	214	2	anti	anti	ADJ
dpc-3703	214	3	-	-	ADJ
dpc-3703	214	4	pd-1	pd-1	ADJ
dpc-3703	214	5	agents	agent	NOUN
dpc-3703	214	6	offer	offer	VERB
dpc-3703	214	7	a	a	DET
dpc-3703	214	8	therapeutic	therapeutic	ADJ
dpc-3703	214	9	option	option	NOUN
dpc-3703	214	10	in	in	ADP
dpc-3703	214	11	patients	patient	NOUN
dpc-3703	214	12	with	with	ADP
dpc-3703	214	13	advanced	advanced	ADJ
dpc-3703	214	14	bcc	bcc	PROPN
dpc-3703	214	15	not	not	PART
dpc-3703	214	16	amenable	amenable	ADJ
dpc-3703	214	17	to	to	PART
dpc-3703	214	18	curative	curative	ADJ
dpc-3703	214	19	surgery	surgery	NOUN
dpc-3703	214	20	or	or	CCONJ
dpc-3703	214	21	radiotherapy	radiotherapy	NOUN
dpc-3703	214	22	,	,	PUNCT
dpc-3703	214	23	who	who	PRON
dpc-3703	214	24	have	have	AUX
dpc-3703	214	25	progressed	progress	VERB
dpc-3703	214	26	or	or	CCONJ
dpc-3703	214	27	are	be	AUX
dpc-3703	214	28	intolerant	intolerant	ADJ
dpc-3703	214	29	to	to	ADP
dpc-3703	214	30	an	an	DET
dpc-3703	214	31	hhi	hhi	NOUN
dpc-3703	214	32	.	.	PUNCT
dpc-3703	215	1	for	for	ADP
dpc-3703	215	2	labcc	labcc	NOUN
dpc-3703	215	3	treated	treat	VERB
dpc-3703	215	4	with	with	ADP
dpc-3703	215	5	second	second	ADJ
dpc-3703	215	6	-	-	PUNCT
dpc-3703	215	7	line	line	NOUN
dpc-3703	215	8	cemiplimab	cemiplimab	NOUN
dpc-3703	215	9	,	,	PUNCT
dpc-3703	215	10	the	the	DET
dpc-3703	215	11	possibility	possibility	NOUN
dpc-3703	215	12	of	of	ADP
dpc-3703	215	13	a	a	DET
dpc-3703	215	14	response	response	NOUN
dpc-3703	215	15	in	in	ADP
dpc-3703	215	16	approximately	approximately	ADV
dpc-3703	215	17	one	one	NUM
dpc-3703	215	18	third	third	NOUN
dpc-3703	215	19	of	of	ADP
dpc-3703	215	20	patients	patient	NOUN
dpc-3703	215	21	and	and	CCONJ
dpc-3703	215	22	of	of	ADP
dpc-3703	215	23	a	a	DET
dpc-3703	215	24	prolonged	prolonged	ADJ
dpc-3703	215	25	duration	duration	NOUN
dpc-3703	215	26	of	of	ADP
dpc-3703	215	27	response	response	NOUN
dpc-3703	215	28	,	,	PUNCT
dpc-3703	215	29	make	make	VERB
dpc-3703	215	30	anti	anti	ADJ
dpc-3703	215	31	-	-	ADJ
dpc-3703	215	32	pd-1	pd-1	ADJ
dpc-3703	215	33	immunotherapy	immunotherapy	NOUN
dpc-3703	215	34	an	an	DET
dpc-3703	215	35	important	important	ADJ
dpc-3703	215	36	treatment	treatment	NOUN
dpc-3703	215	37	solution	solution	NOUN
dpc-3703	215	38	.	.	PUNCT
dpc-3703	216	1	in	in	ADP
dpc-3703	216	2	addition	addition	NOUN
dpc-3703	216	3	,	,	PUNCT
dpc-3703	216	4	results	result	NOUN
dpc-3703	216	5	from	from	ADP
dpc-3703	216	6	melanoma	melanoma	NOUN
dpc-3703	216	7	trials	trial	NOUN
dpc-3703	216	8	underscore	underscore	VERB
dpc-3703	216	9	the	the	DET
dpc-3703	216	10	emergence	emergence	NOUN
dpc-3703	216	11	of	of	ADP
dpc-3703	216	12	neoadjuvant	neoadjuvant	ADJ
dpc-3703	216	13	immunotherapy	immunotherapy	NOUN
dpc-3703	216	14	with	with	ADP
dpc-3703	216	15	anti	anti	ADJ
dpc-3703	216	16	-	-	ADJ
dpc-3703	216	17	pd-1	pd-1	ADJ
dpc-3703	216	18	agents	agent	NOUN
dpc-3703	216	19	as	as	ADP
dpc-3703	216	20	a	a	DET
dpc-3703	216	21	treatment	treatment	NOUN
dpc-3703	216	22	positively	positively	ADV
dpc-3703	216	23	affecting	affect	VERB
dpc-3703	216	24	the	the	DET
dpc-3703	216	25	prognostic	prognostic	ADJ
dpc-3703	216	26	outcomes	outcome	NOUN
dpc-3703	216	27	in	in	ADP
dpc-3703	216	28	skin	skin	NOUN
dpc-3703	216	29	cancer	cancer	NOUN
dpc-3703	216	30	.	.	PUNCT
dpc-3703	217	1	treating	treat	VERB
dpc-3703	217	2	advanced	advanced	ADJ
dpc-3703	217	3	bcc	bcc	PROPN
dpc-3703	217	4	with	with	ADP
dpc-3703	217	5	immunotherapy	immunotherapy	NOUN
dpc-3703	217	6	can	can	AUX
dpc-3703	217	7	achieve	achieve	VERB
dpc-3703	217	8	durable	durable	ADJ
dpc-3703	217	9	response	response	NOUN
dpc-3703	217	10	in	in	ADP
dpc-3703	217	11	some	some	DET
dpc-3703	217	12	patients	patient	NOUN
dpc-3703	217	13	,	,	PUNCT
dpc-3703	217	14	however	however	ADV
dpc-3703	217	15	there	there	PRON
dpc-3703	217	16	is	be	VERB
dpc-3703	217	17	a	a	DET
dpc-3703	217	18	considerable	considerable	ADJ
dpc-3703	217	19	number	number	NOUN
dpc-3703	217	20	of	of	ADP
dpc-3703	217	21	patients	patient	NOUN
dpc-3703	217	22	who	who	PRON
dpc-3703	217	23	will	will	AUX
dpc-3703	217	24	not	not	PART
dpc-3703	217	25	respond	respond	VERB
dpc-3703	217	26	or	or	CCONJ
dpc-3703	217	27	will	will	AUX
dpc-3703	217	28	lose	lose	VERB
dpc-3703	217	29	response	response	NOUN
dpc-3703	217	30	.	.	PUNCT
dpc-3703	218	1	the	the	DET
dpc-3703	218	2	use	use	NOUN
dpc-3703	218	3	of	of	ADP
dpc-3703	218	4	biomarkers	biomarker	NOUN
dpc-3703	218	5	for	for	ADP
dpc-3703	218	6	identifying	identify	VERB
dpc-3703	218	7	and	and	CCONJ
dpc-3703	218	8	treating	treat	VERB
dpc-3703	218	9	those	those	DET
dpc-3703	218	10	patients	patient	NOUN
dpc-3703	218	11	more	more	ADV
dpc-3703	218	12	likely	likely	ADJ
dpc-3703	218	13	to	to	PART
dpc-3703	218	14	respond	respond	VERB
dpc-3703	218	15	to	to	ADP
dpc-3703	218	16	anti	anti	ADJ
dpc-3703	218	17	-	-	ADJ
dpc-3703	218	18	pd-1	pd-1	ADJ
dpc-3703	218	19	therapy	therapy	NOUN
dpc-3703	218	20	is	be	AUX
dpc-3703	218	21	a	a	DET
dpc-3703	218	22	promising	promising	ADJ
dpc-3703	218	23	area	area	NOUN
dpc-3703	218	24	of	of	ADP
dpc-3703	218	25	active	active	ADJ
dpc-3703	218	26	research	research	NOUN
dpc-3703	218	27	towards	towards	ADP
dpc-3703	218	28	personalized	personalized	ADJ
dpc-3703	218	29	treatment	treatment	NOUN
dpc-3703	218	30	.	.	PUNCT
dpc-3703	219	1	clinical	clinical	ADJ
dpc-3703	219	2	and	and	CCONJ
dpc-3703	219	3	translational	translational	ADJ
dpc-3703	219	4	research	research	NOUN
dpc-3703	219	5	has	have	AUX
dpc-3703	219	6	led	lead	VERB
dpc-3703	219	7	to	to	ADP
dpc-3703	219	8	a	a	DET
dpc-3703	219	9	paradigm	paradigm	NOUN
dpc-3703	219	10	shift	shift	NOUN
dpc-3703	219	11	in	in	ADP
dpc-3703	219	12	the	the	DET
dpc-3703	219	13	treatment	treatment	NOUN
dpc-3703	219	14	of	of	ADP
dpc-3703	219	15	advanced	advanced	ADJ
dpc-3703	219	16	bcc	bcc	PROPN
dpc-3703	219	17	with	with	ADP
dpc-3703	219	18	the	the	DET
dpc-3703	219	19	advent	advent	NOUN
dpc-3703	219	20	of	of	ADP
dpc-3703	219	21	targeted	target	VERB
dpc-3703	219	22	therapies	therapy	NOUN
dpc-3703	219	23	,	,	PUNCT
dpc-3703	219	24	eg	eg	NOUN
dpc-3703	219	25	hhi	hhi	NOUN
dpc-3703	219	26	and	and	CCONJ
dpc-3703	219	27	anti	anti	ADJ
dpc-3703	219	28	-	-	ADJ
dpc-3703	219	29	pd-1	pd-1	ADJ
dpc-3703	219	30	immune	immune	ADJ
dpc-3703	219	31	checkpoint	checkpoint	NOUN
dpc-3703	219	32	blockade	blockade	NOUN
dpc-3703	219	33	.	.	PUNCT
dpc-3703	220	1	however	however	ADV
dpc-3703	220	2	,	,	PUNCT
dpc-3703	220	3	important	important	ADJ
dpc-3703	220	4	treatment	treatment	NOUN
dpc-3703	220	5	gaps	gap	NOUN
dpc-3703	220	6	still	still	ADV
dpc-3703	220	7	remain	remain	VERB
dpc-3703	220	8	on	on	ADP
dpc-3703	220	9	the	the	DET
dpc-3703	220	10	management	management	NOUN
dpc-3703	220	11	of	of	ADP
dpc-3703	220	12	those	those	DET
dpc-3703	220	13	patients	patient	NOUN
dpc-3703	220	14	that	that	PRON
dpc-3703	220	15	have	have	VERB
dpc-3703	220	16	resistance	resistance	NOUN
dpc-3703	220	17	or	or	CCONJ
dpc-3703	220	18	unacceptable	unacceptable	ADJ
dpc-3703	220	19	toxicities	toxicity	NOUN
dpc-3703	220	20	with	with	ADP
dpc-3703	220	21	hhi	hhi	NOUN
dpc-3703	220	22	and	and	CCONJ
dpc-3703	220	23	anti	anti	ADJ
dpc-3703	220	24	-	-	ADJ
dpc-3703	220	25	pd-1	pd-1	ADJ
dpc-3703	220	26	agents	agent	NOUN
dpc-3703	220	27	.	.	PUNCT
dpc-3703	221	1	for	for	ADP
dpc-3703	221	2	the	the	DET
dpc-3703	221	3	challenges	challenge	NOUN
dpc-3703	221	4	that	that	PRON
dpc-3703	221	5	lie	lie	VERB
dpc-3703	221	6	ahead	ahead	ADV
dpc-3703	221	7	,	,	PUNCT
dpc-3703	221	8	precision	precision	NOUN
dpc-3703	221	9	medicine	medicine	NOUN
dpc-3703	221	10	and	and	CCONJ
dpc-3703	221	11	rigorous	rigorous	ADJ
dpc-3703	221	12	clinical	clinical	ADJ
dpc-3703	221	13	research	research	NOUN
dpc-3703	221	14	aim	aim	VERB
dpc-3703	221	15	to	to	PART
dpc-3703	221	16	provide	provide	VERB
dpc-3703	221	17	further	further	ADJ
dpc-3703	221	18	data	datum	NOUN
dpc-3703	221	19	to	to	PART
dpc-3703	221	20	guide	guide	VERB
dpc-3703	221	21	evidence	evidence	NOUN
dpc-3703	221	22	-	-	PUNCT
dpc-3703	221	23	based	base	VERB
dpc-3703	221	24	decisions	decision	NOUN
dpc-3703	221	25	on	on	ADP
dpc-3703	221	26	the	the	DET
dpc-3703	221	27	optimal	optimal	ADJ
dpc-3703	221	28	timing	timing	NOUN
dpc-3703	221	29	and	and	CCONJ
dpc-3703	221	30	combination	combination	NOUN
dpc-3703	221	31	of	of	ADP
dpc-3703	221	32	treatments	treatment	NOUN
dpc-3703	221	33	for	for	ADP
dpc-3703	221	34	patients	patient	NOUN
dpc-3703	221	35	with	with	ADP
dpc-3703	221	36	advanced	advanced	ADJ
dpc-3703	221	37	bcc	bcc	PROPN
dpc-3703	221	38	.	.	PUNCT
dpc-3703	222	1	advanced	advanced	ADJ
dpc-3703	222	2	cscc	cscc	ADJ
dpc-3703	222	3	,	,	PUNCT
dpc-3703	222	4	and	and	CCONJ
dpc-3703	222	5	in	in	ADP
dpc-3703	222	6	combination	combination	NOUN
dpc-3703	222	7	with	with	ADP
dpc-3703	222	8	nivolumab	nivolumab	NOUN
dpc-3703	222	9	for	for	ADP
dpc-3703	222	10	advanced	advanced	ADJ
dpc-3703	222	11	bcc	bcc	PROPN
dpc-3703	223	1	[	[	X
dpc-3703	223	2	88,89	88,89	NOUN
dpc-3703	223	3	]	]	X
dpc-3703	223	4	.	.	PUNCT
dpc-3703	223	5	is	be	AUX
dpc-3703	223	6	there	there	PRON
dpc-3703	223	7	evidence	evidence	NOUN
dpc-3703	223	8	for	for	ADP
dpc-3703	223	9	anti	anti	ADJ
dpc-3703	223	10	-	-	ADJ
dpc-3703	223	11	pd-1	pd-1	ADJ
dpc-3703	223	12	agents	agent	NOUN
dpc-3703	223	13	as	as	ADP
dpc-3703	223	14	first	first	ADJ
dpc-3703	223	15	-	-	PUNCT
dpc-3703	223	16	line	line	NOUN
dpc-3703	223	17	systemic	systemic	ADJ
dpc-3703	223	18	therapy	therapy	NOUN
dpc-3703	223	19	for	for	ADP
dpc-3703	223	20	advanced	advanced	ADJ
dpc-3703	223	21	bcc	bcc	PROPN
dpc-3703	223	22	?	?	PUNCT
dpc-3703	224	1	the	the	DET
dpc-3703	224	2	current	current	ADJ
dpc-3703	224	3	us	us	PROPN
dpc-3703	224	4	nccn	nccn	PROPN
dpc-3703	224	5	guidelines	guideline	NOUN
dpc-3703	224	6	(	(	PUNCT
dpc-3703	224	7	version	version	NOUN
dpc-3703	224	8	1.2023	1.2023	NUM
dpc-3703	224	9	)	)	PUNCT
dpc-3703	224	10	and	and	CCONJ
dpc-3703	224	11	the	the	DET
dpc-3703	224	12	european	european	PROPN
dpc-3703	224	13	guideline	guideline	PROPN
dpc-3703	224	14	update	update	NOUN
dpc-3703	224	15	2023	2023	NUM
dpc-3703	224	16	,	,	PUNCT
dpc-3703	224	17	have	have	AUX
dpc-3703	224	18	issued	issue	VERB
dpc-3703	224	19	recommendations	recommendation	NOUN
dpc-3703	224	20	regarding	regard	VERB
dpc-3703	224	21	the	the	DET
dpc-3703	224	22	place	place	NOUN
dpc-3703	224	23	and	and	CCONJ
dpc-3703	224	24	timing	timing	NOUN
dpc-3703	224	25	of	of	ADP
dpc-3703	224	26	anti	anti	ADJ
dpc-3703	224	27	-	-	ADJ
dpc-3703	224	28	pd-1	pd-1	ADJ
dpc-3703	224	29	immunotherapy	immunotherapy	NOUN
dpc-3703	224	30	for	for	ADP
dpc-3703	224	31	advanced	advanced	ADJ
dpc-3703	224	32	bcc	bcc	PROPN
dpc-3703	225	1	[	[	X
dpc-3703	225	2	22,23	22,23	NOUN
dpc-3703	225	3	]	]	X
dpc-3703	225	4	.	.	PUNCT
dpc-3703	226	1	the	the	DET
dpc-3703	226	2	british	british	ADJ
dpc-3703	226	3	guidelines	guideline	NOUN
dpc-3703	226	4	(	(	PUNCT
dpc-3703	226	5	2021	2021	NUM
dpc-3703	226	6	)	)	PUNCT
dpc-3703	226	7	were	be	AUX
dpc-3703	226	8	prepared	prepare	VERB
dpc-3703	226	9	before	before	ADP
dpc-3703	226	10	the	the	DET
dpc-3703	226	11	approval	approval	NOUN
dpc-3703	226	12	of	of	ADP
dpc-3703	226	13	cemiplimab	cemiplimab	NOUN
dpc-3703	226	14	for	for	ADP
dpc-3703	226	15	advanced	advanced	ADJ
dpc-3703	226	16	bcc	bcc	PROPN
dpc-3703	226	17	and	and	CCONJ
dpc-3703	226	18	do	do	AUX
dpc-3703	226	19	not	not	PART
dpc-3703	226	20	include	include	VERB
dpc-3703	226	21	a	a	DET
dpc-3703	226	22	recommendation	recommendation	NOUN
dpc-3703	226	23	on	on	ADP
dpc-3703	226	24	anti	anti	ADJ
dpc-3703	226	25	-	-	ADJ
dpc-3703	226	26	pd-1	pd-1	ADJ
dpc-3703	226	27	immunotherapy	immunotherapy	NOUN
dpc-3703	226	28	[	[	X
dpc-3703	226	29	21	21	NUM
dpc-3703	226	30	]	]	PUNCT
dpc-3703	226	31	.	.	PUNCT
dpc-3703	227	1	the	the	DET
dpc-3703	227	2	nccn	nccn	PROPN
dpc-3703	227	3	guidelines	guideline	NOUN
dpc-3703	227	4	recommend	recommend	VERB
dpc-3703	227	5	cemiplimab	cemiplimab	NOUN
dpc-3703	227	6	according	accord	VERB
dpc-3703	227	7	to	to	ADP
dpc-3703	227	8	the	the	DET
dpc-3703	227	9	us	us	PROPN
dpc-3703	227	10	fda	fda	PROPN
dpc-3703	227	11	approval	approval	NOUN
dpc-3703	227	12	,	,	PUNCT
dpc-3703	227	13	as	as	ADP
dpc-3703	227	14	a	a	DET
dpc-3703	227	15	monotherapy	monotherapy	NOUN
dpc-3703	227	16	for	for	ADP
dpc-3703	227	17	patients	patient	NOUN
dpc-3703	227	18	with	with	ADP
dpc-3703	227	19	labcc	labcc	NOUN
dpc-3703	227	20	or	or	CCONJ
dpc-3703	227	21	mbcc	mbcc	PROPN
dpc-3703	227	22	previously	previously	ADV
dpc-3703	227	23	treated	treat	VERB
dpc-3703	227	24	with	with	ADP
dpc-3703	227	25	an	an	DET
dpc-3703	227	26	hhi	hhi	NOUN
dpc-3703	227	27	or	or	CCONJ
dpc-3703	227	28	for	for	ADP
dpc-3703	227	29	whom	whom	PRON
dpc-3703	227	30	an	an	DET
dpc-3703	227	31	hhi	hhi	NOUN
dpc-3703	227	32	is	be	AUX
dpc-3703	227	33	not	not	PART
dpc-3703	227	34	appropriate	appropriate	ADJ
dpc-3703	228	1	[	[	X
dpc-3703	228	2	22	22	NUM
dpc-3703	228	3	]	]	PUNCT
dpc-3703	228	4	.	.	PUNCT
dpc-3703	229	1	currently	currently	ADV
dpc-3703	229	2	,	,	PUNCT
dpc-3703	229	3	when	when	SCONJ
dpc-3703	229	4	a	a	DET
dpc-3703	229	5	patient	patient	NOUN
dpc-3703	229	6	is	be	AUX
dpc-3703	229	7	eligible	eligible	ADJ
dpc-3703	229	8	for	for	ADP
dpc-3703	229	9	systemic	systemic	ADJ
dpc-3703	229	10	therapy	therapy	NOUN
dpc-3703	229	11	,	,	PUNCT
dpc-3703	229	12	including	include	VERB
dpc-3703	229	13	hhi	hhi	NOUN
dpc-3703	229	14	or	or	CCONJ
dpc-3703	229	15	anti	anti	ADJ
dpc-3703	229	16	-	-	ADJ
dpc-3703	229	17	pd-1	pd-1	ADJ
dpc-3703	229	18	therapy	therapy	NOUN
dpc-3703	229	19	,	,	PUNCT
dpc-3703	229	20	anti	anti	ADJ
dpc-3703	229	21	-	-	ADJ
dpc-3703	229	22	pd-1	pd-1	ADJ
dpc-3703	229	23	agents	agent	NOUN
dpc-3703	229	24	are	be	AUX
dpc-3703	229	25	recommended	recommend	VERB
dpc-3703	229	26	as	as	ADP
dpc-3703	229	27	second	second	ADJ
dpc-3703	229	28	-	-	PUNCT
dpc-3703	229	29	line	line	NOUN
dpc-3703	229	30	systemic	systemic	ADJ
dpc-3703	229	31	therapy	therapy	NOUN
dpc-3703	229	32	for	for	ADP
dpc-3703	229	33	patients	patient	NOUN
dpc-3703	229	34	with	with	ADP
dpc-3703	229	35	advanced	advanced	ADJ
dpc-3703	229	36	bcc	bcc	PROPN
dpc-3703	229	37	previously	previously	ADV
dpc-3703	229	38	treated	treat	VERB
dpc-3703	229	39	with	with	ADP
dpc-3703	229	40	hhi	hhi	NOUN
dpc-3703	229	41	.	.	PUNCT
dpc-3703	230	1	the	the	DET
dpc-3703	230	2	european	european	PROPN
dpc-3703	230	3	guideline	guideline	PROPN
dpc-3703	230	4	update	update	NOUN
dpc-3703	230	5	2023	2023	NUM
dpc-3703	230	6	on	on	ADP
dpc-3703	230	7	bcc	bcc	PROPN
dpc-3703	230	8	,	,	PUNCT
dpc-3703	230	9	recommends	recommend	VERB
dpc-3703	230	10	that	that	SCONJ
dpc-3703	230	11	anti	anti	ADJ
dpc-3703	230	12	-	-	ADJ
dpc-3703	230	13	pd-1	pd-1	ADJ
dpc-3703	230	14	immunotherapy	immunotherapy	NOUN
dpc-3703	230	15	should	should	AUX
dpc-3703	230	16	be	be	AUX
dpc-3703	230	17	offered	offer	VERB
dpc-3703	230	18	as	as	ADP
dpc-3703	230	19	second	second	ADJ
dpc-3703	230	20	-	-	PUNCT
dpc-3703	230	21	line	line	NOUN
dpc-3703	230	22	treatment	treatment	NOUN
dpc-3703	230	23	in	in	ADP
dpc-3703	230	24	patients	patient	NOUN
dpc-3703	230	25	who	who	PRON
dpc-3703	230	26	progress	progress	VERB
dpc-3703	230	27	or	or	CCONJ
dpc-3703	230	28	have	have	VERB
dpc-3703	230	29	contraindications	contraindication	NOUN
dpc-3703	230	30	to	to	ADP
dpc-3703	230	31	hedgehog	hedgehog	ADJ
dpc-3703	230	32	inhibitors	inhibitor	NOUN
dpc-3703	230	33	[	[	X
dpc-3703	230	34	23	23	NUM
dpc-3703	230	35	]	]	PUNCT
dpc-3703	230	36	.	.	PUNCT
dpc-3703	231	1	in	in	ADP
dpc-3703	231	2	the	the	DET
dpc-3703	231	3	clinical	clinical	ADJ
dpc-3703	231	4	trials	trial	NOUN
dpc-3703	231	5	of	of	ADP
dpc-3703	231	6	vismodegib	vismodegib	NOUN
dpc-3703	231	7	and	and	CCONJ
dpc-3703	231	8	cemiplimab	cemiplimab	NOUN
dpc-3703	231	9	for	for	ADP
dpc-3703	231	10	labcc	labcc	NOUN
dpc-3703	231	11	,	,	PUNCT
dpc-3703	231	12	a	a	DET
dpc-3703	231	13	similar	similar	ADJ
dpc-3703	231	14	treatment	treatment	NOUN
dpc-3703	231	15	duration	duration	NOUN
dpc-3703	231	16	was	be	AUX
dpc-3703	231	17	reported	report	VERB
dpc-3703	231	18	with	with	ADP
dpc-3703	231	19	cemiplimab	cemiplimab	NOUN
dpc-3703	231	20	(	(	PUNCT
dpc-3703	231	21	median	median	NOUN
dpc-3703	231	22	12	12	NUM
dpc-3703	231	23	months	month	NOUN
dpc-3703	231	24	)	)	PUNCT
dpc-3703	231	25	and	and	CCONJ
dpc-3703	231	26	vismodegib	vismodegib	NOUN
dpc-3703	231	27	(	(	PUNCT
dpc-3703	231	28	median	median	NOUN
dpc-3703	231	29	12	12	NUM
dpc-3703	231	30	months)2	months)2	NOUN
dpc-3703	231	31	the	the	DET
dpc-3703	231	32	objective	objective	ADJ
dpc-3703	231	33	response	response	NOUN
dpc-3703	231	34	rate	rate	NOUN
dpc-3703	231	35	was	be	AUX
dpc-3703	231	36	31	31	NUM
dpc-3703	231	37	%	%	NOUN
dpc-3703	231	38	with	with	ADP
dpc-3703	231	39	cemiplimab	cemiplimab	NOUN
dpc-3703	231	40	and	and	CCONJ
dpc-3703	231	41	60	60	NUM
dpc-3703	231	42	%	%	NOUN
dpc-3703	231	43	with	with	ADP
dpc-3703	231	44	vismodegib	vismodegib	NOUN
dpc-3703	231	45	,	,	PUNCT
dpc-3703	231	46	and	and	CCONJ
dpc-3703	231	47	the	the	DET
dpc-3703	231	48	median	median	ADJ
dpc-3703	231	49	duration	duration	NOUN
dpc-3703	231	50	of	of	ADP
dpc-3703	231	51	response	response	NOUN
dpc-3703	231	52	in	in	ADP
dpc-3703	231	53	responders	responder	NOUN
dpc-3703	231	54	was	be	AUX
dpc-3703	231	55	not	not	PART
dpc-3703	231	56	reached	reach	VERB
dpc-3703	231	57	with	with	ADP
dpc-3703	231	58	cemiplimab	cemiplimab	NOUN
dpc-3703	231	59	and	and	CCONJ
dpc-3703	231	60	was	be	AUX
dpc-3703	231	61	26	26	NUM
dpc-3703	231	62	months	month	NOUN
dpc-3703	231	63	with	with	ADP
dpc-3703	231	64	vismodegib	vismodegib	NOUN
dpc-3703	232	1	[	[	X
dpc-3703	232	2	29,65	29,65	NOUN
dpc-3703	232	3	]	]	X
dpc-3703	232	4	.	.	PUNCT
dpc-3703	233	1	however	however	ADV
dpc-3703	233	2	,	,	PUNCT
dpc-3703	233	3	a	a	DET
dpc-3703	233	4	direct	direct	ADJ
dpc-3703	233	5	comparison	comparison	NOUN
dpc-3703	233	6	of	of	ADP
dpc-3703	233	7	these	these	DET
dpc-3703	233	8	studies	study	NOUN
dpc-3703	233	9	can	can	AUX
dpc-3703	233	10	not	not	PART
dpc-3703	233	11	be	be	AUX
dpc-3703	233	12	made	make	VERB
dpc-3703	233	13	as	as	SCONJ
dpc-3703	233	14	they	they	PRON
dpc-3703	233	15	included	include	VERB
dpc-3703	233	16	heterogeneous	heterogeneous	ADJ
dpc-3703	233	17	patients	patient	NOUN
dpc-3703	233	18	;	;	PUNCT
dpc-3703	233	19	cemiplimab	cemiplimab	NOUN
dpc-3703	233	20	was	be	AUX
dpc-3703	233	21	used	use	VERB
dpc-3703	233	22	in	in	ADP
dpc-3703	233	23	a	a	DET
dpc-3703	233	24	highly	highly	ADV
dpc-3703	233	25	challenging	challenging	ADJ
dpc-3703	233	26	group	group	NOUN
dpc-3703	233	27	of	of	ADP
dpc-3703	233	28	patients	patient	NOUN
dpc-3703	233	29	who	who	PRON
dpc-3703	233	30	had	have	AUX
dpc-3703	233	31	progressed	progress	VERB
dpc-3703	233	32	or	or	CCONJ
dpc-3703	233	33	not	not	PART
dpc-3703	233	34	responded	respond	VERB
dpc-3703	233	35	or	or	CCONJ
dpc-3703	233	36	were	be	AUX
dpc-3703	233	37	intolerant	intolerant	ADJ
dpc-3703	233	38	to	to	ADP
dpc-3703	233	39	previous	previous	ADJ
dpc-3703	233	40	hhi	hhi	NOUN
dpc-3703	233	41	treatment	treatment	NOUN
dpc-3703	233	42	.	.	PUNCT
dpc-3703	234	1	at	at	ADP
dpc-3703	234	2	the	the	DET
dpc-3703	234	3	moment	moment	NOUN
dpc-3703	234	4	,	,	PUNCT
dpc-3703	234	5	there	there	PRON
dpc-3703	234	6	is	be	VERB
dpc-3703	234	7	no	no	DET
dpc-3703	234	8	validated	validate	VERB
dpc-3703	234	9	predictive	predictive	ADJ
dpc-3703	234	10	biomarker	biomarker	NOUN
dpc-3703	234	11	to	to	PART
dpc-3703	234	12	select	select	VERB
dpc-3703	234	13	those	those	DET
dpc-3703	234	14	patients	patient	NOUN
dpc-3703	234	15	with	with	ADP
dpc-3703	234	16	advanced	advanced	ADJ
dpc-3703	234	17	bcc	bcc	PROPN
dpc-3703	234	18	more	more	ADV
dpc-3703	234	19	likely	likely	ADJ
dpc-3703	234	20	to	to	PART
dpc-3703	234	21	benefit	benefit	VERB
dpc-3703	234	22	from	from	ADP
dpc-3703	234	23	anti	anti	ADJ
dpc-3703	234	24	-	-	ADJ
dpc-3703	234	25	pd-1	pd-1	ADJ
dpc-3703	234	26	ici	ici	NOUN
dpc-3703	234	27	,	,	PUNCT
dpc-3703	234	28	thus	thus	ADV
dpc-3703	234	29	guiding	guide	VERB
dpc-3703	234	30	the	the	DET
dpc-3703	234	31	choice	choice	NOUN
dpc-3703	234	32	of	of	ADP
dpc-3703	234	33	anti	anti	ADJ
dpc-3703	234	34	-	-	ADJ
dpc-3703	234	35	pd-1	pd-1	ADJ
dpc-3703	234	36	immunotherapy	immunotherapy	NOUN
dpc-3703	234	37	as	as	ADP
dpc-3703	234	38	first	first	ADJ
dpc-3703	234	39	-	-	PUNCT
dpc-3703	234	40	line	line	NOUN
dpc-3703	234	41	therapy	therapy	NOUN
dpc-3703	234	42	for	for	ADP
dpc-3703	234	43	advanced	advanced	ADJ
dpc-3703	234	44	bcc	bcc	PROPN
dpc-3703	235	1	[	[	X
dpc-3703	235	2	26	26	NUM
dpc-3703	235	3	]	]	PUNCT
dpc-3703	235	4	.	.	PUNCT
dpc-3703	236	1	pd	pd	PROPN
dpc-3703	236	2	-	-	PROPN
dpc-3703	236	3	l1	l1	PROPN
dpc-3703	236	4	positivity	positivity	NOUN
dpc-3703	236	5	by	by	ADP
dpc-3703	236	6	immunohistochemistry	immunohistochemistry	NOUN
dpc-3703	236	7	has	have	AUX
dpc-3703	236	8	been	be	AUX
dpc-3703	236	9	shown	show	VERB
dpc-3703	236	10	in	in	ADP
dpc-3703	236	11	some	some	DET
dpc-3703	236	12	advanced	advanced	ADJ
dpc-3703	236	13	bcc	bcc	PROPN
dpc-3703	236	14	tumors	tumor	NOUN
dpc-3703	236	15	,	,	PUNCT
dpc-3703	236	16	but	but	CCONJ
dpc-3703	236	17	it	it	PRON
dpc-3703	236	18	has	have	AUX
dpc-3703	236	19	not	not	PART
dpc-3703	236	20	been	be	AUX
dpc-3703	236	21	associated	associate	VERB
dpc-3703	236	22	with	with	ADP
dpc-3703	236	23	clinical	clinical	ADJ
dpc-3703	236	24	responses	response	NOUN
dpc-3703	236	25	to	to	ADP
dpc-3703	236	26	anti	anti	ADJ
dpc-3703	236	27	-	-	ADJ
dpc-3703	236	28	pd-1	pd-1	ADJ
dpc-3703	236	29	immunotherapy	immunotherapy	NOUN
dpc-3703	236	30	[	[	X
dpc-3703	236	31	15,57,65,90	15,57,65,90	NUM
dpc-3703	236	32	]	]	PUNCT
dpc-3703	236	33	.	.	PUNCT
dpc-3703	237	1	a	a	DET
dpc-3703	237	2	high	high	ADJ
dpc-3703	237	3	tmb	tmb	NOUN
dpc-3703	237	4	has	have	AUX
dpc-3703	237	5	been	be	AUX
dpc-3703	237	6	consistently	consistently	ADV
dpc-3703	237	7	reported	report	VERB
dpc-3703	237	8	in	in	ADP
dpc-3703	237	9	advanced	advanced	ADJ
dpc-3703	237	10	bcc	bcc	PROPN
dpc-3703	238	1	[	[	X
dpc-3703	238	2	65,91	65,91	NOUN
dpc-3703	238	3	]	]	PUNCT
dpc-3703	238	4	.	.	PUNCT
dpc-3703	239	1	also	also	ADV
dpc-3703	239	2	,	,	PUNCT
dpc-3703	239	3	a	a	DET
dpc-3703	239	4	higher	high	ADJ
dpc-3703	239	5	tmb	tmb	NOUN
dpc-3703	239	6	has	have	AUX
dpc-3703	239	7	been	be	AUX
dpc-3703	239	8	reported	report	VERB
dpc-3703	239	9	in	in	ADP
dpc-3703	239	10	advanced	advanced	ADJ
dpc-3703	239	11	bccs	bccs	NOUN
dpc-3703	239	12	with	with	ADP
dpc-3703	239	13	response	response	NOUN
dpc-3703	239	14	to	to	ADP
dpc-3703	239	15	anti	anti	ADJ
dpc-3703	239	16	-	-	ADJ
dpc-3703	239	17	pd-1	pd-1	ADJ
dpc-3703	239	18	therapy	therapy	NOUN
dpc-3703	239	19	,	,	PUNCT
dpc-3703	239	20	however	however	ADV
dpc-3703	239	21	the	the	DET
dpc-3703	239	22	median	median	PROPN
dpc-3703	239	23	tmb	tmb	PROPN
dpc-3703	239	24	in	in	ADP
dpc-3703	239	25	non	non	NOUN
dpc-3703	239	26	responders	responder	NOUN
dpc-3703	239	27	was	be	AUX
dpc-3703	239	28	23	23	NUM
dpc-3703	239	29	mt	mt	PROPN
dpc-3703	239	30	/	/	SYM
dpc-3703	239	31	mb	mb	NOUN
dpc-3703	239	32	,	,	PUNCT
dpc-3703	239	33	that	that	PRON
dpc-3703	239	34	is	be	AUX
dpc-3703	239	35	above	above	ADP
dpc-3703	239	36	the	the	DET
dpc-3703	239	37	defined	define	VERB
dpc-3703	239	38	high	high	ADJ
dpc-3703	239	39	tmb	tmb	NOUN
dpc-3703	239	40	threshold	threshold	NOUN
dpc-3703	239	41	of	of	ADP
dpc-3703	239	42	≥10	≥10	PROPN
dpc-3703	239	43	mut	mut	PROPN
dpc-3703	239	44	/	/	SYM
dpc-3703	239	45	mb	mb	PROPN
dpc-3703	240	1	[	[	X
dpc-3703	240	2	65,92	65,92	NOUN
dpc-3703	240	3	]	]	PUNCT
dpc-3703	240	4	.	.	PUNCT
dpc-3703	241	1	in	in	ADP
dpc-3703	241	2	the	the	DET
dpc-3703	241	3	pivotal	pivotal	ADJ
dpc-3703	241	4	phase	phase	NOUN
dpc-3703	241	5	2	2	NUM
dpc-3703	241	6	clinical	clinical	ADJ
dpc-3703	241	7	trial	trial	NOUN
dpc-3703	241	8	of	of	ADP
dpc-3703	241	9	cemiplimab	cemiplimab	NOUN
dpc-3703	241	10	for	for	ADP
dpc-3703	241	11	labcc	labcc	NOUN
dpc-3703	241	12	,	,	PUNCT
dpc-3703	241	13	exploratory	exploratory	ADJ
dpc-3703	241	14	biomarker	biomarker	NOUN
dpc-3703	241	15	data	datum	NOUN
dpc-3703	241	16	showed	show	VERB
dpc-3703	241	17	similar	similar	ADJ
dpc-3703	241	18	response	response	NOUN
dpc-3703	241	19	to	to	ADP
dpc-3703	241	20	cemiplimab	cemiplimab	NOUN
dpc-3703	241	21	by	by	ADP
dpc-3703	241	22	pd	pd	PROPN
dpc-3703	241	23	-	-	PROPN
dpc-3703	241	24	l1	l1	PROPN
dpc-3703	241	25	immunohistochemistry	immunohistochemistry	NOUN
dpc-3703	241	26	status	status	NOUN
dpc-3703	241	27	of	of	ADP
dpc-3703	241	28	tumor	tumor	NOUN
dpc-3703	241	29	cells	cell	NOUN
dpc-3703	241	30	(	(	PUNCT
dpc-3703	241	31	pd	pd	NOUN
dpc-3703	241	32	-	-	PUNCT
dpc-3703	241	33	l1<1	l1<1	PROPN
dpc-3703	241	34	%	%	NOUN
dpc-3703	241	35	,	,	PUNCT
dpc-3703	241	36	n	n	PROPN
dpc-3703	241	37	=	=	NOUN
dpc-3703	241	38	 	 	SPACE
dpc-3703	241	39	35	35	NUM
dpc-3703	241	40	,	,	PUNCT
dpc-3703	241	41	versus	versus	ADP
dpc-3703	241	42	pd	pd	PROPN
dpc-3703	241	43	-	-	PROPN
dpc-3703	241	44	l1	l1	PROPN
dpc-3703	241	45	≥1	≥1	NUM
dpc-3703	241	46	%	%	NOUN
dpc-3703	241	47	,	,	PUNCT
dpc-3703	241	48	n	n	NOUN
dpc-3703	241	49	=	=	SYM
dpc-3703	241	50	15	15	NUM
dpc-3703	241	51	)	)	PUNCT
dpc-3703	242	1	[	[	X
dpc-3703	242	2	65	65	NUM
dpc-3703	242	3	]	]	PUNCT
dpc-3703	242	4	.	.	PUNCT
dpc-3703	243	1	there	there	PRON
dpc-3703	243	2	was	be	VERB
dpc-3703	243	3	similar	similar	ADJ
dpc-3703	243	4	,	,	PUNCT
dpc-3703	243	5	review	review	NOUN
dpc-3703	243	6	|	|	ADV
dpc-3703	243	7	dermatol	dermatol	ADJ
dpc-3703	243	8	pract	pract	NOUN
dpc-3703	243	9	concept	concept	NOUN
dpc-3703	243	10	.	.	PUNCT
dpc-3703	244	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	244	2	9	9	NUM
dpc-3703	244	3	cell	cell	NOUN
dpc-3703	244	4	.	.	PUNCT
dpc-3703	245	1	2015;27(4):450	2015;27(4):450	NUM
dpc-3703	245	2	-	-	PUNCT
dpc-3703	245	3	461	461	NUM
dpc-3703	245	4	.	.	PUNCT
dpc-3703	246	1	doi	doi	NOUN
dpc-3703	246	2	:	:	PUNCT
dpc-3703	246	3	10.1016	10.1016	NUM
dpc-3703	246	4	/	/	SYM
dpc-3703	246	5	j.ccell.2015.03.001	j.ccell.2015.03.001	PROPN
dpc-3703	246	6	.	.	PUNCT
dpc-3703	247	1	pmid	pmid	NOUN
dpc-3703	247	2	:	:	PUNCT
dpc-3703	247	3	25858804	25858804	NUM
dpc-3703	247	4	.	.	PUNCT
dpc-3703	248	1	pmcid	pmcid	NOUN
dpc-3703	248	2	:	:	PUNCT
dpc-3703	248	3	pmc4400238	pmc4400238	ADJ
dpc-3703	248	4	.	.	PUNCT
dpc-3703	249	1	15	15	X
dpc-3703	249	2	.	.	PUNCT
dpc-3703	250	1	chang	chang	PROPN
dpc-3703	250	2	j	j	PROPN
dpc-3703	250	3	,	,	PUNCT
dpc-3703	250	4	zhu	zhu	PROPN
dpc-3703	250	5	ga	ga	PROPN
dpc-3703	250	6	,	,	PUNCT
dpc-3703	250	7	cheung	cheung	PROPN
dpc-3703	250	8	c	c	PROPN
dpc-3703	250	9	,	,	PUNCT
dpc-3703	250	10	li	li	PROPN
dpc-3703	250	11	s	s	PROPN
dpc-3703	250	12	,	,	PUNCT
dpc-3703	250	13	kim	kim	PROPN
dpc-3703	250	14	j	j	PROPN
dpc-3703	250	15	,	,	PUNCT
dpc-3703	250	16	chang	chang	PROPN
dpc-3703	250	17	al	al	PROPN
dpc-3703	250	18	.	.	PROPN
dpc-3703	250	19	association	association	PROPN
dpc-3703	250	20	between	between	ADP
dpc-3703	250	21	programmed	program	VERB
dpc-3703	250	22	death	death	NOUN
dpc-3703	250	23	ligand	ligand	NOUN
dpc-3703	250	24	1	1	NUM
dpc-3703	250	25	expression	expression	NOUN
dpc-3703	250	26	in	in	ADP
dpc-3703	250	27	patients	patient	NOUN
dpc-3703	250	28	with	with	ADP
dpc-3703	250	29	basal	basal	ADJ
dpc-3703	250	30	cell	cell	NOUN
dpc-3703	250	31	carcinomas	carcinoma	NOUN
dpc-3703	250	32	and	and	CCONJ
dpc-3703	250	33	the	the	DET
dpc-3703	250	34	number	number	NOUN
dpc-3703	250	35	of	of	ADP
dpc-3703	250	36	treatment	treatment	NOUN
dpc-3703	250	37	modalities	modality	NOUN
dpc-3703	250	38	.	.	PUNCT
dpc-3703	251	1	jama	jama	PROPN
dpc-3703	251	2	dermatol	dermatol	NOUN
dpc-3703	251	3	.	.	PUNCT
dpc-3703	252	1	2017;153(4):285	2017;153(4):285	NUM
dpc-3703	252	2	-	-	SYM
dpc-3703	252	3	290	290	NUM
dpc-3703	252	4	.	.	PUNCT
dpc-3703	252	5	doi	doi	NOUN
dpc-3703	252	6	:	:	PUNCT
dpc-3703	252	7	10.1001	10.1001	NUM
dpc-3703	252	8	/jamadermatol.2016.5062	/jamadermatol.2016.5062	PRON
dpc-3703	252	9	.	.	PUNCT
dpc-3703	253	1	pmid	pmid	NOUN
dpc-3703	253	2	:	:	PUNCT
dpc-3703	253	3	28259105	28259105	NUM
dpc-3703	253	4	.	.	PUNCT
dpc-3703	254	1	16	16	NUM
dpc-3703	254	2	.	.	PUNCT
dpc-3703	255	1	lipson	lipson	PROPN
dpc-3703	255	2	ej	ej	PROPN
dpc-3703	255	3	,	,	PUNCT
dpc-3703	255	4	lilo	lilo	PROPN
dpc-3703	255	5	mt	mt	PROPN
dpc-3703	255	6	,	,	PUNCT
dpc-3703	255	7	ogurtsova	ogurtsova	VERB
dpc-3703	255	8	a	a	PRON
dpc-3703	255	9	,	,	PUNCT
dpc-3703	255	10	et	et	PROPN
dpc-3703	255	11	al	al	PROPN
dpc-3703	255	12	.	.	PROPN
dpc-3703	255	13	basal	basal	PROPN
dpc-3703	255	14	cell	cell	NOUN
dpc-3703	255	15	carcinoma	carcinoma	NOUN
dpc-3703	255	16	:	:	PUNCT
dpc-3703	255	17	pd	pd	PROPN
dpc-3703	255	18	-	-	PUNCT
dpc-3703	255	19	l1	l1	PROPN
dpc-3703	255	20	/	/	SYM
dpc-3703	255	21	pd-1	pd-1	NOUN
dpc-3703	255	22	checkpoint	checkpoint	NOUN
dpc-3703	255	23	expression	expression	NOUN
dpc-3703	255	24	and	and	CCONJ
dpc-3703	255	25	tumor	tumor	NOUN
dpc-3703	255	26	regression	regression	NOUN
dpc-3703	255	27	after	after	ADP
dpc-3703	255	28	pd-1	pd-1	ADP
dpc-3703	255	29	blockade	blockade	NOUN
dpc-3703	255	30	.	.	PUNCT
dpc-3703	256	1	j	j	PROPN
dpc-3703	256	2	immunother	immunother	ADJ
dpc-3703	256	3	cancer	cancer	NOUN
dpc-3703	256	4	.	.	PUNCT
dpc-3703	257	1	2017;5:23	2017;5:23	NOUN
dpc-3703	257	2	.	.	PUNCT
dpc-3703	258	1	doi	doi	NOUN
dpc-3703	258	2	:	:	PUNCT
dpc-3703	258	3	10.1186	10.1186	NUM
dpc-3703	258	4	/	/	SYM
dpc-3703	258	5	s40425	s40425	NOUN
dpc-3703	258	6	-	-	PUNCT
dpc-3703	258	7	017	017	NUM
dpc-3703	258	8	-	-	PUNCT
dpc-3703	258	9	0228	0228	NUM
dpc-3703	258	10	-	-	PUNCT
dpc-3703	258	11	3	3	NUM
dpc-3703	258	12	.	.	PUNCT
dpc-3703	259	1	pmid	pmid	NOUN
dpc-3703	259	2	:	:	PUNCT
dpc-3703	259	3	28344809	28344809	NUM
dpc-3703	259	4	.	.	PUNCT
dpc-3703	260	1	pmcid	pmcid	NOUN
dpc-3703	260	2	:	:	PUNCT
dpc-3703	260	3	pmc5360064	pmc5360064	PROPN
dpc-3703	260	4	.	.	PUNCT
dpc-3703	261	1	17	17	NUM
dpc-3703	261	2	.	.	PUNCT
dpc-3703	262	1	chalmers	chalmers	PROPN
dpc-3703	262	2	zr	zr	PROPN
dpc-3703	262	3	,	,	PUNCT
dpc-3703	262	4	connelly	connelly	PROPN
dpc-3703	262	5	cf	cf	PROPN
dpc-3703	262	6	,	,	PUNCT
dpc-3703	262	7	fabrizio	fabrizio	PROPN
dpc-3703	262	8	d	d	PROPN
dpc-3703	262	9	,	,	PUNCT
dpc-3703	262	10	et	et	PROPN
dpc-3703	262	11	al	al	PROPN
dpc-3703	262	12	.	.	PUNCT
dpc-3703	263	1	analysis	analysis	NOUN
dpc-3703	263	2	of	of	ADP
dpc-3703	263	3	100,000	100,000	NUM
dpc-3703	263	4	human	human	ADJ
dpc-3703	263	5	cancer	cancer	NOUN
dpc-3703	263	6	genomes	genome	NOUN
dpc-3703	263	7	reveals	reveal	VERB
dpc-3703	263	8	the	the	DET
dpc-3703	263	9	landscape	landscape	NOUN
dpc-3703	263	10	of	of	ADP
dpc-3703	263	11	tumor	tumor	NOUN
dpc-3703	263	12	mutational	mutational	ADJ
dpc-3703	263	13	burden	burden	NOUN
dpc-3703	263	14	.	.	PUNCT
dpc-3703	264	1	genome	genome	NOUN
dpc-3703	264	2	med	me	VERB
dpc-3703	264	3	.	.	PUNCT
dpc-3703	265	1	2017;9(1):34	2017;9(1):34	NUM
dpc-3703	265	2	.	.	PUNCT
dpc-3703	266	1	doi	doi	NOUN
dpc-3703	266	2	:	:	PUNCT
dpc-3703	266	3	10.1186	10.1186	NUM
dpc-3703	266	4	/	/	SYM
dpc-3703	266	5	s13073	s13073	NOUN
dpc-3703	266	6	-	-	PUNCT
dpc-3703	266	7	017	017	NUM
dpc-3703	266	8	-	-	PUNCT
dpc-3703	266	9	0424	0424	NUM
dpc-3703	266	10	-	-	SYM
dpc-3703	266	11	2	2	NUM
dpc-3703	266	12	.	.	PUNCT
dpc-3703	267	1	pmid	pmid	NOUN
dpc-3703	267	2	:	:	PUNCT
dpc-3703	267	3	28420421	28420421	NUM
dpc-3703	267	4	.	.	PUNCT
dpc-3703	268	1	pmcid	pmcid	NOUN
dpc-3703	268	2	:	:	PUNCT
dpc-3703	268	3	pmc5395719	pmc5395719	NOUN
dpc-3703	268	4	.	.	PUNCT
dpc-3703	269	1	18	18	NUM
dpc-3703	269	2	.	.	PUNCT
dpc-3703	270	1	salem	salem	PROPN
dpc-3703	270	2	p	p	PROPN
dpc-3703	270	3	,	,	PUNCT
dpc-3703	270	4	hall	hall	PROPN
dpc-3703	270	5	sw	sw	PROPN
dpc-3703	270	6	,	,	PUNCT
dpc-3703	270	7	benjamin	benjamin	PROPN
dpc-3703	270	8	rs	rs	PROPN
dpc-3703	270	9	,	,	PUNCT
dpc-3703	270	10	murphy	murphy	PROPN
dpc-3703	270	11	wk	wk	PROPN
dpc-3703	270	12	,	,	PUNCT
dpc-3703	270	13	wharton	wharton	PROPN
dpc-3703	270	14	jt	jt	PROPN
dpc-3703	270	15	,	,	PUNCT
dpc-3703	270	16	bodey	bodey	NOUN
dpc-3703	270	17	gp	gp	NOUN
dpc-3703	270	18	.	.	PUNCT
dpc-3703	271	1	clinical	clinical	ADJ
dpc-3703	271	2	phase	phase	NOUN
dpc-3703	271	3	i	i	PROPN
dpc-3703	271	4	-	-	PUNCT
dpc-3703	271	5	ii	ii	PROPN
dpc-3703	271	6	study	study	NOUN
dpc-3703	271	7	of	of	ADP
dpc-3703	271	8	cis	cis	NOUN
dpc-3703	271	9	-	-	PUNCT
dpc-3703	271	10	dichloro	dichloro	NOUN
dpc-3703	271	11	diammineplatinum(ii	diammineplatinum(ii	NOUN
dpc-3703	271	12	)	)	PUNCT
dpc-3703	271	13	given	give	VERB
dpc-3703	271	14	by	by	ADP
dpc-3703	271	15	continuous	continuous	ADJ
dpc-3703	271	16	lv	lv	PROPN
dpc-3703	271	17	infusion	infusion	NOUN
dpc-3703	271	18	.	.	PUNCT
dpc-3703	272	1	cancer	cancer	NOUN
dpc-3703	272	2	treat	treat	PROPN
dpc-3703	272	3	rep	rep	PROPN
dpc-3703	272	4	.	.	PROPN
dpc-3703	272	5	1978;62(10):1553	1978;62(10):1553	PROPN
dpc-3703	272	6	-	-	SYM
dpc-3703	272	7	1555	1555	NUM
dpc-3703	272	8	.	.	PUNCT
dpc-3703	273	1	pmid	pmid	NOUN
dpc-3703	273	2	:	:	PUNCT
dpc-3703	273	3	361227	361227	NUM
dpc-3703	273	4	.	.	PUNCT
dpc-3703	274	1	19	19	NUM
dpc-3703	274	2	.	.	PUNCT
dpc-3703	274	3	coker	coker	PROPN
dpc-3703	274	4	dd	dd	PROPN
dpc-3703	274	5	,	,	PUNCT
dpc-3703	274	6	elias	elias	PROPN
dpc-3703	274	7	eg	eg	PROPN
dpc-3703	274	8	,	,	PUNCT
dpc-3703	274	9	viravathana	viravathana	PROPN
dpc-3703	274	10	t	t	PROPN
dpc-3703	274	11	,	,	PUNCT
dpc-3703	274	12	mccrea	mccrea	PROPN
dpc-3703	274	13	e	e	PROPN
dpc-3703	274	14	,	,	PUNCT
dpc-3703	274	15	hafiz	hafiz	PROPN
dpc-3703	274	16	m.	m.	PROPN
dpc-3703	274	17	chemotherapy	chemotherapy	NOUN
dpc-3703	274	18	for	for	ADP
dpc-3703	274	19	metastatic	metastatic	ADJ
dpc-3703	274	20	basal	basal	NOUN
dpc-3703	274	21	cell	cell	NOUN
dpc-3703	274	22	carcinoma	carcinoma	NOUN
dpc-3703	274	23	.	.	PUNCT
dpc-3703	275	1	arch	arch	ADJ
dpc-3703	275	2	dermatol	dermatol	NOUN
dpc-3703	275	3	.	.	PUNCT
dpc-3703	276	1	1983;119(1):44	1983;119(1):44	NUM
dpc-3703	276	2	-	-	PUNCT
dpc-3703	276	3	50	50	NUM
dpc-3703	276	4	.	.	PUNCT
dpc-3703	277	1	pmid	pmid	NOUN
dpc-3703	277	2	:	:	PUNCT
dpc-3703	277	3	6849564	6849564	NUM
dpc-3703	277	4	.	.	PUNCT
dpc-3703	278	1	20	20	NUM
dpc-3703	278	2	.	.	PUNCT
dpc-3703	279	1	moeholt	moeholt	PROPN
dpc-3703	279	2	k	k	PROPN
dpc-3703	279	3	,	,	PUNCT
dpc-3703	279	4	aagaard	aagaard	ADJ
dpc-3703	279	5	h	h	NOUN
dpc-3703	279	6	,	,	PUNCT
dpc-3703	279	7	pfeiffer	pfeiffer	PROPN
dpc-3703	279	8	p	p	PROPN
dpc-3703	279	9	,	,	PUNCT
dpc-3703	279	10	hansen	hansen	PROPN
dpc-3703	279	11	o.	o.	PROPN
dpc-3703	279	12	platinum	platinum	NOUN
dpc-3703	279	13	-	-	PUNCT
dpc-3703	279	14	based	base	VERB
dpc-3703	279	15	cytotoxic	cytotoxic	ADJ
dpc-3703	279	16	therapy	therapy	NOUN
dpc-3703	279	17	in	in	ADP
dpc-3703	279	18	basal	basal	ADJ
dpc-3703	279	19	cell	cell	NOUN
dpc-3703	279	20	carcinoma	carcinoma	NOUN
dpc-3703	279	21	--	--	PUNCT
dpc-3703	279	22	a	a	DET
dpc-3703	279	23	review	review	NOUN
dpc-3703	279	24	of	of	ADP
dpc-3703	279	25	the	the	DET
dpc-3703	279	26	literature	literature	NOUN
dpc-3703	279	27	.	.	PUNCT
dpc-3703	280	1	acta	acta	PROPN
dpc-3703	280	2	oncol	oncol	PROPN
dpc-3703	280	3	.	.	PUNCT
dpc-3703	281	1	1996;35(6):677	1996;35(6):677	NUM
dpc-3703	281	2	-	-	PUNCT
dpc-3703	281	3	682	682	NUM
dpc-3703	281	4	.	.	PUNCT
dpc-3703	282	1	doi	doi	NOUN
dpc-3703	282	2	:	:	PUNCT
dpc-3703	282	3	10.3109/02841869609083998	10.3109/02841869609083998	NUM
dpc-3703	282	4	.	.	PUNCT
dpc-3703	283	1	pmid	pmid	NOUN
dpc-3703	283	2	:	:	PUNCT
dpc-3703	283	3	8938213	8938213	NUM
dpc-3703	283	4	.	.	PUNCT
dpc-3703	284	1	21	21	NUM
dpc-3703	284	2	.	.	PUNCT
dpc-3703	285	1	nasr	nasr	PROPN
dpc-3703	285	2	i	i	PROPN
dpc-3703	285	3	,	,	PUNCT
dpc-3703	285	4	mcgrath	mcgrath	PROPN
dpc-3703	285	5	ej	ej	PROPN
dpc-3703	285	6	,	,	PUNCT
dpc-3703	285	7	harwood	harwood	PROPN
dpc-3703	285	8	ca	can	AUX
dpc-3703	285	9	,	,	PUNCT
dpc-3703	285	10	et	et	PROPN
dpc-3703	285	11	al	al	PROPN
dpc-3703	285	12	.	.	PROPN
dpc-3703	286	1	british	british	PROPN
dpc-3703	286	2	association	association	PROPN
dpc-3703	286	3	of	of	ADP
dpc-3703	286	4	dermatologists	dermatologists	PROPN
dpc-3703	286	5	guidelines	guideline	NOUN
dpc-3703	286	6	for	for	ADP
dpc-3703	286	7	the	the	DET
dpc-3703	286	8	management	management	NOUN
dpc-3703	286	9	of	of	ADP
dpc-3703	286	10	adults	adult	NOUN
dpc-3703	286	11	with	with	ADP
dpc-3703	286	12	basal	basal	ADJ
dpc-3703	286	13	cell	cell	NOUN
dpc-3703	286	14	carcinoma	carcinoma	NOUN
dpc-3703	286	15	2021	2021	NUM
dpc-3703	286	16	.	.	PUNCT
dpc-3703	287	1	br	br	PROPN
dpc-3703	287	2	j	j	PROPN
dpc-3703	287	3	dermatol	dermatol	NOUN
dpc-3703	287	4	.	.	PUNCT
dpc-3703	288	1	2021;185(5):899	2021;185(5):899	NUM
dpc-3703	288	2	-	-	SYM
dpc-3703	288	3	920	920	NUM
dpc-3703	288	4	.	.	PUNCT
dpc-3703	289	1	doi	doi	NOUN
dpc-3703	289	2	:	:	PUNCT
dpc-3703	289	3	10.1111	10.1111	NUM
dpc-3703	289	4	/	/	SYM
dpc-3703	289	5	bjd.20524	bjd.20524	PROPN
dpc-3703	289	6	.	.	PUNCT
dpc-3703	290	1	pmid	pmid	NOUN
dpc-3703	290	2	:	:	PUNCT
dpc-3703	290	3	34050920	34050920	NUM
dpc-3703	290	4	.	.	PUNCT
dpc-3703	291	1	22	22	NUM
dpc-3703	291	2	.	.	PUNCT
dpc-3703	292	1	schmults	schmult	NOUN
dpc-3703	292	2	c	c	VERB
dpc-3703	292	3	,	,	PUNCT
dpc-3703	292	4	blitzblau	blitzblau	NOUN
dpc-3703	292	5	r	r	NOUN
dpc-3703	292	6	,	,	PUNCT
dpc-3703	292	7	aasi	aasi	PROPN
dpc-3703	292	8	sz	sz	PROPN
dpc-3703	292	9	,	,	PUNCT
dpc-3703	292	10	et	et	PROPN
dpc-3703	292	11	al	al	PROPN
dpc-3703	292	12	.	.	PROPN
dpc-3703	292	13	basal	basal	PROPN
dpc-3703	292	14	cell	cell	NOUN
dpc-3703	292	15	skin	skin	NOUN
dpc-3703	292	16	cancer	cancer	NOUN
dpc-3703	292	17	.	.	PUNCT
dpc-3703	293	1	national	national	ADJ
dpc-3703	293	2	comprehensive	comprehensive	ADJ
dpc-3703	293	3	cancer	cancer	NOUN
dpc-3703	293	4	network	network	NOUN
dpc-3703	293	5	(	(	PUNCT
dpc-3703	293	6	nccn	nccn	ADJ
dpc-3703	293	7	)	)	PUNCT
dpc-3703	293	8	clinical	clinical	ADJ
dpc-3703	293	9	practice	practice	NOUN
dpc-3703	293	10	guidelines	guideline	NOUN
dpc-3703	293	11	in	in	ADP
dpc-3703	293	12	oncology	oncology	NOUN
dpc-3703	293	13	.	.	PUNCT
dpc-3703	294	1	2023	2023	NUM
dpc-3703	294	2	;	;	PUNCT
dpc-3703	295	1	version	version	NOUN
dpc-3703	295	2	1.2023	1.2023	NUM
dpc-3703	295	3	.	.	PUNCT
dpc-3703	295	4	available	available	ADJ
dpc-3703	295	5	from	from	ADP
dpc-3703	295	6	:	:	PUNCT
dpc-3703	295	7	https://www.nccn.org/professionals/physician_gls/pdf	https://www.nccn.org/professionals/physician_gls/pdf	NOUN
dpc-3703	295	8	/nmsc.pdf	/nmsc.pdf	NOUN
dpc-3703	295	9	,	,	PUNCT
dpc-3703	295	10	accessed	access	VERB
dpc-3703	295	11	july	july	PROPN
dpc-3703	295	12	3	3	NUM
dpc-3703	295	13	,	,	PUNCT
dpc-3703	295	14	2023	2023	NUM
dpc-3703	295	15	.	.	PUNCT
dpc-3703	296	1	23	23	NUM
dpc-3703	296	2	.	.	PUNCT
dpc-3703	297	1	peris	peris	PROPN
dpc-3703	297	2	k	k	PROPN
dpc-3703	297	3	,	,	PUNCT
dpc-3703	297	4	fargnoli	fargnoli	PROPN
dpc-3703	297	5	mc	mc	PROPN
dpc-3703	297	6	,	,	PUNCT
dpc-3703	297	7	kaufmann	kaufmann	PROPN
dpc-3703	297	8	r	r	PROPN
dpc-3703	297	9	,	,	PUNCT
dpc-3703	297	10	et	et	PROPN
dpc-3703	297	11	al	al	PROPN
dpc-3703	297	12	.	.	PUNCT
dpc-3703	298	1	european	european	PROPN
dpc-3703	298	2	consensus	consensus	NOUN
dpc-3703	298	3	-	-	PUNCT
dpc-3703	298	4	based	base	VERB
dpc-3703	298	5	interdisciplinary	interdisciplinary	ADJ
dpc-3703	298	6	guideline	guideline	NOUN
dpc-3703	298	7	for	for	ADP
dpc-3703	298	8	diagnosis	diagnosis	NOUN
dpc-3703	298	9	and	and	CCONJ
dpc-3703	298	10	treatment	treatment	NOUN
dpc-3703	298	11	of	of	ADP
dpc-3703	298	12	basal	basal	ADJ
dpc-3703	298	13	cell	cell	NOUN
dpc-3703	298	14	carcinoma	carcinoma	NOUN
dpc-3703	298	15	-	-	PUNCT
dpc-3703	298	16	update	update	NOUN
dpc-3703	298	17	2023	2023	NUM
dpc-3703	298	18	.	.	PUNCT
dpc-3703	299	1	eur	eur	PROPN
dpc-3703	299	2	j	j	PROPN
dpc-3703	299	3	cancer	cancer	NOUN
dpc-3703	299	4	.	.	PUNCT
dpc-3703	300	1	2023;192:113254	2023;192:113254	NUM
dpc-3703	300	2	.	.	PUNCT
dpc-3703	301	1	doi	doi	NOUN
dpc-3703	301	2	:	:	PUNCT
dpc-3703	301	3	10.1016	10.1016	NUM
dpc-3703	301	4	/	/	SYM
dpc-3703	301	5	j.ejca.2023.113254	j.ejca.2023.113254	ADJ
dpc-3703	301	6	.	.	PUNCT
dpc-3703	302	1	pmid	pmid	NOUN
dpc-3703	302	2	:	:	PUNCT
dpc-3703	302	3	37604067	37604067	NUM
dpc-3703	302	4	.	.	PUNCT
dpc-3703	303	1	24	24	NUM
dpc-3703	303	2	.	.	NUM
dpc-3703	303	3	erivedge	erivedge	NOUN
dpc-3703	303	4	.	.	PUNCT
dpc-3703	304	1	summary	summary	NOUN
dpc-3703	304	2	of	of	ADP
dpc-3703	304	3	product	product	NOUN
dpc-3703	304	4	characteristics	characteristic	NOUN
dpc-3703	304	5	.	.	PUNCT
dpc-3703	305	1	available	available	ADJ
dpc-3703	305	2	from	from	ADP
dpc-3703	305	3	:	:	PUNCT
dpc-3703	305	4	https://www.ema.europa.eu/en/documents/product-information	https://www.ema.europa.eu/en/documents/product-information	NOUN
dpc-3703	305	5	/erivedge	/erivedge	NOUN
dpc-3703	305	6	-	-	PUNCT
dpc-3703	305	7	epar	epar	NOUN
dpc-3703	305	8	-	-	PUNCT
dpc-3703	305	9	product	product	NOUN
dpc-3703	305	10	-	-	PUNCT
dpc-3703	305	11	information_en.pdf	information_en.pdf	NOUN
dpc-3703	305	12	,	,	PUNCT
dpc-3703	305	13	accessed	access	VERB
dpc-3703	305	14	on	on	ADP
dpc-3703	305	15	july	july	PROPN
dpc-3703	305	16	3	3	NUM
dpc-3703	305	17	,	,	PUNCT
dpc-3703	305	18	2023	2023	NUM
dpc-3703	305	19	.	.	PUNCT
dpc-3703	306	1	25	25	NUM
dpc-3703	306	2	.	.	PUNCT
dpc-3703	306	3	odomzo	odomzo	NOUN
dpc-3703	306	4	.	.	PUNCT
dpc-3703	307	1	summary	summary	NOUN
dpc-3703	307	2	of	of	ADP
dpc-3703	307	3	product	product	NOUN
dpc-3703	307	4	characteristics	characteristic	NOUN
dpc-3703	307	5	(	(	PUNCT
dpc-3703	307	6	spc	spc	PROPN
dpc-3703	307	7	)	)	PUNCT
dpc-3703	307	8	.	.	PUNCT
dpc-3703	308	1	available	available	ADJ
dpc-3703	308	2	from	from	ADP
dpc-3703	308	3	:	:	PUNCT
dpc-3703	308	4	https://www.ema.europa.eu/en/documents/product	https://www.ema.europa.eu/en/documents/product	VERB
dpc-3703	308	5	-information	-information	PROPN
dpc-3703	308	6	/	/	SYM
dpc-3703	308	7	odomzo	odomzo	NOUN
dpc-3703	308	8	-	-	PUNCT
dpc-3703	308	9	epar	epar	NOUN
dpc-3703	308	10	-	-	PUNCT
dpc-3703	308	11	product	product	NOUN
dpc-3703	308	12	-	-	PUNCT
dpc-3703	308	13	information_en.pdf	information_en.pdf	NOUN
dpc-3703	308	14	assessed	assess	VERB
dpc-3703	308	15	july	july	PROPN
dpc-3703	308	16	3	3	NUM
dpc-3703	308	17	,	,	PUNCT
dpc-3703	308	18	2023	2023	NUM
dpc-3703	308	19	.	.	PUNCT
dpc-3703	309	1	26	26	NUM
dpc-3703	309	2	.	.	PUNCT
dpc-3703	310	1	barrios	barrios	PROPN
dpc-3703	310	2	dm	dm	NUM
dpc-3703	310	3	,	,	PUNCT
dpc-3703	310	4	do	do	AUX
dpc-3703	310	5	mh	mh	PROPN
dpc-3703	310	6	,	,	PUNCT
dpc-3703	310	7	phillips	phillips	PROPN
dpc-3703	310	8	gs	gs	PROPN
dpc-3703	310	9	,	,	PUNCT
dpc-3703	310	10	et	et	PROPN
dpc-3703	310	11	al	al	PROPN
dpc-3703	310	12	.	.	PROPN
dpc-3703	310	13	immune	immune	ADJ
dpc-3703	310	14	checkpoint	checkpoint	NOUN
dpc-3703	310	15	inhibitors	inhibitor	NOUN
dpc-3703	310	16	to	to	PART
dpc-3703	310	17	treat	treat	VERB
dpc-3703	310	18	cutaneous	cutaneous	ADJ
dpc-3703	310	19	malignancies	malignancy	NOUN
dpc-3703	310	20	.	.	PUNCT
dpc-3703	311	1	j	j	PROPN
dpc-3703	311	2	am	be	AUX
dpc-3703	311	3	acad	acad	ADJ
dpc-3703	311	4	dermatol	dermatol	NOUN
dpc-3703	311	5	.	.	PUNCT
dpc-3703	312	1	2020;83(5):1239	2020;83(5):1239	NUM
dpc-3703	312	2	-	-	SYM
dpc-3703	312	3	1253	1253	NUM
dpc-3703	312	4	.	.	PUNCT
dpc-3703	313	1	doi	doi	NOUN
dpc-3703	313	2	:	:	PUNCT
dpc-3703	313	3	10.1016	10.1016	NUM
dpc-3703	313	4	/	/	SYM
dpc-3703	314	1	j.jaad.2020.03.131	j.jaad.2020.03.131	PROPN
dpc-3703	314	2	.	.	PUNCT
dpc-3703	315	1	pmid	pmid	NOUN
dpc-3703	315	2	:	:	PUNCT
dpc-3703	315	3	32461079	32461079	NUM
dpc-3703	315	4	.	.	PUNCT
dpc-3703	316	1	pmcid	pmcid	ADJ
dpc-3703	316	2	:	:	PUNCT
dpc-3703	316	3	pmc7572574	pmc7572574	NOUN
dpc-3703	316	4	.	.	PUNCT
dpc-3703	317	1	27	27	NUM
dpc-3703	317	2	.	.	PUNCT
dpc-3703	318	1	european	european	PROPN
dpc-3703	318	2	medicines	medicine	NOUN
dpc-3703	318	3	agency	agency	NOUN
dpc-3703	318	4	.	.	PUNCT
dpc-3703	319	1	libtayo	libtayo	PROPN
dpc-3703	319	2	.	.	PUNCT
dpc-3703	320	1	summary	summary	NOUN
dpc-3703	320	2	of	of	ADP
dpc-3703	320	3	product	product	NOUN
dpc-3703	320	4	characteristics	characteristic	NOUN
dpc-3703	320	5	.	.	PUNCT
dpc-3703	321	1	available	available	ADJ
dpc-3703	321	2	from	from	ADP
dpc-3703	321	3	:	:	PUNCT
dpc-3703	321	4	https://www.ema.europa	https://www.ema.europa	PROPN
dpc-3703	321	5	.eu	.eu	PUNCT
dpc-3703	321	6	/	/	SYM
dpc-3703	321	7	en	en	ADP
dpc-3703	321	8	/	/	SYM
dpc-3703	321	9	documents	document	NOUN
dpc-3703	321	10	/	/	SYM
dpc-3703	321	11	product	product	NOUN
dpc-3703	321	12	-	-	PUNCT
dpc-3703	321	13	information	information	NOUN
dpc-3703	321	14	/	/	SYM
dpc-3703	321	15	libtayo	libtayo	NOUN
dpc-3703	321	16	-	-	PUNCT
dpc-3703	321	17	epar	epar	NOUN
dpc-3703	321	18	-	-	PUNCT
dpc-3703	321	19	product	product	NOUN
dpc-3703	321	20	-information_en.pdf	-information_en.pdf	NOUN
dpc-3703	321	21	,	,	PUNCT
dpc-3703	321	22	access	access	NOUN
dpc-3703	321	23	date	date	NOUN
dpc-3703	321	24	:	:	PUNCT
dpc-3703	321	25	july	july	PROPN
dpc-3703	321	26	3	3	NUM
dpc-3703	321	27	,	,	PUNCT
dpc-3703	321	28	2023	2023	NUM
dpc-3703	321	29	.	.	PUNCT
dpc-3703	322	1	28	28	NUM
dpc-3703	322	2	.	.	PUNCT
dpc-3703	323	1	basset	basset	NOUN
dpc-3703	323	2	-	-	PUNCT
dpc-3703	323	3	seguin	seguin	PROPN
dpc-3703	323	4	n	n	CCONJ
dpc-3703	323	5	,	,	PUNCT
dpc-3703	323	6	hauschild	hauschild	NOUN
dpc-3703	323	7	a	a	X
dpc-3703	323	8	,	,	PUNCT
dpc-3703	323	9	kunstfeld	kunstfeld	PROPN
dpc-3703	323	10	r	r	NOUN
dpc-3703	323	11	,	,	PUNCT
dpc-3703	323	12	et	et	PROPN
dpc-3703	323	13	al	al	PROPN
dpc-3703	323	14	.	.	PROPN
dpc-3703	323	15	vismodegib	vismodegib	PROPN
dpc-3703	323	16	in	in	ADP
dpc-3703	323	17	patients	patient	NOUN
dpc-3703	323	18	with	with	ADP
dpc-3703	323	19	advanced	advanced	ADJ
dpc-3703	323	20	basal	basal	NOUN
dpc-3703	323	21	cell	cell	NOUN
dpc-3703	323	22	carcinoma	carcinoma	NOUN
dpc-3703	323	23	:	:	PUNCT
dpc-3703	323	24	primary	primary	ADJ
dpc-3703	323	25	analysis	analysis	NOUN
dpc-3703	323	26	of	of	ADP
dpc-3703	323	27	stevie	stevie	NOUN
dpc-3703	323	28	,	,	PUNCT
dpc-3703	323	29	an	an	DET
dpc-3703	323	30	international	international	ADJ
dpc-3703	323	31	,	,	PUNCT
dpc-3703	323	32	open	open	ADJ
dpc-3703	323	33	-	-	PUNCT
dpc-3703	323	34	label	label	NOUN
dpc-3703	323	35	trial	trial	NOUN
dpc-3703	323	36	.	.	PUNCT
dpc-3703	324	1	eur	eur	PROPN
dpc-3703	324	2	j	j	PROPN
dpc-3703	324	3	cancer	cancer	NOUN
dpc-3703	324	4	.	.	PUNCT
dpc-3703	325	1	references	reference	NOUN
dpc-3703	325	2	1	1	NUM
dpc-3703	325	3	.	.	PUNCT
dpc-3703	326	1	dessinioti	dessinioti	PROPN
dpc-3703	327	1	c	c	X
dpc-3703	327	2	,	,	PUNCT
dpc-3703	327	3	antoniou	antoniou	PROPN
dpc-3703	327	4	c	c	PROPN
dpc-3703	327	5	,	,	PUNCT
dpc-3703	327	6	katsambas	katsambas	PROPN
dpc-3703	327	7	a	a	PRON
dpc-3703	327	8	,	,	PUNCT
dpc-3703	327	9	stratigos	stratigos	PROPN
dpc-3703	327	10	aj	aj	PROPN
dpc-3703	327	11	.	.	PROPN
dpc-3703	327	12	basal	basal	PROPN
dpc-3703	327	13	cell	cell	NOUN
dpc-3703	327	14	carcinoma	carcinoma	NOUN
dpc-3703	327	15	:	:	PUNCT
dpc-3703	327	16	what	what	PRON
dpc-3703	327	17	's	be	AUX
dpc-3703	327	18	new	new	ADJ
dpc-3703	327	19	under	under	ADP
dpc-3703	327	20	the	the	DET
dpc-3703	327	21	sun	sun	NOUN
dpc-3703	327	22	.	.	PROPN
dpc-3703	328	1	photochem	photochem	PROPN
dpc-3703	328	2	photobiol	photobiol	NOUN
dpc-3703	328	3	.	.	PUNCT
dpc-3703	329	1	2010;86(3):481	2010;86(3):481	NUM
dpc-3703	329	2	-	-	PUNCT
dpc-3703	329	3	491	491	NUM
dpc-3703	329	4	.	.	PUNCT
dpc-3703	330	1	doi	doi	NOUN
dpc-3703	330	2	:	:	PUNCT
dpc-3703	330	3	10.1111	10.1111	NUM
dpc-3703	330	4	/	/	SYM
dpc-3703	330	5	j.1751	j.1751	NOUN
dpc-3703	330	6	-	-	PUNCT
dpc-3703	330	7	1097.2010.00735.x	1097.2010.00735.x	NUM
dpc-3703	330	8	.	.	PUNCT
dpc-3703	331	1	pmid	pmid	NOUN
dpc-3703	331	2	:	:	PUNCT
dpc-3703	331	3	20550646	20550646	NUM
dpc-3703	331	4	.	.	PUNCT
dpc-3703	332	1	2	2	X
dpc-3703	332	2	.	.	X
dpc-3703	332	3	laga	laga	PROPN
dpc-3703	332	4	ac	ac	PROPN
dpc-3703	332	5	,	,	PUNCT
dpc-3703	332	6	schaefer	schaefer	PROPN
dpc-3703	332	7	i	i	PRON
dpc-3703	332	8	m	m	PROPN
dpc-3703	332	9	,	,	PUNCT
dpc-3703	332	10	sholl	sholl	PROPN
dpc-3703	332	11	lm	lm	PROPN
dpc-3703	332	12	,	,	PUNCT
dpc-3703	332	13	french	french	PROPN
dpc-3703	332	14	ca	can	AUX
dpc-3703	332	15	,	,	PUNCT
dpc-3703	332	16	hanna	hanna	PROPN
dpc-3703	332	17	j.	j.	PROPN
dpc-3703	332	18	metastatic	metastatic	PROPN
dpc-3703	332	19	basal	basal	PROPN
dpc-3703	332	20	cell	cell	NOUN
dpc-3703	332	21	carcinoma	carcinoma	NOUN
dpc-3703	332	22	.	.	PUNCT
dpc-3703	333	1	am	be	AUX
dpc-3703	333	2	j	j	PROPN
dpc-3703	333	3	clin	clin	PROPN
dpc-3703	333	4	pathol	pathol	NOUN
dpc-3703	333	5	.	.	PUNCT
dpc-3703	334	1	2019;152(6):706	2019;152(6):706	X
dpc-3703	334	2	-	-	SYM
dpc-3703	334	3	717	717	NUM
dpc-3703	334	4	.	.	PUNCT
dpc-3703	335	1	doi	doi	NOUN
dpc-3703	335	2	:	:	PUNCT
dpc-3703	335	3	10.1093	10.1093	NUM
dpc-3703	335	4	/	/	SYM
dpc-3703	335	5	ajcp	ajcp	PROPN
dpc-3703	335	6	/	/	SYM
dpc-3703	335	7	aqz089	aqz089	NOUN
dpc-3703	335	8	.	.	PUNCT
dpc-3703	336	1	pmid	pmid	NOUN
dpc-3703	336	2	:	:	PUNCT
dpc-3703	336	3	31355851	31355851	NUM
dpc-3703	336	4	.	.	PUNCT
dpc-3703	337	1	pmcid	pmcid	NOUN
dpc-3703	337	2	:	:	PUNCT
dpc-3703	337	3	pmc6829017	pmc6829017	X
dpc-3703	337	4	.	.	PUNCT
dpc-3703	338	1	3	3	X
dpc-3703	338	2	.	.	X
dpc-3703	338	3	dessinioti	dessinioti	PROPN
dpc-3703	339	1	c	c	X
dpc-3703	339	2	,	,	PUNCT
dpc-3703	339	3	tzannis	tzannis	PROPN
dpc-3703	339	4	k	k	PROPN
dpc-3703	339	5	,	,	PUNCT
dpc-3703	339	6	sypsa	sypsa	PROPN
dpc-3703	339	7	v	v	PROPN
dpc-3703	339	8	,	,	PUNCT
dpc-3703	339	9	et	et	PROPN
dpc-3703	339	10	al	al	PROPN
dpc-3703	339	11	.	.	PROPN
dpc-3703	339	12	epidemiologic	epidemiologic	ADJ
dpc-3703	339	13	risk	risk	NOUN
dpc-3703	339	14	factors	factor	NOUN
dpc-3703	339	15	of	of	ADP
dpc-3703	339	16	basal	basal	ADJ
dpc-3703	339	17	cell	cell	NOUN
dpc-3703	339	18	carcinoma	carcinoma	NOUN
dpc-3703	339	19	development	development	NOUN
dpc-3703	339	20	and	and	CCONJ
dpc-3703	339	21	age	age	NOUN
dpc-3703	339	22	at	at	ADP
dpc-3703	339	23	onset	onset	NOUN
dpc-3703	339	24	in	in	ADP
dpc-3703	339	25	a	a	DET
dpc-3703	339	26	southern	southern	ADJ
dpc-3703	339	27	european	european	ADJ
dpc-3703	339	28	population	population	NOUN
dpc-3703	339	29	from	from	ADP
dpc-3703	339	30	greece	greece	PROPN
dpc-3703	339	31	.	.	PUNCT
dpc-3703	340	1	exp	exp	NOUN
dpc-3703	340	2	dermatol	dermatol	NOUN
dpc-3703	340	3	.	.	PUNCT
dpc-3703	341	1	2011;20(8):622	2011;20(8):622	NUM
dpc-3703	341	2	-	-	PUNCT
dpc-3703	341	3	626	626	NUM
dpc-3703	341	4	.	.	PUNCT
dpc-3703	342	1	doi	doi	NOUN
dpc-3703	342	2	:	:	PUNCT
dpc-3703	342	3	10.1111	10.1111	NUM
dpc-3703	342	4	/	/	SYM
dpc-3703	342	5	j.1600	j.1600	NOUN
dpc-3703	342	6	-	-	PUNCT
dpc-3703	342	7	0625.2011.01275.x	0625.2011.01275.x	NOUN
dpc-3703	342	8	.	.	PUNCT
dpc-3703	343	1	pmid	pmid	NOUN
dpc-3703	343	2	:	:	PUNCT
dpc-3703	343	3	21521370	21521370	NUM
dpc-3703	343	4	.	.	PUNCT
dpc-3703	344	1	4	4	X
dpc-3703	344	2	.	.	X
dpc-3703	344	3	krakowski	krakowski	PROPN
dpc-3703	344	4	ac	ac	PROPN
dpc-3703	344	5	,	,	PUNCT
dpc-3703	344	6	hafeez	hafeez	PROPN
dpc-3703	344	7	f	f	PROPN
dpc-3703	344	8	,	,	PUNCT
dpc-3703	344	9	westheim	westheim	PROPN
dpc-3703	344	10	a	a	X
dpc-3703	344	11	,	,	PUNCT
dpc-3703	344	12	pan	pan	NOUN
dpc-3703	344	13	ey	ey	PROPN
dpc-3703	344	14	,	,	PUNCT
dpc-3703	344	15	wilson	wilson	PROPN
dpc-3703	344	16	m.	m.	PROPN
dpc-3703	344	17	advanced	advanced	PROPN
dpc-3703	344	18	basal	basal	PROPN
dpc-3703	344	19	cell	cell	NOUN
dpc-3703	344	20	carcinoma	carcinoma	NOUN
dpc-3703	344	21	:	:	PUNCT
dpc-3703	344	22	what	what	PRON
dpc-3703	344	23	dermatologists	dermatologist	NOUN
dpc-3703	344	24	need	need	VERB
dpc-3703	344	25	to	to	PART
dpc-3703	344	26	know	know	VERB
dpc-3703	344	27	about	about	ADP
dpc-3703	344	28	diagnosis	diagnosis	NOUN
dpc-3703	344	29	.	.	PUNCT
dpc-3703	345	1	j	j	PROPN
dpc-3703	345	2	am	be	AUX
dpc-3703	345	3	acad	acad	ADJ
dpc-3703	345	4	dermatol	dermatol	NOUN
dpc-3703	345	5	.	.	PUNCT
dpc-3703	346	1	2022;86(6s):s1	2022;86(6s):s1	NUM
dpc-3703	346	2	-	-	PUNCT
dpc-3703	346	3	s13	s13	NOUN
dpc-3703	346	4	.	.	PUNCT
dpc-3703	347	1	doi	doi	NOUN
dpc-3703	347	2	:	:	PUNCT
dpc-3703	347	3	10.1016	10.1016	NUM
dpc-3703	347	4	/	/	SYM
dpc-3703	347	5	j.jaad.2022.03.023	j.jaad.2022.03.023	PROPN
dpc-3703	347	6	.	.	PUNCT
dpc-3703	348	1	pmid	pmid	NOUN
dpc-3703	348	2	:	:	PUNCT
dpc-3703	348	3	35577405	35577405	NUM
dpc-3703	348	4	.	.	PUNCT
dpc-3703	349	1	5	5	NUM
dpc-3703	349	2	.	.	X
dpc-3703	349	3	dessinioti	dessinioti	PROPN
dpc-3703	350	1	c	c	PROPN
dpc-3703	350	2	,	,	PUNCT
dpc-3703	350	3	stratigos	stratigos	PROPN
dpc-3703	350	4	aj	aj	PROPN
dpc-3703	350	5	.	.	PUNCT
dpc-3703	351	1	an	an	DET
dpc-3703	351	2	epidemiological	epidemiological	ADJ
dpc-3703	351	3	update	update	NOUN
dpc-3703	351	4	on	on	ADP
dpc-3703	351	5	indoor	indoor	ADJ
dpc-3703	351	6	tanning	tanning	NOUN
dpc-3703	351	7	and	and	CCONJ
dpc-3703	351	8	the	the	DET
dpc-3703	351	9	risk	risk	NOUN
dpc-3703	351	10	of	of	ADP
dpc-3703	351	11	skin	skin	NOUN
dpc-3703	351	12	cancers	cancer	NOUN
dpc-3703	351	13	.	.	PUNCT
dpc-3703	352	1	curr	curr	PROPN
dpc-3703	352	2	oncol	oncol	PROPN
dpc-3703	352	3	.	.	PUNCT
dpc-3703	353	1	2022;29(11):8886	2022;29(11):8886	NUM
dpc-3703	353	2	-	-	SYM
dpc-3703	353	3	8903	8903	NUM
dpc-3703	353	4	.	.	PUNCT
dpc-3703	354	1	doi	doi	NOUN
dpc-3703	354	2	:	:	PUNCT
dpc-3703	354	3	10.3390	10.3390	NUM
dpc-3703	354	4	/	/	SYM
dpc-3703	354	5	curroncol29110699	curroncol29110699	PROPN
dpc-3703	354	6	.	.	PUNCT
dpc-3703	355	1	pmid	pmid	NOUN
dpc-3703	355	2	:	:	PUNCT
dpc-3703	355	3	36421352	36421352	NUM
dpc-3703	355	4	.	.	PUNCT
dpc-3703	356	1	pmcid	pmcid	NOUN
dpc-3703	356	2	:	:	PUNCT
dpc-3703	356	3	pmc9689757	pmc9689757	NOUN
dpc-3703	356	4	.	.	PUNCT
dpc-3703	357	1	6	6	X
dpc-3703	357	2	.	.	X
dpc-3703	357	3	molinaro	molinaro	PROPN
dpc-3703	357	4	am	am	PROPN
dpc-3703	357	5	,	,	PUNCT
dpc-3703	357	6	ferrucci	ferrucci	NOUN
dpc-3703	357	7	lm	lm	PROPN
dpc-3703	357	8	,	,	PUNCT
dpc-3703	357	9	cartmel	cartmel	PROPN
dpc-3703	357	10	b	b	PROPN
dpc-3703	357	11	,	,	PUNCT
dpc-3703	357	12	et	et	PROPN
dpc-3703	357	13	al	al	PROPN
dpc-3703	357	14	.	.	PROPN
dpc-3703	357	15	indoor	indoor	ADJ
dpc-3703	357	16	tanning	tanning	NOUN
dpc-3703	357	17	and	and	CCONJ
dpc-3703	357	18	the	the	DET
dpc-3703	357	19	mc1r	mc1r	PROPN
dpc-3703	357	20	genotype	genotype	NOUN
dpc-3703	357	21	:	:	PUNCT
dpc-3703	357	22	risk	risk	NOUN
dpc-3703	357	23	prediction	prediction	NOUN
dpc-3703	357	24	for	for	ADP
dpc-3703	357	25	basal	basal	ADJ
dpc-3703	357	26	cell	cell	NOUN
dpc-3703	357	27	carcinoma	carcinoma	NOUN
dpc-3703	357	28	risk	risk	NOUN
dpc-3703	357	29	in	in	ADP
dpc-3703	357	30	young	young	ADJ
dpc-3703	357	31	people	people	NOUN
dpc-3703	357	32	.	.	PUNCT
dpc-3703	358	1	am	be	AUX
dpc-3703	358	2	j	j	PROPN
dpc-3703	358	3	epidemiol	epidemiol	PROPN
dpc-3703	358	4	.	.	PUNCT
dpc-3703	359	1	2015;181(11	2015;181(11	NUM
dpc-3703	359	2	):	):	PUNCT
dpc-3703	359	3	908	908	NUM
dpc-3703	359	4	-	-	SYM
dpc-3703	359	5	916	916	NUM
dpc-3703	359	6	.	.	PUNCT
dpc-3703	360	1	doi	doi	NOUN
dpc-3703	360	2	:	:	PUNCT
dpc-3703	360	3	10.1093	10.1093	NUM
dpc-3703	360	4	/	/	SYM
dpc-3703	360	5	aje	aje	PROPN
dpc-3703	360	6	/	/	SYM
dpc-3703	360	7	kwu356	kwu356	PROPN
dpc-3703	360	8	.	.	PUNCT
dpc-3703	361	1	pmid	pmid	NOUN
dpc-3703	361	2	:	:	PUNCT
dpc-3703	361	3	25858289	25858289	NUM
dpc-3703	361	4	.	.	PUNCT
dpc-3703	362	1	pmcid	pmcid	NOUN
dpc-3703	362	2	:	:	PUNCT
dpc-3703	362	3	pmc4445390	pmc4445390	NOUN
dpc-3703	362	4	.	.	PUNCT
dpc-3703	363	1	7	7	X
dpc-3703	363	2	.	.	X
dpc-3703	363	3	dessinioti	dessinioti	PROPN
dpc-3703	364	1	c	c	X
dpc-3703	364	2	,	,	PUNCT
dpc-3703	364	3	sypsa	sypsa	NOUN
dpc-3703	364	4	v	v	PROPN
dpc-3703	364	5	,	,	PUNCT
dpc-3703	364	6	kypreou	kypreou	PROPN
dpc-3703	364	7	k	k	PROPN
dpc-3703	364	8	,	,	PUNCT
dpc-3703	364	9	et	et	PROPN
dpc-3703	364	10	al	al	PROPN
dpc-3703	364	11	.	.	PUNCT
dpc-3703	365	1	a	a	DET
dpc-3703	365	2	case	case	NOUN
dpc-3703	365	3	-	-	PUNCT
dpc-3703	365	4	control	control	NOUN
dpc-3703	365	5	study	study	NOUN
dpc-3703	365	6	of	of	ADP
dpc-3703	365	7	mc1r	mc1r	PROPN
dpc-3703	365	8	variants	variant	NOUN
dpc-3703	365	9	in	in	ADP
dpc-3703	365	10	greek	greek	ADJ
dpc-3703	365	11	patients	patient	NOUN
dpc-3703	365	12	with	with	ADP
dpc-3703	365	13	basal	basal	ADJ
dpc-3703	365	14	cell	cell	NOUN
dpc-3703	365	15	carcinoma	carcinoma	NOUN
dpc-3703	365	16	:	:	PUNCT
dpc-3703	365	17	increased	increase	VERB
dpc-3703	365	18	risk	risk	NOUN
dpc-3703	365	19	independently	independently	ADV
dpc-3703	365	20	of	of	ADP
dpc-3703	365	21	pigmentary	pigmentary	ADJ
dpc-3703	365	22	characteristics	characteristic	NOUN
dpc-3703	365	23	.	.	PUNCT
dpc-3703	366	1	exp	exp	NOUN
dpc-3703	366	2	dermatol	dermatol	NOUN
dpc-3703	366	3	.	.	PUNCT
dpc-3703	367	1	2015;24(6):476	2015;24(6):476	NUM
dpc-3703	367	2	-	-	SYM
dpc-3703	367	3	478	478	NUM
dpc-3703	367	4	.	.	PUNCT
dpc-3703	367	5	doi	doi	NOUN
dpc-3703	367	6	:	:	PUNCT
dpc-3703	367	7	10.1111	10.1111	NUM
dpc-3703	367	8	/	/	SYM
dpc-3703	367	9	exd.12703	exd.12703	NOUN
dpc-3703	367	10	.	.	PUNCT
dpc-3703	368	1	pmid	pmid	NOUN
dpc-3703	368	2	:	:	PUNCT
dpc-3703	368	3	25809071	25809071	NUM
dpc-3703	368	4	.	.	PUNCT
dpc-3703	369	1	8	8	X
dpc-3703	369	2	.	.	X
dpc-3703	369	3	tagliabue	tagliabue	PROPN
dpc-3703	369	4	e	e	NOUN
dpc-3703	369	5	,	,	PUNCT
dpc-3703	369	6	fargnoli	fargnoli	PROPN
dpc-3703	369	7	mc	mc	PROPN
dpc-3703	369	8	,	,	PUNCT
dpc-3703	369	9	gandini	gandini	VERB
dpc-3703	369	10	s	s	PROPN
dpc-3703	369	11	,	,	PUNCT
dpc-3703	369	12	et	et	PROPN
dpc-3703	369	13	al	al	PROPN
dpc-3703	369	14	.	.	PUNCT
dpc-3703	370	1	mc1r	mc1r	PROPN
dpc-3703	370	2	gene	gene	NOUN
dpc-3703	370	3	variants	variant	NOUN
dpc-3703	370	4	and	and	CCONJ
dpc-3703	370	5	non	non	ADJ
dpc-3703	370	6	-	-	ADJ
dpc-3703	370	7	melanoma	melanoma	ADJ
dpc-3703	370	8	skin	skin	NOUN
dpc-3703	370	9	cancer	cancer	NOUN
dpc-3703	370	10	:	:	PUNCT
dpc-3703	370	11	a	a	DET
dpc-3703	370	12	pooled	pool	VERB
dpc-3703	370	13	-	-	PUNCT
dpc-3703	370	14	analysis	analysis	NOUN
dpc-3703	370	15	from	from	ADP
dpc-3703	370	16	the	the	DET
dpc-3703	370	17	m	m	NOUN
dpc-3703	370	18	-	-	PUNCT
dpc-3703	370	19	skip	skip	ADJ
dpc-3703	370	20	project	project	NOUN
dpc-3703	370	21	.	.	PUNCT
dpc-3703	371	1	br	br	PROPN
dpc-3703	371	2	j	j	PROPN
dpc-3703	371	3	cancer	cancer	NOUN
dpc-3703	371	4	.	.	PUNCT
dpc-3703	372	1	2015;113(2):354	2015;113(2):354	NUM
dpc-3703	372	2	-	-	SYM
dpc-3703	372	3	363	363	NUM
dpc-3703	372	4	.	.	PUNCT
dpc-3703	373	1	doi	doi	NOUN
dpc-3703	373	2	:	:	PUNCT
dpc-3703	373	3	10.1038	10.1038	NUM
dpc-3703	373	4	/	/	SYM
dpc-3703	373	5	bjc.2015.231	bjc.2015.231	PROPN
dpc-3703	373	6	.	.	PUNCT
dpc-3703	374	1	pmid	pmid	NOUN
dpc-3703	374	2	:	:	PUNCT
dpc-3703	374	3	26103569	26103569	NUM
dpc-3703	374	4	.	.	PUNCT
dpc-3703	375	1	pmcid	pmcid	NOUN
dpc-3703	375	2	:	:	PUNCT
dpc-3703	375	3	pmc4506395	pmc4506395	ADJ
dpc-3703	375	4	.	.	PUNCT
dpc-3703	376	1	9	9	X
dpc-3703	376	2	.	.	X
dpc-3703	376	3	dessinioti	dessinioti	PROPN
dpc-3703	376	4	c	c	X
dpc-3703	376	5	,	,	PUNCT
dpc-3703	376	6	antoniou	antoniou	PROPN
dpc-3703	376	7	c	c	PROPN
dpc-3703	376	8	,	,	PUNCT
dpc-3703	376	9	stratigos	stratigos	PROPN
dpc-3703	376	10	aj	aj	PROPN
dpc-3703	376	11	.	.	PROPN
dpc-3703	377	1	from	from	ADP
dpc-3703	377	2	basal	basal	ADJ
dpc-3703	377	3	cell	cell	NOUN
dpc-3703	377	4	carcinoma	carcinoma	NOUN
dpc-3703	377	5	morphogenesis	morphogenesis	NOUN
dpc-3703	377	6	to	to	ADP
dpc-3703	377	7	the	the	DET
dpc-3703	377	8	alopecia	alopecia	NOUN
dpc-3703	377	9	induced	induce	VERB
dpc-3703	377	10	by	by	ADP
dpc-3703	377	11	hedgehog	hedgehog	ADJ
dpc-3703	377	12	inhibitors	inhibitor	NOUN
dpc-3703	377	13	:	:	PUNCT
dpc-3703	377	14	connecting	connect	VERB
dpc-3703	377	15	the	the	DET
dpc-3703	377	16	dots	dot	NOUN
dpc-3703	377	17	.	.	PUNCT
dpc-3703	378	1	br	br	PROPN
dpc-3703	378	2	j	j	PROPN
dpc-3703	378	3	dermatol	dermatol	NOUN
dpc-3703	378	4	.	.	PUNCT
dpc-3703	379	1	2017;177(6):1485	2017;177(6):1485	NUM
dpc-3703	379	2	-	-	SYM
dpc-3703	379	3	1494	1494	NUM
dpc-3703	379	4	.	.	PUNCT
dpc-3703	380	1	doi	doi	NOUN
dpc-3703	380	2	:	:	PUNCT
dpc-3703	380	3	10.1111	10.1111	NUM
dpc-3703	380	4	/	/	SYM
dpc-3703	380	5	bjd.15738	bjd.15738	NOUN
dpc-3703	380	6	.	.	PUNCT
dpc-3703	381	1	pmid	pmid	NOUN
dpc-3703	381	2	:	:	PUNCT
dpc-3703	381	3	28626889	28626889	NUM
dpc-3703	381	4	.	.	PUNCT
dpc-3703	382	1	10	10	NUM
dpc-3703	382	2	.	.	X
dpc-3703	382	3	epstein	epstein	PROPN
dpc-3703	382	4	eh	eh	PROPN
dpc-3703	382	5	.	.	PROPN
dpc-3703	382	6	basal	basal	PROPN
dpc-3703	382	7	cell	cell	NOUN
dpc-3703	382	8	carcinomas	carcinoma	NOUN
dpc-3703	382	9	:	:	PUNCT
dpc-3703	382	10	attack	attack	NOUN
dpc-3703	382	11	of	of	ADP
dpc-3703	382	12	the	the	DET
dpc-3703	382	13	hedgehog	hedgehog	PROPN
dpc-3703	382	14	.	.	PUNCT
dpc-3703	383	1	nat	nat	PROPN
dpc-3703	383	2	rev	rev	PROPN
dpc-3703	383	3	cancer	cancer	NOUN
dpc-3703	383	4	.	.	PUNCT
dpc-3703	384	1	2008;8(10):743	2008;8(10):743	NUM
dpc-3703	384	2	-	-	SYM
dpc-3703	384	3	754	754	NUM
dpc-3703	384	4	.	.	PUNCT
dpc-3703	385	1	doi	doi	NOUN
dpc-3703	385	2	:	:	PUNCT
dpc-3703	385	3	10.1038	10.1038	NUM
dpc-3703	385	4	/	/	SYM
dpc-3703	385	5	nrc2503	nrc2503	NOUN
dpc-3703	385	6	.	.	PUNCT
dpc-3703	386	1	pmid	pmid	NOUN
dpc-3703	386	2	:	:	PUNCT
dpc-3703	386	3	18813320	18813320	NUM
dpc-3703	386	4	.	.	PUNCT
dpc-3703	387	1	pmcid	pmcid	NOUN
dpc-3703	387	2	:	:	PUNCT
dpc-3703	387	3	pmc4457317	pmc4457317	ADJ
dpc-3703	387	4	.	.	PUNCT
dpc-3703	388	1	11	11	NUM
dpc-3703	388	2	.	.	X
dpc-3703	388	3	topalian	topalian	PROPN
dpc-3703	388	4	sl	sl	PROPN
dpc-3703	388	5	,	,	PUNCT
dpc-3703	388	6	taube	taube	PROPN
dpc-3703	388	7	jm	jm	PROPN
dpc-3703	388	8	,	,	PUNCT
dpc-3703	388	9	pardoll	pardoll	PROPN
dpc-3703	388	10	dm	dm	PROPN
dpc-3703	388	11	.	.	PROPN
dpc-3703	388	12	neoadjuvant	neoadjuvant	ADJ
dpc-3703	388	13	checkpoint	checkpoint	NOUN
dpc-3703	388	14	blockade	blockade	NOUN
dpc-3703	388	15	for	for	ADP
dpc-3703	388	16	cancer	cancer	NOUN
dpc-3703	388	17	immunotherapy	immunotherapy	NOUN
dpc-3703	388	18	.	.	PUNCT
dpc-3703	389	1	science	science	NOUN
dpc-3703	389	2	.	.	PUNCT
dpc-3703	390	1	2020;367(6477):eaax0182	2020;367(6477):eaax0182	NOUN
dpc-3703	390	2	.	.	PUNCT
dpc-3703	391	1	doi	doi	NOUN
dpc-3703	391	2	:	:	PUNCT
dpc-3703	391	3	10.1126	10.1126	NUM
dpc-3703	391	4	/	/	SYM
dpc-3703	391	5	science.aax0182	science.aax0182	NOUN
dpc-3703	391	6	.	.	PUNCT
dpc-3703	392	1	pmid	pmid	NOUN
dpc-3703	392	2	:	:	PUNCT
dpc-3703	392	3	32001626	32001626	NUM
dpc-3703	392	4	.	.	PUNCT
dpc-3703	393	1	pmcid	pmcid	NOUN
dpc-3703	393	2	:	:	PUNCT
dpc-3703	393	3	pmc7789854	pmc7789854	X
dpc-3703	393	4	.	.	PUNCT
dpc-3703	394	1	12	12	NUM
dpc-3703	394	2	.	.	PUNCT
dpc-3703	395	1	neuner	neuner	PROPN
dpc-3703	395	2	ra	ra	PROPN
dpc-3703	395	3	,	,	PUNCT
dpc-3703	395	4	lee	lee	PROPN
dpc-3703	395	5	j	j	PROPN
dpc-3703	395	6	,	,	PUNCT
dpc-3703	395	7	rieger	rieger	PROPN
dpc-3703	395	8	ke	ke	PROPN
dpc-3703	395	9	,	,	PUNCT
dpc-3703	395	10	park	park	NOUN
dpc-3703	395	11	c	c	PROPN
dpc-3703	395	12	,	,	PUNCT
dpc-3703	395	13	colevas	colevas	PROPN
dpc-3703	395	14	ad	ad	NOUN
dpc-3703	395	15	,	,	PUNCT
dpc-3703	395	16	chang	chang	PROPN
dpc-3703	395	17	als	als	PROPN
dpc-3703	395	18	.	.	PUNCT
dpc-3703	396	1	immunotherapy	immunotherapy	NOUN
dpc-3703	396	2	for	for	ADP
dpc-3703	396	3	keratinocyte	keratinocyte	NOUN
dpc-3703	396	4	cancers	cancer	NOUN
dpc-3703	396	5	.	.	PUNCT
dpc-3703	397	1	part	part	NOUN
dpc-3703	398	1	i	i	NOUN
dpc-3703	398	2	:	:	PUNCT
dpc-3703	398	3	immune	immune	NOUN
dpc-3703	398	4	-	-	PUNCT
dpc-3703	398	5	related	relate	VERB
dpc-3703	398	6	epidemiology	epidemiology	NOUN
dpc-3703	398	7	,	,	PUNCT
dpc-3703	398	8	risk	risk	NOUN
dpc-3703	398	9	factors	factor	NOUN
dpc-3703	398	10	,	,	PUNCT
dpc-3703	398	11	pathogenesis	pathogenesis	NOUN
dpc-3703	398	12	,	,	PUNCT
dpc-3703	398	13	and	and	CCONJ
dpc-3703	398	14	immunotherapy	immunotherapy	NOUN
dpc-3703	398	15	management	management	NOUN
dpc-3703	398	16	of	of	ADP
dpc-3703	398	17	keratinocyte	keratinocyte	NOUN
dpc-3703	398	18	cancers	cancer	NOUN
dpc-3703	398	19	.	.	PUNCT
dpc-3703	399	1	j	j	PROPN
dpc-3703	399	2	am	be	AUX
dpc-3703	399	3	acad	acad	ADJ
dpc-3703	399	4	dermatol	dermatol	NOUN
dpc-3703	399	5	.	.	PUNCT
dpc-3703	400	1	2023;88(6):1225	2023;88(6):1225	PROPN
dpc-3703	400	2	-	-	PUNCT
dpc-3703	400	3	1240	1240	NUM
dpc-3703	400	4	.	.	PUNCT
dpc-3703	401	1	doi	doi	NOUN
dpc-3703	401	2	:	:	PUNCT
dpc-3703	401	3	10.1016	10.1016	NUM
dpc-3703	401	4	/	/	SYM
dpc-3703	401	5	j.jaad.2022.06.1206	j.jaad.2022.06.1206	PROPN
dpc-3703	401	6	.	.	PUNCT
dpc-3703	402	1	pmid	pmid	NOUN
dpc-3703	402	2	:	:	PUNCT
dpc-3703	402	3	37268390	37268390	NUM
dpc-3703	402	4	.	.	PUNCT
dpc-3703	403	1	13	13	NUM
dpc-3703	403	2	.	.	PUNCT
dpc-3703	403	3	pardoll	pardoll	PROPN
dpc-3703	403	4	dm	dm	PROPN
dpc-3703	403	5	.	.	PUNCT
dpc-3703	404	1	the	the	DET
dpc-3703	404	2	blockade	blockade	NOUN
dpc-3703	404	3	of	of	ADP
dpc-3703	404	4	immune	immune	ADJ
dpc-3703	404	5	checkpoints	checkpoint	NOUN
dpc-3703	404	6	in	in	ADP
dpc-3703	404	7	cancer	cancer	NOUN
dpc-3703	404	8	immunotherapy	immunotherapy	NOUN
dpc-3703	404	9	.	.	PUNCT
dpc-3703	405	1	nat	nat	PROPN
dpc-3703	405	2	rev	rev	PROPN
dpc-3703	405	3	cancer	cancer	NOUN
dpc-3703	405	4	.	.	PUNCT
dpc-3703	406	1	2012;12(4):252	2012;12(4):252	NUM
dpc-3703	406	2	-	-	PUNCT
dpc-3703	406	3	264	264	NUM
dpc-3703	406	4	.	.	PUNCT
dpc-3703	407	1	doi	doi	NOUN
dpc-3703	407	2	:	:	PUNCT
dpc-3703	407	3	10.1038	10.1038	NUM
dpc-3703	407	4	/	/	SYM
dpc-3703	407	5	nrc3239	nrc3239	NOUN
dpc-3703	407	6	.	.	PUNCT
dpc-3703	408	1	pmid	pmid	NOUN
dpc-3703	408	2	:	:	PUNCT
dpc-3703	408	3	22437870	22437870	NUM
dpc-3703	408	4	.	.	PUNCT
dpc-3703	409	1	pmcid	pmcid	NOUN
dpc-3703	409	2	:	:	PUNCT
dpc-3703	409	3	pmc4856023	pmc4856023	NOUN
dpc-3703	409	4	.	.	PUNCT
dpc-3703	410	1	14	14	NUM
dpc-3703	410	2	.	.	X
dpc-3703	410	3	topalian	topalian	PROPN
dpc-3703	410	4	sl	sl	PROPN
dpc-3703	410	5	,	,	PUNCT
dpc-3703	410	6	drake	drake	PROPN
dpc-3703	410	7	cg	cg	PROPN
dpc-3703	410	8	,	,	PUNCT
dpc-3703	410	9	pardoll	pardoll	PROPN
dpc-3703	410	10	dm	dm	PROPN
dpc-3703	410	11	.	.	PROPN
dpc-3703	410	12	immune	immune	ADJ
dpc-3703	410	13	checkpoint	checkpoint	NOUN
dpc-3703	410	14	blockade	blockade	NOUN
dpc-3703	410	15	:	:	PUNCT
dpc-3703	410	16	a	a	DET
dpc-3703	410	17	common	common	ADJ
dpc-3703	410	18	denominator	denominator	NOUN
dpc-3703	410	19	approach	approach	NOUN
dpc-3703	410	20	to	to	ADP
dpc-3703	410	21	cancer	cancer	NOUN
dpc-3703	410	22	therapy	therapy	NOUN
dpc-3703	410	23	.	.	PUNCT
dpc-3703	411	1	cancer	cancer	NOUN
dpc-3703	411	2	10	10	NUM
dpc-3703	411	3	review	review	NOUN
dpc-3703	411	4	|	|	ADV
dpc-3703	411	5	dermatol	dermatol	ADJ
dpc-3703	411	6	pract	pract	NOUN
dpc-3703	411	7	concept	concept	NOUN
dpc-3703	411	8	.	.	PUNCT
dpc-3703	412	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	412	2	of	of	ADP
dpc-3703	412	3	116	116	NUM
dpc-3703	412	4	patients	patient	NOUN
dpc-3703	412	5	.	.	PUNCT
dpc-3703	413	1	j	j	PROPN
dpc-3703	413	2	clin	clin	PROPN
dpc-3703	413	3	oncol	oncol	PROPN
dpc-3703	413	4	.	.	PUNCT
dpc-3703	414	1	2019;37(34):3275	2019;37(34):3275	NUM
dpc-3703	414	2	-	-	SYM
dpc-3703	414	3	3282	3282	NUM
dpc-3703	414	4	.	.	PUNCT
dpc-3703	415	1	doi	doi	NOUN
dpc-3703	415	2	:	:	PUNCT
dpc-3703	415	3	10.1200	10.1200	NUM
dpc-3703	415	4	/	/	SYM
dpc-3703	415	5	jco.18.00794	jco.18.00794	PROPN
dpc-3703	415	6	.	.	PUNCT
dpc-3703	416	1	pmid	pmid	NOUN
dpc-3703	416	2	:	:	PUNCT
dpc-3703	416	3	31609670	31609670	NUM
dpc-3703	416	4	.	.	PUNCT
dpc-3703	417	1	41	41	NUM
dpc-3703	417	2	.	.	PUNCT
dpc-3703	417	3	bassompierre	bassompierre	PROPN
dpc-3703	417	4	a	a	PRON
dpc-3703	417	5	,	,	PUNCT
dpc-3703	417	6	dalac	dalac	PROPN
dpc-3703	417	7	s	s	PROPN
dpc-3703	417	8	,	,	PUNCT
dpc-3703	417	9	dreno	dreno	ADJ
dpc-3703	417	10	b	b	NOUN
dpc-3703	417	11	,	,	PUNCT
dpc-3703	417	12	et	et	PROPN
dpc-3703	417	13	al	al	PROPN
dpc-3703	417	14	.	.	PROPN
dpc-3703	417	15	efficacy	efficacy	NOUN
dpc-3703	417	16	of	of	ADP
dpc-3703	417	17	sonic	sonic	ADJ
dpc-3703	417	18	hedgehog	hedgehog	NOUN
dpc-3703	417	19	inhibitors	inhibitor	NOUN
dpc-3703	417	20	rechallenge	rechallenge	VERB
dpc-3703	417	21	,	,	PUNCT
dpc-3703	417	22	after	after	ADP
dpc-3703	417	23	initial	initial	ADJ
dpc-3703	417	24	complete	complete	ADJ
dpc-3703	417	25	response	response	NOUN
dpc-3703	417	26	in	in	ADP
dpc-3703	417	27	recurrent	recurrent	ADJ
dpc-3703	417	28	advanced	advanced	ADJ
dpc-3703	417	29	basal	basal	NOUN
dpc-3703	417	30	cell	cell	NOUN
dpc-3703	417	31	carcinoma	carcinoma	NOUN
dpc-3703	417	32	:	:	PUNCT
dpc-3703	417	33	a	a	DET
dpc-3703	417	34	retrospective	retrospective	ADJ
dpc-3703	417	35	study	study	NOUN
dpc-3703	417	36	from	from	ADP
dpc-3703	417	37	the	the	DET
dpc-3703	417	38	caraderm	caraderm	NOUN
dpc-3703	417	39	database	database	NOUN
dpc-3703	417	40	.	.	PUNCT
dpc-3703	418	1	esmo	esmo	NOUN
dpc-3703	418	2	open	open	ADJ
dpc-3703	418	3	.	.	PUNCT
dpc-3703	419	1	2021;6(6):100284	2021;6(6):100284	X
dpc-3703	419	2	.	.	PUNCT
dpc-3703	420	1	doi	doi	NOUN
dpc-3703	420	2	:	:	PUNCT
dpc-3703	420	3	10.1016	10.1016	NUM
dpc-3703	420	4	/	/	SYM
dpc-3703	420	5	j.esmoop.2021.100284	j.esmoop.2021.100284	NOUN
dpc-3703	420	6	.	.	PUNCT
dpc-3703	421	1	pmid	pmid	NOUN
dpc-3703	421	2	:	:	PUNCT
dpc-3703	421	3	34689002	34689002	NUM
dpc-3703	421	4	.	.	PUNCT
dpc-3703	422	1	pmcid	pmcid	ADJ
dpc-3703	422	2	:	:	PUNCT
dpc-3703	422	3	pmc8551849	pmc8551849	ADJ
dpc-3703	422	4	.	.	PUNCT
dpc-3703	423	1	42	42	NUM
dpc-3703	423	2	.	.	PUNCT
dpc-3703	423	3	sanchez	sanchez	PROPN
dpc-3703	423	4	-	-	PUNCT
dpc-3703	423	5	danes	dane	NOUN
dpc-3703	423	6	a	a	DET
dpc-3703	423	7	,	,	PUNCT
dpc-3703	423	8	larsimont	larsimont	PROPN
dpc-3703	423	9	jc	jc	PROPN
dpc-3703	423	10	,	,	PUNCT
dpc-3703	423	11	liagre	liagre	VERB
dpc-3703	423	12	m	m	PROPN
dpc-3703	423	13	,	,	PUNCT
dpc-3703	423	14	et	et	PROPN
dpc-3703	423	15	al	al	PROPN
dpc-3703	423	16	.	.	PUNCT
dpc-3703	424	1	a	a	DET
dpc-3703	424	2	slow	slow	ADV
dpc-3703	424	3	-	-	PUNCT
dpc-3703	424	4	cycling	cycling	NOUN
dpc-3703	424	5	lgr5	lgr5	NOUN
dpc-3703	424	6	tumour	tumour	NOUN
dpc-3703	424	7	population	population	NOUN
dpc-3703	424	8	mediates	mediate	NOUN
dpc-3703	424	9	basal	basal	VERB
dpc-3703	424	10	cell	cell	NOUN
dpc-3703	424	11	carcinoma	carcinoma	NOUN
dpc-3703	424	12	relapse	relapse	NOUN
dpc-3703	424	13	after	after	ADP
dpc-3703	424	14	therapy	therapy	NOUN
dpc-3703	424	15	.	.	PUNCT
dpc-3703	425	1	nature	nature	NOUN
dpc-3703	425	2	.	.	PUNCT
dpc-3703	426	1	2018;562(7727):434	2018;562(7727):434	NUM
dpc-3703	426	2	-	-	SYM
dpc-3703	426	3	438	438	NUM
dpc-3703	426	4	.	.	PUNCT
dpc-3703	427	1	doi	doi	NOUN
dpc-3703	427	2	:	:	PUNCT
dpc-3703	427	3	10.1038	10.1038	NUM
dpc-3703	427	4	/s41586	/s41586	ADJ
dpc-3703	427	5	-	-	PUNCT
dpc-3703	427	6	018	018	NUM
dpc-3703	427	7	-	-	PUNCT
dpc-3703	427	8	0603	0603	NUM
dpc-3703	427	9	-	-	PUNCT
dpc-3703	427	10	3	3	NUM
dpc-3703	427	11	.	.	PUNCT
dpc-3703	428	1	pmid	pmid	NOUN
dpc-3703	428	2	:	:	PUNCT
dpc-3703	428	3	30297799	30297799	NUM
dpc-3703	428	4	.	.	PUNCT
dpc-3703	429	1	pmcid	pmcid	NOUN
dpc-3703	429	2	:	:	PUNCT
dpc-3703	429	3	pmc6295195	pmc6295195	ADJ
dpc-3703	429	4	.	.	PROPN
dpc-3703	430	1	43	43	NUM
dpc-3703	430	2	.	.	PUNCT
dpc-3703	431	1	biehs	biehs	PROPN
dpc-3703	431	2	b	b	PROPN
dpc-3703	431	3	,	,	PUNCT
dpc-3703	431	4	dijkgraaf	dijkgraaf	NOUN
dpc-3703	431	5	gjp	gjp	VERB
dpc-3703	431	6	,	,	PUNCT
dpc-3703	431	7	piskol	piskol	NOUN
dpc-3703	431	8	r	r	NOUN
dpc-3703	431	9	,	,	PUNCT
dpc-3703	431	10	et	et	PROPN
dpc-3703	431	11	al	al	PROPN
dpc-3703	431	12	.	.	PUNCT
dpc-3703	432	1	a	a	DET
dpc-3703	432	2	cell	cell	NOUN
dpc-3703	432	3	identity	identity	NOUN
dpc-3703	432	4	switch	switch	NOUN
dpc-3703	432	5	allows	allow	VERB
dpc-3703	432	6	residual	residual	ADJ
dpc-3703	432	7	bcc	bcc	NOUN
dpc-3703	432	8	to	to	PART
dpc-3703	432	9	survive	survive	VERB
dpc-3703	432	10	hedgehog	hedgehog	ADJ
dpc-3703	432	11	pathway	pathway	NOUN
dpc-3703	432	12	inhibition	inhibition	NOUN
dpc-3703	432	13	.	.	PUNCT
dpc-3703	433	1	nature	nature	NOUN
dpc-3703	433	2	.	.	PUNCT
dpc-3703	434	1	2018;562(7727):429	2018;562(7727):429	NUM
dpc-3703	434	2	-	-	SYM
dpc-3703	434	3	433	433	NUM
dpc-3703	434	4	.	.	PUNCT
dpc-3703	435	1	doi	doi	NOUN
dpc-3703	435	2	:	:	PUNCT
dpc-3703	435	3	10.1038	10.1038	NUM
dpc-3703	435	4	/	/	SYM
dpc-3703	435	5	s41586	s41586	ADJ
dpc-3703	435	6	-	-	PUNCT
dpc-3703	435	7	018	018	NUM
dpc-3703	435	8	-0596	-0596	PROPN
dpc-3703	435	9	-	-	PUNCT
dpc-3703	435	10	y.	y.	NOUN
dpc-3703	435	11	pmid	pmid	PROPN
dpc-3703	435	12	:	:	PUNCT
dpc-3703	435	13	30297801	30297801	NUM
dpc-3703	435	14	.	.	PUNCT
dpc-3703	436	1	44	44	NUM
dpc-3703	436	2	.	.	PUNCT
dpc-3703	437	1	dessinioti	dessinioti	PROPN
dpc-3703	438	1	c	c	X
dpc-3703	438	2	,	,	PUNCT
dpc-3703	438	3	plaka	plaka	PROPN
dpc-3703	438	4	m	m	PROPN
dpc-3703	438	5	,	,	PUNCT
dpc-3703	438	6	dimitrakopoulou	dimitrakopoulou	PROPN
dpc-3703	438	7	a	a	PROPN
dpc-3703	438	8	,	,	PUNCT
dpc-3703	438	9	stratigos	stratigos	PROPN
dpc-3703	438	10	aj	aj	PROPN
dpc-3703	438	11	.	.	PROPN
dpc-3703	438	12	complete	complete	ADJ
dpc-3703	438	13	response	response	NOUN
dpc-3703	438	14	is	be	AUX
dpc-3703	438	15	reversible	reversible	ADJ
dpc-3703	438	16	upon	upon	SCONJ
dpc-3703	438	17	vismodegib	vismodegib	NOUN
dpc-3703	438	18	withdrawal	withdrawal	NOUN
dpc-3703	438	19	and	and	CCONJ
dpc-3703	438	20	re	re	NOUN
dpc-3703	438	21	-	-	VERB
dpc-3703	438	22	inducible	inducible	ADJ
dpc-3703	438	23	upon	upon	SCONJ
dpc-3703	438	24	vismodegib	vismodegib	NOUN
dpc-3703	438	25	rechallenge	rechallenge	NOUN
dpc-3703	438	26	in	in	ADP
dpc-3703	438	27	a	a	DET
dpc-3703	438	28	patient	patient	NOUN
dpc-3703	438	29	with	with	ADP
dpc-3703	438	30	locally	locally	ADV
dpc-3703	438	31	advanced	advance	VERB
dpc-3703	438	32	basal	basal	NOUN
dpc-3703	438	33	cell	cell	NOUN
dpc-3703	438	34	carcinoma	carcinoma	NOUN
dpc-3703	438	35	.	.	PUNCT
dpc-3703	439	1	j	j	PROPN
dpc-3703	439	2	eur	eur	PROPN
dpc-3703	439	3	acad	acad	PROPN
dpc-3703	439	4	dermatol	dermatol	NOUN
dpc-3703	439	5	venereol	venereol	NOUN
dpc-3703	439	6	.	.	PUNCT
dpc-3703	440	1	2019;33(5):e187	2019;33(5):e187	NUM
dpc-3703	440	2	-	-	PUNCT
dpc-3703	440	3	e188	e188	PROPN
dpc-3703	440	4	.	.	PUNCT
dpc-3703	441	1	doi	doi	NOUN
dpc-3703	441	2	:	:	PUNCT
dpc-3703	441	3	10.1111	10.1111	NUM
dpc-3703	441	4	/	/	SYM
dpc-3703	441	5	jdv.15428	jdv.15428	PROPN
dpc-3703	441	6	.	.	PUNCT
dpc-3703	442	1	pmid	pmid	NOUN
dpc-3703	442	2	:	:	PUNCT
dpc-3703	442	3	30653740	30653740	NUM
dpc-3703	442	4	.	.	PUNCT
dpc-3703	443	1	45	45	NUM
dpc-3703	443	2	.	.	PUNCT
dpc-3703	444	1	bower	bower	PROPN
dpc-3703	444	2	je	je	PROPN
dpc-3703	444	3	,	,	PUNCT
dpc-3703	444	4	bak	bak	PROPN
dpc-3703	444	5	k	k	PROPN
dpc-3703	444	6	,	,	PUNCT
dpc-3703	444	7	berger	berger	PROPN
dpc-3703	444	8	a	a	PROPN
dpc-3703	444	9	,	,	PUNCT
dpc-3703	444	10	et	et	PROPN
dpc-3703	444	11	al	al	PROPN
dpc-3703	444	12	.	.	PUNCT
dpc-3703	444	13	screening	screening	NOUN
dpc-3703	444	14	,	,	PUNCT
dpc-3703	444	15	assessment	assessment	NOUN
dpc-3703	444	16	,	,	PUNCT
dpc-3703	444	17	and	and	CCONJ
dpc-3703	444	18	management	management	NOUN
dpc-3703	444	19	of	of	ADP
dpc-3703	444	20	fatigue	fatigue	NOUN
dpc-3703	444	21	in	in	ADP
dpc-3703	444	22	adult	adult	NOUN
dpc-3703	444	23	survivors	survivor	NOUN
dpc-3703	444	24	of	of	ADP
dpc-3703	444	25	cancer	cancer	NOUN
dpc-3703	444	26	:	:	PUNCT
dpc-3703	444	27	an	an	DET
dpc-3703	444	28	american	american	ADJ
dpc-3703	444	29	society	society	NOUN
dpc-3703	444	30	of	of	ADP
dpc-3703	444	31	clinical	clinical	ADJ
dpc-3703	444	32	oncology	oncology	NOUN
dpc-3703	444	33	clinical	clinical	ADJ
dpc-3703	444	34	practice	practice	NOUN
dpc-3703	444	35	guideline	guideline	NOUN
dpc-3703	444	36	adaptation	adaptation	NOUN
dpc-3703	444	37	.	.	PUNCT
dpc-3703	445	1	j	j	PROPN
dpc-3703	445	2	clin	clin	PROPN
dpc-3703	445	3	oncol	oncol	PROPN
dpc-3703	445	4	.	.	PUNCT
dpc-3703	446	1	2014;32(17):1840	2014;32(17):1840	NUM
dpc-3703	446	2	-	-	SYM
dpc-3703	446	3	1850	1850	NUM
dpc-3703	446	4	.	.	PUNCT
dpc-3703	447	1	doi	doi	NOUN
dpc-3703	447	2	:	:	PUNCT
dpc-3703	447	3	10.1200	10.1200	NUM
dpc-3703	447	4	/jco.2013.53.4495	/jco.2013.53.4495	NOUN
dpc-3703	447	5	.	.	PUNCT
dpc-3703	448	1	pmid	pmid	NOUN
dpc-3703	448	2	:	:	PUNCT
dpc-3703	448	3	24733803	24733803	NUM
dpc-3703	448	4	.	.	PUNCT
dpc-3703	449	1	pmcid	pmcid	ADJ
dpc-3703	449	2	:	:	PUNCT
dpc-3703	449	3	pmc4039870	pmc4039870	NOUN
dpc-3703	449	4	.	.	PUNCT
dpc-3703	450	1	46	46	NUM
dpc-3703	450	2	.	.	PUNCT
dpc-3703	451	1	lacouture	lacouture	PROPN
dpc-3703	451	2	me	i	PRON
dpc-3703	451	3	,	,	PUNCT
dpc-3703	451	4	dreno	dreno	ADJ
dpc-3703	451	5	b	b	NOUN
dpc-3703	451	6	,	,	PUNCT
dpc-3703	451	7	ascierto	ascierto	PROPN
dpc-3703	451	8	pa	pa	PROPN
dpc-3703	451	9	,	,	PUNCT
dpc-3703	451	10	et	et	PROPN
dpc-3703	451	11	al	al	PROPN
dpc-3703	451	12	.	.	PUNCT
dpc-3703	451	13	characterization	characterization	NOUN
dpc-3703	451	14	and	and	CCONJ
dpc-3703	451	15	management	management	NOUN
dpc-3703	451	16	of	of	ADP
dpc-3703	451	17	hedgehog	hedgehog	PROPN
dpc-3703	451	18	pathway	pathway	NOUN
dpc-3703	451	19	inhibitor	inhibitor	NOUN
dpc-3703	451	20	-	-	PUNCT
dpc-3703	451	21	related	relate	VERB
dpc-3703	451	22	adverse	adverse	ADJ
dpc-3703	451	23	events	event	NOUN
dpc-3703	451	24	in	in	ADP
dpc-3703	451	25	patients	patient	NOUN
dpc-3703	451	26	with	with	ADP
dpc-3703	451	27	advanced	advanced	ADJ
dpc-3703	451	28	basal	basal	NOUN
dpc-3703	451	29	cell	cell	NOUN
dpc-3703	451	30	carcinoma	carcinoma	NOUN
dpc-3703	451	31	.	.	PUNCT
dpc-3703	452	1	oncologist	oncologist	NOUN
dpc-3703	452	2	.	.	PUNCT
dpc-3703	453	1	2016;21(10):1218	2016;21(10):1218	NUM
dpc-3703	453	2	-	-	NOUN
dpc-3703	453	3	1229	1229	NUM
dpc-3703	453	4	.	.	PUNCT
dpc-3703	454	1	doi	doi	NOUN
dpc-3703	454	2	:	:	PUNCT
dpc-3703	454	3	10.1634	10.1634	NUM
dpc-3703	454	4	/	/	SYM
dpc-3703	454	5	theoncologist	theoncologist	NOUN
dpc-3703	454	6	.2016	.2016	PROPN
dpc-3703	454	7	-	-	PUNCT
dpc-3703	454	8	0186	0186	NUM
dpc-3703	454	9	.	.	PUNCT
dpc-3703	455	1	epub	epub	PROPN
dpc-3703	455	2	2016	2016	NUM
dpc-3703	455	3	aug	aug	PROPN
dpc-3703	455	4	10	10	NUM
dpc-3703	455	5	.	.	PUNCT
dpc-3703	456	1	pmid	pmid	NOUN
dpc-3703	456	2	:	:	PUNCT
dpc-3703	456	3	27511905	27511905	NUM
dpc-3703	456	4	.	.	PUNCT
dpc-3703	457	1	pmcid	pmcid	ADJ
dpc-3703	457	2	:	:	PUNCT
dpc-3703	457	3	pmc5061532	pmc5061532	NOUN
dpc-3703	457	4	.	.	PUNCT
dpc-3703	458	1	47	47	NUM
dpc-3703	458	2	.	.	PUNCT
dpc-3703	459	1	fife	fife	PROPN
dpc-3703	459	2	k	k	PROPN
dpc-3703	459	3	,	,	PUNCT
dpc-3703	459	4	herd	herd	NOUN
dpc-3703	459	5	r	r	NOUN
dpc-3703	459	6	,	,	PUNCT
dpc-3703	459	7	lalondrelle	lalondrelle	VERB
dpc-3703	459	8	s	s	PART
dpc-3703	459	9	,	,	PUNCT
dpc-3703	459	10	et	et	PROPN
dpc-3703	459	11	al	al	PROPN
dpc-3703	459	12	.	.	PUNCT
dpc-3703	460	1	managing	manage	VERB
dpc-3703	460	2	adverse	adverse	ADJ
dpc-3703	460	3	events	event	NOUN
dpc-3703	460	4	associated	associate	VERB
dpc-3703	460	5	with	with	ADP
dpc-3703	460	6	vismodegib	vismodegib	NOUN
dpc-3703	460	7	in	in	ADP
dpc-3703	460	8	the	the	DET
dpc-3703	460	9	treatment	treatment	NOUN
dpc-3703	460	10	of	of	ADP
dpc-3703	460	11	basal	basal	ADJ
dpc-3703	460	12	cell	cell	NOUN
dpc-3703	460	13	carcinoma	carcinoma	NOUN
dpc-3703	460	14	.	.	PUNCT
dpc-3703	461	1	future	future	ADJ
dpc-3703	461	2	oncol	oncol	ADJ
dpc-3703	461	3	.	.	PUNCT
dpc-3703	462	1	2017;13(2):175	2017;13(2):175	NUM
dpc-3703	462	2	-	-	SYM
dpc-3703	462	3	184	184	NUM
dpc-3703	462	4	.	.	PUNCT
dpc-3703	463	1	doi	doi	NOUN
dpc-3703	463	2	:	:	PUNCT
dpc-3703	463	3	10.2217	10.2217	NUM
dpc-3703	463	4	/	/	SYM
dpc-3703	463	5	fon	fon	PROPN
dpc-3703	463	6	-2016	-2016	PROPN
dpc-3703	463	7	-	-	PUNCT
dpc-3703	463	8	0296	0296	NUM
dpc-3703	463	9	.	.	PUNCT
dpc-3703	464	1	pmid	pmid	NOUN
dpc-3703	464	2	:	:	PUNCT
dpc-3703	464	3	27640448	27640448	NUM
dpc-3703	464	4	.	.	PUNCT
dpc-3703	465	1	48	48	NUM
dpc-3703	465	2	.	.	PUNCT
dpc-3703	466	1	sekulic	sekulic	PROPN
dpc-3703	466	2	a	a	PRON
dpc-3703	466	3	,	,	PUNCT
dpc-3703	466	4	migden	migden	PROPN
dpc-3703	466	5	mr	mr	PROPN
dpc-3703	466	6	,	,	PUNCT
dpc-3703	466	7	lewis	lewis	PROPN
dpc-3703	466	8	k	k	PROPN
dpc-3703	466	9	,	,	PUNCT
dpc-3703	466	10	et	et	PROPN
dpc-3703	466	11	al	al	PROPN
dpc-3703	466	12	.	.	PUNCT
dpc-3703	467	1	pivotal	pivotal	ADJ
dpc-3703	467	2	erivance	erivance	NOUN
dpc-3703	467	3	basal	basal	NOUN
dpc-3703	467	4	cell	cell	NOUN
dpc-3703	467	5	carcinoma	carcinoma	NOUN
dpc-3703	467	6	(	(	PUNCT
dpc-3703	467	7	bcc	bcc	PROPN
dpc-3703	467	8	)	)	PUNCT
dpc-3703	467	9	study	study	NOUN
dpc-3703	467	10	:	:	PUNCT
dpc-3703	467	11	12	12	NUM
dpc-3703	467	12	-	-	PUNCT
dpc-3703	467	13	month	month	NOUN
dpc-3703	467	14	update	update	NOUN
dpc-3703	467	15	of	of	ADP
dpc-3703	467	16	efficacy	efficacy	NOUN
dpc-3703	467	17	and	and	CCONJ
dpc-3703	467	18	safety	safety	NOUN
dpc-3703	467	19	of	of	ADP
dpc-3703	467	20	vismodegib	vismodegib	NOUN
dpc-3703	467	21	in	in	ADP
dpc-3703	467	22	advanced	advanced	ADJ
dpc-3703	467	23	bcc	bcc	PROPN
dpc-3703	467	24	.	.	PUNCT
dpc-3703	468	1	j	j	PROPN
dpc-3703	468	2	am	be	AUX
dpc-3703	468	3	acad	acad	ADJ
dpc-3703	468	4	dermatol	dermatol	NOUN
dpc-3703	468	5	.	.	PUNCT
dpc-3703	469	1	2015;72(6):1021	2015;72(6):1021	NUM
dpc-3703	469	2	-	-	PUNCT
dpc-3703	469	3	1026	1026	NUM
dpc-3703	469	4	e1028	e1028	PROPN
dpc-3703	469	5	.	.	PUNCT
dpc-3703	469	6	doi	doi	NOUN
dpc-3703	469	7	:	:	PUNCT
dpc-3703	469	8	10.1016	10.1016	NUM
dpc-3703	469	9	/	/	SYM
dpc-3703	469	10	j	j	PROPN
dpc-3703	469	11	.jaad.2015.03.021	.jaad.2015.03.021	NOUN
dpc-3703	469	12	.	.	PUNCT
dpc-3703	470	1	pmid	pmid	NOUN
dpc-3703	470	2	:	:	PUNCT
dpc-3703	470	3	25981002	25981002	NUM
dpc-3703	470	4	.	.	PUNCT
dpc-3703	471	1	49	49	NUM
dpc-3703	471	2	.	.	PUNCT
dpc-3703	472	1	dessinioti	dessinioti	PROPN
dpc-3703	473	1	c	c	X
dpc-3703	473	2	,	,	PUNCT
dpc-3703	473	3	plaka	plaka	PROPN
dpc-3703	473	4	m	m	PROPN
dpc-3703	473	5	,	,	PUNCT
dpc-3703	473	6	soura	soura	NOUN
dpc-3703	473	7	e	e	NOUN
dpc-3703	473	8	,	,	PUNCT
dpc-3703	473	9	et	et	PROPN
dpc-3703	473	10	al	al	PROPN
dpc-3703	473	11	.	.	PUNCT
dpc-3703	474	1	a	a	DET
dpc-3703	474	2	practical	practical	ADJ
dpc-3703	474	3	guide	guide	NOUN
dpc-3703	474	4	for	for	ADP
dpc-3703	474	5	the	the	DET
dpc-3703	474	6	follow	follow	NOUN
dpc-3703	474	7	-	-	PUNCT
dpc-3703	474	8	up	up	NOUN
dpc-3703	474	9	of	of	ADP
dpc-3703	474	10	patients	patient	NOUN
dpc-3703	474	11	with	with	ADP
dpc-3703	474	12	advanced	advanced	ADJ
dpc-3703	474	13	basal	basal	NOUN
dpc-3703	474	14	cell	cell	NOUN
dpc-3703	474	15	carcinoma	carcinoma	NOUN
dpc-3703	474	16	during	during	ADP
dpc-3703	474	17	treatment	treatment	NOUN
dpc-3703	474	18	with	with	ADP
dpc-3703	474	19	hedgehog	hedgehog	ADJ
dpc-3703	474	20	pathway	pathway	NOUN
dpc-3703	474	21	inhibitors	inhibitor	NOUN
dpc-3703	474	22	.	.	PUNCT
dpc-3703	475	1	oncologist	oncologist	NOUN
dpc-3703	475	2	.	.	PUNCT
dpc-3703	476	1	2019;24(8):e755	2019;24(8):e755	X
dpc-3703	476	2	-	-	PUNCT
dpc-3703	476	3	e764	e764	PROPN
dpc-3703	476	4	.	.	PUNCT
dpc-3703	476	5	doi	doi	NOUN
dpc-3703	476	6	:	:	PUNCT
dpc-3703	476	7	10.1634	10.1634	NUM
dpc-3703	476	8	/	/	SYM
dpc-3703	476	9	theoncologist	theoncologist	NOUN
dpc-3703	476	10	.2018	.2018	NOUN
dpc-3703	476	11	-	-	PUNCT
dpc-3703	476	12	0924	0924	NUM
dpc-3703	476	13	.	.	PUNCT
dpc-3703	477	1	pmid	pmid	NOUN
dpc-3703	477	2	:	:	PUNCT
dpc-3703	477	3	31073024	31073024	NUM
dpc-3703	477	4	.	.	PUNCT
dpc-3703	478	1	pmcid	pmcid	NOUN
dpc-3703	478	2	:	:	PUNCT
dpc-3703	478	3	pmc6693703	pmc6693703	NOUN
dpc-3703	478	4	.	.	PUNCT
dpc-3703	479	1	50	50	NUM
dpc-3703	479	2	.	.	PUNCT
dpc-3703	480	1	basset	basset	NOUN
dpc-3703	480	2	-	-	PUNCT
dpc-3703	480	3	seguin	seguin	PROPN
dpc-3703	480	4	n	n	CCONJ
dpc-3703	480	5	,	,	PUNCT
dpc-3703	480	6	hauschild	hauschild	PROPN
dpc-3703	480	7	a	a	X
dpc-3703	480	8	,	,	PUNCT
dpc-3703	480	9	grob	grob	PROPN
dpc-3703	480	10	jj	jj	PROPN
dpc-3703	480	11	,	,	PUNCT
dpc-3703	481	1	et	et	PROPN
dpc-3703	481	2	al	al	PROPN
dpc-3703	481	3	.	.	PROPN
dpc-3703	481	4	vismodegib	vismodegib	PROPN
dpc-3703	481	5	in	in	ADP
dpc-3703	481	6	patients	patient	NOUN
dpc-3703	481	7	with	with	ADP
dpc-3703	481	8	advanced	advanced	ADJ
dpc-3703	481	9	basal	basal	NOUN
dpc-3703	481	10	cell	cell	NOUN
dpc-3703	481	11	carcinoma	carcinoma	NOUN
dpc-3703	481	12	(	(	PUNCT
dpc-3703	481	13	stevie	stevie	NOUN
dpc-3703	481	14	):	):	PUNCT
dpc-3703	481	15	a	a	DET
dpc-3703	481	16	pre	pre	ADJ
dpc-3703	481	17	-	-	ADJ
dpc-3703	481	18	planned	planned	ADJ
dpc-3703	481	19	interim	interim	ADJ
dpc-3703	481	20	analysis	analysis	NOUN
dpc-3703	481	21	of	of	ADP
dpc-3703	481	22	an	an	DET
dpc-3703	481	23	international	international	ADJ
dpc-3703	481	24	,	,	PUNCT
dpc-3703	481	25	open	open	ADJ
dpc-3703	481	26	-	-	PUNCT
dpc-3703	481	27	label	label	NOUN
dpc-3703	481	28	trial	trial	NOUN
dpc-3703	481	29	.	.	PUNCT
dpc-3703	482	1	lancet	lancet	PROPN
dpc-3703	482	2	oncol	oncol	PROPN
dpc-3703	482	3	.	.	PUNCT
dpc-3703	483	1	2015;16(6):729	2015;16(6):729	NUM
dpc-3703	483	2	-	-	PUNCT
dpc-3703	483	3	736	736	NUM
dpc-3703	483	4	.	.	PUNCT
dpc-3703	484	1	doi	doi	NOUN
dpc-3703	484	2	:	:	PUNCT
dpc-3703	484	3	10.1016	10.1016	NUM
dpc-3703	484	4	/	/	SYM
dpc-3703	484	5	s1470	s1470	PROPN
dpc-3703	484	6	-2045(15)70198	-2045(15)70198	PROPN
dpc-3703	484	7	-	-	PUNCT
dpc-3703	484	8	1	1	NUM
dpc-3703	484	9	.	.	PUNCT
dpc-3703	485	1	pmid	pmid	NOUN
dpc-3703	485	2	:	:	PUNCT
dpc-3703	485	3	25981813	25981813	NUM
dpc-3703	485	4	.	.	PUNCT
dpc-3703	486	1	51	51	NUM
dpc-3703	486	2	.	.	PUNCT
dpc-3703	487	1	otsuka	otsuka	PROPN
dpc-3703	487	2	a	a	PROPN
dpc-3703	487	3	,	,	PUNCT
dpc-3703	487	4	dreier	dreier	PROPN
dpc-3703	487	5	j	j	PROPN
dpc-3703	487	6	,	,	PUNCT
dpc-3703	487	7	cheng	cheng	PROPN
dpc-3703	487	8	pf	pf	PROPN
dpc-3703	487	9	,	,	PUNCT
dpc-3703	487	10	et	et	PROPN
dpc-3703	487	11	al	al	PROPN
dpc-3703	487	12	.	.	PROPN
dpc-3703	488	1	hedgehog	hedgehog	PROPN
dpc-3703	488	2	pathway	pathway	NOUN
dpc-3703	488	3	inhibitors	inhibitor	NOUN
dpc-3703	488	4	promote	promote	VERB
dpc-3703	488	5	adaptive	adaptive	ADJ
dpc-3703	488	6	immune	immune	ADJ
dpc-3703	488	7	responses	response	NOUN
dpc-3703	488	8	in	in	ADP
dpc-3703	488	9	basal	basal	ADJ
dpc-3703	488	10	cell	cell	NOUN
dpc-3703	488	11	carcinoma	carcinoma	NOUN
dpc-3703	488	12	.	.	PUNCT
dpc-3703	489	1	clin	clin	PROPN
dpc-3703	489	2	cancer	cancer	NOUN
dpc-3703	489	3	res	re	NOUN
dpc-3703	489	4	.	.	PUNCT
dpc-3703	490	1	2015;21(6):1289	2015;21(6):1289	PROPN
dpc-3703	490	2	-	-	SYM
dpc-3703	490	3	1297	1297	NUM
dpc-3703	490	4	.	.	PUNCT
dpc-3703	491	1	doi	doi	NOUN
dpc-3703	491	2	:	:	PUNCT
dpc-3703	491	3	10.1158/1078	10.1158/1078	NUM
dpc-3703	491	4	-0432.ccr-14	-0432.ccr-14	NUM
dpc-3703	491	5	-	-	PUNCT
dpc-3703	491	6	2110	2110	NUM
dpc-3703	491	7	.	.	PUNCT
dpc-3703	492	1	pmid	pmid	NOUN
dpc-3703	492	2	:	:	PUNCT
dpc-3703	492	3	25593302	25593302	NUM
dpc-3703	492	4	.	.	PUNCT
dpc-3703	493	1	52	52	NUM
dpc-3703	493	2	.	.	PUNCT
dpc-3703	494	1	falchook	falchook	PROPN
dpc-3703	494	2	gs	gs	PROPN
dpc-3703	494	3	,	,	PUNCT
dpc-3703	494	4	leidner	leidner	NOUN
dpc-3703	494	5	r	r	NOUN
dpc-3703	494	6	,	,	PUNCT
dpc-3703	494	7	stankevich	stankevich	NOUN
dpc-3703	494	8	e	e	NOUN
dpc-3703	494	9	,	,	PUNCT
dpc-3703	494	10	et	et	PROPN
dpc-3703	494	11	al	al	PROPN
dpc-3703	494	12	.	.	PUNCT
dpc-3703	494	13	responses	response	NOUN
dpc-3703	494	14	of	of	ADP
dpc-3703	494	15	metastatic	metastatic	ADJ
dpc-3703	494	16	basal	basal	NOUN
dpc-3703	494	17	cell	cell	NOUN
dpc-3703	494	18	and	and	CCONJ
dpc-3703	494	19	cutaneous	cutaneous	ADJ
dpc-3703	494	20	squamous	squamous	ADJ
dpc-3703	494	21	cell	cell	NOUN
dpc-3703	494	22	carcinomas	carcinoma	NOUN
dpc-3703	494	23	to	to	ADP
dpc-3703	494	24	anti	anti	ADJ
dpc-3703	494	25	-	-	ADJ
dpc-3703	494	26	pd1	pd1	VERB
dpc-3703	494	27	monoclonal	monoclonal	NOUN
dpc-3703	494	28	antibody	antibody	NOUN
dpc-3703	494	29	regn2810	regn2810	PROPN
dpc-3703	494	30	.	.	PUNCT
dpc-3703	495	1	j	j	PROPN
dpc-3703	495	2	immunother	immunother	ADJ
dpc-3703	495	3	cancer	cancer	NOUN
dpc-3703	495	4	.	.	PUNCT
dpc-3703	496	1	2016;4:70	2016;4:70	PROPN
dpc-3703	496	2	.	.	PUNCT
dpc-3703	497	1	doi	doi	NOUN
dpc-3703	497	2	:	:	PUNCT
dpc-3703	497	3	10.1186	10.1186	NUM
dpc-3703	497	4	/	/	SYM
dpc-3703	497	5	s40425	s40425	NOUN
dpc-3703	497	6	-	-	PUNCT
dpc-3703	497	7	016	016	NUM
dpc-3703	497	8	-	-	PUNCT
dpc-3703	497	9	0176	0176	NUM
dpc-3703	497	10	-	-	PUNCT
dpc-3703	497	11	3	3	NUM
dpc-3703	497	12	.	.	PUNCT
dpc-3703	498	1	pmid	pmid	NOUN
dpc-3703	498	2	:	:	PUNCT
dpc-3703	498	3	27879972	27879972	NUM
dpc-3703	498	4	.	.	PUNCT
dpc-3703	499	1	pmcid	pmcid	ADJ
dpc-3703	499	2	:	:	PUNCT
dpc-3703	499	3	pmc5109769	pmc5109769	NOUN
dpc-3703	499	4	.	.	PUNCT
dpc-3703	500	1	2017;86:334	2017;86:334	X
dpc-3703	500	2	-	-	SYM
dpc-3703	500	3	348	348	NUM
dpc-3703	500	4	.	.	PUNCT
dpc-3703	501	1	doi	doi	NOUN
dpc-3703	501	2	:	:	PUNCT
dpc-3703	501	3	10.1016	10.1016	NUM
dpc-3703	501	4	/	/	SYM
dpc-3703	501	5	j.ejca.2017.08.022	j.ejca.2017.08.022	PROPN
dpc-3703	501	6	.	.	PUNCT
dpc-3703	502	1	pmid	pmid	NOUN
dpc-3703	502	2	:	:	PUNCT
dpc-3703	502	3	29073584	29073584	NUM
dpc-3703	502	4	.	.	PUNCT
dpc-3703	503	1	29	29	NUM
dpc-3703	503	2	.	.	PUNCT
dpc-3703	504	1	sekulic	sekulic	PROPN
dpc-3703	504	2	a	a	DET
dpc-3703	504	3	,	,	PUNCT
dpc-3703	504	4	migden	migden	ADJ
dpc-3703	504	5	mr	mr	PROPN
dpc-3703	504	6	,	,	PUNCT
dpc-3703	504	7	basset	basset	NOUN
dpc-3703	504	8	-	-	PUNCT
dpc-3703	504	9	seguin	seguin	NOUN
dpc-3703	504	10	n	n	CCONJ
dpc-3703	504	11	,	,	PUNCT
dpc-3703	504	12	et	et	PROPN
dpc-3703	504	13	al	al	PROPN
dpc-3703	504	14	.	.	PUNCT
dpc-3703	504	15	long	long	ADJ
dpc-3703	504	16	-	-	PUNCT
dpc-3703	504	17	term	term	NOUN
dpc-3703	504	18	safety	safety	NOUN
dpc-3703	504	19	and	and	CCONJ
dpc-3703	504	20	efficacy	efficacy	NOUN
dpc-3703	504	21	of	of	ADP
dpc-3703	504	22	vismodegib	vismodegib	NOUN
dpc-3703	504	23	in	in	ADP
dpc-3703	504	24	patients	patient	NOUN
dpc-3703	504	25	with	with	ADP
dpc-3703	504	26	advanced	advanced	ADJ
dpc-3703	504	27	basal	basal	NOUN
dpc-3703	504	28	cell	cell	NOUN
dpc-3703	504	29	carcinoma	carcinoma	NOUN
dpc-3703	504	30	:	:	PUNCT
dpc-3703	504	31	final	final	ADJ
dpc-3703	504	32	update	update	NOUN
dpc-3703	504	33	of	of	ADP
dpc-3703	504	34	the	the	DET
dpc-3703	504	35	pivotal	pivotal	ADJ
dpc-3703	504	36	erivance	erivance	NOUN
dpc-3703	504	37	bcc	bcc	PROPN
dpc-3703	504	38	study	study	NOUN
dpc-3703	504	39	.	.	PUNCT
dpc-3703	505	1	bmc	bmc	NOUN
dpc-3703	505	2	cancer	cancer	NOUN
dpc-3703	505	3	.	.	PUNCT
dpc-3703	506	1	2017;17(1):332	2017;17(1):332	NUM
dpc-3703	506	2	.	.	PUNCT
dpc-3703	507	1	doi	doi	NOUN
dpc-3703	507	2	:	:	PUNCT
dpc-3703	507	3	10.1186	10.1186	NUM
dpc-3703	507	4	/	/	SYM
dpc-3703	507	5	s12885	s12885	NOUN
dpc-3703	507	6	-	-	PUNCT
dpc-3703	507	7	017	017	NUM
dpc-3703	507	8	-3286	-3286	NOUN
dpc-3703	507	9	-	-	PUNCT
dpc-3703	507	10	5	5	NUM
dpc-3703	507	11	.	.	PUNCT
dpc-3703	508	1	pmid	pmid	NOUN
dpc-3703	508	2	:	:	PUNCT
dpc-3703	508	3	28511673	28511673	NUM
dpc-3703	508	4	.	.	PUNCT
dpc-3703	509	1	pmcid	pmcid	ADJ
dpc-3703	509	2	:	:	PUNCT
dpc-3703	509	3	pmc5433030	pmc5433030	NOUN
dpc-3703	509	4	.	.	PUNCT
dpc-3703	510	1	30	30	NUM
dpc-3703	510	2	.	.	PUNCT
dpc-3703	511	1	dummer	dummer	PROPN
dpc-3703	511	2	r	r	PROPN
dpc-3703	511	3	,	,	PUNCT
dpc-3703	511	4	guminksi	guminksi	X
dpc-3703	511	5	a	a	PRON
dpc-3703	511	6	,	,	PUNCT
dpc-3703	511	7	gutzmer	gutzmer	NOUN
dpc-3703	511	8	r	r	NOUN
dpc-3703	511	9	,	,	PUNCT
dpc-3703	511	10	et	et	PROPN
dpc-3703	511	11	al	al	PROPN
dpc-3703	511	12	.	.	PUNCT
dpc-3703	511	13	long	long	ADJ
dpc-3703	511	14	-	-	PUNCT
dpc-3703	511	15	term	term	NOUN
dpc-3703	511	16	efficacy	efficacy	NOUN
dpc-3703	511	17	and	and	CCONJ
dpc-3703	511	18	safety	safety	NOUN
dpc-3703	511	19	of	of	ADP
dpc-3703	511	20	sonidegib	sonidegib	NOUN
dpc-3703	511	21	in	in	ADP
dpc-3703	511	22	patients	patient	NOUN
dpc-3703	511	23	with	with	ADP
dpc-3703	511	24	advanced	advanced	ADJ
dpc-3703	511	25	basal	basal	NOUN
dpc-3703	511	26	cell	cell	NOUN
dpc-3703	511	27	carcinoma	carcinoma	NOUN
dpc-3703	511	28	:	:	PUNCT
dpc-3703	511	29	42	42	NUM
dpc-3703	511	30	-	-	PUNCT
dpc-3703	511	31	month	month	NOUN
dpc-3703	511	32	analysis	analysis	NOUN
dpc-3703	511	33	of	of	ADP
dpc-3703	511	34	the	the	DET
dpc-3703	511	35	phase	phase	NOUN
dpc-3703	511	36	ii	ii	NOUN
dpc-3703	511	37	randomized	randomize	VERB
dpc-3703	511	38	,	,	PUNCT
dpc-3703	511	39	double	double	ADJ
dpc-3703	511	40	-	-	PUNCT
dpc-3703	511	41	blind	blind	ADJ
dpc-3703	511	42	bolt	bolt	NOUN
dpc-3703	511	43	study	study	NOUN
dpc-3703	511	44	.	.	PUNCT
dpc-3703	512	1	br	br	PROPN
dpc-3703	512	2	j	j	PROPN
dpc-3703	512	3	dermatol	dermatol	NOUN
dpc-3703	512	4	.	.	PUNCT
dpc-3703	513	1	2020;182(6):13691378	2020;182(6):13691378	NUM
dpc-3703	513	2	.	.	PUNCT
dpc-3703	514	1	doi	doi	NOUN
dpc-3703	514	2	:	:	PUNCT
dpc-3703	514	3	10.1111	10.1111	NUM
dpc-3703	514	4	/	/	SYM
dpc-3703	514	5	bjd.18552	bjd.18552	X
dpc-3703	514	6	.	.	PUNCT
dpc-3703	514	7	pmid	pmid	NOUN
dpc-3703	514	8	:	:	PUNCT
dpc-3703	514	9	31545507	31545507	NUM
dpc-3703	514	10	.	.	PUNCT
dpc-3703	515	1	pmcid	pmcid	NOUN
dpc-3703	515	2	:	:	PUNCT
dpc-3703	515	3	pmc7318253	pmc7318253	NOUN
dpc-3703	515	4	.	.	PUNCT
dpc-3703	516	1	31	31	NUM
dpc-3703	516	2	.	.	PUNCT
dpc-3703	517	1	sekulic	sekulic	PROPN
dpc-3703	517	2	a	a	DET
dpc-3703	517	3	,	,	PUNCT
dpc-3703	517	4	migden	migden	PROPN
dpc-3703	517	5	mr	mr	PROPN
dpc-3703	517	6	,	,	PUNCT
dpc-3703	517	7	oro	oro	PROPN
dpc-3703	517	8	ae	ae	PROPN
dpc-3703	517	9	,	,	PUNCT
dpc-3703	517	10	et	et	PROPN
dpc-3703	517	11	al	al	PROPN
dpc-3703	517	12	.	.	PROPN
dpc-3703	517	13	efficacy	efficacy	NOUN
dpc-3703	517	14	and	and	CCONJ
dpc-3703	517	15	safety	safety	NOUN
dpc-3703	517	16	of	of	ADP
dpc-3703	517	17	vismodegib	vismodegib	NOUN
dpc-3703	517	18	in	in	ADP
dpc-3703	517	19	advanced	advanced	ADJ
dpc-3703	517	20	basal	basal	NOUN
dpc-3703	517	21	-	-	PUNCT
dpc-3703	517	22	cell	cell	NOUN
dpc-3703	517	23	carcinoma	carcinoma	NOUN
dpc-3703	517	24	.	.	PUNCT
dpc-3703	518	1	n	n	PRON
dpc-3703	518	2	engl	engl	PROPN
dpc-3703	518	3	j	j	PROPN
dpc-3703	518	4	med	med	PROPN
dpc-3703	518	5	.	.	PUNCT
dpc-3703	519	1	2012;366(23):2171	2012;366(23):2171	NUM
dpc-3703	519	2	-	-	PUNCT
dpc-3703	519	3	2179	2179	NUM
dpc-3703	519	4	.	.	PUNCT
dpc-3703	520	1	doi	doi	NOUN
dpc-3703	520	2	:	:	PUNCT
dpc-3703	520	3	10.1056	10.1056	NUM
dpc-3703	520	4	/	/	SYM
dpc-3703	520	5	nejmoa1113713	nejmoa1113713	PROPN
dpc-3703	520	6	.	.	PUNCT
dpc-3703	521	1	pmid	pmid	NOUN
dpc-3703	521	2	:	:	PUNCT
dpc-3703	521	3	22670903	22670903	NUM
dpc-3703	521	4	.	.	PUNCT
dpc-3703	522	1	pmcid	pmcid	NOUN
dpc-3703	522	2	:	:	PUNCT
dpc-3703	522	3	pmc5278761	pmc5278761	VERB
dpc-3703	522	4	.	.	PUNCT
dpc-3703	523	1	32	32	NUM
dpc-3703	523	2	.	.	PUNCT
dpc-3703	524	1	migden	migden	PROPN
dpc-3703	524	2	mr	mr	PROPN
dpc-3703	524	3	,	,	PUNCT
dpc-3703	524	4	guminski	guminski	X
dpc-3703	524	5	a	a	PRON
dpc-3703	524	6	,	,	PUNCT
dpc-3703	524	7	gutzmer	gutzmer	NOUN
dpc-3703	524	8	r	r	NOUN
dpc-3703	524	9	,	,	PUNCT
dpc-3703	524	10	et	et	PROPN
dpc-3703	524	11	al	al	PROPN
dpc-3703	524	12	.	.	PUNCT
dpc-3703	524	13	treatment	treatment	NOUN
dpc-3703	524	14	with	with	ADP
dpc-3703	524	15	two	two	NUM
dpc-3703	524	16	different	different	ADJ
dpc-3703	524	17	doses	dose	NOUN
dpc-3703	524	18	of	of	ADP
dpc-3703	524	19	sonidegib	sonidegib	NOUN
dpc-3703	524	20	in	in	ADP
dpc-3703	524	21	patients	patient	NOUN
dpc-3703	524	22	with	with	ADP
dpc-3703	524	23	locally	locally	ADV
dpc-3703	524	24	advanced	advanced	ADJ
dpc-3703	524	25	or	or	CCONJ
dpc-3703	524	26	metastatic	metastatic	ADJ
dpc-3703	524	27	basal	basal	NOUN
dpc-3703	524	28	cell	cell	NOUN
dpc-3703	524	29	carcinoma	carcinoma	NOUN
dpc-3703	524	30	(	(	PUNCT
dpc-3703	524	31	bolt	bolt	NOUN
dpc-3703	524	32	):	):	PUNCT
dpc-3703	524	33	a	a	DET
dpc-3703	524	34	multicentre	multicentre	NOUN
dpc-3703	524	35	,	,	PUNCT
dpc-3703	524	36	randomised	randomise	VERB
dpc-3703	524	37	,	,	PUNCT
dpc-3703	524	38	double	double	ADJ
dpc-3703	524	39	-	-	PUNCT
dpc-3703	524	40	blind	blind	ADJ
dpc-3703	524	41	phase	phase	NOUN
dpc-3703	524	42	2	2	NUM
dpc-3703	524	43	trial	trial	NOUN
dpc-3703	524	44	.	.	PUNCT
dpc-3703	525	1	lancet	lancet	PROPN
dpc-3703	525	2	oncol	oncol	PROPN
dpc-3703	525	3	.	.	PUNCT
dpc-3703	526	1	2015;16(6):716	2015;16(6):716	NOUN
dpc-3703	526	2	-	-	SYM
dpc-3703	526	3	728	728	NUM
dpc-3703	526	4	.	.	PUNCT
dpc-3703	527	1	doi	doi	NOUN
dpc-3703	527	2	:	:	PUNCT
dpc-3703	527	3	10.1016	10.1016	NUM
dpc-3703	527	4	/	/	SYM
dpc-3703	527	5	s1470	s1470	PROPN
dpc-3703	527	6	-	-	PUNCT
dpc-3703	527	7	2045(15)70100	2045(15)70100	NUM
dpc-3703	527	8	-	-	PUNCT
dpc-3703	527	9	2	2	NUM
dpc-3703	527	10	.	.	PUNCT
dpc-3703	528	1	pmid	pmid	NOUN
dpc-3703	528	2	:	:	PUNCT
dpc-3703	528	3	25981810	25981810	NUM
dpc-3703	528	4	.	.	PUNCT
dpc-3703	529	1	33	33	NUM
dpc-3703	529	2	.	.	PUNCT
dpc-3703	530	1	dummer	dummer	PROPN
dpc-3703	530	2	r	r	PROPN
dpc-3703	530	3	,	,	PUNCT
dpc-3703	530	4	guminski	guminski	ADJ
dpc-3703	530	5	a	a	PRON
dpc-3703	530	6	,	,	PUNCT
dpc-3703	530	7	gutzmer	gutzmer	NOUN
dpc-3703	530	8	r	r	NOUN
dpc-3703	530	9	,	,	PUNCT
dpc-3703	530	10	et	et	PROPN
dpc-3703	530	11	al	al	PROPN
dpc-3703	530	12	.	.	PUNCT
dpc-3703	531	1	the	the	DET
dpc-3703	531	2	12	12	NUM
dpc-3703	531	3	-	-	PUNCT
dpc-3703	531	4	month	month	NOUN
dpc-3703	531	5	analysis	analysis	NOUN
dpc-3703	531	6	from	from	ADP
dpc-3703	531	7	basal	basal	ADJ
dpc-3703	531	8	cell	cell	NOUN
dpc-3703	531	9	carcinoma	carcinoma	NOUN
dpc-3703	531	10	outcomes	outcome	NOUN
dpc-3703	531	11	with	with	ADP
dpc-3703	531	12	lde225	lde225	PROPN
dpc-3703	531	13	treatment	treatment	NOUN
dpc-3703	531	14	(	(	PUNCT
dpc-3703	531	15	bolt	bolt	NOUN
dpc-3703	531	16	):	):	PUNCT
dpc-3703	531	17	a	a	DET
dpc-3703	531	18	phase	phase	NOUN
dpc-3703	531	19	ii	ii	NOUN
dpc-3703	531	20	,	,	PUNCT
dpc-3703	531	21	randomized	randomize	VERB
dpc-3703	531	22	,	,	PUNCT
dpc-3703	531	23	double	double	ADJ
dpc-3703	531	24	-	-	PUNCT
dpc-3703	531	25	blind	blind	ADJ
dpc-3703	531	26	study	study	NOUN
dpc-3703	531	27	of	of	ADP
dpc-3703	531	28	sonidegib	sonidegib	NOUN
dpc-3703	531	29	in	in	ADP
dpc-3703	531	30	patients	patient	NOUN
dpc-3703	531	31	with	with	ADP
dpc-3703	531	32	advanced	advanced	ADJ
dpc-3703	531	33	basal	basal	NOUN
dpc-3703	531	34	cell	cell	NOUN
dpc-3703	531	35	carcinoma	carcinoma	NOUN
dpc-3703	531	36	.	.	PUNCT
dpc-3703	532	1	j	j	NOUN
dpc-3703	532	2	 	 	SPACE
dpc-3703	532	3	am	be	AUX
dpc-3703	532	4	acad	acad	ADJ
dpc-3703	532	5	dermatol	dermatol	NOUN
dpc-3703	532	6	.	.	PUNCT
dpc-3703	533	1	2016;75(1):113	2016;75(1):113	NUM
dpc-3703	533	2	-	-	SYM
dpc-3703	533	3	125	125	NUM
dpc-3703	533	4	e115	e115	PROPN
dpc-3703	533	5	.	.	PUNCT
dpc-3703	534	1	doi	doi	PROPN
dpc-3703	534	2	:	:	PUNCT
dpc-3703	534	3	10.1016	10.1016	NUM
dpc-3703	534	4	/	/	SYM
dpc-3703	534	5	j	j	PROPN
dpc-3703	534	6	.jaad.2016.02.1226	.jaad.2016.02.1226	PUNCT
dpc-3703	534	7	.	.	PUNCT
dpc-3703	535	1	pmid	pmid	NOUN
dpc-3703	535	2	:	:	PUNCT
dpc-3703	535	3	27067394	27067394	NUM
dpc-3703	535	4	.	.	PUNCT
dpc-3703	536	1	34	34	NUM
dpc-3703	536	2	.	.	PUNCT
dpc-3703	536	3	lear	lear	PROPN
dpc-3703	536	4	jt	jt	PROPN
dpc-3703	536	5	,	,	PUNCT
dpc-3703	536	6	migden	migden	VERB
dpc-3703	536	7	mr	mr	PROPN
dpc-3703	536	8	,	,	PUNCT
dpc-3703	536	9	lewis	lewis	PROPN
dpc-3703	536	10	kd	kd	PROPN
dpc-3703	536	11	,	,	PUNCT
dpc-3703	536	12	et	et	PROPN
dpc-3703	536	13	al	al	PROPN
dpc-3703	536	14	.	.	PUNCT
dpc-3703	537	1	long	long	ADJ
dpc-3703	537	2	-	-	PUNCT
dpc-3703	537	3	term	term	NOUN
dpc-3703	537	4	efficacy	efficacy	NOUN
dpc-3703	537	5	and	and	CCONJ
dpc-3703	537	6	safety	safety	NOUN
dpc-3703	537	7	of	of	ADP
dpc-3703	537	8	sonidegib	sonidegib	NOUN
dpc-3703	537	9	in	in	ADP
dpc-3703	537	10	patients	patient	NOUN
dpc-3703	537	11	with	with	ADP
dpc-3703	537	12	locally	locally	ADV
dpc-3703	537	13	advanced	advanced	ADJ
dpc-3703	537	14	and	and	CCONJ
dpc-3703	537	15	metastatic	metastatic	ADJ
dpc-3703	537	16	basal	basal	NOUN
dpc-3703	537	17	cell	cell	NOUN
dpc-3703	537	18	carcinoma	carcinoma	NOUN
dpc-3703	537	19	:	:	PUNCT
dpc-3703	537	20	30	30	NUM
dpc-3703	537	21	-	-	PUNCT
dpc-3703	537	22	month	month	NOUN
dpc-3703	537	23	analysis	analysis	NOUN
dpc-3703	537	24	of	of	ADP
dpc-3703	537	25	the	the	DET
dpc-3703	537	26	randomized	randomized	ADJ
dpc-3703	537	27	phase	phase	NOUN
dpc-3703	537	28	2	2	NUM
dpc-3703	537	29	bolt	bolt	NOUN
dpc-3703	537	30	study	study	NOUN
dpc-3703	537	31	.	.	PUNCT
dpc-3703	538	1	j	j	PROPN
dpc-3703	538	2	eur	eur	PROPN
dpc-3703	538	3	acad	acad	PROPN
dpc-3703	538	4	dermatol	dermatol	NOUN
dpc-3703	538	5	venereol	venereol	NOUN
dpc-3703	538	6	.	.	PUNCT
dpc-3703	539	1	2018;32(3):372	2018;32(3):372	NUM
dpc-3703	539	2	-	-	SYM
dpc-3703	539	3	381	381	NUM
dpc-3703	539	4	.	.	PUNCT
dpc-3703	539	5	doi	doi	NOUN
dpc-3703	539	6	:	:	PUNCT
dpc-3703	539	7	10.1111	10.1111	NUM
dpc-3703	539	8	/	/	SYM
dpc-3703	539	9	jdv.14542	jdv.14542	NUM
dpc-3703	539	10	.	.	PUNCT
dpc-3703	540	1	pmid	pmid	NOUN
dpc-3703	540	2	:	:	PUNCT
dpc-3703	540	3	28846163	28846163	NUM
dpc-3703	540	4	.	.	PUNCT
dpc-3703	541	1	pmcid	pmcid	NOUN
dpc-3703	541	2	:	:	PUNCT
dpc-3703	541	3	pmc5873455	pmc5873455	ADJ
dpc-3703	541	4	.	.	PUNCT
dpc-3703	542	1	35	35	NUM
dpc-3703	542	2	.	.	PUNCT
dpc-3703	543	1	mannino	mannino	PROPN
dpc-3703	543	2	m	m	PROPN
dpc-3703	543	3	,	,	PUNCT
dpc-3703	543	4	piccerillo	piccerillo	VERB
dpc-3703	543	5	a	a	PRON
dpc-3703	543	6	,	,	PUNCT
dpc-3703	543	7	fabbrocini	fabbrocini	NOUN
dpc-3703	543	8	g	g	NOUN
dpc-3703	543	9	,	,	PUNCT
dpc-3703	543	10	et	et	PROPN
dpc-3703	543	11	al	al	PROPN
dpc-3703	543	12	.	.	PROPN
dpc-3703	544	1	clinical	clinical	ADJ
dpc-3703	544	2	characteristics	characteristic	NOUN
dpc-3703	544	3	of	of	ADP
dpc-3703	544	4	an	an	DET
dpc-3703	544	5	italian	italian	ADJ
dpc-3703	544	6	patient	patient	ADJ
dpc-3703	544	7	population	population	NOUN
dpc-3703	544	8	with	with	ADP
dpc-3703	544	9	advanced	advanced	ADJ
dpc-3703	544	10	bcc	bcc	PROPN
dpc-3703	544	11	and	and	CCONJ
dpc-3703	544	12	real	real	ADJ
dpc-3703	544	13	-	-	PUNCT
dpc-3703	544	14	life	life	NOUN
dpc-3703	544	15	evaluation	evaluation	NOUN
dpc-3703	544	16	of	of	ADP
dpc-3703	544	17	hhi	hhi	NOUN
dpc-3703	544	18	safety	safety	NOUN
dpc-3703	544	19	and	and	CCONJ
dpc-3703	544	20	effectiveness	effectiveness	NOUN
dpc-3703	544	21	.	.	PUNCT
dpc-3703	545	1	dermatology	dermatology	NOUN
dpc-3703	545	2	.	.	PUNCT
dpc-3703	546	1	2023	2023	NUM
dpc-3703	546	2	.	.	PUNCT
dpc-3703	547	1	doi	doi	NOUN
dpc-3703	547	2	:	:	PUNCT
dpc-3703	547	3	10.1159/000531280	10.1159/000531280	NUM
dpc-3703	547	4	.	.	PUNCT
dpc-3703	548	1	pmid	pmid	NOUN
dpc-3703	548	2	:	:	PUNCT
dpc-3703	548	3	37311439	37311439	NUM
dpc-3703	548	4	.	.	PUNCT
dpc-3703	549	1	36	36	NUM
dpc-3703	549	2	.	.	PUNCT
dpc-3703	550	1	atwood	atwood	PROPN
dpc-3703	550	2	sx	sx	PROPN
dpc-3703	550	3	,	,	PUNCT
dpc-3703	550	4	sarin	sarin	PROPN
dpc-3703	550	5	ky	ky	PROPN
dpc-3703	550	6	,	,	PUNCT
dpc-3703	550	7	whitson	whitson	PROPN
dpc-3703	550	8	rj	rj	PROPN
dpc-3703	550	9	,	,	PUNCT
dpc-3703	550	10	et	et	PROPN
dpc-3703	550	11	al	al	PROPN
dpc-3703	550	12	.	.	PROPN
dpc-3703	550	13	smoothened	smoothen	VERB
dpc-3703	550	14	variants	variant	NOUN
dpc-3703	550	15	explain	explain	VERB
dpc-3703	550	16	the	the	DET
dpc-3703	550	17	majority	majority	NOUN
dpc-3703	550	18	of	of	ADP
dpc-3703	550	19	drug	drug	NOUN
dpc-3703	550	20	resistance	resistance	NOUN
dpc-3703	550	21	in	in	ADP
dpc-3703	550	22	basal	basal	ADJ
dpc-3703	550	23	cell	cell	NOUN
dpc-3703	550	24	carcinoma	carcinoma	NOUN
dpc-3703	550	25	.	.	PUNCT
dpc-3703	551	1	cancer	cancer	NOUN
dpc-3703	551	2	cell	cell	NOUN
dpc-3703	551	3	.	.	PUNCT
dpc-3703	552	1	2015;27(3):342	2015;27(3):342	NUM
dpc-3703	552	2	-	-	PUNCT
dpc-3703	552	3	353	353	NUM
dpc-3703	552	4	.	.	PUNCT
dpc-3703	553	1	doi	doi	NOUN
dpc-3703	553	2	:	:	PUNCT
dpc-3703	553	3	10.1016	10.1016	NUM
dpc-3703	553	4	/	/	SYM
dpc-3703	553	5	j	j	PROPN
dpc-3703	553	6	.ccell.2015.02.002	.ccell.2015.02.002	PUNCT
dpc-3703	553	7	.	.	PUNCT
dpc-3703	554	1	pmid	pmid	NOUN
dpc-3703	554	2	:	:	PUNCT
dpc-3703	554	3	25759020	25759020	NUM
dpc-3703	554	4	.	.	PUNCT
dpc-3703	555	1	pmcid	pmcid	NOUN
dpc-3703	555	2	:	:	PUNCT
dpc-3703	555	3	pmc4357167	pmc4357167	NOUN
dpc-3703	555	4	.	.	PUNCT
dpc-3703	556	1	37	37	NUM
dpc-3703	556	2	.	.	PUNCT
dpc-3703	557	1	sharpe	sharpe	PROPN
dpc-3703	557	2	hj	hj	PROPN
dpc-3703	557	3	,	,	PUNCT
dpc-3703	557	4	pau	pau	PROPN
dpc-3703	557	5	g	g	PROPN
dpc-3703	557	6	,	,	PUNCT
dpc-3703	557	7	dijkgraaf	dijkgraaf	PROPN
dpc-3703	557	8	gj	gj	PROPN
dpc-3703	557	9	,	,	PUNCT
dpc-3703	557	10	et	et	PROPN
dpc-3703	557	11	al	al	PROPN
dpc-3703	557	12	.	.	PUNCT
dpc-3703	558	1	genomic	genomic	ADJ
dpc-3703	558	2	analysis	analysis	NOUN
dpc-3703	558	3	of	of	ADP
dpc-3703	558	4	smoothened	smoothen	VERB
dpc-3703	558	5	inhibitor	inhibitor	NOUN
dpc-3703	558	6	resistance	resistance	NOUN
dpc-3703	558	7	in	in	ADP
dpc-3703	558	8	basal	basal	ADJ
dpc-3703	558	9	cell	cell	NOUN
dpc-3703	558	10	carcinoma	carcinoma	NOUN
dpc-3703	558	11	.	.	PUNCT
dpc-3703	559	1	cancer	cancer	NOUN
dpc-3703	559	2	cell	cell	NOUN
dpc-3703	559	3	.	.	PUNCT
dpc-3703	560	1	2015;27(3):327	2015;27(3):327	NUM
dpc-3703	560	2	-	-	SYM
dpc-3703	560	3	341	341	NUM
dpc-3703	560	4	.	.	PUNCT
dpc-3703	561	1	doi	doi	NOUN
dpc-3703	561	2	:	:	PUNCT
dpc-3703	561	3	10.1016	10.1016	NUM
dpc-3703	561	4	/	/	SYM
dpc-3703	561	5	j.ccell.2015.02.001	j.ccell.2015.02.001	PROPN
dpc-3703	561	6	.	.	PUNCT
dpc-3703	562	1	pmid	pmid	NOUN
dpc-3703	562	2	:	:	PUNCT
dpc-3703	562	3	25759019	25759019	NUM
dpc-3703	562	4	.	.	PUNCT
dpc-3703	563	1	pmcid	pmcid	NOUN
dpc-3703	563	2	:	:	PUNCT
dpc-3703	563	3	pmc5675004	pmc5675004	NOUN
dpc-3703	563	4	.	.	PUNCT
dpc-3703	564	1	38	38	NUM
dpc-3703	564	2	.	.	PUNCT
dpc-3703	565	1	danial	danial	PROPN
dpc-3703	565	2	c	c	PROPN
dpc-3703	565	3	,	,	PUNCT
dpc-3703	565	4	sarin	sarin	PROPN
dpc-3703	565	5	ky	ky	PROPN
dpc-3703	565	6	,	,	PUNCT
dpc-3703	565	7	oro	oro	PROPN
dpc-3703	565	8	ae	ae	PROPN
dpc-3703	565	9	,	,	PUNCT
dpc-3703	565	10	chang	chang	PROPN
dpc-3703	565	11	al	al	PROPN
dpc-3703	565	12	.	.	PUNCT
dpc-3703	566	1	an	an	DET
dpc-3703	566	2	investigator	investigator	NOUN
dpc-3703	566	3	initiated	initiate	VERB
dpc-3703	566	4	open	open	ADJ
dpc-3703	566	5	-	-	PUNCT
dpc-3703	566	6	label	label	NOUN
dpc-3703	566	7	trial	trial	NOUN
dpc-3703	566	8	of	of	ADP
dpc-3703	566	9	sonidegib	sonidegib	NOUN
dpc-3703	566	10	in	in	ADP
dpc-3703	566	11	advanced	advanced	ADJ
dpc-3703	566	12	basal	basal	NOUN
dpc-3703	566	13	cell	cell	NOUN
dpc-3703	566	14	carcinoma	carcinoma	NOUN
dpc-3703	566	15	patients	patient	NOUN
dpc-3703	566	16	resistant	resistant	ADJ
dpc-3703	566	17	to	to	ADP
dpc-3703	566	18	vismodegib	vismodegib	PROPN
dpc-3703	566	19	.	.	PUNCT
dpc-3703	567	1	clin	clin	PROPN
dpc-3703	567	2	cancer	cancer	NOUN
dpc-3703	567	3	res	re	NOUN
dpc-3703	567	4	.	.	PUNCT
dpc-3703	568	1	2016;22(6):1325	2016;22(6):1325	PROPN
dpc-3703	568	2	-	-	SYM
dpc-3703	568	3	1329	1329	NUM
dpc-3703	568	4	.	.	PUNCT
dpc-3703	569	1	doi	doi	NOUN
dpc-3703	569	2	:	:	PUNCT
dpc-3703	569	3	10.1158/1078	10.1158/1078	NUM
dpc-3703	569	4	-	-	SYM
dpc-3703	569	5	0432.ccr-15	0432.ccr-15	NUM
dpc-3703	569	6	-1588	-1588	NOUN
dpc-3703	569	7	.	.	PUNCT
dpc-3703	570	1	pmid	pmid	NOUN
dpc-3703	570	2	:	:	PUNCT
dpc-3703	570	3	26546616	26546616	NUM
dpc-3703	570	4	.	.	PUNCT
dpc-3703	571	1	pmcid	pmcid	ADJ
dpc-3703	571	2	:	:	PUNCT
dpc-3703	571	3	pmc4794361	pmc4794361	NOUN
dpc-3703	571	4	.	.	PUNCT
dpc-3703	572	1	39	39	NUM
dpc-3703	572	2	.	.	PUNCT
dpc-3703	573	1	doan	doan	PROPN
dpc-3703	573	2	hq	hq	PROPN
dpc-3703	573	3	,	,	PUNCT
dpc-3703	573	4	chen	chen	PROPN
dpc-3703	573	5	l	l	PROPN
dpc-3703	573	6	,	,	PUNCT
dpc-3703	573	7	nawas	nawas	PROPN
dpc-3703	573	8	z	z	PROPN
dpc-3703	573	9	,	,	PUNCT
dpc-3703	573	10	lee	lee	PROPN
dpc-3703	573	11	hh	hh	PROPN
dpc-3703	573	12	,	,	PUNCT
dpc-3703	573	13	silapunt	silapunt	PROPN
dpc-3703	573	14	s	s	PROPN
dpc-3703	573	15	,	,	PUNCT
dpc-3703	573	16	migden	migden	ADJ
dpc-3703	573	17	m.	m.	NOUN
dpc-3703	573	18	switching	switch	VERB
dpc-3703	573	19	hedgehog	hedgehog	NOUN
dpc-3703	573	20	inhibitors	inhibitor	NOUN
dpc-3703	573	21	and	and	CCONJ
dpc-3703	573	22	other	other	ADJ
dpc-3703	573	23	strategies	strategy	NOUN
dpc-3703	573	24	to	to	PART
dpc-3703	573	25	address	address	VERB
dpc-3703	573	26	resistance	resistance	NOUN
dpc-3703	573	27	when	when	SCONJ
dpc-3703	573	28	treating	treat	VERB
dpc-3703	573	29	advanced	advanced	ADJ
dpc-3703	573	30	basal	basal	ADJ
dpc-3703	573	31	cell	cell	NOUN
dpc-3703	573	32	carcinoma	carcinoma	NOUN
dpc-3703	573	33	.	.	PUNCT
dpc-3703	574	1	oncotarget	oncotarget	NOUN
dpc-3703	574	2	.	.	PUNCT
dpc-3703	575	1	2021;12(20):2089	2021;12(20):2089	NUM
dpc-3703	575	2	-	-	SYM
dpc-3703	575	3	2100	2100	NUM
dpc-3703	575	4	.	.	PUNCT
dpc-3703	576	1	doi	doi	NOUN
dpc-3703	576	2	:	:	PUNCT
dpc-3703	576	3	10.18632	10.18632	NUM
dpc-3703	576	4	/	/	SYM
dpc-3703	576	5	oncotarget.28080	oncotarget.28080	PROPN
dpc-3703	576	6	.	.	PUNCT
dpc-3703	576	7	pmid	pmid	NOUN
dpc-3703	576	8	:	:	PUNCT
dpc-3703	576	9	34611482	34611482	NUM
dpc-3703	576	10	.	.	PUNCT
dpc-3703	577	1	pmcid	pmcid	NOUN
dpc-3703	577	2	:	:	PUNCT
dpc-3703	577	3	pmc8487719	pmc8487719	NOUN
dpc-3703	577	4	.	.	PUNCT
dpc-3703	578	1	40	40	NUM
dpc-3703	578	2	.	.	PUNCT
dpc-3703	579	1	herms	herm	NOUN
dpc-3703	579	2	f	f	PROPN
dpc-3703	579	3	,	,	PUNCT
dpc-3703	579	4	lambert	lambert	PROPN
dpc-3703	579	5	j	j	PROPN
dpc-3703	579	6	,	,	PUNCT
dpc-3703	579	7	grob	grob	PROPN
dpc-3703	579	8	jj	jj	PROPN
dpc-3703	579	9	,	,	PUNCT
dpc-3703	579	10	et	et	PROPN
dpc-3703	579	11	al	al	PROPN
dpc-3703	579	12	.	.	PUNCT
dpc-3703	579	13	follow	follow	PROPN
dpc-3703	579	14	-	-	PUNCT
dpc-3703	579	15	up	up	NOUN
dpc-3703	579	16	of	of	ADP
dpc-3703	579	17	patients	patient	NOUN
dpc-3703	579	18	with	with	ADP
dpc-3703	579	19	complete	complete	ADJ
dpc-3703	579	20	remission	remission	NOUN
dpc-3703	579	21	of	of	ADP
dpc-3703	579	22	locally	locally	ADV
dpc-3703	579	23	advanced	advance	VERB
dpc-3703	579	24	basal	basal	NOUN
dpc-3703	579	25	cell	cell	NOUN
dpc-3703	579	26	carcinoma	carcinoma	NOUN
dpc-3703	579	27	after	after	ADP
dpc-3703	579	28	vismodegib	vismodegib	PROPN
dpc-3703	579	29	discontinuation	discontinuation	NOUN
dpc-3703	579	30	:	:	PUNCT
dpc-3703	579	31	a	a	DET
dpc-3703	579	32	multicenter	multicenter	ADJ
dpc-3703	579	33	french	french	ADJ
dpc-3703	579	34	study	study	NOUN
dpc-3703	579	35	review	review	NOUN
dpc-3703	579	36	|	|	ADV
dpc-3703	579	37	dermatol	dermatol	ADJ
dpc-3703	579	38	pract	pract	NOUN
dpc-3703	579	39	concept	concept	NOUN
dpc-3703	579	40	.	.	PUNCT
dpc-3703	580	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	580	2	11	11	NUM
dpc-3703	580	3	2021;22(6):848	2021;22(6):848	NUM
dpc-3703	580	4	-	-	PUNCT
dpc-3703	580	5	857	857	NUM
dpc-3703	580	6	.	.	PUNCT
dpc-3703	581	1	doi	doi	NOUN
dpc-3703	581	2	:	:	PUNCT
dpc-3703	581	3	10.1016	10.1016	NUM
dpc-3703	581	4	/	/	SYM
dpc-3703	581	5	s1470	s1470	PROPN
dpc-3703	581	6	-	-	PUNCT
dpc-3703	581	7	2045(21)00126	2045(21)00126	NUM
dpc-3703	581	8	-	-	PUNCT
dpc-3703	581	9	1	1	NUM
dpc-3703	581	10	.	.	PUNCT
dpc-3703	582	1	pmid	pmid	NOUN
dpc-3703	582	2	:	:	PUNCT
dpc-3703	582	3	34000246	34000246	NUM
dpc-3703	582	4	.	.	PUNCT
dpc-3703	583	1	66	66	NUM
dpc-3703	583	2	.	.	PUNCT
dpc-3703	584	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	584	2	.	.	PUNCT
dpc-3703	584	3	pd-1	pd-1	VERB
dpc-3703	584	4	in	in	ADP
dpc-3703	584	5	patients	patient	NOUN
dpc-3703	584	6	with	with	ADP
dpc-3703	584	7	advanced	advanced	ADJ
dpc-3703	584	8	basal	basal	NOUN
dpc-3703	584	9	cell	cell	NOUN
dpc-3703	584	10	carcinoma	carcinoma	NOUN
dpc-3703	584	11	who	who	PRON
dpc-3703	584	12	experienced	experience	VERB
dpc-3703	584	13	progression	progression	NOUN
dpc-3703	584	14	of	of	ADP
dpc-3703	584	15	disease	disease	NOUN
dpc-3703	584	16	on	on	ADP
dpc-3703	584	17	hedgehog	hedgehog	NOUN
dpc-3703	584	18	pathway	pathway	NOUN
dpc-3703	584	19	inhibitor	inhibitor	NOUN
dpc-3703	584	20	therapy	therapy	NOUN
dpc-3703	584	21	,	,	PUNCT
dpc-3703	584	22	or	or	CCONJ
dpc-3703	584	23	were	be	AUX
dpc-3703	584	24	intolerant	intolerant	ADJ
dpc-3703	584	25	of	of	ADP
dpc-3703	584	26	prior	prior	ADJ
dpc-3703	584	27	hedgehog	hedgehog	NOUN
dpc-3703	584	28	pathway	pathway	NOUN
dpc-3703	584	29	inhibitor	inhibitor	NOUN
dpc-3703	584	30	therapy	therapy	NOUN
dpc-3703	584	31	.	.	PUNCT
dpc-3703	585	1	2022	2022	NUM
dpc-3703	585	2	;	;	PUNCT
dpc-3703	585	3	available	available	ADJ
dpc-3703	585	4	from	from	ADP
dpc-3703	585	5	:	:	PUNCT
dpc-3703	585	6	https://clinicaltrials.gov/ct2/show/nct03132636	https://clinicaltrials.gov/ct2/show/nct03132636	NOUN
dpc-3703	585	7	.	.	PUNCT
dpc-3703	586	1	accessed	access	VERB
dpc-3703	586	2	march	march	PROPN
dpc-3703	586	3	3	3	NUM
dpc-3703	586	4	,	,	PUNCT
dpc-3703	586	5	2023	2023	NUM
dpc-3703	586	6	.	.	PUNCT
dpc-3703	587	1	67	67	NUM
dpc-3703	587	2	.	.	PUNCT
dpc-3703	588	1	veron	veron	PROPN
dpc-3703	588	2	m	m	PROPN
dpc-3703	588	3	,	,	PUNCT
dpc-3703	588	4	chevret	chevret	VERB
dpc-3703	588	5	s	s	PROPN
dpc-3703	588	6	,	,	PUNCT
dpc-3703	588	7	grob	grob	PROPN
dpc-3703	588	8	jj	jj	PROPN
dpc-3703	588	9	,	,	PUNCT
dpc-3703	588	10	et	et	PROPN
dpc-3703	588	11	al	al	PROPN
dpc-3703	588	12	.	.	PROPN
dpc-3703	588	13	safety	safety	NOUN
dpc-3703	588	14	and	and	CCONJ
dpc-3703	588	15	efficacy	efficacy	NOUN
dpc-3703	588	16	of	of	ADP
dpc-3703	588	17	nivolumab	nivolumab	NOUN
dpc-3703	588	18	,	,	PUNCT
dpc-3703	588	19	an	an	DET
dpc-3703	588	20	anti	anti	ADJ
dpc-3703	588	21	-	-	ADJ
dpc-3703	588	22	pd1	pd1	VERB
dpc-3703	588	23	immunotherapy	immunotherapy	NOUN
dpc-3703	588	24	,	,	PUNCT
dpc-3703	588	25	in	in	ADP
dpc-3703	588	26	patients	patient	NOUN
dpc-3703	588	27	with	with	ADP
dpc-3703	588	28	advanced	advanced	ADJ
dpc-3703	588	29	basal	basal	NOUN
dpc-3703	588	30	cell	cell	NOUN
dpc-3703	588	31	carcinoma	carcinoma	NOUN
dpc-3703	588	32	,	,	PUNCT
dpc-3703	588	33	after	after	ADP
dpc-3703	588	34	failure	failure	NOUN
dpc-3703	588	35	or	or	CCONJ
dpc-3703	588	36	intolerance	intolerance	NOUN
dpc-3703	588	37	to	to	ADP
dpc-3703	588	38	sonic	sonic	ADJ
dpc-3703	588	39	hedgehog	hedgehog	ADJ
dpc-3703	588	40	inhibitors	inhibitor	NOUN
dpc-3703	588	41	:	:	PUNCT
dpc-3703	588	42	unicancer	unicancer	ADJ
dpc-3703	588	43	acse	acse	NOUN
dpc-3703	588	44	nivolumab	nivolumab	NOUN
dpc-3703	588	45	trial	trial	NOUN
dpc-3703	588	46	.	.	PUNCT
dpc-3703	589	1	eur	eur	PROPN
dpc-3703	589	2	j	j	PROPN
dpc-3703	589	3	cancer	cancer	NOUN
dpc-3703	589	4	.	.	PUNCT
dpc-3703	590	1	2022;177:103	2022;177:103	NUM
dpc-3703	590	2	-	-	SYM
dpc-3703	590	3	111	111	NUM
dpc-3703	590	4	.	.	PUNCT
dpc-3703	591	1	doi	doi	NOUN
dpc-3703	591	2	:	:	PUNCT
dpc-3703	591	3	10.1016	10.1016	NUM
dpc-3703	591	4	/	/	SYM
dpc-3703	591	5	j.	j.	PROPN
dpc-3703	591	6	ejca.2022.09.013	ejca.2022.09.013	PROPN
dpc-3703	591	7	.	.	PUNCT
dpc-3703	592	1	pmid	pmid	PROPN
dpc-3703	592	2	:	:	PUNCT
dpc-3703	592	3	36335780	36335780	NUM
dpc-3703	592	4	.	.	PUNCT
dpc-3703	593	1	68	68	NUM
dpc-3703	593	2	.	.	PUNCT
dpc-3703	594	1	bertrand	bertrand	PROPN
dpc-3703	594	2	n	n	CCONJ
dpc-3703	594	3	,	,	PUNCT
dpc-3703	594	4	guerreschi	guerreschi	NOUN
dpc-3703	594	5	p	p	NOUN
dpc-3703	594	6	,	,	PUNCT
dpc-3703	594	7	basset	basset	NOUN
dpc-3703	594	8	-	-	PUNCT
dpc-3703	594	9	seguin	seguin	NOUN
dpc-3703	594	10	n	n	CCONJ
dpc-3703	594	11	,	,	PUNCT
dpc-3703	594	12	et	et	PROPN
dpc-3703	594	13	al	al	PROPN
dpc-3703	594	14	.	.	PROPN
dpc-3703	594	15	vismodegib	vismodegib	PROPN
dpc-3703	594	16	in	in	ADP
dpc-3703	594	17	neoadjuvant	neoadjuvant	ADJ
dpc-3703	594	18	treatment	treatment	NOUN
dpc-3703	594	19	of	of	ADP
dpc-3703	594	20	locally	locally	ADV
dpc-3703	594	21	advanced	advance	VERB
dpc-3703	594	22	basal	basal	NOUN
dpc-3703	594	23	cell	cell	NOUN
dpc-3703	594	24	carcinoma	carcinoma	NOUN
dpc-3703	594	25	:	:	PUNCT
dpc-3703	594	26	first	first	ADJ
dpc-3703	594	27	results	result	NOUN
dpc-3703	594	28	of	of	ADP
dpc-3703	594	29	a	a	DET
dpc-3703	594	30	multicenter	multicenter	NOUN
dpc-3703	594	31	,	,	PUNCT
dpc-3703	594	32	open	open	ADJ
dpc-3703	594	33	-	-	PUNCT
dpc-3703	594	34	label	label	NOUN
dpc-3703	594	35	,	,	PUNCT
dpc-3703	594	36	phase	phase	NOUN
dpc-3703	594	37	2	2	NUM
dpc-3703	594	38	trial	trial	NOUN
dpc-3703	594	39	(	(	PUNCT
dpc-3703	594	40	vismoneo	vismoneo	NOUN
dpc-3703	594	41	study	study	VERB
dpc-3703	594	42	):	):	PUNCT
dpc-3703	594	43	neoadjuvant	neoadjuvant	ADJ
dpc-3703	594	44	vismodegib	vismodegib	NOUN
dpc-3703	594	45	in	in	ADP
dpc-3703	594	46	locally	locally	ADV
dpc-3703	594	47	advanced	advance	VERB
dpc-3703	594	48	basal	basal	NOUN
dpc-3703	594	49	cell	cell	NOUN
dpc-3703	594	50	carcinoma	carcinoma	NOUN
dpc-3703	594	51	.	.	PUNCT
dpc-3703	595	1	eclinicalmedicine	eclinicalmedicine	NOUN
dpc-3703	595	2	.	.	PUNCT
dpc-3703	596	1	2021;35:100844	2021;35:100844	NUM
dpc-3703	596	2	.	.	PUNCT
dpc-3703	596	3	doi	doi	PROPN
dpc-3703	596	4	:	:	PUNCT
dpc-3703	596	5	10.1016	10.1016	NUM
dpc-3703	596	6	/	/	SYM
dpc-3703	596	7	j.eclinm.2021.100844	j.eclinm.2021.100844	NOUN
dpc-3703	596	8	.	.	PUNCT
dpc-3703	597	1	pmid	pmid	NOUN
dpc-3703	597	2	:	:	PUNCT
dpc-3703	597	3	33997740	33997740	NUM
dpc-3703	597	4	.	.	PUNCT
dpc-3703	598	1	pmcid	pmcid	NOUN
dpc-3703	598	2	:	:	PUNCT
dpc-3703	598	3	pmc8093898	pmc8093898	PROPN
dpc-3703	598	4	.	.	PUNCT
dpc-3703	599	1	69	69	NUM
dpc-3703	599	2	.	.	PUNCT
dpc-3703	600	1	garbe	garbe	PROPN
dpc-3703	600	2	c	c	PROPN
dpc-3703	600	3	,	,	PUNCT
dpc-3703	600	4	dummer	dummer	PROPN
dpc-3703	600	5	r	r	PROPN
dpc-3703	600	6	,	,	PUNCT
dpc-3703	600	7	amaral	amaral	PROPN
dpc-3703	600	8	t	t	PROPN
dpc-3703	600	9	,	,	PUNCT
dpc-3703	600	10	et	et	PROPN
dpc-3703	600	11	al	al	PROPN
dpc-3703	600	12	.	.	PROPN
dpc-3703	600	13	neoadjuvant	neoadjuvant	ADJ
dpc-3703	600	14	immunotherapy	immunotherapy	NOUN
dpc-3703	600	15	for	for	ADP
dpc-3703	600	16	melanoma	melanoma	NOUN
dpc-3703	600	17	is	be	AUX
dpc-3703	600	18	now	now	ADV
dpc-3703	600	19	ready	ready	ADJ
dpc-3703	600	20	for	for	ADP
dpc-3703	600	21	clinical	clinical	ADJ
dpc-3703	600	22	practice	practice	NOUN
dpc-3703	600	23	.	.	PUNCT
dpc-3703	601	1	nat	nat	PROPN
dpc-3703	601	2	med	med	PROPN
dpc-3703	601	3	.	.	PUNCT
dpc-3703	602	1	2023;29(6):1310	2023;29(6):1310	NUM
dpc-3703	602	2	-	-	SYM
dpc-3703	602	3	1312	1312	NUM
dpc-3703	602	4	.	.	PUNCT
dpc-3703	603	1	doi	doi	NOUN
dpc-3703	603	2	:	:	PUNCT
dpc-3703	603	3	10.1038	10.1038	NUM
dpc-3703	603	4	/	/	SYM
dpc-3703	603	5	s41591	s41591	VERB
dpc-3703	603	6	-	-	PUNCT
dpc-3703	603	7	023	023	NUM
dpc-3703	603	8	-	-	PUNCT
dpc-3703	603	9	02336	02336	NUM
dpc-3703	603	10	-	-	PUNCT
dpc-3703	603	11	1	1	NUM
dpc-3703	603	12	.	.	PUNCT
dpc-3703	604	1	pmid	pmid	NOUN
dpc-3703	604	2	:	:	PUNCT
dpc-3703	604	3	37193799	37193799	NUM
dpc-3703	604	4	.	.	PUNCT
dpc-3703	605	1	70	70	NUM
dpc-3703	605	2	.	.	X
dpc-3703	606	1	patel	patel	PROPN
dpc-3703	606	2	sp	sp	PROPN
dpc-3703	606	3	,	,	PUNCT
dpc-3703	606	4	othus	othus	PROPN
dpc-3703	606	5	m	m	PROPN
dpc-3703	606	6	,	,	PUNCT
dpc-3703	606	7	chen	chen	PROPN
dpc-3703	606	8	y	y	PROPN
dpc-3703	606	9	,	,	PUNCT
dpc-3703	606	10	et	et	PROPN
dpc-3703	606	11	al	al	PROPN
dpc-3703	606	12	.	.	PROPN
dpc-3703	606	13	neoadjuvant	neoadjuvant	ADJ
dpc-3703	606	14	-	-	PUNCT
dpc-3703	606	15	adjuvant	adjuvant	ADJ
dpc-3703	606	16	or	or	CCONJ
dpc-3703	606	17	adjuvant	adjuvant	NOUN
dpc-3703	606	18	-	-	PUNCT
dpc-3703	606	19	only	only	ADV
dpc-3703	606	20	pembrolizumab	pembrolizumab	NOUN
dpc-3703	606	21	in	in	ADP
dpc-3703	606	22	advanced	advanced	ADJ
dpc-3703	606	23	melanoma	melanoma	NOUN
dpc-3703	606	24	.	.	PUNCT
dpc-3703	607	1	n	n	PRON
dpc-3703	607	2	engl	engl	PROPN
dpc-3703	607	3	j	j	PROPN
dpc-3703	607	4	med	med	PROPN
dpc-3703	607	5	.	.	PUNCT
dpc-3703	608	1	2023;388(9):813	2023;388(9):813	NUM
dpc-3703	608	2	-	-	SYM
dpc-3703	608	3	823	823	NUM
dpc-3703	608	4	.	.	PUNCT
dpc-3703	609	1	doi	doi	NOUN
dpc-3703	609	2	:	:	PUNCT
dpc-3703	609	3	10.1056	10.1056	NUM
dpc-3703	609	4	/	/	SYM
dpc-3703	609	5	nejmoa2211437	nejmoa2211437	PROPN
dpc-3703	609	6	.	.	PUNCT
dpc-3703	610	1	pmid	pmid	NOUN
dpc-3703	610	2	:	:	PUNCT
dpc-3703	610	3	36856617	36856617	NUM
dpc-3703	610	4	.	.	PUNCT
dpc-3703	611	1	pmcid	pmcid	NOUN
dpc-3703	611	2	:	:	PUNCT
dpc-3703	611	3	pmc10410527	pmc10410527	NOUN
dpc-3703	611	4	.	.	PUNCT
dpc-3703	612	1	71	71	NUM
dpc-3703	612	2	.	.	PUNCT
dpc-3703	613	1	reijers	reijers	PROPN
dpc-3703	613	2	ilm	ilm	PROPN
dpc-3703	613	3	,	,	PUNCT
dpc-3703	613	4	menzies	menzies	PROPN
dpc-3703	613	5	am	be	AUX
dpc-3703	613	6	,	,	PUNCT
dpc-3703	613	7	van	van	PROPN
dpc-3703	613	8	akkooi	akkooi	PROPN
dpc-3703	613	9	acj	acj	PROPN
dpc-3703	613	10	,	,	PUNCT
dpc-3703	613	11	et	et	PROPN
dpc-3703	613	12	al	al	PROPN
dpc-3703	613	13	.	.	PROPN
dpc-3703	614	1	personalized	personalized	ADJ
dpc-3703	614	2	response	response	NOUN
dpc-3703	614	3	-	-	PUNCT
dpc-3703	614	4	directed	direct	VERB
dpc-3703	614	5	surgery	surgery	NOUN
dpc-3703	614	6	and	and	CCONJ
dpc-3703	614	7	adjuvant	adjuvant	ADJ
dpc-3703	614	8	therapy	therapy	NOUN
dpc-3703	614	9	after	after	ADP
dpc-3703	614	10	neoadjuvant	neoadjuvant	ADJ
dpc-3703	614	11	ipilimumab	ipilimumab	NOUN
dpc-3703	614	12	and	and	CCONJ
dpc-3703	614	13	nivolumab	nivolumab	NOUN
dpc-3703	614	14	in	in	ADP
dpc-3703	614	15	high	high	ADJ
dpc-3703	614	16	-	-	PUNCT
dpc-3703	614	17	risk	risk	NOUN
dpc-3703	614	18	stage	stage	NOUN
dpc-3703	614	19	iii	iii	NUM
dpc-3703	614	20	melanoma	melanoma	NOUN
dpc-3703	614	21	:	:	PUNCT
dpc-3703	614	22	the	the	DET
dpc-3703	614	23	prado	prado	PROPN
dpc-3703	614	24	trial	trial	NOUN
dpc-3703	614	25	.	.	PUNCT
dpc-3703	615	1	nat	nat	PROPN
dpc-3703	615	2	med	me	VERB
dpc-3703	615	3	.	.	PUNCT
dpc-3703	616	1	2022;28(6):1178	2022;28(6):1178	NUM
dpc-3703	616	2	-	-	SYM
dpc-3703	616	3	1188	1188	NUM
dpc-3703	616	4	.	.	PUNCT
dpc-3703	617	1	doi	doi	NOUN
dpc-3703	617	2	:	:	PUNCT
dpc-3703	617	3	10.1038	10.1038	NUM
dpc-3703	617	4	/	/	SYM
dpc-3703	617	5	s41591	s41591	VERB
dpc-3703	617	6	-	-	PUNCT
dpc-3703	617	7	022	022	NUM
dpc-3703	617	8	-	-	PUNCT
dpc-3703	617	9	01851	01851	NUM
dpc-3703	617	10	-	-	PUNCT
dpc-3703	617	11	x.	x.	NOUN
dpc-3703	617	12	pmid	pmid	PROPN
dpc-3703	617	13	:	:	PUNCT
dpc-3703	617	14	35661157	35661157	NUM
dpc-3703	617	15	.	.	PUNCT
dpc-3703	618	1	72	72	NUM
dpc-3703	618	2	.	.	PUNCT
dpc-3703	619	1	gross	gross	PROPN
dpc-3703	619	2	nd	nd	PROPN
dpc-3703	619	3	,	,	PUNCT
dpc-3703	619	4	miller	miller	PROPN
dpc-3703	619	5	dm	dm	PROPN
dpc-3703	619	6	,	,	PUNCT
dpc-3703	619	7	khushalani	khushalani	PROPN
dpc-3703	619	8	ni	ni	PROPN
dpc-3703	619	9	,	,	PUNCT
dpc-3703	619	10	et	et	PROPN
dpc-3703	619	11	al	al	PROPN
dpc-3703	619	12	.	.	PROPN
dpc-3703	620	1	neoadjuvant	neoadjuvant	ADJ
dpc-3703	620	2	cemiplimab	cemiplimab	NOUN
dpc-3703	620	3	for	for	ADP
dpc-3703	620	4	stage	stage	NOUN
dpc-3703	620	5	ii	ii	PROPN
dpc-3703	620	6	to	to	AUX
dpc-3703	620	7	iv	iv	NUM
dpc-3703	620	8	cutaneous	cutaneous	ADJ
dpc-3703	620	9	squamous	squamous	ADJ
dpc-3703	620	10	-	-	PUNCT
dpc-3703	620	11	cell	cell	NOUN
dpc-3703	620	12	carcinoma	carcinoma	NOUN
dpc-3703	620	13	.	.	PUNCT
dpc-3703	621	1	n	n	PRON
dpc-3703	621	2	engl	engl	PROPN
dpc-3703	621	3	j	j	PROPN
dpc-3703	621	4	med	med	PROPN
dpc-3703	621	5	.	.	PUNCT
dpc-3703	622	1	2022;387(17):1557	2022;387(17):1557	X
dpc-3703	622	2	-	-	SYM
dpc-3703	622	3	1568	1568	NUM
dpc-3703	622	4	.	.	PUNCT
dpc-3703	623	1	doi	doi	NOUN
dpc-3703	623	2	:	:	PUNCT
dpc-3703	623	3	10.1056	10.1056	NUM
dpc-3703	623	4	/	/	SYM
dpc-3703	623	5	nejmoa2209813	nejmoa2209813	PROPN
dpc-3703	623	6	.	.	PUNCT
dpc-3703	624	1	pmid	pmid	NOUN
dpc-3703	624	2	:	:	PUNCT
dpc-3703	624	3	36094839	36094839	NUM
dpc-3703	624	4	.	.	PUNCT
dpc-3703	625	1	pmcid	pmcid	NOUN
dpc-3703	625	2	:	:	PUNCT
dpc-3703	625	3	pmc9844515	pmc9844515	NOUN
dpc-3703	625	4	.	.	PUNCT
dpc-3703	626	1	73	73	NUM
dpc-3703	626	2	.	.	PUNCT
dpc-3703	627	1	schmults	schmult	NOUN
dpc-3703	627	2	c	c	VERB
dpc-3703	627	3	,	,	PUNCT
dpc-3703	627	4	blitzblau	blitzblau	NOUN
dpc-3703	627	5	r	r	NOUN
dpc-3703	627	6	,	,	PUNCT
dpc-3703	627	7	aasi	aasi	PROPN
dpc-3703	627	8	sz	sz	PROPN
dpc-3703	627	9	,	,	PUNCT
dpc-3703	627	10	et	et	PROPN
dpc-3703	627	11	al	al	PROPN
dpc-3703	627	12	.	.	PROPN
dpc-3703	627	13	squamous	squamous	ADJ
dpc-3703	627	14	cell	cell	NOUN
dpc-3703	627	15	skin	skin	NOUN
dpc-3703	627	16	cancer	cancer	NOUN
dpc-3703	627	17	.	.	PUNCT
dpc-3703	628	1	national	national	ADJ
dpc-3703	628	2	comprehensive	comprehensive	ADJ
dpc-3703	628	3	cancer	cancer	NOUN
dpc-3703	628	4	network	network	NOUN
dpc-3703	628	5	(	(	PUNCT
dpc-3703	628	6	nccn	nccn	ADJ
dpc-3703	628	7	)	)	PUNCT
dpc-3703	628	8	clinical	clinical	ADJ
dpc-3703	628	9	practice	practice	NOUN
dpc-3703	628	10	guidelines	guideline	NOUN
dpc-3703	628	11	in	in	ADP
dpc-3703	628	12	oncology	oncology	NOUN
dpc-3703	628	13	.	.	PUNCT
dpc-3703	629	1	2023	2023	NUM
dpc-3703	629	2	;	;	PUNCT
dpc-3703	630	1	version	version	NOUN
dpc-3703	630	2	1.2023	1.2023	NUM
dpc-3703	630	3	.	.	PUNCT
dpc-3703	630	4	available	available	ADJ
dpc-3703	630	5	from	from	ADP
dpc-3703	630	6	:	:	PUNCT
dpc-3703	630	7	https://www.nccn.org/professionals/physician_gls/	https://www.nccn.org/professionals/physician_gls/	PROPN
dpc-3703	630	8	pdf	pdf	NOUN
dpc-3703	630	9	/	/	SYM
dpc-3703	630	10	squamous.pdf	squamous.pdf	PROPN
dpc-3703	630	11	.	.	PUNCT
dpc-3703	630	12	accessed	access	VERB
dpc-3703	630	13	april	april	PROPN
dpc-3703	630	14	21	21	NUM
dpc-3703	630	15	,	,	PUNCT
dpc-3703	630	16	2023	2023	NUM
dpc-3703	630	17	.	.	PUNCT
dpc-3703	631	1	74	74	NUM
dpc-3703	631	2	.	.	PUNCT
dpc-3703	632	1	neoadjuvant	neoadjuvant	ADJ
dpc-3703	632	2	regn2810	regn2810	PROPN
dpc-3703	632	3	(	(	PUNCT
dpc-3703	632	4	cemiplimab	cemiplimab	NOUN
dpc-3703	632	5	)	)	PUNCT
dpc-3703	632	6	in	in	ADP
dpc-3703	632	7	cutaneous	cutaneous	ADJ
dpc-3703	632	8	basal	basal	NOUN
dpc-3703	632	9	cell	cell	NOUN
dpc-3703	632	10	carcinoma	carcinoma	NOUN
dpc-3703	632	11	of	of	ADP
dpc-3703	632	12	the	the	DET
dpc-3703	632	13	head	head	NOUN
dpc-3703	632	14	and	and	CCONJ
dpc-3703	632	15	neck	neck	NOUN
dpc-3703	632	16	.	.	PUNCT
dpc-3703	633	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	633	2	i	i	PROPN
dpc-3703	633	3	d	d	PROPN
dpc-3703	633	4	:	:	PUNCT
dpc-3703	633	5	nct05929664	nct05929664	PROPN
dpc-3703	633	6	.	.	PUNCT
dpc-3703	634	1	available	available	ADJ
dpc-3703	634	2	from	from	ADP
dpc-3703	634	3	:	:	PUNCT
dpc-3703	634	4	https://www.clinicaltrials	https://www.clinicaltrial	NOUN
dpc-3703	634	5	.	.	PUNCT
dpc-3703	635	1	gov	gov	NOUN
dpc-3703	635	2	/	/	SYM
dpc-3703	635	3	study	study	NOUN
dpc-3703	635	4	/	/	SYM
dpc-3703	635	5	nct05929664?cond	nct05929664?cond	NOUN
dpc-3703	635	6	=	=	SYM
dpc-3703	635	7	basal%20cell%20carcinoma&term	basal%20cell%20carcinoma&term	NOUN
dpc-3703	635	8	=	=	SYM
dpc-3703	635	9	neoadjuvant&rank=4	neoadjuvant&rank=4	PROPN
dpc-3703	635	10	.	.	PUNCT
dpc-3703	636	1	accessed	access	VERB
dpc-3703	636	2	on	on	ADP
dpc-3703	636	3	july	july	PROPN
dpc-3703	636	4	11	11	NUM
dpc-3703	636	5	,	,	PUNCT
dpc-3703	636	6	2023	2023	NUM
dpc-3703	636	7	.	.	PUNCT
dpc-3703	637	1	75	75	NUM
dpc-3703	637	2	.	.	PUNCT
dpc-3703	638	1	a	a	DET
dpc-3703	638	2	phase	phase	NOUN
dpc-3703	638	3	1b	1b	NUM
dpc-3703	638	4	,	,	PUNCT
dpc-3703	638	5	single	single	ADJ
dpc-3703	638	6	arm	arm	NOUN
dpc-3703	638	7	study	study	NOUN
dpc-3703	638	8	of	of	ADP
dpc-3703	638	9	neoadjuvant	neoadjuvant	ADJ
dpc-3703	638	10	-	-	PUNCT
dpc-3703	638	11	adjuvant	adjuvant	ADJ
dpc-3703	638	12	pembrolizumab	pembrolizumab	NOUN
dpc-3703	638	13	in	in	ADP
dpc-3703	638	14	resectable	resectable	ADJ
dpc-3703	638	15	advanced	advanced	ADJ
dpc-3703	638	16	basal	basal	NOUN
dpc-3703	638	17	cell	cell	NOUN
dpc-3703	638	18	carcinoma	carcinoma	NOUN
dpc-3703	638	19	of	of	ADP
dpc-3703	638	20	the	the	DET
dpc-3703	638	21	head	head	NOUN
dpc-3703	638	22	and	and	CCONJ
dpc-3703	638	23	neck	neck	NOUN
dpc-3703	638	24	to	to	PART
dpc-3703	638	25	assess	assess	VERB
dpc-3703	638	26	for	for	ADP
dpc-3703	638	27	pathologic	pathologic	ADJ
dpc-3703	638	28	responses	response	NOUN
dpc-3703	638	29	in	in	ADP
dpc-3703	638	30	the	the	DET
dpc-3703	638	31	tumor	tumor	NOUN
dpc-3703	638	32	microenvironment	microenvironment	NOUN
dpc-3703	638	33	.	.	PUNCT
dpc-3703	639	1	clinicaltrial.gov	clinicaltrial.gov	X
dpc-3703	640	1	i	i	PROPN
dpc-3703	640	2	d	d	PROPN
dpc-3703	640	3	:	:	PUNCT
dpc-3703	640	4	nct04323202	nct04323202	NOUN
dpc-3703	640	5	.	.	PUNCT
dpc-3703	641	1	available	available	ADJ
dpc-3703	641	2	from	from	ADP
dpc-3703	641	3	:	:	PUNCT
dpc-3703	641	4	https://www.clinicaltrials	https://www.clinicaltrial	NOUN
dpc-3703	641	5	.gov	.gov	ADJ
dpc-3703	641	6	/	/	SYM
dpc-3703	641	7	study	study	NOUN
dpc-3703	641	8	/	/	SYM
dpc-3703	641	9	nct04323202?cond	nct04323202?cond	NOUN
dpc-3703	641	10	=	=	SYM
dpc-3703	641	11	basal%20cell%20carcinoma	basal%20cell%20carcinoma	PROPN
dpc-3703	641	12	&	&	CCONJ
dpc-3703	641	13	term	term	NOUN
dpc-3703	641	14	=	=	SYM
dpc-3703	641	15	neoadjuvant&rank=6	neoadjuvant&rank=6	PROPN
dpc-3703	641	16	.	.	PUNCT
dpc-3703	642	1	accessed	access	VERB
dpc-3703	642	2	on	on	ADP
dpc-3703	642	3	july	july	PROPN
dpc-3703	642	4	11	11	NUM
dpc-3703	642	5	,	,	PUNCT
dpc-3703	642	6	2023	2023	NUM
dpc-3703	642	7	.	.	PUNCT
dpc-3703	643	1	76	76	NUM
dpc-3703	643	2	.	.	PUNCT
dpc-3703	644	1	ligtenberg	ligtenberg	PROPN
dpc-3703	644	2	kg	kg	PROPN
dpc-3703	644	3	,	,	PUNCT
dpc-3703	644	4	hu	hu	PROPN
dpc-3703	644	5	jk	jk	PROPN
dpc-3703	644	6	,	,	PUNCT
dpc-3703	644	7	damsky	damsky	PROPN
dpc-3703	644	8	w	w	PROPN
dpc-3703	644	9	,	,	PUNCT
dpc-3703	644	10	et	et	PROPN
dpc-3703	644	11	al	al	PROPN
dpc-3703	644	12	.	.	PROPN
dpc-3703	645	1	neoadjuvant	neoadjuvant	ADJ
dpc-3703	645	2	anti	anti	ADJ
dpc-3703	645	3	-	-	ADJ
dpc-3703	645	4	programmed	programmed	ADJ
dpc-3703	645	5	cell	cell	NOUN
dpc-3703	645	6	death	death	NOUN
dpc-3703	645	7	1	1	NUM
dpc-3703	645	8	therapy	therapy	NOUN
dpc-3703	645	9	for	for	ADP
dpc-3703	645	10	locally	locally	ADV
dpc-3703	645	11	advanced	advance	VERB
dpc-3703	645	12	basal	basal	NOUN
dpc-3703	645	13	cell	cell	NOUN
dpc-3703	645	14	carcinoma	carcinoma	NOUN
dpc-3703	645	15	in	in	ADP
dpc-3703	645	16	treatment	treatment	NOUN
dpc-3703	645	17	-	-	PUNCT
dpc-3703	645	18	naive	naive	ADJ
dpc-3703	645	19	patients	patient	NOUN
dpc-3703	645	20	:	:	PUNCT
dpc-3703	645	21	a	a	DET
dpc-3703	645	22	case	case	NOUN
dpc-3703	645	23	series	series	NOUN
dpc-3703	645	24	.	.	PUNCT
dpc-3703	646	1	jaad	jaad	PROPN
dpc-3703	646	2	case	case	PROPN
dpc-3703	646	3	rep	rep	PROPN
dpc-3703	646	4	.	.	PROPN
dpc-3703	646	5	2020;6(7):628	2020;6(7):628	NUM
dpc-3703	646	6	-	-	PUNCT
dpc-3703	646	7	633	633	NUM
dpc-3703	646	8	.	.	PUNCT
dpc-3703	647	1	doi	doi	NOUN
dpc-3703	647	2	:	:	PUNCT
dpc-3703	647	3	10.1016	10.1016	NUM
dpc-3703	647	4	/	/	SYM
dpc-3703	647	5	j.jdcr.2020.05.010	j.jdcr.2020.05.010	PROPN
dpc-3703	647	6	.	.	PUNCT
dpc-3703	648	1	pmid	pmid	NOUN
dpc-3703	648	2	:	:	PUNCT
dpc-3703	648	3	32613057	32613057	NUM
dpc-3703	648	4	.	.	PUNCT
dpc-3703	649	1	pmcid	pmcid	NOUN
dpc-3703	649	2	:	:	PUNCT
dpc-3703	649	3	pmc7317689	pmc7317689	NOUN
dpc-3703	649	4	.	.	PUNCT
dpc-3703	650	1	53	53	NUM
dpc-3703	650	2	.	.	PUNCT
dpc-3703	651	1	cohen	cohen	PROPN
dpc-3703	651	2	pr	pr	PROPN
dpc-3703	651	3	,	,	PUNCT
dpc-3703	651	4	kato	kato	PROPN
dpc-3703	651	5	s	s	PROPN
dpc-3703	651	6	,	,	PUNCT
dpc-3703	651	7	goodman	goodman	PROPN
dpc-3703	651	8	am	am	PROPN
dpc-3703	651	9	,	,	PUNCT
dpc-3703	651	10	ikeda	ikeda	PROPN
dpc-3703	651	11	s	s	PROPN
dpc-3703	651	12	,	,	PUNCT
dpc-3703	651	13	kurzrock	kurzrock	PROPN
dpc-3703	651	14	r.	r.	PROPN
dpc-3703	651	15	appearance	appearance	NOUN
dpc-3703	651	16	of	of	ADP
dpc-3703	651	17	new	new	ADJ
dpc-3703	651	18	cutaneous	cutaneous	ADJ
dpc-3703	651	19	superficial	superficial	ADJ
dpc-3703	651	20	basal	basal	NOUN
dpc-3703	651	21	cell	cell	NOUN
dpc-3703	651	22	carcinomas	carcinoma	NOUN
dpc-3703	651	23	during	during	ADP
dpc-3703	651	24	successful	successful	ADJ
dpc-3703	651	25	nivolumab	nivolumab	NOUN
dpc-3703	651	26	treatment	treatment	NOUN
dpc-3703	651	27	of	of	ADP
dpc-3703	651	28	refractory	refractory	NOUN
dpc-3703	651	29	metastatic	metastatic	ADJ
dpc-3703	651	30	disease	disease	NOUN
dpc-3703	651	31	:	:	PUNCT
dpc-3703	651	32	implications	implication	NOUN
dpc-3703	651	33	for	for	ADP
dpc-3703	651	34	immunotherapy	immunotherapy	NOUN
dpc-3703	651	35	in	in	ADP
dpc-3703	651	36	early	early	ADJ
dpc-3703	651	37	versus	versus	ADP
dpc-3703	651	38	late	late	ADJ
dpc-3703	651	39	disease	disease	NOUN
dpc-3703	651	40	.	.	PUNCT
dpc-3703	652	1	int	int	PROPN
dpc-3703	652	2	j	j	PROPN
dpc-3703	652	3	mol	mol	ADP
dpc-3703	652	4	sci	sci	PROPN
dpc-3703	652	5	.	.	PUNCT
dpc-3703	653	1	2017;18(8):1663	2017;18(8):1663	NUM
dpc-3703	653	2	.	.	PUNCT
dpc-3703	654	1	doi	doi	PROPN
dpc-3703	654	2	:	:	PUNCT
dpc-3703	654	3	10.3390	10.3390	NUM
dpc-3703	654	4	/ijms18081663	/ijms18081663	PUNCT
dpc-3703	654	5	.	.	PUNCT
dpc-3703	655	1	pmid	pmid	NOUN
dpc-3703	655	2	:	:	PUNCT
dpc-3703	655	3	28788102	28788102	NUM
dpc-3703	655	4	.	.	PUNCT
dpc-3703	656	1	pmcid	pmcid	NOUN
dpc-3703	656	2	:	:	PUNCT
dpc-3703	656	3	pmc5578053	pmc5578053	ADJ
dpc-3703	656	4	.	.	PUNCT
dpc-3703	657	1	54	54	NUM
dpc-3703	657	2	.	.	PUNCT
dpc-3703	657	3	borradori	borradori	PROPN
dpc-3703	657	4	l	l	PROPN
dpc-3703	657	5	,	,	PUNCT
dpc-3703	657	6	sutton	sutton	PROPN
dpc-3703	657	7	b	b	PROPN
dpc-3703	657	8	,	,	PUNCT
dpc-3703	657	9	shayesteh	shayesteh	NOUN
dpc-3703	657	10	p	p	PROPN
dpc-3703	657	11	,	,	PUNCT
dpc-3703	657	12	daniels	daniels	PROPN
dpc-3703	657	13	ga	ga	PROPN
dpc-3703	657	14	.	.	PUNCT
dpc-3703	657	15	rescue	rescue	NOUN
dpc-3703	657	16	therapy	therapy	NOUN
dpc-3703	657	17	with	with	ADP
dpc-3703	657	18	anti	anti	ADJ
dpc-3703	657	19	-	-	ADJ
dpc-3703	657	20	programmed	programmed	ADJ
dpc-3703	657	21	cell	cell	NOUN
dpc-3703	657	22	death	death	NOUN
dpc-3703	657	23	protein	protein	NOUN
dpc-3703	657	24	1	1	NUM
dpc-3703	657	25	inhibitors	inhibitor	NOUN
dpc-3703	657	26	of	of	ADP
dpc-3703	657	27	advanced	advanced	ADJ
dpc-3703	657	28	cutaneous	cutaneous	ADJ
dpc-3703	657	29	squamous	squamous	ADJ
dpc-3703	657	30	cell	cell	NOUN
dpc-3703	657	31	carcinoma	carcinoma	NOUN
dpc-3703	657	32	and	and	CCONJ
dpc-3703	657	33	basosquamous	basosquamous	ADJ
dpc-3703	657	34	carcinoma	carcinoma	NOUN
dpc-3703	657	35	:	:	PUNCT
dpc-3703	657	36	preliminary	preliminary	ADJ
dpc-3703	657	37	experience	experience	NOUN
dpc-3703	657	38	in	in	ADP
dpc-3703	657	39	five	five	NUM
dpc-3703	657	40	cases	case	NOUN
dpc-3703	657	41	.	.	PUNCT
dpc-3703	658	1	br	br	PROPN
dpc-3703	658	2	j	j	PROPN
dpc-3703	658	3	dermatol	dermatol	NOUN
dpc-3703	658	4	.	.	PUNCT
dpc-3703	659	1	2016;175(6):1382	2016;175(6):1382	NUM
dpc-3703	659	2	-	-	SYM
dpc-3703	659	3	1386	1386	NUM
dpc-3703	659	4	.	.	PUNCT
dpc-3703	660	1	doi	doi	NOUN
dpc-3703	660	2	:	:	PUNCT
dpc-3703	660	3	10.1111	10.1111	NUM
dpc-3703	660	4	/	/	SYM
dpc-3703	660	5	bjd.14642	bjd.14642	PROPN
dpc-3703	660	6	.	.	PUNCT
dpc-3703	661	1	pmid	pmid	NOUN
dpc-3703	661	2	:	:	PUNCT
dpc-3703	661	3	27059424	27059424	NUM
dpc-3703	661	4	.	.	PUNCT
dpc-3703	662	1	55	55	NUM
dpc-3703	662	2	.	.	PUNCT
dpc-3703	662	3	winkler	winkler	PROPN
dpc-3703	662	4	jk	jk	PROPN
dpc-3703	662	5	,	,	PUNCT
dpc-3703	662	6	schneiderbauer	schneiderbauer	PROPN
dpc-3703	662	7	r	r	PROPN
dpc-3703	662	8	,	,	PUNCT
dpc-3703	662	9	bender	bender	NOUN
dpc-3703	662	10	c	c	AUX
dpc-3703	662	11	,	,	PUNCT
dpc-3703	662	12	et	et	PROPN
dpc-3703	662	13	al	al	PROPN
dpc-3703	662	14	.	.	PUNCT
dpc-3703	662	15	anti	anti	ADJ
dpc-3703	662	16	-	-	ADJ
dpc-3703	662	17	programmed	programmed	ADJ
dpc-3703	662	18	cell	cell	NOUN
dpc-3703	662	19	death-1	death-1	NUM
dpc-3703	662	20	therapy	therapy	NOUN
dpc-3703	662	21	in	in	ADP
dpc-3703	662	22	nonmelanoma	nonmelanoma	ADJ
dpc-3703	662	23	skin	skin	NOUN
dpc-3703	662	24	cancer	cancer	NOUN
dpc-3703	662	25	.	.	PUNCT
dpc-3703	663	1	br	br	PROPN
dpc-3703	663	2	j	j	PROPN
dpc-3703	663	3	dermatol	dermatol	NOUN
dpc-3703	663	4	.	.	PUNCT
dpc-3703	664	1	2017;176(2):498	2017;176(2):498	NUM
dpc-3703	664	2	-	-	SYM
dpc-3703	664	3	502	502	NUM
dpc-3703	664	4	.	.	PUNCT
dpc-3703	665	1	doi	doi	NOUN
dpc-3703	665	2	:	:	PUNCT
dpc-3703	665	3	10.1111	10.1111	NUM
dpc-3703	665	4	/	/	SYM
dpc-3703	665	5	bjd.14664	bjd.14664	PROPN
dpc-3703	665	6	.	.	PUNCT
dpc-3703	666	1	pmid	pmid	NOUN
dpc-3703	666	2	:	:	PUNCT
dpc-3703	666	3	27061826	27061826	NUM
dpc-3703	666	4	.	.	PUNCT
dpc-3703	667	1	56	56	NUM
dpc-3703	667	2	.	.	X
dpc-3703	667	3	lipson	lipson	PROPN
dpc-3703	667	4	ej	ej	PROPN
dpc-3703	667	5	,	,	PUNCT
dpc-3703	667	6	bagnasco	bagnasco	PROPN
dpc-3703	667	7	sm	sm	PROPN
dpc-3703	667	8	,	,	PUNCT
dpc-3703	667	9	moore	moore	PROPN
dpc-3703	667	10	j	j	PROPN
dpc-3703	667	11	,	,	PUNCT
dpc-3703	667	12	jr	jr	PROPN
dpc-3703	667	13	.	.	PROPN
dpc-3703	667	14	,	,	PUNCT
dpc-3703	667	15	et	et	PROPN
dpc-3703	667	16	al	al	PROPN
dpc-3703	667	17	.	.	PROPN
dpc-3703	667	18	tumor	tumor	PROPN
dpc-3703	667	19	regression	regression	NOUN
dpc-3703	667	20	and	and	CCONJ
dpc-3703	667	21	allograft	allograft	VERB
dpc-3703	667	22	rejection	rejection	NOUN
dpc-3703	667	23	after	after	ADP
dpc-3703	667	24	administration	administration	NOUN
dpc-3703	667	25	of	of	ADP
dpc-3703	667	26	anti	anti	NOUN
dpc-3703	667	27	-	-	PROPN
dpc-3703	667	28	pd-1	pd-1	NOUN
dpc-3703	667	29	.	.	PUNCT
dpc-3703	668	1	n	n	PROPN
dpc-3703	668	2	engl	engl	PROPN
dpc-3703	668	3	j	j	PROPN
dpc-3703	668	4	med	med	PROPN
dpc-3703	668	5	.	.	PUNCT
dpc-3703	669	1	2016;374(9):896	2016;374(9):896	NUM
dpc-3703	669	2	-	-	SYM
dpc-3703	669	3	898	898	NUM
dpc-3703	669	4	.	.	PUNCT
dpc-3703	670	1	doi	doi	NOUN
dpc-3703	670	2	:	:	PUNCT
dpc-3703	670	3	10.1056	10.1056	NUM
dpc-3703	670	4	/	/	SYM
dpc-3703	670	5	nejmc1509268	nejmc1509268	PROPN
dpc-3703	670	6	.	.	PUNCT
dpc-3703	671	1	pmid	pmid	NOUN
dpc-3703	671	2	:	:	PUNCT
dpc-3703	671	3	26962927	26962927	NUM
dpc-3703	671	4	.	.	PUNCT
dpc-3703	672	1	pmcid	pmcid	NOUN
dpc-3703	672	2	:	:	PUNCT
dpc-3703	672	3	pmc4850555	pmc4850555	ADJ
dpc-3703	672	4	.	.	PUNCT
dpc-3703	673	1	57	57	NUM
dpc-3703	673	2	.	.	X
dpc-3703	673	3	cannon	cannon	NOUN
dpc-3703	673	4	jgd	jgd	PROPN
dpc-3703	673	5	,	,	PUNCT
dpc-3703	673	6	russell	russell	PROPN
dpc-3703	673	7	js	js	PROPN
dpc-3703	673	8	,	,	PUNCT
dpc-3703	673	9	kim	kim	PROPN
dpc-3703	673	10	j	j	PROPN
dpc-3703	673	11	,	,	PUNCT
dpc-3703	673	12	chang	chang	PROPN
dpc-3703	673	13	als	als	PROPN
dpc-3703	673	14	.	.	PUNCT
dpc-3703	674	1	a	a	DET
dpc-3703	674	2	case	case	NOUN
dpc-3703	674	3	of	of	ADP
dpc-3703	674	4	metastatic	metastatic	ADJ
dpc-3703	674	5	basal	basal	NOUN
dpc-3703	674	6	cell	cell	NOUN
dpc-3703	674	7	carcinoma	carcinoma	NOUN
dpc-3703	674	8	treated	treat	VERB
dpc-3703	674	9	with	with	ADP
dpc-3703	674	10	continuous	continuous	ADJ
dpc-3703	674	11	pd-1	pd-1	ADJ
dpc-3703	674	12	inhibitor	inhibitor	NOUN
dpc-3703	674	13	exposure	exposure	NOUN
dpc-3703	674	14	even	even	ADV
dpc-3703	674	15	after	after	ADP
dpc-3703	674	16	subsequent	subsequent	ADJ
dpc-3703	674	17	initiation	initiation	NOUN
dpc-3703	674	18	of	of	ADP
dpc-3703	674	19	radiotherapy	radiotherapy	NOUN
dpc-3703	674	20	and	and	CCONJ
dpc-3703	674	21	surgery	surgery	NOUN
dpc-3703	674	22	.	.	PUNCT
dpc-3703	675	1	jaad	jaad	NOUN
dpc-3703	675	2	case	case	NOUN
dpc-3703	675	3	rep	rep	PROPN
dpc-3703	675	4	.	.	PROPN
dpc-3703	675	5	2018;4(3):248	2018;4(3):248	NUM
dpc-3703	675	6	-	-	SYM
dpc-3703	675	7	250	250	NUM
dpc-3703	675	8	.	.	PUNCT
dpc-3703	676	1	doi	doi	NOUN
dpc-3703	676	2	:	:	PUNCT
dpc-3703	676	3	10.1016	10.1016	NUM
dpc-3703	676	4	/	/	SYM
dpc-3703	676	5	j	j	PROPN
dpc-3703	676	6	.jdcr.2018.01.015	.jdcr.2018.01.015	PUNCT
dpc-3703	676	7	.	.	PUNCT
dpc-3703	677	1	pmid	pmid	NOUN
dpc-3703	677	2	:	:	PUNCT
dpc-3703	677	3	29687062	29687062	NUM
dpc-3703	677	4	.	.	PUNCT
dpc-3703	678	1	pmcid	pmcid	NOUN
dpc-3703	678	2	:	:	PUNCT
dpc-3703	678	3	pmc5909484	pmc5909484	NOUN
dpc-3703	678	4	.	.	PUNCT
dpc-3703	679	1	58	58	NUM
dpc-3703	679	2	.	.	PUNCT
dpc-3703	680	1	fischer	fischer	PROPN
dpc-3703	680	2	s	s	PROPN
dpc-3703	680	3	,	,	PUNCT
dpc-3703	680	4	hasan	hasan	PROPN
dpc-3703	680	5	ali	ali	PROPN
dpc-3703	680	6	o	o	PROPN
dpc-3703	680	7	,	,	PUNCT
dpc-3703	680	8	jochum	jochum	PROPN
dpc-3703	680	9	w	w	PROPN
dpc-3703	680	10	,	,	PUNCT
dpc-3703	680	11	kluckert	kluckert	PROPN
dpc-3703	680	12	t	t	PROPN
dpc-3703	680	13	,	,	PUNCT
dpc-3703	680	14	flatz	flatz	PROPN
dpc-3703	680	15	l	l	PROPN
dpc-3703	680	16	,	,	PUNCT
dpc-3703	680	17	siano	siano	PROPN
dpc-3703	680	18	m.	m.	NOUN
dpc-3703	680	19	anti	anti	ADJ
dpc-3703	680	20	-	-	ADJ
dpc-3703	680	21	pd-1	pd-1	ADJ
dpc-3703	680	22	therapy	therapy	NOUN
dpc-3703	680	23	leads	lead	VERB
dpc-3703	680	24	to	to	ADP
dpc-3703	680	25	near	near	ADJ
dpc-3703	680	26	-	-	PUNCT
dpc-3703	680	27	complete	complete	ADJ
dpc-3703	680	28	remission	remission	NOUN
dpc-3703	680	29	in	in	ADP
dpc-3703	680	30	a	a	DET
dpc-3703	680	31	patient	patient	NOUN
dpc-3703	680	32	with	with	ADP
dpc-3703	680	33	metastatic	metastatic	ADJ
dpc-3703	680	34	basal	basal	NOUN
dpc-3703	680	35	cell	cell	NOUN
dpc-3703	680	36	carcinoma	carcinoma	NOUN
dpc-3703	680	37	.	.	PUNCT
dpc-3703	681	1	oncol	oncol	ADJ
dpc-3703	681	2	res	re	NOUN
dpc-3703	681	3	treat	treat	NOUN
dpc-3703	681	4	.	.	PUNCT
dpc-3703	682	1	2018;41(6):391	2018;41(6):391	NUM
dpc-3703	682	2	-	-	SYM
dpc-3703	682	3	394	394	NUM
dpc-3703	682	4	.	.	PUNCT
dpc-3703	683	1	doi	doi	NOUN
dpc-3703	683	2	:	:	PUNCT
dpc-3703	683	3	10.1159/000487084	10.1159/000487084	NUM
dpc-3703	683	4	.	.	PUNCT
dpc-3703	684	1	pmid	pmid	NOUN
dpc-3703	684	2	:	:	PUNCT
dpc-3703	684	3	29734143	29734143	NUM
dpc-3703	684	4	.	.	PUNCT
dpc-3703	685	1	59	59	NUM
dpc-3703	685	2	.	.	PUNCT
dpc-3703	685	3	choi	choi	PROPN
dpc-3703	685	4	fd	fd	PROPN
dpc-3703	685	5	,	,	PUNCT
dpc-3703	685	6	kraus	kraus	PROPN
dpc-3703	685	7	cn	cn	PROPN
dpc-3703	685	8	,	,	PUNCT
dpc-3703	685	9	elsensohn	elsensohn	PROPN
dpc-3703	685	10	an	an	PROPN
dpc-3703	685	11	,	,	PUNCT
dpc-3703	685	12	et	et	PROPN
dpc-3703	685	13	al	al	PROPN
dpc-3703	685	14	.	.	PROPN
dpc-3703	685	15	programmed	program	VERB
dpc-3703	685	16	cell	cell	NOUN
dpc-3703	685	17	death	death	NOUN
dpc-3703	685	18	1	1	NUM
dpc-3703	685	19	protein	protein	NOUN
dpc-3703	685	20	and	and	CCONJ
dpc-3703	685	21	programmed	program	VERB
dpc-3703	685	22	death	death	NOUN
dpc-3703	685	23	-	-	PUNCT
dpc-3703	685	24	ligand	ligand	NOUN
dpc-3703	685	25	1	1	NUM
dpc-3703	685	26	inhibitors	inhibitor	NOUN
dpc-3703	685	27	in	in	ADP
dpc-3703	685	28	the	the	DET
dpc-3703	685	29	treatment	treatment	NOUN
dpc-3703	685	30	of	of	ADP
dpc-3703	685	31	nonmelanoma	nonmelanoma	ADJ
dpc-3703	685	32	skin	skin	NOUN
dpc-3703	685	33	cancer	cancer	NOUN
dpc-3703	685	34	:	:	PUNCT
dpc-3703	685	35	a	a	DET
dpc-3703	685	36	systematic	systematic	ADJ
dpc-3703	685	37	review	review	NOUN
dpc-3703	685	38	.	.	PUNCT
dpc-3703	686	1	j	j	PROPN
dpc-3703	686	2	am	be	AUX
dpc-3703	686	3	acad	acad	ADJ
dpc-3703	686	4	dermatol	dermatol	NOUN
dpc-3703	686	5	.	.	PUNCT
dpc-3703	687	1	2020;82(2):440	2020;82(2):440	NUM
dpc-3703	687	2	-	-	PUNCT
dpc-3703	687	3	459	459	NUM
dpc-3703	687	4	.	.	PUNCT
dpc-3703	688	1	doi	doi	NOUN
dpc-3703	688	2	:	:	PUNCT
dpc-3703	688	3	10.1016	10.1016	NUM
dpc-3703	688	4	/	/	SYM
dpc-3703	688	5	j	j	PROPN
dpc-3703	688	6	.jaad.2019.05.077	.jaad.2019.05.077	PROPN
dpc-3703	688	7	.	.	PUNCT
dpc-3703	689	1	pmid	pmid	NOUN
dpc-3703	689	2	:	:	PUNCT
dpc-3703	689	3	31163235	31163235	NUM
dpc-3703	689	4	.	.	PUNCT
dpc-3703	690	1	60	60	NUM
dpc-3703	690	2	.	.	PUNCT
dpc-3703	691	1	dumann	dumann	PROPN
dpc-3703	691	2	k	k	PROPN
dpc-3703	691	3	,	,	PUNCT
dpc-3703	691	4	artz	artz	PROPN
dpc-3703	691	5	n	n	CCONJ
dpc-3703	691	6	,	,	PUNCT
dpc-3703	691	7	ziemer	ziemer	PROPN
dpc-3703	691	8	m.	m.	PROPN
dpc-3703	691	9	complete	complete	PROPN
dpc-3703	691	10	remission	remission	NOUN
dpc-3703	691	11	of	of	ADP
dpc-3703	691	12	basal	basal	ADJ
dpc-3703	691	13	cell	cell	NOUN
dpc-3703	691	14	carcinoma	carcinoma	NOUN
dpc-3703	691	15	following	follow	VERB
dpc-3703	691	16	treatment	treatment	NOUN
dpc-3703	691	17	with	with	ADP
dpc-3703	691	18	cemiplimab	cemiplimab	NOUN
dpc-3703	691	19	after	after	ADP
dpc-3703	691	20	2	2	NUM
dpc-3703	691	21	years	year	NOUN
dpc-3703	691	22	.	.	PUNCT
dpc-3703	692	1	jama	jama	PROPN
dpc-3703	692	2	dermatol	dermatol	NOUN
dpc-3703	692	3	.	.	PUNCT
dpc-3703	693	1	2021;157(8):1004	2021;157(8):1004	NUM
dpc-3703	693	2	-	-	SYM
dpc-3703	693	3	1006	1006	NUM
dpc-3703	693	4	.	.	PUNCT
dpc-3703	694	1	doi	doi	NOUN
dpc-3703	694	2	:	:	PUNCT
dpc-3703	694	3	10.1001	10.1001	NUM
dpc-3703	694	4	/jamadermatol.2021.2206	/jamadermatol.2021.2206	X
dpc-3703	694	5	.	.	PUNCT
dpc-3703	695	1	pmid	pmid	NOUN
dpc-3703	695	2	:	:	PUNCT
dpc-3703	695	3	34232273	34232273	NUM
dpc-3703	695	4	.	.	PUNCT
dpc-3703	696	1	61	61	NUM
dpc-3703	696	2	.	.	PUNCT
dpc-3703	697	1	johansson	johansson	PROPN
dpc-3703	697	2	i	i	PROPN
dpc-3703	697	3	,	,	PUNCT
dpc-3703	697	4	levin	levin	PROPN
dpc-3703	697	5	m	m	PROPN
dpc-3703	697	6	,	,	PUNCT
dpc-3703	697	7	akyurek	akyurek	NOUN
dpc-3703	697	8	lm	lm	PROPN
dpc-3703	697	9	,	,	PUNCT
dpc-3703	697	10	olofsson	olofsson	PROPN
dpc-3703	697	11	bagge	bagge	PROPN
dpc-3703	697	12	r	r	PROPN
dpc-3703	697	13	,	,	PUNCT
dpc-3703	697	14	ny	ny	PROPN
dpc-3703	697	15	l.	l.	PROPN
dpc-3703	697	16	pd-1	pd-1	NOUN
dpc-3703	697	17	inhibitor	inhibitor	NOUN
dpc-3703	697	18	therapy	therapy	NOUN
dpc-3703	697	19	of	of	ADP
dpc-3703	697	20	basal	basal	PROPN
dpc-3703	697	21	cell	cell	NOUN
dpc-3703	697	22	carcinoma	carcinoma	NOUN
dpc-3703	697	23	with	with	ADP
dpc-3703	697	24	pulmonary	pulmonary	ADJ
dpc-3703	697	25	metastasis	metastasis	NOUN
dpc-3703	697	26	.	.	PUNCT
dpc-3703	698	1	j	j	PROPN
dpc-3703	698	2	eur	eur	PROPN
dpc-3703	698	3	acad	acad	PROPN
dpc-3703	698	4	dermatol	dermatol	NOUN
dpc-3703	698	5	venereol	venereol	NOUN
dpc-3703	698	6	.	.	PUNCT
dpc-3703	699	1	2022;36	2022;36	NOUN
dpc-3703	699	2	suppl	suppl	ADJ
dpc-3703	699	3	1:70	1:70	NUM
dpc-3703	699	4	-	-	SYM
dpc-3703	699	5	73	73	NUM
dpc-3703	699	6	.	.	PUNCT
dpc-3703	700	1	doi	doi	NOUN
dpc-3703	700	2	:	:	PUNCT
dpc-3703	700	3	10.1111	10.1111	NUM
dpc-3703	700	4	/	/	SYM
dpc-3703	700	5	jdv.17530	jdv.17530	PROPN
dpc-3703	700	6	.	.	PUNCT
dpc-3703	701	1	pmid	pmid	NOUN
dpc-3703	701	2	:	:	PUNCT
dpc-3703	701	3	34855248	34855248	NUM
dpc-3703	701	4	.	.	PUNCT
dpc-3703	702	1	62	62	NUM
dpc-3703	702	2	.	.	PUNCT
dpc-3703	703	1	de	de	PROPN
dpc-3703	703	2	giorgi	giorgi	PROPN
dpc-3703	703	3	v	v	PROPN
dpc-3703	703	4	,	,	PUNCT
dpc-3703	703	5	trane	trane	PROPN
dpc-3703	703	6	l	l	PROPN
dpc-3703	703	7	,	,	PUNCT
dpc-3703	703	8	savarese	savarese	PROPN
dpc-3703	703	9	i	i	PRON
dpc-3703	703	10	,	,	PUNCT
dpc-3703	703	11	et	et	PROPN
dpc-3703	703	12	al	al	PROPN
dpc-3703	703	13	.	.	PUNCT
dpc-3703	704	1	lasting	last	VERB
dpc-3703	704	2	response	response	NOUN
dpc-3703	704	3	after	after	ADP
dpc-3703	704	4	discontinuation	discontinuation	NOUN
dpc-3703	704	5	of	of	ADP
dpc-3703	704	6	cemiplimab	cemiplimab	NOUN
dpc-3703	704	7	in	in	ADP
dpc-3703	704	8	a	a	DET
dpc-3703	704	9	patient	patient	NOUN
dpc-3703	704	10	with	with	ADP
dpc-3703	704	11	locally	locally	ADV
dpc-3703	704	12	advanced	advance	VERB
dpc-3703	704	13	basal	basal	NOUN
dpc-3703	704	14	cell	cell	NOUN
dpc-3703	704	15	carcinoma	carcinoma	NOUN
dpc-3703	704	16	.	.	PUNCT
dpc-3703	705	1	clin	clin	PROPN
dpc-3703	705	2	exp	exp	NOUN
dpc-3703	705	3	dermatol	dermatol	NOUN
dpc-3703	705	4	.	.	PUNCT
dpc-3703	706	1	2021;46(8	2021;46(8	NUM
dpc-3703	706	2	):	):	PUNCT
dpc-3703	706	3	1612	1612	NUM
dpc-3703	706	4	-	-	SYM
dpc-3703	706	5	1614	1614	NUM
dpc-3703	706	6	.	.	PUNCT
dpc-3703	707	1	doi	doi	NOUN
dpc-3703	707	2	:	:	PUNCT
dpc-3703	707	3	10.1111	10.1111	NUM
dpc-3703	707	4	/	/	SYM
dpc-3703	707	5	ced.14804	ced.14804	PROPN
dpc-3703	707	6	.	.	PUNCT
dpc-3703	708	1	pmid	pmid	NOUN
dpc-3703	708	2	:	:	PUNCT
dpc-3703	708	3	34157152	34157152	NUM
dpc-3703	708	4	.	.	PUNCT
dpc-3703	709	1	63	63	NUM
dpc-3703	709	2	.	.	PUNCT
dpc-3703	710	1	delaitre	delaitre	PROPN
dpc-3703	710	2	l	l	PROPN
dpc-3703	710	3	,	,	PUNCT
dpc-3703	710	4	martins	martin	NOUN
dpc-3703	710	5	-	-	PUNCT
dpc-3703	710	6	héricher	héricher	PROPN
dpc-3703	710	7	j	j	PROPN
dpc-3703	710	8	,	,	PUNCT
dpc-3703	710	9	truchot	truchot	NOUN
dpc-3703	710	10	e	e	NOUN
dpc-3703	710	11	,	,	PUNCT
dpc-3703	710	12	et	et	PROPN
dpc-3703	710	13	al	al	PROPN
dpc-3703	710	14	.	.	PROPN
dpc-3703	710	15	régression	régression	PROPN
dpc-3703	710	16	de	de	PROPN
dpc-3703	710	17	carcinomes	carcinomes	PROPN
dpc-3703	710	18	basocellulaire	basocellulaire	VERB
dpc-3703	710	19	et	et	PROPN
dpc-3703	710	20	épidermoïde	épidermoïde	PROPN
dpc-3703	710	21	cutanés	cutanés	NOUN
dpc-3703	710	22	sous	sous	ADJ
dpc-3703	710	23	pembrolizumab	pembrolizumab	NOUN
dpc-3703	711	1	[	[	X
dpc-3703	711	2	regression	regression	NOUN
dpc-3703	711	3	of	of	ADP
dpc-3703	711	4	cutaneous	cutaneous	ADJ
dpc-3703	711	5	basal	basal	NOUN
dpc-3703	711	6	cell	cell	NOUN
dpc-3703	711	7	and	and	CCONJ
dpc-3703	711	8	squamous	squamous	ADJ
dpc-3703	711	9	cell	cell	NOUN
dpc-3703	711	10	carcinoma	carcinoma	NOUN
dpc-3703	711	11	under	under	ADP
dpc-3703	711	12	pembrolizumab	pembrolizumab	NOUN
dpc-3703	711	13	]	]	PUNCT
dpc-3703	711	14	.	.	PUNCT
dpc-3703	712	1	ann	ann	PROPN
dpc-3703	712	2	dermatol	dermatol	NOUN
dpc-3703	712	3	venereol	venereol	NOUN
dpc-3703	712	4	.	.	PUNCT
dpc-3703	713	1	2020;147(4):279	2020;147(4):279	NUM
dpc-3703	713	2	-	-	SYM
dpc-3703	713	3	284	284	NUM
dpc-3703	713	4	.	.	PUNCT
dpc-3703	714	1	doi	doi	NOUN
dpc-3703	714	2	:	:	PUNCT
dpc-3703	714	3	10.1016	10.1016	NUM
dpc-3703	714	4	/	/	SYM
dpc-3703	714	5	j.annder.2019.10.031	j.annder.2019.10.031	PROPN
dpc-3703	714	6	.	.	PUNCT
dpc-3703	715	1	pmid	pmid	NOUN
dpc-3703	715	2	:	:	PUNCT
dpc-3703	715	3	31879092	31879092	NUM
dpc-3703	715	4	.	.	PUNCT
dpc-3703	716	1	64	64	NUM
dpc-3703	716	2	.	.	PUNCT
dpc-3703	717	1	ikeda	ikeda	PROPN
dpc-3703	717	2	s	s	PROPN
dpc-3703	717	3	,	,	PUNCT
dpc-3703	717	4	goodman	goodman	PROPN
dpc-3703	717	5	am	be	AUX
dpc-3703	717	6	,	,	PUNCT
dpc-3703	717	7	cohen	cohen	PROPN
dpc-3703	717	8	pr	pr	PROPN
dpc-3703	717	9	,	,	PUNCT
dpc-3703	717	10	et	et	PROPN
dpc-3703	717	11	al	al	PROPN
dpc-3703	717	12	.	.	PROPN
dpc-3703	718	1	metastatic	metastatic	PROPN
dpc-3703	718	2	basal	basal	PROPN
dpc-3703	718	3	cell	cell	NOUN
dpc-3703	718	4	carcinoma	carcinoma	NOUN
dpc-3703	718	5	with	with	ADP
dpc-3703	718	6	amplification	amplification	NOUN
dpc-3703	718	7	of	of	ADP
dpc-3703	718	8	pd	pd	PROPN
dpc-3703	718	9	-	-	PUNCT
dpc-3703	718	10	l1	l1	PROPN
dpc-3703	718	11	:	:	PUNCT
dpc-3703	718	12	exceptional	exceptional	ADJ
dpc-3703	718	13	response	response	NOUN
dpc-3703	718	14	to	to	ADP
dpc-3703	718	15	anti	anti	ADJ
dpc-3703	718	16	-	-	ADJ
dpc-3703	718	17	pd1	pd1	VERB
dpc-3703	718	18	therapy	therapy	NOUN
dpc-3703	718	19	.	.	PUNCT
dpc-3703	719	1	npj	npj	PROPN
dpc-3703	719	2	genom	genom	PROPN
dpc-3703	719	3	med	me	VERB
dpc-3703	719	4	.	.	PUNCT
dpc-3703	720	1	2016;1:16037-	2016;1:16037-	NUM
dpc-3703	720	2	.	.	PUNCT
dpc-3703	721	1	doi	doi	NOUN
dpc-3703	721	2	:	:	PUNCT
dpc-3703	721	3	10.1038	10.1038	NUM
dpc-3703	721	4	/	/	SYM
dpc-3703	721	5	npjgenmed.2016.37	npjgenmed.2016.37	NOUN
dpc-3703	721	6	.	.	PUNCT
dpc-3703	722	1	pmid	pmid	NOUN
dpc-3703	722	2	:	:	PUNCT
dpc-3703	722	3	27942391	27942391	NUM
dpc-3703	722	4	.	.	PUNCT
dpc-3703	723	1	pmcid	pmcid	NOUN
dpc-3703	723	2	:	:	PUNCT
dpc-3703	723	3	pmc5142752	pmc5142752	ADJ
dpc-3703	723	4	.	.	PUNCT
dpc-3703	724	1	65	65	NUM
dpc-3703	724	2	.	.	PUNCT
dpc-3703	725	1	stratigos	stratigos	PROPN
dpc-3703	725	2	aj	aj	PROPN
dpc-3703	725	3	,	,	PUNCT
dpc-3703	725	4	sekulic	sekulic	PROPN
dpc-3703	725	5	a	a	PROPN
dpc-3703	725	6	,	,	PUNCT
dpc-3703	725	7	peris	peris	PROPN
dpc-3703	725	8	k	k	PROPN
dpc-3703	725	9	,	,	PUNCT
dpc-3703	725	10	et	et	PROPN
dpc-3703	725	11	al	al	PROPN
dpc-3703	725	12	.	.	PROPN
dpc-3703	725	13	cemiplimab	cemiplimab	NOUN
dpc-3703	725	14	in	in	ADP
dpc-3703	725	15	locally	locally	ADV
dpc-3703	725	16	advanced	advance	VERB
dpc-3703	725	17	basal	basal	NOUN
dpc-3703	725	18	cell	cell	NOUN
dpc-3703	725	19	carcinoma	carcinoma	NOUN
dpc-3703	725	20	after	after	ADP
dpc-3703	725	21	hedgehog	hedgehog	NOUN
dpc-3703	725	22	inhibitor	inhibitor	NOUN
dpc-3703	725	23	therapy	therapy	NOUN
dpc-3703	725	24	:	:	PUNCT
dpc-3703	725	25	an	an	DET
dpc-3703	725	26	open	open	ADJ
dpc-3703	725	27	-	-	PUNCT
dpc-3703	725	28	label	label	NOUN
dpc-3703	725	29	,	,	PUNCT
dpc-3703	725	30	multi	multi	ADJ
dpc-3703	725	31	-	-	ADJ
dpc-3703	725	32	centre	centre	ADJ
dpc-3703	725	33	,	,	PUNCT
dpc-3703	725	34	single	single	ADJ
dpc-3703	725	35	-	-	PUNCT
dpc-3703	725	36	arm	arm	NOUN
dpc-3703	725	37	,	,	PUNCT
dpc-3703	725	38	phase	phase	NOUN
dpc-3703	725	39	2	2	NUM
dpc-3703	725	40	trial	trial	NOUN
dpc-3703	725	41	.	.	PUNCT
dpc-3703	726	1	lancet	lancet	PROPN
dpc-3703	726	2	oncol	oncol	PROPN
dpc-3703	726	3	.	.	PUNCT
dpc-3703	727	1	12	12	NUM
dpc-3703	727	2	review	review	NOUN
dpc-3703	727	3	|	|	ADV
dpc-3703	727	4	dermatol	dermatol	ADJ
dpc-3703	727	5	pract	pract	NOUN
dpc-3703	727	6	concept	concept	NOUN
dpc-3703	727	7	.	.	PUNCT
dpc-3703	728	1	2023;13(4):e2023252	2023;13(4):e2023252	NUM
dpc-3703	728	2	86	86	NUM
dpc-3703	728	3	.	.	PUNCT
dpc-3703	729	1	ribas	ribas	PROPN
dpc-3703	729	2	a	a	PRON
dpc-3703	729	3	,	,	PUNCT
dpc-3703	729	4	dummer	dummer	PROPN
dpc-3703	729	5	r	r	PROPN
dpc-3703	729	6	,	,	PUNCT
dpc-3703	729	7	puzanov	puzanov	NOUN
dpc-3703	729	8	i	i	PROPN
dpc-3703	729	9	,	,	PUNCT
dpc-3703	729	10	et	et	PROPN
dpc-3703	729	11	al	al	PROPN
dpc-3703	729	12	.	.	PROPN
dpc-3703	730	1	oncolytic	oncolytic	PROPN
dpc-3703	730	2	virotherapy	virotherapy	PROPN
dpc-3703	730	3	promotes	promote	VERB
dpc-3703	730	4	intratumoral	intratumoral	PROPN
dpc-3703	730	5	t	t	PROPN
dpc-3703	730	6	cell	cell	NOUN
dpc-3703	730	7	infiltration	infiltration	NOUN
dpc-3703	730	8	and	and	CCONJ
dpc-3703	730	9	improves	improve	VERB
dpc-3703	730	10	anti	anti	ADJ
dpc-3703	730	11	-	-	ADJ
dpc-3703	730	12	pd-1	pd-1	ADJ
dpc-3703	730	13	immunotherapy	immunotherapy	NOUN
dpc-3703	730	14	.	.	PUNCT
dpc-3703	731	1	cell	cell	NOUN
dpc-3703	731	2	.	.	PUNCT
dpc-3703	732	1	2017;170(6):1109	2017;170(6):1109	NUM
dpc-3703	732	2	-	-	SYM
dpc-3703	732	3	1119	1119	NUM
dpc-3703	732	4	e1110	e1110	PROPN
dpc-3703	732	5	.	.	PUNCT
dpc-3703	732	6	doi	doi	PROPN
dpc-3703	732	7	:	:	PUNCT
dpc-3703	732	8	10.1016	10.1016	NUM
dpc-3703	732	9	/	/	SYM
dpc-3703	732	10	j.cell.2017.08.027	j.cell.2017.08.027	NOUN
dpc-3703	732	11	.	.	PUNCT
dpc-3703	733	1	pmid	pmid	NOUN
dpc-3703	733	2	:	:	PUNCT
dpc-3703	733	3	28886381	28886381	NUM
dpc-3703	733	4	.	.	PUNCT
dpc-3703	734	1	pmcid	pmcid	NOUN
dpc-3703	734	2	:	:	PUNCT
dpc-3703	734	3	pmc8034392	pmc8034392	NOUN
dpc-3703	734	4	.	.	PUNCT
dpc-3703	735	1	87	87	NUM
dpc-3703	735	2	.	.	PUNCT
dpc-3703	736	1	liu	liu	PROPN
dpc-3703	736	2	bl	bl	PROPN
dpc-3703	736	3	,	,	PUNCT
dpc-3703	736	4	robinson	robinson	PROPN
dpc-3703	736	5	m	m	PROPN
dpc-3703	736	6	,	,	PUNCT
dpc-3703	736	7	han	han	PROPN
dpc-3703	736	8	zq	zq	PROPN
dpc-3703	736	9	,	,	PUNCT
dpc-3703	736	10	et	et	PROPN
dpc-3703	736	11	al	al	PROPN
dpc-3703	736	12	.	.	PUNCT
dpc-3703	737	1	icp34.5	icp34.5	PROPN
dpc-3703	737	2	deleted	delete	VERB
dpc-3703	737	3	herpes	herpe	NOUN
dpc-3703	737	4	simplex	simplex	NOUN
dpc-3703	737	5	virus	virus	NOUN
dpc-3703	737	6	with	with	ADP
dpc-3703	737	7	enhanced	enhanced	ADJ
dpc-3703	737	8	oncolytic	oncolytic	ADJ
dpc-3703	737	9	,	,	PUNCT
dpc-3703	737	10	immune	immune	ADJ
dpc-3703	737	11	stimulating	stimulating	NOUN
dpc-3703	737	12	,	,	PUNCT
dpc-3703	737	13	and	and	CCONJ
dpc-3703	737	14	anti	anti	ADJ
dpc-3703	737	15	-	-	ADJ
dpc-3703	737	16	tumour	tumour	ADJ
dpc-3703	737	17	properties	property	NOUN
dpc-3703	737	18	.	.	PUNCT
dpc-3703	738	1	gene	gene	NOUN
dpc-3703	738	2	ther	ther	ADV
dpc-3703	738	3	.	.	PUNCT
dpc-3703	739	1	2003;10(4):292	2003;10(4):292	NUM
dpc-3703	739	2	-	-	SYM
dpc-3703	739	3	303	303	NUM
dpc-3703	739	4	.	.	PUNCT
dpc-3703	740	1	doi	doi	NOUN
dpc-3703	740	2	:	:	PUNCT
dpc-3703	740	3	10.1038	10.1038	NUM
dpc-3703	740	4	/	/	SYM
dpc-3703	740	5	sj.gt.3301885	sj.gt.3301885	NOUN
dpc-3703	740	6	.	.	PUNCT
dpc-3703	741	1	pmid	pmid	NOUN
dpc-3703	741	2	:	:	PUNCT
dpc-3703	741	3	12595888	12595888	NUM
dpc-3703	741	4	.	.	PUNCT
dpc-3703	742	1	88	88	NUM
dpc-3703	742	2	.	.	PUNCT
dpc-3703	743	1	a	a	DET
dpc-3703	743	2	phase	phase	NOUN
dpc-3703	743	3	1	1	NUM
dpc-3703	743	4	study	study	NOUN
dpc-3703	743	5	of	of	ADP
dpc-3703	743	6	talimogene	talimogene	NOUN
dpc-3703	743	7	laherparepvec	laherparepvec	ADJ
dpc-3703	743	8	and	and	CCONJ
dpc-3703	743	9	panitumumab	panitumumab	NOUN
dpc-3703	743	10	in	in	ADP
dpc-3703	743	11	patients	patient	NOUN
dpc-3703	743	12	with	with	ADP
dpc-3703	743	13	locally	locally	ADV
dpc-3703	743	14	advanced	advanced	ADJ
dpc-3703	743	15	squamous	squamous	ADJ
dpc-3703	743	16	cell	cell	NOUN
dpc-3703	743	17	carcinoma	carcinoma	NOUN
dpc-3703	743	18	of	of	ADP
dpc-3703	743	19	the	the	DET
dpc-3703	743	20	skin	skin	NOUN
dpc-3703	743	21	(	(	PUNCT
dpc-3703	743	22	sccs	sccs	PROPN
dpc-3703	743	23	)	)	PUNCT
dpc-3703	743	24	.	.	PUNCT
dpc-3703	744	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	744	2	i	i	PROPN
dpc-3703	744	3	d	d	PROPN
dpc-3703	744	4	nct04163952	nct04163952	NOUN
dpc-3703	744	5	.	.	PUNCT
dpc-3703	745	1	available	available	ADJ
dpc-3703	745	2	from	from	ADP
dpc-3703	745	3	:	:	PUNCT
dpc-3703	745	4	https://www.clinicaltrials.gov/study/nct04163952	https://www.clinicaltrials.gov/study/nct04163952	NOUN
dpc-3703	745	5	?	?	PUNCT
dpc-3703	746	1	cond	cond	NOUN
dpc-3703	746	2	=	=	SYM
dpc-3703	746	3	squamous%20cell%20carcinoma%20of%20the	squamous%20cell%20carcinoma%20of%20the	NOUN
dpc-3703	746	4	%	%	NOUN
dpc-3703	746	5	20skin&term	20skin&term	NUM
dpc-3703	746	6	=	=	NOUN
dpc-3703	746	7	talimogene&rank=1	talimogene&rank=1	PROPN
dpc-3703	746	8	.	.	PUNCT
dpc-3703	747	1	accessed	access	VERB
dpc-3703	747	2	on	on	ADP
dpc-3703	747	3	july	july	PROPN
dpc-3703	747	4	20	20	NUM
dpc-3703	747	5	,	,	PUNCT
dpc-3703	747	6	2023	2023	NUM
dpc-3703	747	7	.	.	PUNCT
dpc-3703	748	1	89	89	NUM
dpc-3703	748	2	.	.	PUNCT
dpc-3703	749	1	a	a	DET
dpc-3703	749	2	phase	phase	NOUN
dpc-3703	749	3	ii	ii	NOUN
dpc-3703	749	4	study	study	NOUN
dpc-3703	749	5	of	of	ADP
dpc-3703	749	6	talimogene	talimogene	PROPN
dpc-3703	749	7	laherparepvec	laherparepvec	PROPN
dpc-3703	749	8	followed	follow	VERB
dpc-3703	749	9	by	by	ADP
dpc-3703	749	10	talimogene	talimogene	NOUN
dpc-3703	749	11	laherparepvec	laherparepvec	PROPN
dpc-3703	750	1	+	+	X
dpc-3703	750	2	nivolumab	nivolumab	ADV
dpc-3703	750	3	in	in	ADP
dpc-3703	750	4	refractory	refractory	NOUN
dpc-3703	750	5	t	t	PROPN
dpc-3703	750	6	cell	cell	NOUN
dpc-3703	750	7	and	and	CCONJ
dpc-3703	750	8	nk	nk	PROPN
dpc-3703	750	9	cell	cell	NOUN
dpc-3703	750	10	lymphomas	lymphoma	NOUN
dpc-3703	750	11	,	,	PUNCT
dpc-3703	750	12	cutaneous	cutaneous	ADJ
dpc-3703	750	13	squamous	squamous	ADJ
dpc-3703	750	14	cell	cell	NOUN
dpc-3703	750	15	carcinoma	carcinoma	NOUN
dpc-3703	750	16	,	,	PUNCT
dpc-3703	750	17	merkel	merkel	NOUN
dpc-3703	750	18	cell	cell	NOUN
dpc-3703	750	19	carcinoma	carcinoma	NOUN
dpc-3703	750	20	,	,	PUNCT
dpc-3703	750	21	and	and	CCONJ
dpc-3703	750	22	other	other	ADJ
dpc-3703	750	23	rare	rare	ADJ
dpc-3703	750	24	skin	skin	NOUN
dpc-3703	750	25	tumors	tumor	NOUN
dpc-3703	750	26	.	.	PUNCT
dpc-3703	751	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	751	2	i	i	PROPN
dpc-3703	751	3	d	d	PROPN
dpc-3703	751	4	:	:	PUNCT
dpc-3703	751	5	nct02978625	nct02978625	NOUN
dpc-3703	751	6	.	.	PUNCT
dpc-3703	751	7	available	available	ADJ
dpc-3703	751	8	from	from	ADP
dpc-3703	751	9	:	:	PUNCT
dpc-3703	751	10	https://www	https://www	PROPN
dpc-3703	751	11	.clinicaltrials.gov	.clinicaltrials.gov	PUNCT
dpc-3703	751	12	/	/	SYM
dpc-3703	751	13	study	study	NOUN
dpc-3703	751	14	/	/	SYM
dpc-3703	751	15	nct02978625?cond	nct02978625?cond	NOUN
dpc-3703	751	16	=	=	NOUN
dpc-3703	751	17	nct02978625	nct02978625	NOUN
dpc-3703	751	18	&	&	CCONJ
dpc-3703	751	19	rank=1	rank=1	PROPN
dpc-3703	751	20	.	.	PUNCT
dpc-3703	752	1	accessed	access	VERB
dpc-3703	752	2	on	on	ADP
dpc-3703	752	3	july	july	PROPN
dpc-3703	752	4	10	10	NUM
dpc-3703	752	5	,	,	PUNCT
dpc-3703	752	6	2023	2023	NUM
dpc-3703	752	7	.	.	PUNCT
dpc-3703	753	1	90	90	NUM
dpc-3703	753	2	.	.	PUNCT
dpc-3703	754	1	gompertz	gompertz	NOUN
dpc-3703	754	2	-	-	PUNCT
dpc-3703	754	3	mattar	mattar	PROPN
dpc-3703	754	4	m	m	PROPN
dpc-3703	754	5	,	,	PUNCT
dpc-3703	754	6	perales	perales	PROPN
dpc-3703	754	7	j	j	PROPN
dpc-3703	754	8	,	,	PUNCT
dpc-3703	754	9	sahu	sahu	PROPN
dpc-3703	754	10	a	a	PROPN
dpc-3703	754	11	,	,	PUNCT
dpc-3703	754	12	et	et	PROPN
dpc-3703	754	13	al	al	PROPN
dpc-3703	754	14	.	.	PROPN
dpc-3703	754	15	differential	differential	ADJ
dpc-3703	754	16	expression	expression	NOUN
dpc-3703	754	17	of	of	ADP
dpc-3703	754	18	programmed	program	VERB
dpc-3703	754	19	cell	cell	NOUN
dpc-3703	754	20	death	death	NOUN
dpc-3703	754	21	ligand	ligand	NOUN
dpc-3703	754	22	1	1	NUM
dpc-3703	754	23	(	(	PUNCT
dpc-3703	754	24	pd	pd	NOUN
dpc-3703	754	25	-	-	PUNCT
dpc-3703	754	26	l1	l1	NOUN
dpc-3703	754	27	)	)	PUNCT
dpc-3703	754	28	and	and	CCONJ
dpc-3703	754	29	inflammatory	inflammatory	ADJ
dpc-3703	754	30	cells	cell	NOUN
dpc-3703	754	31	in	in	ADP
dpc-3703	754	32	basal	basal	ADJ
dpc-3703	754	33	cell	cell	NOUN
dpc-3703	754	34	carcinoma	carcinoma	NOUN
dpc-3703	754	35	subtypes	subtype	NOUN
dpc-3703	754	36	.	.	PUNCT
dpc-3703	755	1	arch	arch	ADJ
dpc-3703	755	2	dermatol	dermatol	NOUN
dpc-3703	755	3	res	re	NOUN
dpc-3703	755	4	.	.	PUNCT
dpc-3703	756	1	2022;314(8):777	2022;314(8):777	NUM
dpc-3703	756	2	-	-	SYM
dpc-3703	756	3	786	786	NUM
dpc-3703	756	4	.	.	PUNCT
dpc-3703	757	1	doi	doi	NOUN
dpc-3703	757	2	:	:	PUNCT
dpc-3703	757	3	10.1007	10.1007	NUM
dpc-3703	757	4	/	/	SYM
dpc-3703	757	5	s00403	s00403	NOUN
dpc-3703	757	6	-	-	PUNCT
dpc-3703	757	7	021	021	NUM
dpc-3703	757	8	-	-	PUNCT
dpc-3703	757	9	02289	02289	NUM
dpc-3703	757	10	-	-	PUNCT
dpc-3703	757	11	w.	w.	NOUN
dpc-3703	757	12	pmid	pmid	PROPN
dpc-3703	757	13	:	:	PUNCT
dpc-3703	757	14	34647186	34647186	NUM
dpc-3703	757	15	.	.	PUNCT
dpc-3703	758	1	91	91	NUM
dpc-3703	758	2	.	.	PUNCT
dpc-3703	759	1	goodman	goodman	PROPN
dpc-3703	759	2	am	am	PROPN
dpc-3703	759	3	,	,	PUNCT
dpc-3703	759	4	kato	kato	PROPN
dpc-3703	759	5	s	s	PROPN
dpc-3703	759	6	,	,	PUNCT
dpc-3703	759	7	cohen	cohen	PROPN
dpc-3703	759	8	pr	pr	PROPN
dpc-3703	759	9	,	,	PUNCT
dpc-3703	759	10	et	et	PROPN
dpc-3703	759	11	al	al	PROPN
dpc-3703	759	12	.	.	PUNCT
dpc-3703	760	1	genomic	genomic	ADJ
dpc-3703	760	2	landscape	landscape	NOUN
dpc-3703	760	3	of	of	ADP
dpc-3703	760	4	advanced	advanced	ADJ
dpc-3703	760	5	basal	basal	NOUN
dpc-3703	760	6	cell	cell	NOUN
dpc-3703	760	7	carcinoma	carcinoma	NOUN
dpc-3703	760	8	:	:	PUNCT
dpc-3703	760	9	implications	implication	NOUN
dpc-3703	760	10	for	for	ADP
dpc-3703	760	11	precision	precision	NOUN
dpc-3703	760	12	treatment	treatment	NOUN
dpc-3703	760	13	with	with	ADP
dpc-3703	760	14	targeted	targeted	ADJ
dpc-3703	760	15	and	and	CCONJ
dpc-3703	760	16	immune	immune	ADJ
dpc-3703	760	17	therapies	therapy	NOUN
dpc-3703	760	18	.	.	PUNCT
dpc-3703	761	1	oncoimmunology	oncoimmunology	NOUN
dpc-3703	761	2	.	.	PUNCT
dpc-3703	762	1	2018;7(3):e1404217	2018;7(3):e1404217	X
dpc-3703	762	2	.	.	PUNCT
dpc-3703	763	1	doi	doi	NOUN
dpc-3703	763	2	:	:	PUNCT
dpc-3703	763	3	10.1080/2162402x.2017.1404217	10.1080/2162402x.2017.1404217	NOUN
dpc-3703	763	4	.	.	PUNCT
dpc-3703	764	1	pmid	pmid	NOUN
dpc-3703	764	2	:	:	PUNCT
dpc-3703	764	3	29399405	29399405	NUM
dpc-3703	764	4	.	.	PUNCT
dpc-3703	765	1	pmcid	pmcid	NOUN
dpc-3703	765	2	:	:	PUNCT
dpc-3703	765	3	pmc5790366	pmc5790366	ADJ
dpc-3703	765	4	.	.	PUNCT
dpc-3703	766	1	92	92	NUM
dpc-3703	766	2	.	.	PUNCT
dpc-3703	767	1	yamakawa	yamakawa	PROPN
dpc-3703	767	2	k	k	PROPN
dpc-3703	767	3	,	,	PUNCT
dpc-3703	767	4	ogata	ogata	PROPN
dpc-3703	767	5	d	d	PROPN
dpc-3703	767	6	,	,	PUNCT
dpc-3703	767	7	hiki	hiki	PROPN
dpc-3703	767	8	k	k	PROPN
dpc-3703	767	9	,	,	PUNCT
dpc-3703	767	10	et	et	PROPN
dpc-3703	767	11	al	al	PROPN
dpc-3703	767	12	.	.	PROPN
dpc-3703	768	1	metastatic	metastatic	PROPN
dpc-3703	768	2	basal	basal	PROPN
dpc-3703	768	3	cell	cell	NOUN
dpc-3703	768	4	carcinoma	carcinoma	NOUN
dpc-3703	768	5	with	with	ADP
dpc-3703	768	6	a	a	DET
dpc-3703	768	7	high	high	ADJ
dpc-3703	768	8	tumor	tumor	NOUN
dpc-3703	768	9	mutational	mutational	ADJ
dpc-3703	768	10	burden	burden	NOUN
dpc-3703	768	11	that	that	PRON
dpc-3703	768	12	achieved	achieve	VERB
dpc-3703	768	13	complete	complete	ADJ
dpc-3703	768	14	response	response	NOUN
dpc-3703	768	15	with	with	ADP
dpc-3703	768	16	pembrolizumab	pembrolizumab	NOUN
dpc-3703	768	17	.	.	PUNCT
dpc-3703	769	1	int	int	NOUN
dpc-3703	769	2	j	j	PROPN
dpc-3703	769	3	dermatol	dermatol	NOUN
dpc-3703	769	4	.	.	PUNCT
dpc-3703	770	1	2023;62(2):e79	2023;62(2):e79	PROPN
dpc-3703	770	2	-	-	PUNCT
dpc-3703	770	3	e80	e80	PROPN
dpc-3703	770	4	.	.	PUNCT
dpc-3703	771	1	doi	doi	NOUN
dpc-3703	771	2	:	:	PUNCT
dpc-3703	771	3	10.1111	10.1111	NUM
dpc-3703	771	4	/	/	SYM
dpc-3703	771	5	ijd.16245	ijd.16245	PROPN
dpc-3703	771	6	.	.	PUNCT
dpc-3703	772	1	pmid	pmid	NOUN
dpc-3703	772	2	:	:	PUNCT
dpc-3703	772	3	35553058	35553058	NUM
dpc-3703	772	4	.	.	PUNCT
dpc-3703	773	1	93	93	NUM
dpc-3703	773	2	.	.	PUNCT
dpc-3703	774	1	hall	hall	PROPN
dpc-3703	774	2	et	et	PROPN
dpc-3703	774	3	,	,	PUNCT
dpc-3703	774	4	fernandez	fernandez	NOUN
dpc-3703	774	5	-	-	PUNCT
dpc-3703	774	6	lopez	lopez	NOUN
dpc-3703	774	7	e	e	PROPN
dpc-3703	774	8	,	,	PUNCT
dpc-3703	774	9	silk	silk	PROPN
dpc-3703	774	10	aw	aw	INTJ
dpc-3703	774	11	,	,	PUNCT
dpc-3703	774	12	dummer	dummer	PROPN
dpc-3703	774	13	r	r	PROPN
dpc-3703	774	14	,	,	PUNCT
dpc-3703	774	15	bhatia	bhatia	PROPN
dpc-3703	774	16	s.	s.	PROPN
dpc-3703	774	17	immunologic	immunologic	PROPN
dpc-3703	774	18	characteristics	characteristic	NOUN
dpc-3703	774	19	of	of	ADP
dpc-3703	774	20	nonmelanoma	nonmelanoma	ADJ
dpc-3703	774	21	skin	skin	NOUN
dpc-3703	774	22	cancers	cancer	NOUN
dpc-3703	774	23	:	:	PUNCT
dpc-3703	774	24	implications	implication	NOUN
dpc-3703	774	25	for	for	ADP
dpc-3703	774	26	immunotherapy	immunotherapy	NOUN
dpc-3703	774	27	.	.	PUNCT
dpc-3703	775	1	am	be	AUX
dpc-3703	775	2	soc	soc	PROPN
dpc-3703	775	3	clin	clin	PROPN
dpc-3703	775	4	oncol	oncol	PROPN
dpc-3703	775	5	educ	educ	PROPN
dpc-3703	775	6	book	book	NOUN
dpc-3703	775	7	.	.	PUNCT
dpc-3703	776	1	2020;40:1	2020;40:1	NUM
dpc-3703	776	2	-	-	SYM
dpc-3703	776	3	10	10	NUM
dpc-3703	776	4	.	.	PUNCT
dpc-3703	777	1	doi	doi	NOUN
dpc-3703	777	2	:	:	PUNCT
dpc-3703	777	3	10.1200	10.1200	NUM
dpc-3703	777	4	/	/	SYM
dpc-3703	777	5	edbk_278953	edbk_278953	ADJ
dpc-3703	777	6	.	.	PUNCT
dpc-3703	778	1	pmid	pmid	NOUN
dpc-3703	778	2	:	:	PUNCT
dpc-3703	778	3	32207669	32207669	NUM
dpc-3703	778	4	.	.	PUNCT
dpc-3703	779	1	94	94	NUM
dpc-3703	779	2	.	.	PUNCT
dpc-3703	780	1	durante	durante	PROPN
dpc-3703	780	2	g	g	PROPN
dpc-3703	780	3	,	,	PUNCT
dpc-3703	780	4	comito	comito	PROPN
dpc-3703	780	5	f	f	PROPN
dpc-3703	780	6	,	,	PUNCT
dpc-3703	780	7	lambertini	lambertini	PROPN
dpc-3703	780	8	m	m	PROPN
dpc-3703	780	9	,	,	PUNCT
dpc-3703	780	10	broseghini	broseghini	PROPN
dpc-3703	780	11	e	e	NOUN
dpc-3703	780	12	,	,	PUNCT
dpc-3703	780	13	dika	dika	X
dpc-3703	780	14	e	e	NOUN
dpc-3703	780	15	,	,	PUNCT
dpc-3703	780	16	ferracin	ferracin	ADJ
dpc-3703	780	17	m.	m.	NOUN
dpc-3703	780	18	non	non	ADJ
dpc-3703	780	19	-	-	ADJ
dpc-3703	780	20	coding	code	VERB
dpc-3703	780	21	rna	rna	NOUN
dpc-3703	780	22	dysregulation	dysregulation	NOUN
dpc-3703	780	23	in	in	ADP
dpc-3703	780	24	skin	skin	NOUN
dpc-3703	780	25	cancers	cancer	NOUN
dpc-3703	780	26	.	.	PUNCT
dpc-3703	781	1	essays	essays	PROPN
dpc-3703	781	2	biochem	biochem	PROPN
dpc-3703	781	3	.	.	PUNCT
dpc-3703	782	1	2021;65(4):641	2021;65(4):641	NUM
dpc-3703	782	2	-	-	PUNCT
dpc-3703	782	3	655	655	NUM
dpc-3703	782	4	.	.	PUNCT
dpc-3703	783	1	doi	doi	NOUN
dpc-3703	783	2	:	:	PUNCT
dpc-3703	783	3	10.1042	10.1042	NUM
dpc-3703	783	4	/ebc20200048	/ebc20200048	SYM
dpc-3703	783	5	.	.	PUNCT
dpc-3703	784	1	pmid	pmid	NOUN
dpc-3703	784	2	:	:	PUNCT
dpc-3703	784	3	34414406	34414406	NUM
dpc-3703	784	4	.	.	PUNCT
dpc-3703	785	1	77	77	NUM
dpc-3703	785	2	.	.	PUNCT
dpc-3703	786	1	stratigos	stratigos	PROPN
dpc-3703	786	2	aj	aj	PROPN
dpc-3703	786	3	,	,	PUNCT
dpc-3703	786	4	garbe	garbe	NOUN
dpc-3703	786	5	c	c	PROPN
dpc-3703	786	6	,	,	PUNCT
dpc-3703	786	7	dessinioti	dessinioti	ADP
dpc-3703	787	1	c	c	X
dpc-3703	787	2	,	,	PUNCT
dpc-3703	787	3	et	et	PROPN
dpc-3703	787	4	al	al	PROPN
dpc-3703	787	5	.	.	PUNCT
dpc-3703	788	1	european	european	ADJ
dpc-3703	788	2	interdisciplinary	interdisciplinary	ADJ
dpc-3703	788	3	guideline	guideline	NOUN
dpc-3703	788	4	on	on	ADP
dpc-3703	788	5	invasive	invasive	ADJ
dpc-3703	788	6	squamous	squamous	ADJ
dpc-3703	788	7	cell	cell	NOUN
dpc-3703	788	8	carcinoma	carcinoma	NOUN
dpc-3703	788	9	of	of	ADP
dpc-3703	788	10	the	the	DET
dpc-3703	788	11	skin	skin	NOUN
dpc-3703	788	12	:	:	PUNCT
dpc-3703	788	13	part	part	NOUN
dpc-3703	788	14	2	2	NUM
dpc-3703	788	15	.	.	PUNCT
dpc-3703	788	16	treatment	treatment	NOUN
dpc-3703	788	17	.	.	PUNCT
dpc-3703	789	1	eur	eur	PROPN
dpc-3703	789	2	j	j	PROPN
dpc-3703	789	3	cancer	cancer	NOUN
dpc-3703	789	4	.	.	PUNCT
dpc-3703	790	1	2020;128:83	2020;128:83	NUM
dpc-3703	790	2	-	-	SYM
dpc-3703	790	3	102	102	NUM
dpc-3703	790	4	.	.	PUNCT
dpc-3703	791	1	doi	doi	NOUN
dpc-3703	791	2	:	:	PUNCT
dpc-3703	791	3	10.1016	10.1016	NUM
dpc-3703	791	4	/	/	SYM
dpc-3703	791	5	j.ejca.2020.01.008	j.ejca.2020.01.008	PROPN
dpc-3703	791	6	.	.	PUNCT
dpc-3703	792	1	pmid	pmid	NOUN
dpc-3703	792	2	:	:	PUNCT
dpc-3703	792	3	32113942	32113942	NUM
dpc-3703	792	4	.	.	PUNCT
dpc-3703	793	1	78	78	NUM
dpc-3703	793	2	.	.	PUNCT
dpc-3703	794	1	keohane	keohane	PROPN
dpc-3703	794	2	sg	sg	PROPN
dpc-3703	794	3	,	,	PUNCT
dpc-3703	794	4	botting	botte	VERB
dpc-3703	794	5	j	j	PROPN
dpc-3703	794	6	,	,	PUNCT
dpc-3703	794	7	budny	budny	VERB
dpc-3703	794	8	pg	pg	PROPN
dpc-3703	794	9	,	,	PUNCT
dpc-3703	794	10	et	et	PROPN
dpc-3703	794	11	al	al	PROPN
dpc-3703	794	12	.	.	PROPN
dpc-3703	795	1	british	british	PROPN
dpc-3703	795	2	association	association	PROPN
dpc-3703	795	3	of	of	ADP
dpc-3703	795	4	dermatologists	dermatologists	PROPN
dpc-3703	795	5	guidelines	guideline	NOUN
dpc-3703	795	6	for	for	ADP
dpc-3703	795	7	the	the	DET
dpc-3703	795	8	management	management	NOUN
dpc-3703	795	9	of	of	ADP
dpc-3703	795	10	people	people	NOUN
dpc-3703	795	11	with	with	ADP
dpc-3703	795	12	cutaneous	cutaneous	ADJ
dpc-3703	795	13	squamous	squamous	ADJ
dpc-3703	795	14	cell	cell	NOUN
dpc-3703	795	15	carcinoma	carcinoma	NOUN
dpc-3703	795	16	2020	2020	NUM
dpc-3703	795	17	.	.	PUNCT
dpc-3703	796	1	br	br	PROPN
dpc-3703	796	2	j	j	PROPN
dpc-3703	796	3	dermatol	dermatol	NOUN
dpc-3703	796	4	.	.	PUNCT
dpc-3703	797	1	2021;184(3):401	2021;184(3):401	NUM
dpc-3703	797	2	-	-	SYM
dpc-3703	797	3	414	414	NUM
dpc-3703	797	4	.	.	PUNCT
dpc-3703	798	1	doi	doi	NOUN
dpc-3703	798	2	:	:	PUNCT
dpc-3703	798	3	10.1111	10.1111	NUM
dpc-3703	798	4	/	/	SYM
dpc-3703	798	5	bjd.19621	bjd.19621	NUM
dpc-3703	798	6	.	.	PUNCT
dpc-3703	799	1	pmid	pmid	NOUN
dpc-3703	799	2	:	:	PUNCT
dpc-3703	799	3	33150585	33150585	NUM
dpc-3703	799	4	.	.	PUNCT
dpc-3703	800	1	79	79	NUM
dpc-3703	800	2	.	.	PUNCT
dpc-3703	801	1	weis	weis	PROPN
dpc-3703	801	2	j	j	PROPN
dpc-3703	801	3	,	,	PUNCT
dpc-3703	801	4	grote	grote	PROPN
dpc-3703	801	5	c	c	X
dpc-3703	801	6	,	,	PUNCT
dpc-3703	801	7	weichenthal	weichenthal	PROPN
dpc-3703	801	8	m	m	PROPN
dpc-3703	801	9	,	,	PUNCT
dpc-3703	801	10	hauschild	hauschild	ADJ
dpc-3703	801	11	a.	a.	NOUN
dpc-3703	801	12	complete	complete	ADJ
dpc-3703	801	13	response	response	NOUN
dpc-3703	801	14	of	of	ADP
dpc-3703	801	15	advanced	advanced	ADJ
dpc-3703	801	16	cutaneous	cutaneous	ADJ
dpc-3703	801	17	squamous	squamous	ADJ
dpc-3703	801	18	cell	cell	NOUN
dpc-3703	801	19	and	and	CCONJ
dpc-3703	801	20	basal	basal	NOUN
dpc-3703	801	21	cell	cell	NOUN
dpc-3703	801	22	carcinomas	carcinoma	NOUN
dpc-3703	801	23	with	with	ADP
dpc-3703	801	24	sequential	sequential	ADJ
dpc-3703	801	25	cemiplimab	cemiplimab	NOUN
dpc-3703	801	26	and	and	CCONJ
dpc-3703	801	27	sonidegib	sonidegib	NOUN
dpc-3703	801	28	therapy	therapy	NOUN
dpc-3703	801	29	.	.	PUNCT
dpc-3703	802	1	j	j	PROPN
dpc-3703	802	2	eur	eur	PROPN
dpc-3703	802	3	acad	acad	PROPN
dpc-3703	802	4	dermatol	dermatol	NOUN
dpc-3703	802	5	venereol	venereol	NOUN
dpc-3703	802	6	.	.	PUNCT
dpc-3703	803	1	2022;36	2022;36	NOUN
dpc-3703	803	2	suppl	suppl	ADJ
dpc-3703	803	3	1:66	1:66	NUM
dpc-3703	803	4	-	-	SYM
dpc-3703	803	5	69	69	NUM
dpc-3703	803	6	.	.	PUNCT
dpc-3703	804	1	doi	doi	NOUN
dpc-3703	804	2	:	:	PUNCT
dpc-3703	804	3	10.1111/	10.1111/	NUM
dpc-3703	804	4	jdv.17403	jdv.17403	PROPN
dpc-3703	804	5	.	.	PUNCT
dpc-3703	805	1	pmid	pmid	NOUN
dpc-3703	805	2	:	:	PUNCT
dpc-3703	805	3	34855253	34855253	NUM
dpc-3703	805	4	.	.	PUNCT
dpc-3703	806	1	80	80	NUM
dpc-3703	806	2	.	.	PUNCT
dpc-3703	807	1	colombo	colombo	PROPN
dpc-3703	807	2	e	e	NOUN
dpc-3703	807	3	,	,	PUNCT
dpc-3703	807	4	gurizzan	gurizzan	NOUN
dpc-3703	807	5	c	c	NOUN
dpc-3703	807	6	,	,	PUNCT
dpc-3703	807	7	ottini	ottini	X
dpc-3703	807	8	a	a	PRON
dpc-3703	807	9	,	,	PUNCT
dpc-3703	807	10	et	et	PROPN
dpc-3703	807	11	al	al	PROPN
dpc-3703	807	12	.	.	PUNCT
dpc-3703	808	1	the	the	DET
dpc-3703	808	2	association	association	NOUN
dpc-3703	808	3	of	of	ADP
dpc-3703	808	4	cemiplimab	cemiplimab	NOUN
dpc-3703	808	5	plus	plus	CCONJ
dpc-3703	808	6	sonidegib	sonidegib	NOUN
dpc-3703	808	7	for	for	ADP
dpc-3703	808	8	synchronous	synchronous	ADJ
dpc-3703	808	9	cutaneous	cutaneous	ADJ
dpc-3703	808	10	squamous	squamous	ADJ
dpc-3703	808	11	cell	cell	NOUN
dpc-3703	808	12	carcinoma	carcinoma	NOUN
dpc-3703	808	13	and	and	CCONJ
dpc-3703	808	14	basal	basal	NOUN
dpc-3703	808	15	cell	cell	NOUN
dpc-3703	808	16	carcinoma	carcinoma	NOUN
dpc-3703	808	17	of	of	ADP
dpc-3703	808	18	the	the	DET
dpc-3703	808	19	head	head	NOUN
dpc-3703	808	20	and	and	CCONJ
dpc-3703	808	21	neck	neck	NOUN
dpc-3703	808	22	:	:	PUNCT
dpc-3703	808	23	two	two	NUM
dpc-3703	808	24	case	case	NOUN
dpc-3703	808	25	reports	report	VERB
dpc-3703	808	26	.	.	PUNCT
dpc-3703	809	1	front	front	ADJ
dpc-3703	809	2	oncol	oncol	ADJ
dpc-3703	809	3	.	.	PUNCT
dpc-3703	810	1	2023;13:1111146	2023;13:1111146	NUM
dpc-3703	810	2	.	.	PUNCT
dpc-3703	810	3	doi	doi	NOUN
dpc-3703	810	4	:	:	PUNCT
dpc-3703	810	5	10.3389	10.3389	NUM
dpc-3703	810	6	/	/	SYM
dpc-3703	810	7	fonc.2023.1111146	fonc.2023.1111146	NOUN
dpc-3703	810	8	.	.	PUNCT
dpc-3703	811	1	pmid	pmid	NOUN
dpc-3703	811	2	:	:	PUNCT
dpc-3703	811	3	36925925	36925925	NUM
dpc-3703	811	4	.	.	PUNCT
dpc-3703	812	1	pmcid	pmcid	NOUN
dpc-3703	812	2	:	:	PUNCT
dpc-3703	812	3	pmc10013465	pmc10013465	NOUN
dpc-3703	812	4	.	.	PUNCT
dpc-3703	813	1	81	81	NUM
dpc-3703	813	2	.	.	PUNCT
dpc-3703	813	3	sabbatino	sabbatino	PROPN
dpc-3703	813	4	f	f	PROPN
dpc-3703	813	5	,	,	PUNCT
dpc-3703	813	6	marra	marra	X
dpc-3703	813	7	a	a	DET
dpc-3703	813	8	,	,	PUNCT
dpc-3703	813	9	liguori	liguori	ADJ
dpc-3703	813	10	l	l	NOUN
dpc-3703	813	11	,	,	PUNCT
dpc-3703	813	12	et	et	PROPN
dpc-3703	813	13	al	al	PROPN
dpc-3703	813	14	.	.	PROPN
dpc-3703	813	15	resistance	resistance	NOUN
dpc-3703	813	16	to	to	ADP
dpc-3703	813	17	anti	anti	ADJ
dpc-3703	813	18	-	-	ADJ
dpc-3703	813	19	pd-1	pd-1	ADV
dpc-3703	813	20	-	-	PUNCT
dpc-3703	813	21	based	base	VERB
dpc-3703	813	22	immunotherapy	immunotherapy	NOUN
dpc-3703	813	23	in	in	ADP
dpc-3703	813	24	basal	basal	ADJ
dpc-3703	813	25	cell	cell	NOUN
dpc-3703	813	26	carcinoma	carcinoma	NOUN
dpc-3703	813	27	:	:	PUNCT
dpc-3703	813	28	a	a	DET
dpc-3703	813	29	case	case	NOUN
dpc-3703	813	30	report	report	NOUN
dpc-3703	813	31	and	and	CCONJ
dpc-3703	813	32	review	review	NOUN
dpc-3703	813	33	of	of	ADP
dpc-3703	813	34	the	the	DET
dpc-3703	813	35	literature	literature	NOUN
dpc-3703	813	36	.	.	PUNCT
dpc-3703	814	1	j	j	PROPN
dpc-3703	814	2	immunother	immunother	ADJ
dpc-3703	814	3	cancer	cancer	NOUN
dpc-3703	814	4	.	.	PUNCT
dpc-3703	815	1	2018;6(1):126	2018;6(1):126	X
dpc-3703	815	2	.	.	PUNCT
dpc-3703	816	1	doi	doi	NOUN
dpc-3703	816	2	:	:	PUNCT
dpc-3703	816	3	10.1186	10.1186	NUM
dpc-3703	816	4	/	/	SYM
dpc-3703	816	5	s40425	s40425	NOUN
dpc-3703	816	6	-	-	PUNCT
dpc-3703	816	7	018	018	NUM
dpc-3703	816	8	-	-	PUNCT
dpc-3703	816	9	0439	0439	NUM
dpc-3703	816	10	-	-	PUNCT
dpc-3703	816	11	2	2	NUM
dpc-3703	816	12	.	.	PUNCT
dpc-3703	817	1	pmid	pmid	NOUN
dpc-3703	817	2	:	:	PUNCT
dpc-3703	817	3	30458852	30458852	NUM
dpc-3703	817	4	.	.	PUNCT
dpc-3703	818	1	pmcid	pmcid	NOUN
dpc-3703	818	2	:	:	PUNCT
dpc-3703	818	3	pmc6247622	pmc6247622	NOUN
dpc-3703	818	4	.	.	PUNCT
dpc-3703	819	1	82	82	NUM
dpc-3703	819	2	.	.	PUNCT
dpc-3703	820	1	chang	chang	PROPN
dpc-3703	820	2	als	als	PROPN
dpc-3703	820	3	,	,	PUNCT
dpc-3703	820	4	tran	tran	PROPN
dpc-3703	820	5	dc	dc	PROPN
dpc-3703	820	6	,	,	PUNCT
dpc-3703	820	7	cannon	cannon	NOUN
dpc-3703	820	8	jgd	jgd	NOUN
dpc-3703	820	9	,	,	PUNCT
dpc-3703	820	10	et	et	PROPN
dpc-3703	820	11	al	al	PROPN
dpc-3703	820	12	.	.	PROPN
dpc-3703	820	13	pembrolizumab	pembrolizumab	NOUN
dpc-3703	820	14	for	for	ADP
dpc-3703	820	15	advanced	advanced	ADJ
dpc-3703	820	16	basal	basal	NOUN
dpc-3703	820	17	cell	cell	NOUN
dpc-3703	820	18	carcinoma	carcinoma	NOUN
dpc-3703	820	19	:	:	PUNCT
dpc-3703	820	20	an	an	DET
dpc-3703	820	21	investigator	investigator	NOUN
dpc-3703	820	22	-	-	PUNCT
dpc-3703	820	23	initiated	initiate	VERB
dpc-3703	820	24	,	,	PUNCT
dpc-3703	820	25	proof	proof	NOUN
dpc-3703	820	26	-	-	PUNCT
dpc-3703	820	27	of	of	ADP
dpc-3703	820	28	-	-	PUNCT
dpc-3703	820	29	concept	concept	NOUN
dpc-3703	820	30	study	study	NOUN
dpc-3703	820	31	.	.	PUNCT
dpc-3703	821	1	j	j	PROPN
dpc-3703	821	2	am	be	AUX
dpc-3703	821	3	acad	acad	ADJ
dpc-3703	821	4	dermatol	dermatol	NOUN
dpc-3703	821	5	.	.	PUNCT
dpc-3703	822	1	2019;80(2	2019;80(2	NUM
dpc-3703	822	2	):	):	PUNCT
dpc-3703	822	3	564	564	NUM
dpc-3703	822	4	-	-	SYM
dpc-3703	822	5	566	566	NUM
dpc-3703	822	6	.	.	PUNCT
dpc-3703	822	7	doi	doi	NOUN
dpc-3703	822	8	:	:	PUNCT
dpc-3703	822	9	10.1016	10.1016	NUM
dpc-3703	822	10	/	/	SYM
dpc-3703	822	11	j.jaad.2018.08.017	j.jaad.2018.08.017	PROPN
dpc-3703	822	12	.	.	PUNCT
dpc-3703	823	1	pmid	pmid	NOUN
dpc-3703	823	2	:	:	PUNCT
dpc-3703	823	3	30145186	30145186	NUM
dpc-3703	823	4	.	.	PUNCT
dpc-3703	824	1	pmcid	pmcid	NOUN
dpc-3703	824	2	:	:	PUNCT
dpc-3703	824	3	pmc6839543	pmc6839543	ADJ
dpc-3703	824	4	.	.	PUNCT
dpc-3703	825	1	83	83	NUM
dpc-3703	825	2	.	.	PUNCT
dpc-3703	826	1	a	a	DET
dpc-3703	826	2	prospective	prospective	ADJ
dpc-3703	826	3	,	,	PUNCT
dpc-3703	826	4	open	open	ADJ
dpc-3703	826	5	,	,	PUNCT
dpc-3703	826	6	single	single	ADJ
dpc-3703	826	7	-	-	PUNCT
dpc-3703	826	8	arm	arm	NOUN
dpc-3703	826	9	,	,	PUNCT
dpc-3703	826	10	single	single	ADJ
dpc-3703	826	11	center	center	NOUN
dpc-3703	826	12	,	,	PUNCT
dpc-3703	826	13	phase	phase	NOUN
dpc-3703	826	14	ii	ii	NOUN
dpc-3703	826	15	trial	trial	NOUN
dpc-3703	826	16	to	to	PART
dpc-3703	826	17	assess	assess	VERB
dpc-3703	826	18	the	the	DET
dpc-3703	826	19	efficacy	efficacy	NOUN
dpc-3703	826	20	of	of	ADP
dpc-3703	826	21	anti	anti	ADJ
dpc-3703	826	22	-	-	ADJ
dpc-3703	826	23	pd1	pd1	NOUN
dpc-3703	826	24	antibody	antibody	NOUN
dpc-3703	826	25	in	in	ADP
dpc-3703	826	26	combination	combination	NOUN
dpc-3703	826	27	with	with	ADP
dpc-3703	826	28	pulsed	pulse	VERB
dpc-3703	826	29	hedgehog	hedgehog	NOUN
dpc-3703	826	30	inhibitor	inhibitor	NOUN
dpc-3703	826	31	in	in	ADP
dpc-3703	826	32	advanced	advanced	ADJ
dpc-3703	826	33	basal	basal	NOUN
dpc-3703	826	34	cell	cell	NOUN
dpc-3703	826	35	carcinoma	carcinoma	NOUN
dpc-3703	826	36	.	.	PUNCT
dpc-3703	827	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	827	2	i	i	PROPN
dpc-3703	827	3	d	d	PROPN
dpc-3703	827	4	:	:	PUNCT
dpc-3703	827	5	nct04679480	nct04679480	PROPN
dpc-3703	827	6	.	.	PUNCT
dpc-3703	828	1	availabe	availabe	VERB
dpc-3703	828	2	from	from	ADP
dpc-3703	828	3	:	:	PUNCT
dpc-3703	828	4	https://www	https://www	PROPN
dpc-3703	828	5	.clinicaltrials.gov	.clinicaltrials.gov	PUNCT
dpc-3703	828	6	/	/	SYM
dpc-3703	828	7	study	study	NOUN
dpc-3703	828	8	/	/	SYM
dpc-3703	828	9	nct04679480?cond	nct04679480?cond	NOUN
dpc-3703	828	10	=	=	NOUN
dpc-3703	828	11	basal%20cell	basal%20cell	NOUN
dpc-3703	828	12	%	%	NOUN
dpc-3703	828	13	20carcinoma&intr	20carcinoma&intr	NOUN
dpc-3703	828	14	=	=	SYM
dpc-3703	828	15	cemiplimab&rank=4	cemiplimab&rank=4	PROPN
dpc-3703	828	16	.accessed	.accesse	VERB
dpc-3703	828	17	on	on	ADP
dpc-3703	828	18	july	july	PROPN
dpc-3703	828	19	16	16	NUM
dpc-3703	828	20	,	,	PUNCT
dpc-3703	828	21	2023	2023	NUM
dpc-3703	828	22	.	.	PUNCT
dpc-3703	829	1	84	84	NUM
dpc-3703	829	2	.	.	PUNCT
dpc-3703	830	1	nivolumab	nivolumab	NOUN
dpc-3703	830	2	alone	alone	ADV
dpc-3703	830	3	or	or	CCONJ
dpc-3703	830	4	plus	plus	CCONJ
dpc-3703	830	5	relatlimab	relatlimab	NOUN
dpc-3703	830	6	or	or	CCONJ
dpc-3703	830	7	ipilimumab	ipilimumab	VERB
dpc-3703	830	8	for	for	ADP
dpc-3703	830	9	patients	patient	NOUN
dpc-3703	830	10	with	with	ADP
dpc-3703	830	11	locally	locally	ADV
dpc-3703	830	12	-	-	PUNCT
dpc-3703	830	13	advanced	advance	VERB
dpc-3703	830	14	unresectable	unresectable	ADJ
dpc-3703	830	15	or	or	CCONJ
dpc-3703	830	16	metastatic	metastatic	ADJ
dpc-3703	830	17	basal	basal	NOUN
dpc-3703	830	18	cell	cell	NOUN
dpc-3703	830	19	carcinoma	carcinoma	NOUN
dpc-3703	830	20	.	.	PUNCT
dpc-3703	831	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3703	831	2	i	i	PROPN
dpc-3703	831	3	d	d	PROPN
dpc-3703	831	4	:	:	PUNCT
dpc-3703	831	5	nct03521830	nct03521830	PROPN
dpc-3703	831	6	.	.	PUNCT
dpc-3703	831	7	available	available	ADJ
dpc-3703	831	8	from	from	ADP
dpc-3703	831	9	:	:	PUNCT
dpc-3703	831	10	https://www.clinicaltrials.gov/study/nct03521830	https://www.clinicaltrials.gov/study/nct03521830	NUM
dpc-3703	831	11	?	?	PUNCT
dpc-3703	831	12	cond	cond	NOUN
dpc-3703	831	13	=	=	SYM
dpc-3703	831	14	basal%20cell%20carcinoma&intr	basal%20cell%20carcinoma&intr	NOUN
dpc-3703	831	15	=	=	NOUN
dpc-3703	831	16	nivolumab&rank=1	nivolumab&rank=1	PROPN
dpc-3703	831	17	.	.	PUNCT
dpc-3703	832	1	accessed	access	VERB
dpc-3703	832	2	on	on	ADP
dpc-3703	832	3	july	july	PROPN
dpc-3703	832	4	16	16	NUM
dpc-3703	832	5	,	,	PUNCT
dpc-3703	832	6	2023	2023	NUM
dpc-3703	832	7	.	.	PUNCT
dpc-3703	832	8	85	85	NUM
dpc-3703	832	9	.	.	PUNCT
dpc-3703	832	10	ziogas	ziogas	PROPN
dpc-3703	832	11	dc	dc	PROPN
dpc-3703	832	12	,	,	PUNCT
dpc-3703	832	13	martinos	martino	NOUN
dpc-3703	832	14	a	a	PRON
dpc-3703	832	15	,	,	PUNCT
dpc-3703	832	16	petsiou	petsiou	NOUN
dpc-3703	832	17	dp	dp	NOUN
dpc-3703	832	18	,	,	PUNCT
dpc-3703	832	19	anastasopoulou	anastasopoulou	NOUN
dpc-3703	832	20	a	a	PRON
dpc-3703	832	21	,	,	PUNCT
dpc-3703	832	22	gogas	gogas	NOUN
dpc-3703	832	23	h.	h.	PROPN
dpc-3703	832	24	beyond	beyond	ADP
dpc-3703	832	25	immunotherapy	immunotherapy	NOUN
dpc-3703	832	26	:	:	PUNCT
dpc-3703	832	27	seizing	seize	VERB
dpc-3703	832	28	the	the	DET
dpc-3703	832	29	momentum	momentum	NOUN
dpc-3703	832	30	of	of	ADP
dpc-3703	832	31	oncolytic	oncolytic	ADJ
dpc-3703	832	32	viruses	virus	NOUN
dpc-3703	832	33	in	in	ADP
dpc-3703	832	34	the	the	DET
dpc-3703	832	35	ideal	ideal	ADJ
dpc-3703	832	36	platform	platform	NOUN
dpc-3703	832	37	of	of	ADP
dpc-3703	832	38	skin	skin	NOUN
dpc-3703	832	39	cancers	cancer	NOUN
dpc-3703	832	40	.	.	PUNCT
dpc-3703	833	1	cancers	cancer	NOUN
dpc-3703	833	2	(	(	PUNCT
dpc-3703	833	3	basel	basel	PROPN
dpc-3703	833	4	)	)	PUNCT
dpc-3703	833	5	.	.	PUNCT
dpc-3703	834	1	2022;14(12	2022;14(12	NUM
dpc-3703	834	2	)	)	PUNCT
dpc-3703	834	3	.	.	PUNCT
dpc-3703	835	1	doi	doi	NOUN
dpc-3703	835	2	:	:	PUNCT
dpc-3703	835	3	10.3390	10.3390	NUM
dpc-3703	835	4	/	/	SYM
dpc-3703	835	5	cancers14122873	cancers14122873	PROPN
dpc-3703	835	6	.	.	PUNCT
dpc-3703	836	1	pmid	pmid	NOUN
dpc-3703	836	2	:	:	PUNCT
dpc-3703	836	3	35740539	35740539	NUM
dpc-3703	836	4	.	.	PUNCT
dpc-3703	837	1	pmcid	pmcid	NOUN
dpc-3703	837	2	:	:	PUNCT
dpc-3703	837	3	pmc9221332	pmc9221332	NOUN
dpc-3703	837	4	.	.	PUNCT